[
  {
    "drugName": "Emgality",
    "setId": "33a147be-233a-40e8-a55e-e40936e28db0",
    "slug": "emgality-33a147b",
    "labeler": "Eli Lilly and Company",
    "label": {
      "genericName": "galcanezumab-gnlm",
      "labelerName": "Eli Lilly and Company",
      "productType": "HUMAN PRESCRIPTION DRUG LABEL",
      "effectiveTime": "20210311",
      "title": "EMGALITY",
      "indicationsAndUsage": "\n<h3>1.1 Migraine</h3>\n<p>EMGALITY is indicated for the preventive treatment of migraine in adults.</p>\n<h3>1.2 Episodic Cluster Headache</h3>\n<p>EMGALITY is indicated for the treatment of episodic cluster headache in adults.</p>",
      "dosageAndAdministration": "\n<h3>2.1 Recommended Dosing for Migraine</h3>\n<p>The recommended dosage of EMGALITY is 240 mg, which consists of two consecutive subcutaneous injections of 120 mg each, administered once as a loading dose. This is followed by monthly doses of 120 mg injected subcutaneously.</p>\n<p>If a dose of EMGALITY is missed, it should be administered as soon as possible. Thereafter, EMGALITY can be scheduled monthly from the date of the last dose.</p>\n<h3>2.2 Recommended Dosing for Episodic Cluster Headache</h3>\n<p>The recommended dosage of EMGALITY is 300 mg, which consists of three consecutive subcutaneous injections of 100 mg each, administered at the onset of the cluster period. This is followed by monthly doses until the end of the cluster period.</p>\n<p>If a dose of EMGALITY is missed during a cluster period, it should be administered as soon as possible. Thereafter, EMGALITY can be scheduled monthly from the date of the last dose until the end of the cluster period.</p>\n<h3>2.3 Important Administration Instructions</h3>\n<p>EMGALITY is for subcutaneous use only.</p>\n<p>EMGALITY is intended for patient self-administration. Prior to use, provide proper training to patients and/or caregivers on how to prepare and administer EMGALITY using the single-dose prefilled pen or single-dose prefilled syringe, including aseptic technique:</p>\n<ul>\n<li>Protect EMGALITY from direct sunlight.</li>\n<li>Prior to subcutaneous administration, allow EMGALITY to sit at room temperature for 30 minutes. Do not warm by using a heat source such as hot water or a microwave.</li>\n<li>Do not shake the product.</li>\n<li>Inspect EMGALITY visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use EMGALITY if it is cloudy or there are visible particles.</li>\n<li>Administer EMGALITY in the abdomen, thigh, back of the upper arm, or buttocks subcutaneously. Do not inject into areas where the skin is tender, bruised, red, or hard.</li>\n<li>Both the prefilled pen and prefilled syringe are single-dose and deliver the entire contents.</li>\n</ul>",
      "dosageFormsAndStrengths": "\n<p>EMGALITY is a sterile clear to opalescent, colorless to slightly yellow to slightly brown solution available as follows:</p>\n<ul>\n<li>Injection: 120 mg/mL in a single-dose prefilled pen</li>\n<li>Injection: 120 mg/mL in a single-dose prefilled syringe</li>\n<li>Injection: 100 mg/mL in a single-dose prefilled syringe</li>\n</ul>",
      "warningsAndPrecautions": "\n<h3>5.1 Hypersensitivity Reactions</h3>\n<p>Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with EMGALITY in clinical studies and the postmarketing setting. Cases of anaphylaxis and angioedema have also been reported in the postmarketing setting. If a serious or severe hypersensitivity reaction occurs, discontinue administration of EMGALITY and initiate appropriate therapy [see Contraindications (4), Adverse Reactions (6.1), and Patient Counseling Information (17)]. Hypersensitivity reactions can occur days after administration and may be prolonged.</p>",
      "adverseReactions": "\n<p>The following clinically significant adverse reactions are described elsewhere in the labeling:</p>\n<ul>\n<li>Hypersensitivity Reactions [see Contraindications (4) and Warnings and Precautions (5.1)]</li>\n</ul>\n<h3>6.1 Clinical Trials Experience</h3>\n<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared with rates in clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>\n<p>Migraine</p>\n<p>The safety of EMGALITY has been evaluated in 2586 patients with migraine who received at least one dose of EMGALITY, representing 1487 patient-years of exposure. Of these, 1920 patients were exposed to EMGALITY once monthly for at least 6 months, and 526 patients were exposed for 12 months.</p>\n<p>In placebo-controlled clinical studies (Studies 1, 2, and 3), 705 patients received at least one dose of EMGALITY 120mg once monthly, and 1451 patients received placebo, during 3 months or 6 months of double-blind treatment [see Clinical Studies (14.1)]. Of the EMGALITY-treated patients, approximately 85% were female, 77% were white, and the mean age was 41 years at study entry.</p>\n<p>The most common adverse reaction was injection site reactions. In Studies 1, 2, and 3, 1.8% of patients discontinued double-blind treatment because of adverse events. Table 1 summarizes the adverse reactions that occurred within up to 6 months of treatment in the migraine studies.</p>\n<table>\n<thead>\n<tr>\n<th>Adverse Reaction</th>\n<th>EMGALITY 120mg Monthly (N=705) %</th>\n<th>Placebo Monthly (N=1451) %</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Injection site reactions</td>\n<td>18</td>\n<td>13</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"3\">\n<p>Injection site reactions include multiple related adverse event terms, such as injection site pain, injection site reaction, injection site erythema, and injection site pruritus.</p>\n</td>\n</tr>\n</tfoot>\n</table>\n<p>Episodic Cluster Headache</p>\n<p>EMGALITY was studied for up to 2 months in a placebo-controlled trial in patients with episodic cluster headache (Study 4) [see Clinical Studies (14.2)]. A total of 106 patients were studied (49 on EMGALITY and 57 on placebo). Of the EMGALITY-treated patients, approximately 84% were male, 88% were white, and the mean age was 47 years at study entry. Two EMGALITY-treated patients discontinued double-blind treatment because of adverse events.</p>\n<p>Overall, the safety profile observed in patients with episodic cluster headache treated with EMGALITY 300 mg monthly is consistent with the safety profile in migraine patients.</p>\n<h3>6.2 Immunogenicity</h3>\n<p>As with all therapeutic proteins, there is potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease.</p>\n<p>For these reasons, comparison of the incidence of antibodies to galcanezumab-gnlm in the studies described below with the incidence of antibodies in other studies or to other products may be misleading.</p>\n<p>The immunogenicity of EMGALITY has been evaluated using an in vitro immunoassay for the detection of binding anti-galcanezumab-gnlm antibodies. For patients whose sera tested positive in the screening immunoassay, an in vitro ligand-binding immunoassay was performed to detect neutralizing antibodies.</p>\n<p>In controlled studies with EMGALITY up to 6 months (Study 1, Study 2, and Study 3), the incidence of anti-galcanezumab-gnlm antibody development was 4.8% (33/688) in patients receiving EMGALITY once monthly (32 out of 33 of whom had in vitro neutralizing activity). With 12 months of treatment in an open-label study, up to 12.5% (16/128) of EMGALITY-treated patients developed anti-galcanezumab-gnlm antibodies, most of whom tested positive for neutralizing antibodies.</p>\n<p>Although anti-galcanezumab-gnlm antibody development was not found to affect the pharmacokinetics, safety or efficacy of EMGALITY in these patients, the available data are too limited to make definitive conclusions.</p>\n<h3>6.3 Postmarketing Experience</h3>\n<p>The following adverse reactions have been identified during post-approval use of EMGALITY. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to EMGALITY exposure.</p>\n<p>Immune System Disorders: Anaphylaxis, angioedema [see Contraindications (4) and Warnings and Precautions (5.1)].</p>\n<p>Skin and Subcutaneous Tissue Disorders: Rash.</p>",
      "clinicalPharmacology": "<h1>12 CLINICAL PHARMACOLOGY</h1><h2>12.1 Mechanism of Action</h2><p>Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.</p><h2>12.2 Pharmacodynamics</h2><p>There are no relevant data on the pharmacodynamic effects of galcanezumab-gnlm.</p><h2>12.3 Pharmacokinetics</h2><p>Galcanezumab-gnlm exhibits linear pharmacokinetics and exposure increases proportionally with doses between 1 and 600 mg.</p><p>A loading dose of 240mg achieved the serum galcanezumab-gnlm steady-state concentration after the first dose. A dose of 300mg monthly would achieve steady-state concentration after the fourth dose. The time to maximum concentration is 5 days, and the elimination half-life is 27 days.</p><p>There was no difference in pharmacokinetic parameters between healthy volunteers, patients with episodic or chronic migraine, and patients with episodic cluster headache.</p><p>Absorption</p><p>Following a subcutaneous dose of galcanezumab-gnlm, the time to maximum concentration was about 5 days.</p><p>Injection site location did not significantly influence the absorption of galcanezumab-gnlm.</p><p>Distribution</p><p>The apparent volume of distribution (V/F) of galcanezumab-gnlm was 7.3L (34% Inter Individual Variability [IIV]).</p><p>Metabolism and Elimination</p><p>Galcanezumab-gnlm is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.</p><p>The apparent clearance (CL/F) of galcanezumab-gnlm was 0.008L/h and the elimination half-life of galcanezumab was approximately 27 days.</p><p>Specific Populations</p><p>Age, Sex, Weight, Race, Ethnicity</p><p>The pharmacokinetics of galcanezumab-gnlm were not affected by age, sex, race, subtypes of migraine spectrum (episodic or chronic migraine), or headache diagnosis (migraine vs. episodic cluster headache) based on a population pharmacokinetics analysis. Body weight has no clinically relevant effect on the pharmacokinetics of galcanezumab-gnlm.</p><p>Patients with Renal or Hepatic Impairment</p><p>Renal and hepatic impairment are not expected to affect the pharmacokinetics of galcanezumab-gnlm. Population pharmacokinetic analysis of integrated data from the galcanezumab-gnlm clinical studies revealed that creatinine clearance did not affect the pharmacokinetics of galcanezumab-gnlm in patients with mild or moderate renal impairment. Patients with severe renal impairment (creatinine clearance &lt;30mL/min) have not been studied. Based on a population PK analysis, bilirubin concentration did not significantly influence the CL/F of galcanezumab-gnlm.</p><p>No dedicated clinical studies were conducted to evaluate the effect of hepatic impairment or renal impairment on the pharmacokinetics of galcanezumab-gnlm.</p><p>Drug Interaction Studies</p><p>P450 Enzymes</p><p>Galcanezumab-gnlm is not metabolized by cytochrome P450 enzymes; therefore, interactions with concomitant medications that are substrates, inducers, or inhibitors of cytochrome P450 enzymes are unlikely.</p>",
      "clinicalStudies": "<h1>14 CLINICAL STUDIES</h1><h2>14.1 Migraine</h2><p>The efficacy of EMGALITY was evaluated as a preventive treatment of episodic or chronic migraine in three multicenter, randomized, double-blind, placebo-controlled studies: two 6-month studies in patients with episodic migraine (Studies 1 and 2) and one 3-month study in patients with chronic migraine (Study 3).</p><p>Episodic Migraine</p><p>Study 1 (NCT02614183) and Study 2 (NCT02614196) included adults with a history of episodic migraine (4 to 14 migraine days per month). All patients were randomized in a 1:1:2 ratio to receive once-monthly subcutaneous injections of EMGALITY 120mg, EMGALITY 240mg, or placebo. All patients in the 120 mg EMGALITY group received an initial 240mg loading dose. Patients were allowed to use acute headache treatments, including migraine-specific medications (i.e., triptans, ergotamine derivatives), NSAIDs, and acetaminophen during the study.</p><p>The studies excluded patients on any other migraine preventive treatment, patients with medication overuse headache, patients with ECG abnormalities compatible with an acute cardiovascular event and patients with a history of stroke, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, deep vein thrombosis, or pulmonary embolism within 6 months of screening.</p><p>The primary efficacy endpoint for Studies 1 and 2 was the mean change from baseline in the number of monthly migraine headache days over the 6-month treatment period. Key secondary endpoints included response rates (the mean percentages of patients reaching at least 50%, 75%, and 100% reduction from baseline in the number of monthly migraine headache days over the 6-month treatment period), the mean change from baseline in the number of monthly migraine headache days with use of any acute headache medication during the 6-month treatment period, and the impact of migraine on daily activities, as assessed by the mean change from baseline in the average Migraine-Specific Quality of Life Questionnaire version 2.1 (MSQ v2.1) Role Function-Restrictive domain score during the last 3 months of treatment (Months 4 to 6). Scores are scaled from 0 to 100, with higher scores indicating less impact of migraine on daily activities.</p><p>In Study 1, a total of 858 patients (718 females, 140 males) ranging in age from 18 to 65 years, were randomized. A total of 703 patients completed the 6-month double-blind phase. In Study 2, a total of 915 patients (781 female, 134 male) ranging in age from 18 to 65 years, were randomized. A total of 785 patients completed the 6-month double-blind phase. In Study1 and Study2, the mean migraine frequency at baseline was approximately 9 migraine days per month, and was similar across treatment groups.</p><p>EMGALITY 120mg demonstrated statistically significant improvements for efficacy endpoints compared to placebo over the 6-month period, as summarized in Table 2. EMGALITY treatment with the 240mg once-monthly dose showed no additional benefit over the EMGALITY 120mg once-monthly dose.</p><table><caption>Table 2: Efficacy Endpoints in Studies 1 and 2</caption><tfoot><tr><td colspan=\"5\"><p>a p&lt;0.001</p></td></tr><tr><td colspan=\"5\"><p>b N = 189 for EMGALITY 120 mg and N = 377 for placebo in Study 1; N = 213 for EMGALITY 120 mg and N = 396 for placebo in Study 2.</p></td></tr></tfoot><tbody><tr><td colspan=\"2\">Study 1</td><td colspan=\"2\">Study 2</td></tr><tr><td>EMGALITY120mgN = 210</td><td>PlaceboN = 425</td><td>EMGALITY120mgN = 226</td><td>PlaceboN = 450</td></tr><tr><td colspan=\"5\">Monthly Migraine Headache Days (over Months 1 to 6)</td></tr><tr><td> Baseline migraine headache days</td><td>9.2</td><td>9.1</td><td>9.1</td><td>9.2</td></tr><tr><td> Mean change from baseline</td><td>-4.7</td><td>-2.8</td><td>-4.3</td><td>-2.3</td></tr><tr><td> Difference from placeboa</td><td>-1.9</td><td>-2.0</td></tr><tr><td colspan=\"5\">50% Migraine Headache Days Responders (over Months 1 to 6)</td></tr><tr><td> % Respondersa</td><td>62%</td><td>39%</td><td>59%</td><td>36%</td></tr><tr><td colspan=\"5\">75% Migraine Headache Days Responders (over Months 1 to 6)</td></tr><tr><td> % Respondersa</td><td>39%</td><td>19%</td><td>34%</td><td>18%</td></tr><tr><td colspan=\"5\">100% Migraine Headache Days Responders (over Months 1 to 6)</td></tr><tr><td> % Respondersa</td><td>16%</td><td>6%</td><td>12%</td><td>6%</td></tr><tr><td colspan=\"5\">Monthly Migraine Headache Days that Acute Medication was Taken (over Months 1 to 6)</td></tr><tr><td> Mean change from baseline (days)a</td><td>-4.0</td><td>-2.2</td><td>-3.7</td><td>-1.9</td></tr><tr><td colspan=\"5\">MSQ Role Function-Restrictive Domain Score (over Months 4 to 6)</td></tr><tr><td> Baseline</td><td>51.4</td><td>52.9</td><td>52.5</td><td>51.4</td></tr><tr><td> Mean change from baselineb</td><td>32.4</td><td>24.7</td><td>28.5</td><td>19.7</td></tr><tr><td> Difference from placeboa</td><td>7.7</td><td>8.8</td></tr></tbody></table><p>Figure 1: Change from Baseline in Monthly Migraine Headache Days in Study 1a</p><p>a Least-square means and 95% confidence intervals are presented.</p><p>Figure 2: Change from Baseline in Monthly Migraine Headache Days in Study 2a</p><p>a Least-square means and 95% confidence intervals are presented.</p><p>Figure 3 shows the distribution of change from baseline in the mean number of monthly migraine headache days in bins of 2 days, by treatment group, in Study 1. A treatment benefit over placebo for EMGALITY is seen across a range of changes from baseline in monthly migraine headache days.</p><p>Figure 3: Distribution of Change from Baseline in Mean Monthly Migraine Headache Days over Months 1 to 6 by Treatment Group in Study 1</p><p>Figure 4 shows the distribution of change from baseline in the mean number of monthly migraine headache days in bins of 2 days, by treatment group, in Study 2. A treatment benefit over placebo for EMGALITY is seen across a range of changes from baseline in monthly migraine headache days.</p><p>Figure 4: Distribution of Change from Baseline in Mean Monthly Migraine Headache Days over Months 1 to 6 by Treatment Group in Study 2</p><p>Chronic Migraine</p><p>Study 3 (NCT02614261) included adults with a history of chronic migraine (15 headache days per month with 8migraine days per month). All patients were randomized in a 1:1:2 ratio to receive once-monthly subcutaneous injections of EMGALITY 120mg, EMGALITY 240mg, or placebo over a 3-month treatment period. All patients in the 120mg EMGALITY group received an initial 240mg loading dose.</p><p>Patients were allowed to use acute headache treatments including migraine-specific medications (i.e., triptans, ergotamine derivatives), NSAIDs, and acetaminophen. A subset of patients (15%) was allowed to use one concomitant migraine preventive medication. Patients with medication overuse headache were allowed to enroll.</p><p>The study excluded patients with ECG abnormalities compatible with an acute cardiovascular event, and patients with a history of stroke, myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, deep vein thrombosis, or pulmonary embolism within 6 months of screening.</p><p>The primary endpoint was the mean change from baseline in the number of monthly migraine headache days over the 3-month treatment period. The secondary endpoints were response rates (the mean percentages of patients reaching at least 50%, 75% and 100% reduction from baseline in the number of monthly migraine headache days over the 3-month treatment period), the mean change from baseline in the number of monthly migraine headache days with use of any acute headache medication during the 3-month treatment period, and the impact of migraine on daily activities as assessed by the mean change from baseline in the MSQ v2.1 Role Function-Restrictive domain score at Month 3. Scores are scaled from 0 to 100, with higher scores indicating less impact of migraine on daily activities.</p><p>In Study 3, a total of 1113 patients (946 female, 167 male) ranging in age from 18 to 65 years, were randomized. A total of 1037 patients completed the 3-month double-blind phase. The mean number of monthly migraine headache days at baseline was approximately 19.</p><p>EMGALITY 120mg demonstrated statistically significant improvement for the mean change from baseline in the number of monthly migraine headache days over the 3-month treatment period, and in the mean percentage of patients reaching at least 50% reduction from baseline in the number of monthly migraine headache days over the 3-month treatment period, as summarized in Table 3. EMGALITY treatment with the 240mg once-monthly dose showed no additional benefit over the EMGALITY 120mg once-monthly dose.</p><table><caption>Table 3: Efficacy Endpoints in Study 3</caption><tfoot><tr><td colspan=\"3\"><p>a p&lt;0.001</p></td></tr></tfoot><tbody><tr><td>EMGALITY120mgN = 273</td><td>PlaceboN =538</td></tr><tr><td colspan=\"3\">Monthly Migraine Headache Days (over Months 1 to 3)</td></tr><tr><td> Baseline migraine headache days</td><td>19.4</td><td>19.6</td></tr><tr><td> Mean change from baseline</td><td>-4.8</td><td>-2.7</td></tr><tr><td> Difference from placeboa</td><td>-2.1</td></tr><tr><td colspan=\"3\">50% Migraine Headache Days Responders (over Months 1 to 3)</td></tr><tr><td> % Respondersa</td><td>28%</td><td>15%</td></tr></tbody></table><p>Study 3 utilized a sequential testing procedure to control the Type-I error rate for the multiple secondary endpoints. Once a secondary endpoint failed to reach the required level for statistical significance, formal hypothesis testing was terminated for subsequent endpoints, and p-values were considered nominal only. In Study 3, EMGALITY 120mg was not significantly better than placebo for the proportion of patients with 75% or 100% reduction in migraine headache days. Patients treated with EMGALITY 120mg showed a nominally greater reduction in the number of monthly migraine headache days that acute medication was taken (-4.7 for EMGALITY 120 mg vs. -2.2 for placebo; nominal p-value &lt;0.001), and the mean change from baseline in the MSQ Role Function-Restrictive Domain score at Month 3 was nominally greater in patients treated with EMGALITY 120mg than in patients on placebo (21.8 for EMGALITY 120mg vs. 16.8 for placebo; nominal p-value&lt;0.001).</p><p>Figure 5: Change from Baseline in Monthly Migraine Headache Days in Study 3a</p><p>a Least-square means and 95% confidence intervals are presented.</p><p>Figure 6 shows the distribution of change from baseline in the mean number of monthly migraine headache days for the 3-month study period in bins of 3 days by treatment group. A treatment benefit over placebo for EMGALITY is seen across a range of changes from baseline in monthly migraine headache days.</p><p>Figure 6: Distribution of Change from Baseline in Mean Monthly Migraine Headache Days over Months 1 to 3 by Treatment Group in Study 3</p><h2>14.2 Episodic Cluster Headache</h2><p>The efficacy of EMGALITY was evaluated for the treatment of episodic cluster headache in a randomized, 8-week, double-blind, placebo-controlled study (Study 4).</p><p>Study 4 (NCT02397473) included adults who met the International Classification of Headache Disorders 3rd edition (beta version) diagnostic criteria for episodic cluster headache and had a maximum of 8 attacks per day, a minimum of one attack every other day, and at least 4attacks during the prospective 7-day baseline period. All patients were randomized in a 1:1 ratio to receive once-monthly subcutaneous injections of EMGALITY 300mg or placebo. Patients were allowed to use certain specified acute/abortive cluster headache treatments, including triptans, oxygen, acetaminophen, and NSAIDs during the study.</p><p>The study excluded patients on other treatments intended to reduce the frequency of cluster headache attacks; patients with medication overuse headache; patients with ECG abnormalities compatible with an acute cardiovascular event or conduction delay; and patients with a history of myocardial infarction, unstable angina, percutaneous coronary intervention, coronary artery bypass grafting, deep vein thrombosis, or pulmonary embolism within 6 months of screening. In addition, patients with any history of stroke, intracranial or carotid aneurysm, intracranial hemorrhage, or vasospastic angina; clinical evidence of peripheral vascular disease; or diagnosis of Raynauds disease were excluded.</p><p>The primary efficacy endpoint for Study 4 was the mean change from baseline in weekly cluster headache attack frequency across Weeks 1 to 3. A secondary endpoint was the percentage of patients who achieved a response (defined as a reduction from baseline of 50% or greater in the weekly cluster headache attack frequency) at Week 3.</p><p>In Study 4, a total of 106 patients (88 males, 18 females) ranging in age from 19 to 65 years were randomized and treated. A total of 90 patients completed the 8-week double-blind phase. In the prospective baseline phase, the mean number of weekly cluster headache attacks was 17.5, and was similar across treatment groups.</p><p>EMGALITY 300mg demonstrated statistically significant improvements for efficacy endpoints compared to placebo, as summarized in Table 4.</p><table><caption>Table 4: Efficacy Endpoints in Study 4</caption><tbody><tr><td>EMGALITY300mgN = 49</td><td>PlaceboN = 57</td></tr><tr><td colspan=\"3\">Mean Reduction in Weekly Cluster Headache Attack Frequency (over Weeks 1 to 3)</td></tr><tr><td> Prospective Baseline Cluster Headache Attack Frequency</td><td>17.8</td><td>17.3</td></tr><tr><td> Mean change from baseline</td><td>-8.7</td><td>-5.2</td></tr><tr><td> Difference from placebo</td><td>-3.5</td></tr><tr><td> p-value</td><td>0.036</td></tr><tr><td colspan=\"3\">50% Weekly Cluster Headache Attack Frequency Responders (at Week 3)</td></tr><tr><td> % Responders</td><td>71.4%</td><td>52.6%</td></tr><tr><td> Difference from placebo</td><td>18.8%</td></tr><tr><td> p-value</td><td>0.046</td></tr></tbody></table><p>Figure 7: Mean Change in Weekly Cluster Headache Attack Frequency over Weeks 1 to 3 in Study 4a</p><p>a Abbreviations: BL = baseline; LS = least square; SE = standard error.</p><p>Figure 8 shows the distribution of the average percent change from baseline in weekly cluster headache attack frequency across Weeks 1 to 3 in bins of 25%, by treatment group, in Study 4.</p><p>Figure 8: Distribution of the Average Percent Change from Baseline in Weekly Cluster Headache Attack Frequency over Weeks 1 to 3 in Study 4a</p><p>a N = number of intent to treat patients with non-missing average percentage change from baseline in weekly cluster headache attack frequency over weeks 1 to 3.</p>",
      "howSupplied": "<h2>16.1 How Supplied</h2><p>EMGALITY (galcanezumab-gnlm) injection is a sterile, preservative-free, clear to opalescent, colorless to slightly yellow to slightly brown solution for subcutaneous administration.</p><p>EMGALITY is not made with natural rubber latex.</p><p>EMGALITY is supplied as follows:</p><table><tbody><tr><td>Pack Size</td><td>NDC</td></tr><tr><td colspan=\"3\">Prefilled pen</td></tr><tr><td>120mg/mL single-dose</td><td>Carton of 1</td><td>0002-1436-11</td></tr><tr><td>120mg/mL single-dose</td><td>Carton of 2</td><td>0002-1436-27</td></tr><tr><td colspan=\"3\">Prefilled syringe</td></tr><tr><td>100mg/mL single-dose</td><td>Carton of 3</td><td>0002-3115-09</td></tr><tr><td>120mg/mL single-dose</td><td>Carton of 1</td><td>0002-2377-11</td></tr><tr><td>120mg/mL single-dose</td><td>Carton of 2</td><td>0002-2377-27</td></tr></tbody></table>",
      "useInSpecificPopulations": "<h1>8 USE IN SPECIFIC POPULATIONS</h1><h2>8.1 Pregnancy</h2><p>Pregnancy Exposure Registry</p><p>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to EMGALITY during pregnancy. Healthcare providers are encouraged to register pregnant patients, or pregnant women may enroll themselves in the registry by calling 1-833-464-4724 or by contacting the company at www.migrainepregnancyregistry.com.</p><p>Risk Summary</p><p>There are no adequate data on the developmental risk associated with the use of EMGALITY in pregnant women. Administration of galcanezumab-gnlm to rats and rabbits during the period of organogenesis or to rats throughout pregnancy and lactation at plasma exposures greater than that expected clinically did not result in adverse effects on development (see Animal Data).</p><p>In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% - 4% and 15% - 20%, respectively. The estimated rate of major birth defects (2.2% - 2.9%) and miscarriage (17%) among deliveries to women with migraine are similar to rates reported in women without migraine.</p><p>Clinical Considerations</p><p>Disease-Associated Maternal and/or Embryo/Fetal Risk</p><p>Published data have suggested that women with migraine may be at increased risk of preeclampsia during pregnancy.</p><p>Data</p><p>Animal Data</p><p>When galcanezumab-gnlm was administered to female rats by subcutaneous injection in two studies (0, 30, or 100mg/kg; 0 or 250mg/kg) prior to and during mating and continuing throughout organogenesis, no adverse effects on embryofetal development were observed. The highest dose tested (250mg/kg) was associated with a plasma exposure (Cave,ss) 38 or 18times that in humans at the recommended human dose (RHD) for migraine (120mg) or episodic cluster headache (300mg), respectively. Administration of galcanezumab-gnlm (0, 30, or 100mg/kg) by subcutaneous injection to pregnant rabbits throughout the period of organogenesis produced no adverse effects on embryofetal development. The higher dose tested was associated with a plasma Cave, ss 64 or 29times that in humans at 120mg or 300mg, respectively.</p><p>Administration of galcanezumab-gnlm (0, 30, or 250mg/kg) by subcutaneous injection to rats throughout pregnancy and lactation produced no adverse effects on pre- and postnatal development. The higher dose tested was associated with a plasma Cave, ss 34 or 16times that in humans at 120mg or 300mg, respectively.</p><h2>8.2 Lactation</h2><p>Risk Summary</p><p>There are no data on the presence of galcanezumab-gnlm in human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EMGALITY and any potential adverse effects on the breastfed infant from EMGALITY or from the underlying maternal condition.</p><h2>8.4 Pediatric Use</h2><p>Safety and effectiveness in pediatric patients have not been established.</p><h2>8.5 Geriatric Use</h2><p>Clinical studies of EMGALITY did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients.</p>",
      "description": "<p>Galcanezumab-gnlm is a humanized IgG4 monoclonal antibody specific for calcitonin-gene related peptide (CGRP) ligand, produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. It consists of two identical immunoglobulin kappa light chains and two identical immunoglobulin gamma heavy chains, with a molecular weight of approximately 147kDa. EMGALITY (galcanezumab-gnlm) injection is a sterile, preservative-free solution for subcutaneous use, supplied in a 1mL single-dose prefilled pen or syringe delivering 100mg or 120mg of galcanezumab-gnlm. Each mL contains L-histidine (0.5mg), L-histidine hydrochloride monohydrate (1.5mg), Polysorbate 80 (0.5mg), Sodium Chloride (8.8mg), and Water for Injection, USP, with a pH range of 5.3 - 6.3.</p>",
      "nonclinicalToxicology": "<h1>13 NONCLINICAL TOXICOLOGY</h1><h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><p>Carcinogenesis</p><p>The carcinogenic potential of galcanezumab-gnlm has not been assessed.</p><p>Mutagenesis</p><p>Genetic toxicology studies of galcanezumab-gnlm have not been conducted.</p><p>Impairment of Fertility</p><p>When galcanezumab-gnlm (0, 30, or 250mg/kg) was administered to male rats by subcutaneous injection prior to and during mating, no adverse effects on fertility was observed. The higher dose tested was associated with a plasma exposure (Cave, ss) 8 or 4times that in humans at the recommended human dose (RHD) for migraine (120mg) or episodic cluster headache (300mg), respectively. When galcanezumab-gnlm was administered to female rats by subcutaneous injection in two studies (0, 30, or 100mg/kg; 0 or 250mg/kg) prior to and during mating and continuing throughout organogenesis, no adverse effects on fertility were observed. The highest dose tested (250mg/kg) was associated with a plasma Cave, ss 38 or 18times that in humans at 120mg or 300mg, respectively.</p>",
      "instructionsForUse": "<table><tbody><tr><td>INSTRUCTIONS FOR USE</td></tr><tr><td>EMGALITY (em-GAL-it-)</td></tr><tr><td>(galcanezumab-gnlm)</td></tr><tr><td>injection, for subcutaneous use</td></tr><tr><td>Prefilled Syringe</td></tr><tr><td>This Instructions for Use is for patients with episodic cluster headache.</td></tr><tr><td><ul><li>If you are using EMGALITY for preventive treatment of migraine, there is a different Instructions for Use because the dose and number of syringes needed is different.</li></ul></td></tr><tr><td>For subcutaneous injection only.</td></tr><tr><td>Before you use the EMGALITY prefilled syringe, read and carefully follow all the step-by-step instructions.</td></tr><tr><td>Important Information</td></tr><tr><td><ul><li>Your healthcare provider or nurse should show you how to prepare and inject EMGALITY using the prefilled syringe. Do not inject yourself or someone else until you have been shown how to inject EMGALITY.</li></ul></td></tr><tr><td><ul><li>Keep this Instructions for Use and refer to it as needed.</li></ul></td></tr><tr><td><ul><li>Each EMGALITY prefilled syringe is for one-time use only. Do not share or reuse your EMGALITY prefilled syringe. You may give or get an infection.</li></ul></td></tr><tr><td><ul><li>Your healthcare provider may help you decide where on your body to inject your dose. You can also read the Choose your injection site section of these instructions to help you choose which area can work best for you.</li></ul></td></tr><tr><td><ul><li>If you have vision problems, do not use EMGALITY prefilled syringe without help from a caregiver.</li></ul></td></tr><tr><td><ul><li>See Storage and Handling Information for important storage information.</li></ul></td></tr></tbody></table><table><tbody><tr><td>INSTRUCTIONS FOR USE</td></tr><tr><td>Before you use the EMGALITY prefilled syringe, read and carefully follow all the step-by-step instructions.</td></tr><tr><td>Parts of the EMGALITY Prefilled Syringe</td></tr></tbody></table><table><tbody><tr><td colspan=\"2\">Before You Get Started</td></tr><tr><td>Take the Prefilled Syringes from the refrigerator</td><td>Take 3 EMGALITY prefilled syringes from the refrigerator.</td></tr><tr><td>Check your prescription.<ul><li>EMGALITY comes as a single-dose prefilled syringe.</li><li>You will need 3 prefilled syringes for each dose.</li></ul></td></tr><tr><td>Leave the needle caps on until you are ready to inject.</td></tr><tr><td>Leave the prefilled syringes at room temperature for 30 minutes before injecting.</td></tr><tr><td>Do not microwave the prefilled syringes, run hot water over them, or leave them in direct sunlight.</td></tr><tr><td>Do not shake.</td></tr><tr><td>Gather Supplies</td><td>For each injection you will need: <ul><li>1 alcohol wipe</li><li>1 cotton ball or piece of gauze</li><li>1 sharps disposal container. See After You Inject Your Medicine.</li></ul></td></tr><tr><td>Inspect the Prefilled Syringe and the medicine</td><td>Make sure you have the right medicine. The medicine inside should be clear. Its color may be colorless to slightly yellow to slightly brown.</td></tr><tr><td>Do not use the prefilled syringe, and throw away (dispose of) as directed by your healthcare provider or pharmacist if:<ul><li>it looks damaged</li><li>the medicine is cloudy, is discolored, or has small particles</li><li>the Expiration Date (Exp.) printed on the label has passed</li><li>the medicine is frozen</li></ul></td></tr><tr><td>Expiration Date</td></tr><tr><td>Prepare for injection</td><td>Wash your hands with soap and water before you inject your EMGALITY. Make sure a sharps disposal container is close by.</td></tr></tbody></table><table><tbody><tr><td><p>Choose your injection site</p></td><td>Your healthcare provider can help you choose the injection site that is best for you.</td></tr><tr><td><ul><li>You may inject the medicine into your stomach area (abdomen). Do not inject within 2 inches of the belly button (navel).</li></ul></td></tr><tr><td><ul><li>You may inject the medicine into the front of your thighs. This area should be at least 2 inches above the knee and 2 inches below the groin.</li></ul></td></tr><tr><td><ul><li>Another person may give you the injection in the back of your upper arm or buttocks.</li></ul></td></tr><tr><td><ul><li>Do not inject in the exact same spot. For example, if your first injection was in your abdomen, your next injection could be in another area of your abdomen.</li></ul></td></tr><tr><td><ul><li>Do not inject into areas where the skin is tender, bruised, red, or hard.</li></ul></td></tr><tr><td><ul><li>Clean your injection site with an alcohol wipe. Let the injection site dry before you inject.</li></ul></td></tr></tbody></table><table><tbody><tr><td rowspan=\"5\">1</td><td colspan=\"3\">Uncap</td></tr><tr><td colspan=\"3\"><ul><li>Leave the needle cap on until you are ready to inject.</li></ul></td></tr><tr><td colspan=\"3\"><ul><li> Pull the needle cap off and throw it away in your household trash.</li></ul></td></tr><tr><td colspan=\"3\"><ul><li>Do not put the needle cap back on. You could damage the needle or stick yourself by accident.</li></ul></td></tr><tr><td colspan=\"3\"><ul><li>Do not touch the needle.</li></ul></td></tr><tr><td>2</td><td colspan=\"3\">Insert</td></tr><tr><td colspan=\"3\"><ul><li>Gently pinch and hold a fold of skin where you will inject.</li></ul></td></tr><tr><td colspan=\"3\"><ul><li>Insert the needle at a 45-degree angle.</li></ul></td></tr><tr><td rowspan=\"5\">3</td><td colspan=\"3\">Inject</td></tr><tr><td colspan=\"3\"><ul><li>Slowly push on the thumb pad to push the plunger all the way in until all the medicine is injected.</li><li>The gray syringe plunger should be pushed all the way to the needle end of the syringe.</li></ul></td></tr><tr><td colspan=\"3\"><ul><li>You should see the coral plunger rod show through the syringe body when the injection is complete as shown.</li><li>Remove the needle from your skin and gently let go of your skin.</li><li>If you have bleeding at the injection site, press a cotton ball or gauze over the injection site. Do not rub the injection site.</li><li>Do not put the needle cap back on the prefilled syringe.</li></ul></td></tr><tr><td colspan=\"5\"><p>After You Inject Your Medicine</p></td></tr><tr><td colspan=\"5\">Throw away the used prefilled syringe</td></tr><tr><td colspan=\"3\"><ul><li>Put the used EMGALITY prefilled syringe in an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) the EMGALITY prefilled syringe in your household trash.</li></ul></td></tr><tr><td colspan=\"5\"><ul><li>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:</li></ul></td></tr><tr><td colspan=\"3\"><dl><dd>made of a heavy-duty plastic,</dd></dl></td></tr><tr><td colspan=\"3\"><dl><dd>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</dd></dl></td></tr><tr><td colspan=\"3\"><dl><dd>upright and stable during use,</dd></dl></td></tr><tr><td colspan=\"3\"><dl><dd>leak-resistant, and</dd></dl></td></tr><tr><td colspan=\"3\"><dl><dd>properly labeled to warn of hazardous waste inside the container.</dd></dl></td></tr><tr><td colspan=\"5\"><ul><li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.</li></ul></td></tr><tr><td colspan=\"5\"><ul><li>Do not recycle your used sharps disposal container.</li></ul></td></tr><tr><td colspan=\"5\">For each of the 3 injections, repeat all instructions with a new prefilled syringe.</td></tr></tbody></table><table><tbody><tr><td colspan=\"3\">Commonly Asked Questions</td></tr><tr><td>Q.</td><td colspan=\"2\">What if I see air bubbles in my EMGALITY prefilled syringe?</td></tr><tr><td>A.</td><td colspan=\"2\">It is normal to have air bubbles in the prefilled syringe. EMGALITY is injected under your skin (subcutaneous injection), so these air bubbles will not harm you.</td></tr><tr><td>Q.</td><td colspan=\"2\">What if there is a drop of liquid on the tip of the needle when I remove the needle cap?</td></tr><tr><td>A.</td><td colspan=\"2\">It is okay to see a drop of liquid on the tip of the needle.</td></tr><tr><td>Q.</td><td colspan=\"2\">What if I cannot push in the plunger?</td></tr><tr><td>A.</td><td colspan=\"2\">If the plunger is stuck or damaged:</td></tr><tr><td colspan=\"2\"><ul><li>Do not continue to use the syringe</li></ul></td></tr><tr><td colspan=\"2\"><ul><li>Remove the needle from your skin</li></ul></td></tr><tr><td colspan=\"2\"><ul><li>Dispose of the syringe and get a new one</li></ul></td></tr><tr><td>Q.</td><td colspan=\"2\">What if there is a drop of liquid or blood on my skin after my injection?</td></tr><tr><td>A.</td><td colspan=\"2\">This is normal. Press a cotton ball or gauze over the injection site. Do not rub the injection site.</td></tr><tr><td>Q.</td><td colspan=\"2\">How can I tell if my injection is complete?</td></tr><tr><td>A.</td><td colspan=\"2\">When your injection is complete:</td></tr><tr><td colspan=\"2\"><ul><li>The coral plunger rod should show through the body of the syringe.</li></ul></td></tr><tr><td colspan=\"2\"><ul><li>The gray syringe plunger should be pushed all the way to the needle end of the syringe.</li></ul></td></tr><tr><td colspan=\"3\">If you have more questions about how to use the EMGALITY prefilled syringe:</td></tr><tr><td><ul><li>Call your healthcare provider</li></ul></td></tr><tr><td><ul><li>Call 1-833-EMGALITY (1-833-364-2548)</li></ul></td></tr><tr><td><ul><li>Visit www.emgality.com</li></ul></td></tr></tbody></table><table><tbody><tr><td><p>Storage and Handling Information</p></td></tr><tr><td colspan=\"2\"><ul><li>Store your prefilled syringes in the refrigerator between 36F to 46F (2C to 8C).</li></ul></td></tr><tr><td colspan=\"2\"><ul><li>Your prefilled syringes may be stored out of the refrigerator in the original carton at temperatures up to 86F (30C) for up to 7 days. After storing out of the refrigerator, do not place EMGALITY back in the refrigerator.</li></ul></td></tr><tr><td colspan=\"2\"><ul><li>Do not freeze your prefilled syringes.</li></ul></td></tr><tr><td colspan=\"2\"><ul><li>Keep your prefilled syringes in the carton they come in to protect them from light until time of use.</li></ul></td></tr><tr><td colspan=\"2\"><ul><li>Do not shake your prefilled syringes.</li></ul></td></tr><tr><td colspan=\"2\"><ul><li>Throw away your prefilled syringes if any of the above conditions are not followed.</li></ul></td></tr><tr><td colspan=\"2\"><ul><li>Keep your prefilled syringes and all medicines out of the reach of children.</li></ul></td></tr><tr><td colspan=\"2\">Read the full Prescribing Information and Patient Information for EMGALITY inside this box to learn more about your medicine.</td></tr></tbody></table><table><tbody><tr><td colspan=\"3\">This Instructions for Use has been approved by the U.S. Food and Drug Administration.</td></tr><tr><td colspan=\"3\">Eli Lilly and Company</td></tr><tr><td colspan=\"3\">Indianapolis, IN 46285, USA</td></tr><tr><td colspan=\"3\">US License Number 1891</td></tr><tr><td colspan=\"3\">EMGALITY is a registered trademark of Eli Lilly and Company.</td></tr><tr><td colspan=\"3\">Copyright 2019, Eli Lilly and Company. All rights reserved.</td></tr><tr><td colspan=\"3\">Issued: 06/2019</td></tr><tr><td colspan=\"3\">EMG-0001-PFS-100MG-IFU-20190604</td></tr></tbody></table>",
      "mechanismOfAction": "<h2>12.1 Mechanism of Action</h2><p>Galcanezumab-gnlm is a humanized monoclonal antibody that binds to calcitonin gene-related peptide (CGRP) ligand and blocks its binding to the receptor.</p>",
      "contraindications": "<p>EMGALITY is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients. See Warnings and Precautions section 5.1 for more information.</p>",
      "highlights": {
        "dosageAndAdministration": "<ul><li>For subcutaneous use only. (2.1, 2.2, 2.3)</li><li>Migraine recommended dosage: 240mg loading dose (administered as two consecutive injections of 120mg each), followed by monthly doses of 120mg. (2.1)</li><li>Episodic cluster headache recommended dosage: 300mg (administered as three consecutive injections of 100mg each) at the onset of the cluster period, and then monthly until the end of the cluster period. (2.2)</li><li>Administer in the abdomen, thigh, back of the upper arm, or buttocks subcutaneously. (2.3)</li></ul>"
      },
      "metaDescription": "<p>Galcanezumab-gnlm is a humanized IgG4 monoclonal antibody for CGRP ligand, produced in CHO cells. EMGALITY is a sterile injection for subcutaneous use.</p>",
      "useAndConditions": "<p><h3>Approved Indications</h3></p>\n<ul>\n<li>Preventive treatment of migraine in adults</li>\n<li>Treatment of episodic cluster headache in adults</li>\n</ul>",
      "contraIndications": "<h3>Contraindications</h3>\n<ul>\n<li>Serious hypersensitivity to galcanezumab-gnlm or to any of the excipients</li>\n</ul>",
      "warnings": "<h3>Warnings and Precautions</h3>\n<ul>\n<li>Hypersensitivity reactions, including dyspnea, urticaria, and rash, have occurred with EMGALITY in clinical studies and the postmarketing setting.</li>\n<li>Cases of anaphylaxis and angioedema have been reported in the postmarketing setting.</li>\n<li>If a serious or severe hypersensitivity reaction occurs, discontinue administration of EMGALITY and initiate appropriate therapy.</li>\n<li>Hypersensitivity reactions can occur days after administration and may be prolonged.</li>\n</ul>",
      "dosing": "<p><h3>Adult Dosing for Migraine</h3></p>\n<ul>\n<li>Loading dose: 240 mg, consisting of two consecutive subcutaneous injections of 120 mg each, administered once.</li>\n<li>Maintenance dose: 120 mg injected subcutaneously monthly.</li>\n<li>If a dose is missed, administer as soon as possible and schedule monthly from the date of the last dose.</li>\n</ul>\n\n<p><h3>Adult Dosing for Episodic Cluster Headache</h3></p>\n<ul>\n<li>Initial dose: 300 mg, consisting of three consecutive subcutaneous injections of 100 mg each, administered at the onset of the cluster period.</li>\n<li>Follow-up doses: Administer monthly until the end of the cluster period.</li>\n<li>If a dose is missed during a cluster period, administer as soon as possible and schedule monthly from the date of the last dose until the end of the cluster period.</li>\n</ul>\n\n<p><h3>Important Administration Instructions</h3></p>\n<ul>\n<li>EMGALITY is for subcutaneous use only.</li>\n<li>Intended for patient self-administration with proper training on preparation and administration using the single-dose prefilled pen or syringe.</li>\n<li>Allow EMGALITY to sit at room temperature for 30 minutes before administration. Do not warm using a heat source.</li>\n<li>Do not shake the product.</li>\n<li>Inspect visually for particulate matter and discoloration. Do not use if cloudy or if particles are visible.</li>\n<li>Administer in the abdomen, thigh, back of the upper arm, or buttocks. Avoid areas where the skin is tender, bruised, red, or hard.</li>\n<li>Both the prefilled pen and syringe are single-dose and deliver the entire contents.</li>\n</ul>"
    }
  },
  {
    "drugName": "Olumiant",
    "setId": "866e9f35-9035-4581-a4b1-75a621ab55cf",
    "slug": "olumiant-866e9f3",
    "labeler": "Eli Lilly and Company",
    "label": {
      "boxedWarning": "<h2>WARNING: SERIOUS INFECTIONS, MORTALITY, MALIGNANCY, MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE), and THROMBOSIS</h2><h2>See full prescribing information for complete boxed warning.</h2><ul><li>Increased risk of serious bacterial, fungal, viral and opportunistic infections leading to hospitalization or death, including tuberculosis (TB). Interrupt treatment with OLUMIANT if serious infection occurs until the infection is controlled. OLUMIANT should not be given to patients with active tuberculosis. Test for latent TB before and during therapy, except for COVID-19; treat latent TB prior to use. Monitor all patients for active TB during treatment, even patients with initial negative, latent TB test. (5.1)</li><li>Higher rate of all-cause mortality, including sudden cardiovascular death with another Janus kinase inhibitor (JAK) vs. TNF blockers in rheumatoid arthritis (RA) patients. (5.2)</li><li>Malignancies have occurred in patients treated with OLUMIANT. Higher rate of lymphomas and lung cancers with another JAK inhibitor vs. TNF blockers in RA patients. (5.3)</li><li>Higher rate of MACE (defined as cardiovascular death, myocardial infarction, and stroke) with another JAK inhibitor vs. TNF blockers in RA patients. (5.4)</li><li>Thrombosis has occurred in patients treated with OLUMIANT. Increased incidence of pulmonary embolism, venous and arterial thrombosis with another JAK inhibitor vs. TNF blockers. (5.5)</li></ul>",
      "genericName": "baricitinib",
      "labelerName": "Eli Lilly and Company",
      "productType": "HUMAN PRESCRIPTION DRUG LABEL",
      "effectiveTime": "20241113",
      "title": "Olumiant",
      "indicationsAndUsage": "\n<h3>1.1 Rheumatoid Arthritis</h3>\n<p>OLUMIANT (baricitinib) is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.</p>\n<p>Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic disease-modifying antirheumatic drugs (DMARDs), or with potent immunosuppressants such as azathioprine and cyclosporine.</p>\n<h3>1.2 Coronavirus Disease 2019 (COVID-19)</h3>\n<p>OLUMIANT is indicated for the treatment of coronavirus disease 2019 (COVID-19) in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).</p>\n<h3>1.3 Alopecia Areata</h3>\n<p>OLUMIANT is indicated for the treatment of adult patients with severe alopecia areata.</p>\n<p>Limitations of Use: Not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants.</p>",
      "dosageAndAdministration": "\n<h3>2.1 Recommended Evaluations and Immunization Prior to Treatment Initiation</h3>\n<p>Prior to OLUMIANT treatment initiation, consider performing the following evaluations:</p>\n<ul>\n<li>Active and latent tuberculosis (TB) infection evaluation. OLUMIANT should not be given to patients with active tuberculosis (TB). If latent infection is positive in patients with rheumatoid arthritis or alopecia areata, consider treatment for TB prior to OLUMIANT use [see Warnings and Precautions (5.1)].</li>\n<li>Viral hepatitis screening in accordance with clinical guidelines [see Warnings and Precautions (5.1)].</li>\n<li>Complete blood count. Assess baseline values and verify whether treatment can be initiated:\n        <ul>\n<li>In patients with rheumatoid arthritis or alopecia areata, OLUMIANT initiation is not recommended in patients with an absolute lymphocyte count (ALC) less than 500 cells/l, absolute neutrophil count (ANC) less than 1000 cells/l, or hemoglobin level less than 8 g/dL.</li>\n<li>In patients with COVID-19, OLUMIANT initiation is not recommended if the ALC is less than 200 cells/l or if the ANC is less than 500 cells/l.</li>\n</ul>\n        Monitor complete blood counts during treatment and modify dosage as recommended [see Dosage and Administration (2.5) and Warnings and Precautions (5.7)].\n    </li>\n<li>Baseline hepatic and renal function. Assess baseline values and monitor patients for laboratory changes. Modify dosage based on hepatic and renal impairment, and laboratory abnormalities [see Dosage and Administration (2.5) and Warnings and Precautions (5.7)].</li>\n</ul>\n<p>In patients with rheumatoid arthritis or alopecia areata, update immunizations in agreement with current immunization guidelines [see Warnings and Precautions (5.9)].</p>\n<h3>2.2 Dosage Recommendations in Rheumatoid Arthritis</h3>\n<p>The recommended dosage of OLUMIANT is 2 mg once daily orally, with or without food [see Clinical Pharmacology (12.3)]. An alternative administration for patients unable to swallow tablets may be used [see Dosage and Administration (2.8)]. OLUMIANT may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.</p>\n<h3>2.3 Dosage Recommendations in COVID-19</h3>\n<p>The recommended dosage of OLUMIANT for adults is 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first. An alternative administration for patients unable to swallow tablets may be used [see Dosage and Administration (2.8)].</p>\n<h3>2.4 Dosage Recommendations in Alopecia Areata</h3>\n<p>The recommended dosage of OLUMIANT is 2 mg once daily orally, with or without food. Increase to 4 mg once daily if the response to treatment is not adequate.</p>\n<p>For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4 mg once daily, with or without food.</p>\n<p>Once patients achieve an adequate response to treatment with 4 mg, decrease the dosage to 2 mg once daily.</p>\n<h3>2.5 Dosage Modifications Due to Infections, Cytopenias and Anemia</h3>\n<p>Rheumatoid Arthritis and Alopecia Areata</p>\n<ul>\n<li>Avoid use of OLUMIANT in patients with active, serious or opportunistic infection, including localized infections. If a patient develops a serious infection, hold treatment with OLUMIANT until the infection is controlled [see Warnings and Precautions (5.1)].</li>\n<li>Dosage modifications for patients with rheumatoid arthritis or alopecia areata and cytopenias or anemia are described in Table 1.</li>\n</ul>\n<table>\n<caption>Table 1: Dosage Modifications for Cytopenias and Anemia in Patients with Rheumatoid Arthritis or Alopecia Areata</caption>\n<thead>\n<tr>\n<th>Laboratory Analyte</th>\n<th>Laboratory Analyte Value</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td rowspan=\"2\">Absolute Lymphocyte Count (ALC)</td>\n<td>500 cells/L</td>\n<td>Maintain dosage</td>\n</tr>\n<tr>\n<td>&lt;500 cells/L</td>\n<td>Interrupt OLUMIANT until ALC 500 cells/L</td>\n</tr>\n<tr>\n<td rowspan=\"2\">Absolute Neutrophil Count (ANC)</td>\n<td>1000 cells/L</td>\n<td>Maintain dosage</td>\n</tr>\n<tr>\n<td>&lt;1000 cells/L</td>\n<td>Interrupt OLUMIANT until ANC 1000 cells/L</td>\n</tr>\n<tr>\n<td rowspan=\"2\">Hemoglobin</td>\n<td>8 g/dL</td>\n<td>Maintain dosage</td>\n</tr>\n<tr>\n<td>&lt;8 g/dL</td>\n<td>Interrupt OLUMIANT until hemoglobin 8 g/dL</td>\n</tr>\n</tbody>\n</table>\n<p>COVID-19</p>\n<ul>\n<li>Monitor patients for signs and symptoms of new infections during treatment with OLUMIANT. The risks and benefits of treatment with OLUMIANT in COVID-19 patients with other concurrent infections should be considered [see Warnings and Precautions (5.1)].</li>\n<li>Dosage modifications for patients with COVID-19 and cytopenias are described in Table 2.</li>\n</ul>\n<table>\n<caption>Table 2: Dosage Modifications for Cytopenias in Patients with COVID-19</caption>\n<thead>\n<tr>\n<th>Laboratory Analyte</th>\n<th>Laboratory Analyte Value</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td rowspan=\"2\">Absolute Lymphocyte Count (ALC)</td>\n<td>200 cells/L</td>\n<td>Maintain dosage</td>\n</tr>\n<tr>\n<td>&lt;200 cells/L</td>\n<td>Interrupt OLUMIANT until ALC 200 cells/L</td>\n</tr>\n<tr>\n<td rowspan=\"2\">Absolute Neutrophil Count (ANC)</td>\n<td>500 cells/L</td>\n<td>Maintain dosage</td>\n</tr>\n<tr>\n<td>&lt;500 cells/L</td>\n<td>Interrupt OLUMIANT until ANC 500 cells/L</td>\n</tr>\n</tbody>\n</table>\n<h3>2.6 Dosage Modifications for Patients with Renal Impairment or Hepatic Impairment</h3>\n<p>Rheumatoid Arthritis</p>\n<p>Renal Impairment</p>\n<p>Dosage modifications for patients with rheumatoid arthritis and renal impairment are described in Table 3.</p>\n<table>\n<caption>Table 3: Dosage Modifications for Patients with Rheumatoid Arthritis and Renal Impairment</caption>\n<thead>\n<tr>\n<th>Renal Impairment Stage</th>\n<th>Estimated Glomerular Filtration Rate (eGFR)</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Mild</td>\n<td>60 &lt;90 mL/minute/1.73 m<sup>2</sup></td>\n<td>2 mg once daily</td>\n</tr>\n<tr>\n<td>Moderate</td>\n<td>30 - &lt;60 mL/min/1.73 m<sup>2</sup></td>\n<td>1 mg once daily</td>\n</tr>\n<tr>\n<td>Severe</td>\n<td>&lt;30 mL/minute/1.73 m<sup>2</sup></td>\n<td>Not recommended</td>\n</tr>\n</tbody>\n</table>\n<p>Hepatic Impairment</p>\n<ul>\n<li>OLUMIANT is not recommended for use in patients with severe hepatic impairment.</li>\n<li>Interrupt OLUMIANT, if increases in ALT or AST are observed and drug-induced liver injury (DILI) is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.8)].</li>\n</ul>\n<p>COVID-19</p>\n<p>Renal Impairment</p>\n<ul>\n<li>Dosage modifications for patients with COVID-19 and renal impairment are described in Table 4.</li>\n</ul>\n<table>\n<caption>Table 4: Dosage Modifications for Patients with COVID-19 and Renal Impairment</caption>\n<thead>\n<tr>\n<th>Renal Impairment Stage</th>\n<th>Estimated Glomerular Filtration Rate (eGFR)</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Mild</td>\n<td>60 - &lt;90 mL/min/1.73 m<sup>2</sup></td>\n<td>4 mg once daily</td>\n</tr>\n<tr>\n<td>Moderate</td>\n<td>30 - &lt;60 mL/min/1.73 m<sup>2</sup></td>\n<td>2 mg once daily</td>\n</tr>\n<tr>\n<td>Severe</td>\n<td>15 - &lt;30 mL/min/1.73 m<sup>2</sup></td>\n<td>1 mg once daily</td>\n</tr>\n<tr>\n<td>End Stage Renal Disease, Patients on Dialysis, or Acute Kidney Injury</td>\n<td>&lt;15 mL/min/1.73 m<sup>2</sup></td>\n<td>Not recommended</td>\n</tr>\n</tbody>\n</table>\n<p>Hepatic Impairment</p>\n<ul>\n<li>It is not known if dosage adjustment is needed in patients with COVID-19 and severe hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk.</li>\n<li>Interrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.8)].</li>\n</ul>\n<p>Alopecia Areata</p>\n<p>Renal Impairment</p>\n<p>Dosage modifications for patients with alopecia areata and renal impairment are described in Table 5.</p>\n<table>\n<caption>Table 5: Dosage Modifications for Patients with Alopecia Areata and Renal Impairment</caption>\n<thead>\n<tr>\n<th rowspan=\"2\">Renal Impairment Stage</th>\n<th rowspan=\"2\">Estimated Glomerular Filtration Rate (eGFR)</th>\n<th colspan=\"2\">Recommendation</th>\n</tr>\n<tr>\n<th>If the recommended dosage is 2 mg once daily</th>\n<th>If the recommended dosage is 4 mg once daily</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Mild</td>\n<td>60 &lt;90 mL/minute/1.73 m<sup>2</sup></td>\n<td colspan=\"2\">Maintain dosage</td>\n</tr>\n<tr>\n<td>Moderate</td>\n<td>30 &lt;60 mL/min/1.73 m<sup>2</sup></td>\n<td>Reduce to 1 mg once daily</td>\n<td>Reduce to 2 mg once daily</td>\n</tr>\n<tr>\n<td>Severe</td>\n<td>&lt;30 mL/minute/1.73 m<sup>2</sup></td>\n<td colspan=\"2\">Not recommended</td>\n</tr>\n</tbody>\n</table>\n<p>Hepatic Impairment</p>\n<ul>\n<li>OLUMIANT is not recommended for use in patients with severe hepatic impairment.</li>\n<li>Interrupt OLUMIANT, if increases in ALT or AST are observed and DILI is suspected, until the diagnosis of DILI is excluded [see Warnings and Precautions (5.8)].</li>\n</ul>\n<h3>2.7 Dosage Modifications Due to Drug Interactions</h3>\n<p>Rheumatoid Arthritis, COVID-19 or Alopecia Areata</p>\n<p>The recommended dosage of OLUMIANT in patients taking strong Organic Anion Transporter 3 (OAT3) inhibitors, such as probenecid, are shown in Table 6 [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].</p>\n<table>\n<caption>Table 6: Dosage Modifications when Coadministered with Strong OAT3 Inhibitors in Patients With Rheumatoid Arthritis, COVID-19 or Alopecia Areata</caption>\n<thead>\n<tr>\n<th>Concomitant Medication</th>\n<th>Recommendation</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td rowspan=\"3\">Strong OAT3 inhibitors (e.g., probenecid)</td>\n<td>If the recommended dosage is 4 mg once daily, reduce dosage to 2 mg once daily.</td>\n</tr>\n<tr>\n<td>If the recommended dosage is 2 mg once daily, reduce dosage to 1 mg once daily.</td>\n</tr>\n<tr>\n<td>If the recommended dosage is 1 mg once daily, consider discontinuing probenecid.</td>\n</tr>\n</tbody>\n</table>\n<h3>2.8 Alternative Administration for Patients Unable to Swallow Tablets</h3>\n<p>For patients who are unable to swallow whole tablets, an alternative mode of administration may be considered:</p>\n<ul>\n<li>Oral dispersion</li>\n<li>Gastrostomy tube (G tube)</li>\n<li>Nasogastric tube (NG tube) or orogastric tube (OG tube)</li>\n</ul>\n<p>Intact tablets are not hazardous. Tablets may be crushed to facilitate dispersion. It is not known if powder from the crushed tablets may constitute a reproductive hazard to the preparer. If tablets are crushed, use proper control measures (e.g., ventilated enclosure) or personal protective equipment (i.e., N95 respirator). Dispersed tablets are stable in water for up to 4 hours.</p>\n<p>Preparation Instructions for Alternative Administration:</p>\n<ul>\n<li>Oral administration of dispersed tablets in water: For patients who are unable to swallow whole tablets, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 10 mL (5 mL minimum) of room temperature water, dispersed by gently swirling the tablet(s) and immediately taken orally. The container should be rinsed with an additional 10 mL (5 mL minimum) of room temperature water and the entire contents swallowed by the patient (Table 7).</li>\n<li>Administration via G tube: For patients with a G tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or any combination of tablets necessary to achieve the desired dose up to 4-mg may be placed in a container with approximately 15 mL (10 mL minimum) of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw entire contents from the container into an appropriate syringe and immediately administer through the gastric feeding tube. Rinse container with approximately 15 mL (10 mL minimum) of room temperature water, withdraw the contents into the syringe, and administer through the tube (Table 7).</li>\n<li>Administration via NG or OG tube: For patients with a NG or OG tube, 1-mg, 2-mg, or 4-mg baricitinib tablet(s), or a combination of tablets necessary to achieve the desired dose up to 4-mg may be placed into a container with approximately 30 mL of room temperature water and dispersed with gentle swirling. Ensure the tablet(s) are sufficiently dispersed to allow free passage through the tip of the syringe. Withdraw the entire contents from the container into an appropriate syringe and immediately administer through the enteral feeding tube. To avoid clogging of small diameter tubes (smaller than 12 Fr), the syringe can be held horizontally and shaken during administration. Rinse container with a sufficient amount (minimum of 15 mL) of room temperature water, withdraw the contents into the syringe, and administer through the tube (Table 7).</li>\n</ul>\n<table>\n<caption>Table 7: Dispersion and Rinse Volume for Alternative Administration</caption>\n<thead>\n<tr>\n<th>Administration via</th>\n<th>Dispersion Volume</th>\n<th>Container Rinse Volume</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Oral dispersion</td>\n<td>10 mL</td>\n<td>10 mL</td></tr></tbody></table>",
      "dosageFormsAndStrengths": "<h3>3 DOSAGE FORMS AND STRENGTHS</h3>\n<p>OLUMIANT is available as debossed, film-coated tablets:</p>\n<ul>\n<li>1mg tablet: This tablet contains a recessed area on each face of the tablet surface, is very light pink, round, and debossed with \"Lilly\" on one side and \"1\" on the other.</li>\n<li>2mg tablet: This tablet contains a recessed area on each face of the tablet surface, is light pink, oblong, and debossed with \"Lilly\" on one side and \"2\" on the other.</li>\n<li>4mg tablet: This tablet contains a recessed area on each face of the tablet surface, is medium pink, round, and debossed with \"Lilly\" on one side and \"4\" on the other.</li>\n</ul>",
      "warningsAndPrecautions": "\n<h3>5.1 Serious Infections</h3>\n<p>Serious and sometimes fatal infections due to bacterial, mycobacterial, invasive fungal, viral, or other opportunistic pathogens have been reported in patients with rheumatoid arthritis receiving OLUMIANT. The most common serious infections reported with OLUMIANT included pneumonia, herpes zoster, and urinary tract infection [see Adverse Reactions (6.1)]. Among opportunistic infections, tuberculosis, multidermatomal herpes zoster, esophageal candidiasis, pneumocystosis, acute histoplasmosis, cryptococcosis, cytomegalovirus, and BK virus were reported with OLUMIANT. Some patients have presented with disseminated rather than localized disease, and were often taking concomitant immunosuppressants such as methotrexate or corticosteroids.</p>\n<p>Avoid use of OLUMIANT in patients with an active, serious infection, including localized infections. Consider the risks and benefits of treatment prior to initiating OLUMIANT in patients:</p>\n<ul>\n<li>with chronic or recurrent infection</li>\n<li>who have been exposed to tuberculosis</li>\n<li>with a history of a serious or an opportunistic infection</li>\n<li>who have resided or traveled in areas of endemic tuberculosis or endemic mycoses; or</li>\n<li>with underlying conditions that may predispose them to infection.</li>\n</ul>\n<p>In patients with rheumatoid arthritis or alopecia areata, closely monitor for the development of signs and symptoms of infection during and after treatment with OLUMIANT. Interrupt OLUMIANT in patients with rheumatoid arthritis or alopecia areata, if the patient develops a serious infection, an opportunistic infection, or sepsis. A patient who develops a new infection during treatment with OLUMIANT should undergo prompt and complete diagnostic testing appropriate for an immunocompromised patient; appropriate antimicrobial therapy should be initiated, the patient should be closely monitored, and OLUMIANT should be interrupted if the patient is not responding to therapy. Do not resume OLUMIANT until the infection is controlled.</p>\n<p>In patients with COVID-19, monitor for signs and symptoms of new infections during and after treatment with OLUMIANT. There is limited information regarding the use of OLUMIANT in patients with COVID-19 and concomitant active serious infections. The risks and benefits of treatment with OLUMIANT in COVID-19 patients with other concurrent infections should be considered.</p>\n<p>Tuberculosis</p>\n<p>Evaluate patients for active infection prior to administration of OLUMIANT. OLUMIANT should not be given to patients with active TB.</p>\n<p>Test patients with rheumatoid arthritis or alopecia areata for latent tuberculosis. Patients with rheumatoid arthritis or alopecia areata and latent tuberculosis (TB) should be treated with standard antimycobacterial therapy before initiating OLUMIANT. Consider anti-TB therapy prior to initiation of OLUMIANT in patients with a history of latent or active TB in whom an adequate course of treatment cannot be confirmed, and for patients with a negative test for latent TB but who have risk factors for TB infection. Consultation with a physician with expertise in the treatment of TB is recommended to aid in the decision about whether initiating anti-TB therapy is appropriate for an individual patient.</p>\n<p>During OLUMIANT use, monitor patients for the development of signs and symptoms of TB, including patients who tested negative for latent TB infection prior to initiating therapy.</p>\n<p>Viral Reactivation</p>\n<p>Viral reactivation, including cases of herpes virus reactivation (e.g., herpes zoster), were reported in clinical studies with OLUMIANT. If a patient develops herpes zoster, interrupt OLUMIANT treatment until the episode resolves.</p>\n<p>The impact of OLUMIANT on chronic viral hepatitis reactivation is unknown. Patients with evidence of active hepatitis B or C infection were excluded from clinical trials. In clinical trials in patients with rheumatoid arthritis or alopecia areata, patients who were positive for hepatitis C antibody but negative for hepatitis C virus RNA were permitted to enroll. Patients with positive hepatitis B surface antibody and hepatitis B core antibody, without hepatitis B surface antigen, were permitted to enroll; such patients should be monitored for expression of hepatitis B virus (HBV) DNA. Should HBV DNA be detected, consult with a hepatologist. Perform screening for viral hepatitis in accordance with clinical guidelines before starting therapy with OLUMIANT.</p>\n<h3>5.2 Mortality</h3>\n<p>In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of all-cause mortality, including sudden cardiovascular death, was observed in patients treated with the JAK inhibitor compared with TNF blockers. Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT.</p>\n<h3>5.3 Malignancy and Lymphoproliferative Disorders</h3>\n<p>Malignancies were observed in clinical studies of OLUMIANT [see Adverse Reactions (6.1)].</p>\n<p>In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients, a higher rate of malignancies (excluding non-melanoma skin cancer (NMSC)) was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lymphomas was observed in patients treated with the JAK inhibitor compared to those treated with TNF blockers. A higher rate of lung cancers was observed in current or past smokers treated with the JAK inhibitor compared to those treated with TNF blockers. In this study, current or past smokers had an additional increased risk of overall malignancies.</p>\n<p>Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients with a known malignancy (other than successfully treated NMSC), patients who develop a malignancy, and patients who are current or past smokers.</p>\n<p>Non-melanoma skin cancers</p>\n<p>Non-melanoma skin cancers (NMSCs) have been reported in patients treated with OLUMIANT. Periodic skin examination is recommended for patients who are at increased risk for skin cancer.</p>\n<h3>5.4 Major Adverse Cardiovascular Events</h3>\n<p>In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, a higher rate of major adverse cardiovascular events (MACE) defined as cardiovascular death, non-fatal myocardial infarction (MI), and non-fatal stroke was observed with the JAK inhibitor compared to those treated with TNF blockers. Patients who are current or past smokers are at additional increased risk.</p>\n<p>Consider the benefits and risks for the individual patient prior to initiating or continuing therapy with OLUMIANT, particularly in patients who are current or past smokers and patients with other cardiovascular risk factors. Patients should be informed about the symptoms of serious cardiovascular events and the steps to take if they occur. Discontinue OLUMIANT in patients that have experienced a myocardial infarction or stroke.</p>\n<h3>5.5 Thrombosis</h3>\n<p>Thrombosis, including deep venous thrombosis (DVT) and pulmonary embolism (PE), has been observed at an increased incidence in patients treated with OLUMIANT compared to placebo. In addition, arterial thrombosis events in the extremities have been reported in clinical studies with OLUMIANT. Many of these adverse events were serious and some resulted in death. There was no clear relationship between platelet count elevations and thrombotic events. In a large, randomized, postmarketing safety study of another JAK inhibitor in RA patients 50 years of age and older with at least one cardiovascular risk factor, higher rates of overall thrombosis, DVT, and PE were observed compared to those treated with TNF blockers.</p>\n<p>If clinical features of DVT/PE or arterial thrombosis occur, patients should discontinue OLUMIANT and be evaluated promptly and treated appropriately. Avoid OLUMIANT in patients that may be at increased risk of thrombosis.</p>\n<h3>5.6 Hypersensitivity</h3>\n<p>Reactions such as angioedema, urticaria, and rash that may reflect drug hypersensitivity have been observed in patients receiving OLUMIANT, including serious reactions. If a serious hypersensitivity reaction occurs, promptly discontinue OLUMIANT while evaluating the potential causes of the reaction [see Adverse Reactions (6.2)].</p>\n<h3>5.7 Gastrointestinal Perforations</h3>\n<p>Gastrointestinal perforations have been reported in clinical studies with OLUMIANT.</p>\n<p>Monitor OLUMIANT-treated patients who may be at increased risk for gastrointestinal perforation (e.g., patients with a history of diverticulitis). Evaluate promptly patients presenting with new onset abdominal symptoms for early identification of gastrointestinal perforation.</p>\n<h3>5.8 Laboratory Abnormalities</h3>\n<p>Neutropenia Treatment with OLUMIANT was associated with an increased incidence of neutropenia (ANC less than 1000cells/mm3) compared to placebo.</p>\n<p>In patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with an ANC less than 1000cells/mm3.</p>\n<p>In patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with ANC less than 1000cells/mm3. Avoid initiation or interrupt OLUMIANT treatment in patients with COVID-19 and an ANC less than 500cells/mm3.</p>\n<p>Evaluate at baseline and thereafter according to routine patient management. Adjust dosing based on ANC [see Dosage and Administration (2.1, 2.5) and Adverse Reactions (6.1)].</p>\n<p>Lymphopenia ALC less than 500cells/mm3 were reported in OLUMIANT clinical trials. Lymphocyte counts less than the lower limit of normal were associated with infection in patients treated with OLUMIANT, but not placebo.</p>\n<p>In patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with an ALC less than 500cells/mm3.</p>\n<p>In patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with ALC less than 200cells/mm3. Avoid initiation or interrupt OLUMIANT treatment in patients with COVID-19 and an ALC less than 200cells/mm3.</p>\n<p>Evaluate at baseline and thereafter according to routine patient management. Adjust dosing based on ALC [see Dosage and Administration (2.1, 2.5)].</p>\n<p>Anemia Decreases in hemoglobin levels to less than 8g/dL were reported in OLUMIANT clinical trials. In patients with rheumatoid arthritis or alopecia areata, avoid initiation or interrupt OLUMIANT treatment in patients with hemoglobin less than 8g/dL. Evaluate at baseline and thereafter according to routine patient management. Adjust dosing based on hemoglobin levels [see Dosage and Administration (2.1, 2.5)].</p>\n<p>In patients with COVID-19, there is limited information regarding use of OLUMIANT in patients with hemoglobin less than 8g/dL.</p>\n<p>Liver Enzyme Elevations Treatment with OLUMIANT was associated with increased incidence of liver enzyme elevation compared to placebo. Increases of ALT 5 times the upper limit of normal (ULN) and increases of AST 10 times the ULN were observed in patients in OLUMIANT clinical trials. Evaluate at baseline and thereafter according to routine patient management. Prompt investigation of the cause of liver enzyme elevation is recommended to identify potential cases of drug-induced liver injury. If increases in ALT or AST are observed and drug-induced liver injury is suspected, interrupt OLUMIANT until this diagnosis is excluded [see Adverse Reactions (6.1)].</p>\n<p>Lipid Elevations Treatment with OLUMIANT was associated with increases in lipid parameters, including total cholesterol, low-density lipoprotein (LDL) cholesterol, and high-density lipoprotein (HDL) cholesterol. Assessment of lipid parameters should be performed approximately 12weeks following OLUMIANT initiation in patients with rheumatoid arthritis or alopecia areata [see Adverse Reactions (6.1)]. Manage patients according to clinical guidelines for the management of hyperlipidemia.</p>\n<h3>5.9 Vaccinations</h3>\n<p>Avoid use of live vaccines with OLUMIANT. Update immunizations in patients with rheumatoid arthritis or alopecia areata prior to initiating OLUMIANT therapy in agreement with current immunization guidelines.</p>",
      "adverseReactions": "\n<p>The following clinically significant adverse reactions are described elsewhere in the labeling:</p>\n<ul>\n<li>Serious Infections [see Warnings and Precautions (5.1)]</li>\n<li>Mortality [see Warnings and Precautions (5.2)]</li>\n<li>Malignancy and Lymphoproliferative Disorders [see Warnings and Precautions (5.3)]</li>\n<li>Major Adverse Cardiovascular Events [see Warnings and Precautions (5.4)]</li>\n<li>Thrombosis [see Warnings and Precautions (5.5)]</li>\n<li>Hypersensitivity [see Warnings and Precautions (5.6)]</li>\n<li>Gastrointestinal Perforations [see Warnings and Precautions (5.7)]</li>\n<li>Laboratory Abnormalities [see Warnings and Precautions (5.8)]</li>\n</ul>\n<h3>6.1 Clinical Trials Experience</h3>\n<p>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not predict the rates observed in a broader patient population in clinical practice.</p>\n<p>Adverse Reactions in Patients with Rheumatoid Arthritis</p>\n<p>The safety of OLUMIANT was evaluated in six randomized double-blind placebo-controlled studies (three Phase 2, three Phase 3) and a long-term extension study in patients with moderately to severely active RA. Patients were randomized to placebo (1070 patients), OLUMIANT 2mg (479 patients), or baricitinib 4mg (997 patients).</p>\n<p>Patients could be switched to baricitinib 4mg from placebo or OLUMIANT 2mg from as early as Week 12 depending on the study design. All patients initially randomized to placebo were switched to baricitinib 4mg by Week 24.</p>\n<p>During the 16-week treatment period, adverse events leading to discontinuation of treatment were reported by 35 patients (11.4 per 100 patient-years) treated with placebo, 17 patients (12.1 per 100 patient-years) with OLUMIANT 2mg, and 40 patients (13.4 per 100 patient-years) treated with baricitinib 4mg.</p>\n<p>During 0 to 52-week exposure, adverse events leading to discontinuation of treatment were reported by 31 patients (9.2 per 100 patient-years) with OLUMIANT 2mg, and 92 patients (10.2 per 100 patient-years) treated with baricitinib 4mg.</p>\n<p>Overall Infections During the 16-week treatment period, infections were reported by 253 patients (82.1 per 100 patient-years) treated with placebo, 139 patients (99.1 per 100 patient-years) treated with OLUMIANT 2mg, and 298 patients (100.1 per 100 patient-years) treated with baricitinib 4mg.</p>\n<p>During 0 to 52-week exposure, infections were reported by 200 patients (59.6 per 100 patients-years) treated with OLUMIANT 2mg, and 500 patients (55.3 per 100 patient-years) treated with baricitinib 4mg.</p>\n<p>In the 0 to 52-week exposure population, the most commonly reported infections with OLUMIANT were viral upper respiratory tract infection, upper respiratory tract infection, urinary tract infection, and bronchitis.</p>\n<p>Serious Infections During the 16-week treatment period, serious infections were reported in 13 patients (4.2 per 100 patient-years) treated with placebo, 5 patients (3.6 per 100 patient-years) treated with OLUMIANT 2mg, and 11 patients (3.7 per 100 patient-years) treated with baricitinib 4mg.</p>\n<p>During 0 to 52-week exposure, serious infections were reported in 14 patients (4.2 per 100 patient-years) treated with OLUMIANT 2mg and 32 patients (3.5 per 100 patient-years) treated with baricitinib 4mg.</p>\n<p>In the 0 to 52-week exposure population, the most commonly reported serious infections with OLUMIANT were pneumonia, herpes zoster, and urinary tract infection [see Warnings and Precautions (5.1)].</p>\n<p>Tuberculosis During the 16-week treatment period, no events of tuberculosis were reported.</p>\n<p>During 0 to 52-week exposure, events of tuberculosis were reported in 0 patients treated with OLUMIANT 2mg and 1 patient (0.1 per 100 patient-years) treated with baricitinib 4mg [see Warnings and Precautions (5.1)].</p>\n<p>Cases of disseminated tuberculosis were also reported.</p>\n<p>Opportunistic Infections (excluding tuberculosis) During the 16-week treatment period, opportunistic infections were reported in 2 patients (0.6 per 100 patient-years) treated with placebo, 0 patients treated with OLUMIANT 2mg and 2 patients (0.7 per 100 patient-years) treated with baricitinib 4mg. During 0 to 52-week exposure, opportunistic infections were reported in 1 patient (0.3 per 100 patient-years) treated with OLUMIANT 2mg and 5 patients (0.6 per 100 patient-years) treated with baricitinib 4mg [see Warnings and Precautions (5.1)].</p>\n<p>Malignancies</p>\n<p>During the 16-week treatment period, malignancies excluding non-melanoma skin cancers (NMSC) were reported in 0 patients treated with placebo, 1 patient (0.7 per 100 patient-years) treated with OLUMIANT 2mg, and 1 patient (0.3 per 100 patient-years) treated with baricitinib 4mg.</p>\n<p>During the 0 to 52-week treatment period, malignancies excluding NMSC were reported in 2 patients (0.6 per 100 patient-years) treated with OLUMIANT 2mg and 6 patients (0.7 per 100 patient-years) treated with baricitinib 4mg [see Warnings and Precautions (5.3)].</p>\n<p>Thrombosis</p>\n<p>Venous Thrombosis During the 16-week treatment period, venous thromboses (deep vein thrombosis or pulmonary embolism) were reported in 0 patients treated with placebo, 0 patients treated with OLUMIANT 2mg, and 5 patients (1.7 per 100 patient-years) treated with baricitinib 4mg. During the 0 to 52-week treatment period, venous thromboses were reported in 2 patients (0.6 per 100 patient-years) treated with OLUMIANT 2 mg and 7 patients (0.8 per 100 patient-years) treated with baricitinib 4mg.</p>\n<p>Arterial Thrombosis During the 16-week treatment period, arterial thromboses were reported in 1 patient treated with placebo (0.3 per 100 patient-years), 2 patients (1.4 per 100 patient-years) treated with OLUMIANT 2mg, and 2 patients (0.7 per 100 patient-years) treated with baricitinib 4mg. During the 0 to 52-week treatment period, arterial thromboses were reported in 3 patients (0.9 per 100 patient-years) treated with OLUMIANT 2mg and 3 patients (0.3 per 100 patient-years) treated with baricitinib 4mg.</p>\n<p>Laboratory Abnormalities</p>\n<p>Neutropenia During the 16-week treatment period, neutrophil counts below 1000 cells/mm<sup>3</sup> occurred in 0% of patients treated with placebo, 0.6% of patients treated with OLUMIANT 2mg, and 0.3% of patients treated with baricitinib 4mg. There were no neutrophil counts below 500 cells/mm<sup>3</sup> observed in any treatment group [see Warnings and Precautions (5.1, 5.8)].</p>\n<p>Platelet Elevations During the 16-week treatment period, increases in platelet counts above 600,000 cells/mm<sup>3</sup> occurred in 1.1% of patients treated with placebo, 1.1% of patients treated with OLUMIANT 2mg, and 2.0% of patients treated with baricitinib 4mg. Mean platelet count increased by 3000 cells/mm<sup>3</sup> at 16 weeks in patients treated with placebo, by 15,000 cells/mm<sup>3</sup> at 16 weeks in patients treated with OLUMIANT 2mg and by 23,000 cells/mm<sup>3</sup> in patients treated with baricitinib 4mg.</p>\n<p>Liver Enzyme Elevations Events of increases in liver enzymes 3 times the ULN were observed in patients treated with OLUMIANT [see Warnings and Precautions (5.8)].</p>\n<ul>\n<li>During the 16-week treatment period, ALT elevations 3 times the ULN occurred in 1.0% of patients treated with placebo, 1.7% of patients treated with OLUMIANT 2mg, and 1.4% of patients treated with baricitinib 4mg.</li>\n<li>During the 16-week treatment period, AST elevations 3 times the ULN occurred in 0.8% of patients treated with placebo, 1.3% of patients treated with OLUMIANT 2mg, and 0.8% of patients treated with baricitinib 4mg.</li>\n<li>In a phase 3 study of DMARD naive patients, during the 24-week treatment period, ALT and AST elevations 3 times the ULN occurred in 1.9% and 0% of patients treated with methotrexate monotherapy, 1.9% and 1.3% of patients treated with baricitinib 4mg monotherapy, and 4.7% and 1.9% of patients treated with baricitinib 4mg plus methotrexate.</li>\n</ul>\n<p>Lipid Elevations In controlled clinical trials, OLUMIANT treatment was associated with dose-related increases in lipid parameters including total cholesterol, triglycerides, LDL cholesterol, and HDL cholesterol. Elevations were observed at 12 weeks and remained stable thereafter. During the 12-week treatment period, changes in lipid parameters are summarized below:</p>\n<ul>\n<li>Mean LDL cholesterol increased by 8 mg/dL in patients treated with OLUMIANT 2mg and by 14 mg/dL in patients treated with baricitinib 4mg.</li>\n<li>Mean HDL cholesterol increased by 7 mg/dL in patients treated with OLUMIANT 2mg and by 9 mg/dL in patients treated with baricitinib 4mg.</li>\n<li>The mean LDL/HDL ratio remained stable.</li>\n<li>Mean triglycerides increased by 7 mg/dL in patients treated with OLUMIANT 2mg and by 15 mg/dL in patients treated with baricitinib 4mg.</li>\n</ul>\n<p>[See Warnings and Precautions (5.8)].</p>\n<p>Creatine Phosphokinase (CPK) OLUMIANT treatment was associated with increases in CPK within one week of starting OLUMIANT and plateauing after 8 to 12 weeks. At 16 weeks, the mean change in CPK for OLUMIANT 2mg and baricitinib 4mg was 37 IU/L and 52 IU/L, respectively.</p>\n<p>Creatinine In controlled clinical trials, dose-related increases in serum creatinine were observed with OLUMIANT treatment. At 52 weeks, the mean increase in serum creatinine was less than 0.1 mg/dL with baricitinib 4mg. The clinical significance of the observed serum creatinine increases is unknown.</p>\n<p>Other Adverse Reactions</p>\n<p>Other adverse reactions are summarized in Table 8.</p>\n<table>\n<caption>Table 8: Adverse Reactions Occurring in Greater Than or Equal to 1% of OLUMIANT 2mg and Baricitinib 4mg Treated Patients in Placebo-Controlled Trials for Rheumatoid Arthritis</caption>\n<thead>\n<tr>\n<th>Events</th>\n<th>Placebo</th>\n<th>OLUMIANT 2 mg</th>\n<th>Baricitinib 4 mg</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Upper respiratory tract infections</td>\n<td>11.7%</td>\n<td>16.3%</td>\n<td>14.7%</td>\n</tr>\n<tr>\n<td>Nausea</td>\n<td>1.6%</td>\n<td>2.7%</td>\n<td>2.8%</td>\n</tr>\n<tr>\n<td>Herpes simplex</td>\n<td>0.7%</td>\n<td>0.8%</td>\n<td>1.8%</td>\n</tr>\n<tr>\n<td>Herpes zoster</td>\n<td>0.4%</td>\n<td>1.0%</td>\n<td>1.4%</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"4\">a Includes acute sinusitis, acute tonsillitis, chronic tonsillitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis, pharyngotonsillitis, rhinitis, sinobronchitis, sinusitis, tonsillitis, tracheitis, and upper respiratory tract infection.</td>\n</tr>\n<tr>\n<td colspan=\"4\">b Includes eczema herpeticum, genital herpes, herpes simplex, ophthalmic herpes simplex, and oral herpes.</td>\n</tr>\n</tfoot>\n</table>\n<p>Additional adverse drug reactions occurring in fewer than 1% of patients: acne.</p>\n<p>Adverse Reactions in Patients with COVID-19</p>\n<p>The safety of OLUMIANT was evaluated in two randomized, double-blind, placebo-controlled clinical trials of hospitalized adults with COVID-19 for up to 29 days, in which 1307 patients received at least one dose of OLUMIANT 4 mg once daily, and 1310 patients received placebo, for up to 14 days or until hospital discharge, whichever occurred first. In these studies, prophylaxis for venous thromboembolic event (VTEs) was recommended or required for all patients unless a major contraindication was noted.</p>\n<p>Overall, the safety profile observed in patients with COVID-19 treated with OLUMIANT was consistent with the safety profile in patients with rheumatoid arthritis.</p>\n<p>Overall Infections During the first 29 days of the randomized clinical trials, infections were reported in 194 patients (14.8%) treated with OLUMIANT 4mg and by 219 patients (16.7%) treated with placebo. The most commonly reported infection with OLUMIANT was pneumonia (3.1%).</p>\n<p>Serious Infections During the first 29 days of the randomized clinical trials, serious infections were reported in 98 patients (7.5%) treated with OLUMIANT 4mg and 120 patients (9.2%) treated with placebo. The most commonly reported serious infections with OLUMIANT were COVID-19 pneumonia (2.1%) and septic shock (2.1%).</p>\n<p>Opportunistic Infections During the first 29 days of the randomized clinical trials, opportunistic infections were reported in 12 patients (0.9%) treated with OLUMIANT 4mg and 14 patients (1.1%) treated with placebo. Tuberculosis was reported in 1 patient (0.1%) treated with OLUMIANT 4mg and 0 patients treated with placebo.</p>\n<p>Venous Thrombosis Events - During the first 29 days of the randomized clinical trials, pulmonary embolism was reported in 20 patients (1.5%) treated with OLUMIANT 4mg and 11 patients (0.8%) treated with placebo. Deep vein thrombosis was reported in 20 patients (1.5%) treated with OLUMIANT 4mg and 18 patients (1.4%) treated with placebo.</p>\n<p>Adverse drug reactions in greater than or equal to 1% of patients in trials for COVID-19 are summarized in Table 9.</p>\n<table>\n<caption>Table 9: Adverse Reactions That Occurred in Greater Than or Equal to 1% of Patients Treated with OLUMIANT 4mg During the First 29 Days in Placebo-Controlled Trials for COVID-19</caption>\n<thead>\n<tr>\n<th>Placebo N = 1310 n (%)</th>\n<th>OLUMIANT 4 mg N = 1307 n (%)</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>ALT 3 x ULN</td>\n<td>201 (16.0)</td>\n<td>230 (18.1)</td>\n</tr>\n<tr>\n<td>AST 3 x ULN</td>\n<td>117 (9.4)</td>\n<td>149 (11.8)</td>\n</tr>\n<tr>\n<td>Thrombocytosis &gt;600,000 cells/mm<sup>3</sup></td>\n<td>34 (4.6)</td>\n<td>59 (7.9)</td>\n</tr>\n<tr>\n<td>Creatine phosphokinase (CPK) &gt;5 x ULN</td>\n<td>38 (4.7)</td>\n<td>36 (4.5)</td>\n</tr>\n<tr>\n<td>Neutropenia &lt;1000 cells/mm<sup>3</sup></td>\n<td>22 (1.8)</td>\n<td>26 (2.2)</td>\n</tr>\n<tr>\n<td>Deep vein thrombosis</td>\n<td>18 (1.4)</td>\n<td>20 (1.5)</td>\n</tr>\n<tr>\n<td>Pulmonary embolism</td>\n<td>11 (0.8)</td>\n<td>20 (1.5)</td>\n</tr>\n<tr>\n<td>Urinary tract infection</td>\n<td>13</td></tr></tbody></table>",
      "drugInteractions": "<h1>7 DRUG INTERACTIONS</h1><h2>7.1 Strong OAT3 Inhibitors</h2><p>Baricitinib exposure is increased when OLUMIANT is co-administered with strong OAT3 inhibitors (such as probenecid), hence the dosage of baricitinib should be reduced by half the recommended dose [see Dosage and Administration (2.2, 2.3) and Clinical Pharmacology (12.3)].</p><h2>7.2 Other JAK Inhibitors or Biologic DMARDs</h2><p>OLUMIANT has not been studied in combination with other JAK inhibitors or with biologic DMARDs [see Indications and Usage (1.1, 1.2)].</p>",
      "clinicalPharmacology": "<h1>12 CLINICAL PHARMACOLOGY</h1><h2>12.1 Mechanism of Action</h2><p>Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Baricitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.</p><p>JAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2). In cell-free isolated enzyme assays, baricitinib had greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3. In human leukocytes, baricitinib inhibited cytokine induced STAT phosphorylation mediated by JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, or JAK2/TYK2 with comparable potencies. However, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.</p><h2>12.2 Pharmacodynamics</h2><p>Baricitinib inhibition of IL-6 induced STAT3 phosphorylation Baricitinib administration resulted in a dose dependent inhibition of IL-6 induced STAT3 phosphorylation in whole blood from healthy subjects with maximal inhibition observed approximately 1hour after dosing, which returned to near baseline by 24hours. Similar levels of inhibition were observed using either IL-6 or TPO as the stimulus.</p><p>Immunoglobulins Mean serum IgG, IgM, and IgA values decreased by 12weeks after starting treatment with OLUMIANT, and remained stable through at least 52weeks. For most patients, changes in immunoglobulins occurred within the normal reference range.</p><p>C-reactive protein In patients with rheumatoid arthritis, decreases in serum C-reactive protein (CRP) were observed as early as one week after starting treatment with OLUMIANT and were maintained throughout dosing.</p><p>Cardiac Electrophysiology At a dose 10 times the maximum recommended dose, baricitinib does not prolong the QT interval to any clinically relevant extent.</p><h2>12.3 Pharmacokinetics</h2><p>Following oral administration of OLUMIANT, peak plasma concentrations are reached approximately at 1hour. A dose-proportional increase in systemic exposure was observed in the therapeutic dose range. The pharmacokinetics of baricitinib do not change over time. Steady-state concentrations are achieved in 2 to 3days with minimal accumulation after once-daily administration.</p><p>Absorption The absolute bioavailability of baricitinib is approximately 80%. An assessment of food effects in healthy subjects showed that a high-fat meal decreased the mean AUC and Cmax of baricitinib by approximately 11% and 18%, respectively, and delayed the tmax by 0.5hours. Administration with meals is not associated with a clinically relevant effect on exposure. In clinical studies, OLUMIANT was administered without regard to meals.</p><p>Distribution After intravenous administration, the volume of distribution is 76L, indicating distribution of baricitinib into tissues. Baricitinib is approximately 50% bound to plasma proteins and 45% bound to serum proteins. Baricitinib is a substrate of the Pgp, BCRP, OAT3 and MATE2-K transporters, which play roles in drug distribution.</p><p>Elimination</p><p>Rheumatoid Arthritis and Alopecia Areata: The total body clearance of baricitinib is 8.9L/h in patients with rheumatoid arthritis and 11L/h in patients with alopecia areata. Elimination half-life in patients with rheumatoid arthritis and alopecia areata is approximately 12to 16 hours.</p><p>COVID-19: The total body clearance and half-life of baricitinib is 14.2L/h and 10.8 hours, respectively, in patients with COVID-19 who are intubated and have baricitinib administered via NG or OG tube.</p><p>Metabolism Approximately 6% of the orally administered baricitinib dose is identified as metabolites (three from urine and one from feces), with CYP3A4 identified as the main metabolizing enzyme. No metabolites of baricitinib were quantifiable in plasma.</p><p>Excretion Renal elimination is the principal clearance mechanism for baricitinib through filtration and active secretion as baricitinib is identified as a substrate of OAT3, Pgp, BCRP and MATE2-K from in vitro studies. In a clinical pharmacology study, approximately 75% of the administered dose was eliminated in the urine, while about 20% of the dose was eliminated in the feces. Baricitinib was excreted predominately as unchanged drug in urine (69%) and feces (15%).</p><p>Specific Populations</p><p>Effects of Body Weight, Gender, Race, and Age</p><p>Body weight, gender, race, ethnicity, and age did not have a clinically relevant effect on the PK (AUC and Cmax) of baricitinib (Figure 1). The mean effects of intrinsic factors on PK parameters (AUC and Cmax) were generally within the inter-subject PK variability of baricitinib. The inter-subject variabilities (% coefficients of variation) in AUC and Cmax of baricitinib are approximately 41% and 22%, respectively, in patients with rheumatoid arthritis [see Use in Specific Populations (8.5)].</p><p>Patients with Renal Impairment</p><p>Baricitinib systemic exposure in AUC was increased by 1.41-, 2.22-, 4.05- and 2.41-fold for mild, moderate, severe, and ESRD (with hemodialysis) renal impairment sub-groups, respectively, compared to subjects with normal renal function. The corresponding values for increase in Cmax were 1.16-, 1.46-, 1.40- and 0.88-fold, respectively (Figure 1) [see Use in Specific Populations (8.7)].</p><p>Patients with Hepatic Impairment</p><p>Baricitinib systemic exposure and Cmax increased by 1.19- and 1.08-fold for the moderate hepatic impairment group, respectively, compared to subjects with normal hepatic function (Figure 1) [see Use in Specific Populations (8.6)].</p><p>Figure 1: Impact of Intrinsic Factors on Baricitinib Pharmacokineticsa, b</p><p>a Reference values for weight, age, gender, and race comparisons are 70kg, 54years, male, and white, respectively; reference groups for renal and hepatic impairment are subjects with normal renal and hepatic function, respectively.</p><p>b Effects of renal and hepatic impairment on baricitinib exposure were summarized from dedicated renal and hepatic impairment studies, respectively. Effects of other intrinsic factors on baricitinib exposure were summarized from population PK analysis.</p><p>c The recommended dose for patients with COVID-19 and severe renal impairment (eGFR 15 - &lt;30mL/min/1.73m2) is 1 mg once daily. OLUMIANT is not recommended for use in patients with COVID-19 who are on dialysis, have end-stage renal disease (ESRD), or acute kidney injury (eGFR &lt;15mL/min/1.73m2). [see Dosage and Administration (2.6)]</p><p>Drug Interactions</p><p>Potential for Baricitinib to Influence the PK of Other Drugs</p><p>In vitro, baricitinib did not significantly inhibit or induce the activity of cytochrome P450enzymes (CYPs 3A, 1A2, 2B6, 2C8, 2C9, 2C19, and 2D6). In clinical pharmacology studies, there were no clinically meaningful changes in the pharmacokinetics (PK) of simvastatin, ethinyl estradiol, or levonorgestrel (CYP3A substrates) when co-administered with baricitinib.</p><p>In vitro studies suggest that baricitinib is not an inhibitor of the transporters, P-glycoprotein (Pgp) or Organic Anion Transporting Polypeptide (OATP) 1B1. In vitro data indicate baricitinib does inhibit organic anionic transporter (OAT) 1, OAT2, OAT3, organic cationic transporter (OCT) 1, OCT2, OATP1B3, Breast Cancer Resistance Protein (BCRP) and Multidrug and Toxic Extrusion Protein (MATE) 1 and MATE2-K, but clinically meaningful changes in the pharmacokinetics of drugs that are substrates for these transporters are unlikely. In clinical pharmacology studies there were no clinically meaningful effects on the PK of digoxin (Pgp substrate) or methotrexate (substrate of several transporters) when co-administered with baricitinib.</p><p>Exposure changes of drugs following co-administration with baricitinib are shown in Figure 2.</p><p>Figure 2: Impact of Baricitinib on the Pharmacokinetics of Other Drugsa</p><p>a Reference group is administration of concomitant drug alone.</p><p>Potential for Other Drugs to Influence the PK of Baricitinib</p><p>In vitro studies suggest that baricitinib is a CYP3A4 substrate. In clinical pharmacology studies there was no effect on the PK of baricitinib when co-administered with ketoconazole (CYP3A inhibitor). There were no clinically meaningful changes in the PK of baricitinib when co-administered with fluconazole (CYP3A/CYP2C19/CYP2C9 inhibitor) or rifampicin (CYP3A inducer).</p><p>In vitro studies suggest that baricitinib is a substrate for OAT3, Pgp, BCRP and MATE2-K. In a clinical study, probenecid administration (strong OAT3 inhibitor) resulted in an approximately 2-fold increase in baricitinib AUC0- with no effect on Cmax and tmax[see Dosage and Administration (2.2, 2.3) and Drug Interactions (7.1)]. However, simulations with diclofenac and ibuprofen (OAT3 inhibitors with less inhibition potential) predicted minimal effect on the PK of baricitinib. In clinical pharmacology studies there was no clinically meaningful effect on the PK of baricitinib when co-administered with cyclosporine (Pgp and BCRP inhibitor). Co-administration with methotrexate (substrate of several transporters) did not have a clinically meaningful effect on the PK of baricitinib.</p><p>Exposure changes of baricitinib following co-administration with CYP inhibitors or inducers, transporter inhibitors, as well as methotrexate and the proton pump inhibitor, omeprazole, are shown in Figure 3.</p><p>Figure 3: Impact of Other Drugs on the Pharmacokinetics of Baricitinibb</p><p>a Values are based on simulated studies.</p><p>b Reference group is administration of baricitinib alone.</p>",
      "clinicalStudies": "<h1>14 CLINICAL STUDIES</h1><h2>14.1 Rheumatoid Arthritis</h2><p>The OLUMIANT clinical development program included two dose-ranging trials and four confirmatory phase3trials in patients with rheumatoid arthritis (RA). Although other doses have been studied, the recommended dosage of OLUMIANT is 2mg once daily.</p><p>Dose-Ranging Studies</p><p>The dose-ranging studies RA-1 (NCT01185353) and RA-2 (NCT01469013) included a 12-week randomized comparison of baricitinib 1, 2, 4, and 8mg orally once daily versus placebo in 301 and 145 patients, respectively.</p><p>The results from the dose-ranging studies are shown in Table 11. In dose-ranging Study RA-1, the observed ACR response was similar for baricitinib 1 and 2mg daily and for baricitinib 4 and 8mg daily, with the highest response for baricitinib 8mg daily. In dose-ranging Study RA-2, there was not a clear trend of dose response, with similar response rates for 1mg and 4mg and 2mg and 8mg.</p><table><caption>Table 11: Proportion of Patients with ACR20 Response at Week 12 in Dose-Ranging RA Studies</caption><tbody><tr><td colspan=\"5\">% ACR20 Responders</td></tr><tr><td>Dose-Ranging Study</td><td>Placebo</td><td>Baricitinib1 mg daily</td><td>Baricitinib2 mg daily</td><td>Baricitinib4 mg daily</td><td>Baricitinib8 mg daily</td></tr><tr><td>RA-1 (N=301)</td><td>41</td><td>57</td><td>54</td><td>75</td><td>78</td></tr><tr><td>RA-2 (N=145)</td><td>31</td><td>67</td><td>83</td><td>67</td><td>88</td></tr></tbody></table><p>Confirmatory Studies</p><p>The efficacy and safety of OLUMIANT 2mg once daily was assessed in two confirmatory phase 3 trials. These trials were randomized, double-blind, multicenter studies in patients with active rheumatoid arthritis diagnosed according to American College of Rheumatology (ACR)/European League Against Rheumatism 2010 criteria. Patients over 18years of age were eligible if at least 6 tender and 6 swollen joints were present at baseline. The two studies (Studies RA-3 and RA-4) evaluated OLUMIANT 2mg and baricitinib 4mg.</p><p>Study RA-3 (NCT01721057) was a 24-week trial in 684patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to conventional DMARDs (cDMARDs). Patients received OLUMIANT 2mg or 4mg once daily or placebo added to existing background cDMARD treatment. From Week 16, non-responding patients could be rescued to receive baricitinib 4mg once daily. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week12.</p><p>Study RA-4 (NCT01721044) was a 24-week trial in 527patients with moderately to severely active rheumatoid arthritis who had an inadequate response or intolerance to 1or moreTNF inhibitor therapies with or without other biologic DMARDs (TNFi-IR). Patients received OLUMIANT 2mg or baricitinib 4mg once daily or placebo added to background cDMARD treatment. From Week16, non-responding patients could be rescued to receive baricitinib 4mg once daily. The primary endpoint was the proportion of patients who achieved an ACR20 response at Week12.</p><p>Clinical Response</p><p>The percentages of OLUMIANT-treated patients achieving ACR20, ACR50, and ACR70 responses, and Disease Activity Score (DAS28-CRP) &lt;2.6 in Studies RA-3 and RA-4 are shown in Table 8.</p><p>Patients treated with OLUMIANT had higher rates of ACR response and DAS28-CRP &lt;2.6 versus placebo-treated patients at Week12 (Studies RA-3 and RA-4) (Table 12).</p><p>In Study RA-4, higher ACR20 response rates (Figure 4) were observed as early as 1 week with OLUMIANT 2mg versus placebo.</p><p>In Study RA-4, the proportions of patients achieving DAS28-CRP &lt;2.6 who had at least 3 active joints at the end of Week 24 were 18.2% and 10.5%, in the placebo and OLUMIANT 2mg arms, respectively.</p><table><caption>Table 12: Clinical Response in RA Studies RA-3 and RA-4a</caption><tfoot><tr><td colspan=\"5\"><p>a Patients who were rescued or discontinued treatment were considered as non-responders in the analyses.</p></td></tr><tr><td colspan=\"5\"><p>b 95% confidence interval for the difference () in response rate between OLUMIANT treatment and placebo (Study RA-3, Study RA-4).</p></td></tr></tfoot><tbody><tr><td colspan=\"4\">Percent of Patients</td></tr><tr><td colspan=\"2\">cDMARD-IR</td><td colspan=\"2\">TNFi-IR</td></tr><tr><td colspan=\"2\">Study RA-3</td><td colspan=\"2\">Study RA-4</td></tr><tr><td>Placebo + cDMARDs</td><td>OLUMIANT2 mg/day + cDMARDs (95% CI)b</td><td>Placebo + cDMARDs</td><td>OLUMIANT2 mg/day + cDMARDs (95% CI)b</td></tr><tr><td>N</td><td>228</td><td>229</td><td>176</td><td>174</td></tr><tr><td colspan=\"5\">ACR 20</td></tr><tr><td>Week 12%</td><td>39</td><td>6627 (18, 35)</td><td>27</td><td>4922 (12, 32)</td></tr><tr><td>Week 24%</td><td>42</td><td>6119 (10, 28)</td><td>27</td><td>4518 (8, 27)</td></tr><tr><td colspan=\"5\">ACR 50</td></tr><tr><td>Week 12%</td><td>13</td><td>3421 (13, 28)</td><td>8</td><td>2012 (5, 19)</td></tr><tr><td>Week 24%</td><td>21</td><td>4120 (12, 28)</td><td>13</td><td>2310 (2, 18)</td></tr><tr><td colspan=\"5\">ACR 70</td></tr><tr><td>Week 12%</td><td>3</td><td>1815 (9, 20)</td><td>2</td><td>1311 (5, 16)</td></tr><tr><td>Week 24%</td><td>8</td><td>2517 (11, 24)</td><td>3</td><td>1310 (4, 16)</td></tr><tr><td colspan=\"5\">DAS28-CRP&lt;2.6</td></tr><tr><td>Week 12%</td><td>9</td><td>26(10, 24)</td><td>4</td><td>11(2, 12)</td></tr><tr><td>Week 24%</td><td>11</td><td>31(13, 27)</td><td>6</td><td>11(-1, 11)</td></tr></tbody></table><p>The effects of OLUMIANT treatment on the components of the ACR response criteria for Studies RA-3 and RA-4 are shown in Table 13.</p><table><caption>Table 13: Components of ACR Response at Week 12 in RA Studies RA-3 and RA-4a</caption><tfoot><tr><td colspan=\"5\"><p>a Data shown are mean (standard deviation).</p></td></tr><tr><td colspan=\"5\"><p>b Visual analog scale: 0=best, 100=worst.</p></td></tr><tr><td colspan=\"5\"><p>c Health Assessment QuestionnaireDisability Index: 0=best, 3=worst; 20 questions; 8 categories: dressing and grooming, arising, eating, walking, hygiene, reach, grip, and activities.</p></td></tr></tfoot><tbody><tr><td colspan=\"2\">cDMARD-IR</td><td colspan=\"2\">TNFi-IR</td></tr><tr><td colspan=\"2\">Study RA-3</td><td colspan=\"2\">Study RA-4</td></tr><tr><td>Placebo+ cDMARDs</td><td>OLUMIANT2 mg/day+ cDMARDs</td><td>Placebo+ cDMARDs</td><td>OLUMIANT2 mg/day+ cDMARDs</td></tr><tr><td>N</td><td>228</td><td>229</td><td>176</td><td>174</td></tr><tr><td colspan=\"5\">Number of Tender Joints (0-68)</td></tr><tr><td> Baseline</td><td>24 (15)</td><td>24 (14)</td><td>28 (16)</td><td>31 (16)</td></tr><tr><td> Week 12</td><td>15 (14)</td><td>11 (13)</td><td>20 (16)</td><td>19 (18)</td></tr><tr><td colspan=\"5\">Number of Swollen Joints (0-66)</td></tr><tr><td> Baseline</td><td>13 (7)</td><td>14 (9)</td><td>17 (11)</td><td>19 (12)</td></tr><tr><td> Week 12</td><td>8 (8)</td><td>5 (6)</td><td>12 (10)</td><td>10 (12)</td></tr><tr><td colspan=\"5\">Painb</td></tr><tr><td> Baseline</td><td>57 (23)</td><td>60 (21)</td><td>65 (19)</td><td>62 (22)</td></tr><tr><td> Week 12</td><td>43 (24)</td><td>34 (25)</td><td>55 (25)</td><td>46 (28)</td></tr><tr><td colspan=\"5\">Patient Global Assessmentb</td></tr><tr><td> Baseline</td><td>60 (21)</td><td>62 (20)</td><td>66 (19)</td><td>67 (19)</td></tr><tr><td> Week 12</td><td>44 (23)</td><td>36 (25)</td><td>56 (25)</td><td>46 (26)</td></tr><tr><td colspan=\"5\">Physician Global Assessmentb</td></tr><tr><td> Baseline</td><td>62 (17)</td><td>64 (17)</td><td>67 (19)</td><td>67 (17)</td></tr><tr><td> Week 12</td><td>41 (24)</td><td>33 (22)</td><td>50 (26)</td><td>36 (24)</td></tr><tr><td colspan=\"5\">Disability Index (HAQ-DI)c</td></tr><tr><td> Baseline</td><td>1.50 (0.60)</td><td>1.51 (0.62)</td><td>1.78 (0.57)</td><td>1.71 (0.55)</td></tr><tr><td> Week 12</td><td>1.17 (0.62)</td><td>0.96 (0.69)</td><td>1.59 (0.68)</td><td>1.31 (0.72)</td></tr><tr><td colspan=\"5\">hsCRP (mg/L)</td></tr><tr><td> Baseline</td><td>17.7 (20.4)</td><td>18.2 (21.5)</td><td>20.6 (25.3)</td><td>19.9 (22.5)</td></tr><tr><td> Week 12</td><td>17.2 (19.3)</td><td>8.6 (14.6)</td><td>19.9 (23.0)</td><td>13.5 (20.1)</td></tr></tbody></table><p>Figure 4: Percent of RA Patients Achieving ACR20 in Study RA-4</p><p>Physical Function Response</p><p>Improvement in physical function was measured by the Health Assessment Questionnaire-Disability Index (HAQ-DI). Patients receiving OLUMIANT 2mg demonstrated greater improvement from baseline in physical functioning compared to placebo at Week 24. The mean difference (95% CI) from placebo in HAQ-DI change from baseline at Week24 was -0.24 (-0.35, -0.14) in Study RA-3 and -0.23 (-0.35, -0.12) in Study RA-4.</p><p>Other Health Related Outcomes</p><p>General health status was assessed by the Short Form health survey (SF-36). In Studies RA-3 and RA-4, compared to placebo, patients treated with OLUMIANT 2mg demonstrated greater improvement from baseline in the physical component summary (PCS) score and the physical function, role physical, bodily pain, vitality, and general health domains at Week 12, with no consistent improvements in the mental component summary (MCS) scores or the role emotional, mental health, and social functioning domains.</p><h2>14.2 COVID-19</h2><p>The efficacy and safety of baricitinib were assessed in 2Phase 3, randomized, double-blind, placebo-controlled clinical trials:</p><ul><li>COVID I (NCT04401579), which evaluated the combination of baricitinib 4mg+remdesivir compared to placebo+remdesivir.</li><li>COVID II (NCT04421027), which evaluated baricitinib 4mg compared to placebo. Patients could remain on background therapy, as defined per local guidelines. An additional exploratory sub-study in patients requiring invasive mechanical ventilation or ECMO at baseline was also conducted under this protocol and analyzed separately.</li></ul><p>COVID I</p><p>A randomized, double-blind, placebo-controlled clinical trial (NCT04401579) of hospitalized adults with confirmed SARS-CoV-2 infection compared treatment with baricitinib plus remdesivir (n = 515) with placebo plus remdesivir (n=518). Patients had to have laboratory-confirmed SARS-CoV-2 infection as well as at least one of the following to be enrolled in the trial: radiographic infiltrates by imaging, SpO2 94% on room air, a requirement for supplemental oxygen, or a requirement for mechanical ventilation or ECMO. Patients treated with the combination received the following regimen:</p><ul><li>Baricitinib 4 mg once daily (orally) for up to 14 days or until hospital discharge, whichever came first</li><li>Remdesivir 200 mg on Day 1 and 100 mg once daily (via intravenous infusion) on subsequent days for a total treatment duration of 10 days or until hospital discharge</li></ul><p>In this study prophylaxis for venous thromboembolic event (VTEs) was recommended for all patients unless a major contraindication was noted.</p><p>For the overall population (N = 1033 patients) at randomization, mean age was 55 years (with 30% of patients aged 65 or older); 63% of patients were male, 51% were Hispanic or Latino, 48% were White, 15% were Black or African American, and 10% were Asian; 14% did not require supplemental oxygen, 55% required supplemental oxygen, 21% required non-invasive ventilation or high-flow oxygen, and 11% required invasive mechanical ventilation or ECMO. The most common comorbidities were obesity (56%), hypertension (52%), and type 2 diabetes (37%). Demographics and disease characteristics were balanced across the combination group and the placebo group.</p><p>The primary endpoint, for the intent to treat population, was time to recovery within 29 days after randomization. Recovery was defined as being discharged from the hospital without limitations on activities, being discharged from the hospital with limitations on activities and/or requiring home oxygen or hospitalized but not requiring supplemental oxygen and no longer requiring medical care. The key secondary endpoint was clinical status on Day 15 assessed on an 8-point ordinal scale (OS) consisting of the following categories:</p><ol><li>Not hospitalized, no limitations on activities [OS-1];</li><li>Not hospitalized, limitation on activities and/or requiring home oxygen [OS-2];</li><li>Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care [OS-3];</li><li>Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise) [OS 4];</li><li>Hospitalized, requiring supplemental oxygen [OS 5];</li><li>Hospitalized, on non-invasive ventilation or high-flow oxygen devices [OS 6];</li><li>Hospitalized, on invasive mechanical ventilation or ECMO [OS 7]; and</li><li>Death [OS 8]</li></ol><p>For the overall population, the median time to recovery (defined as discharged from hospital or hospitalized but not requiring supplemental oxygen or ongoing medical care) was 7 days for baricitinib + remdesivir compared to 8 days for placebo + remdesivir [hazard ratio: 1.16 (95% CI 1.01, 1.33); p = 0.035].</p><p>Patients assigned to baricitinib + remdesivir were more likely to have a better clinical status (according to an 8-point ordinal scale) at Day 15 compared to patients assigned to placebo + remdesivir [odds ratio: 1.26 (95% CI 1.01, 1.57); p=0.044].</p><p>The proportion of patients who died or progressed to non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation by Day 29 was lower in baricitinib + remdesivir (23%) compared to placebo + remdesivir (28%) [odds ratio: 0.74 (95% CI 0.56, 0.99); p = 0.039]. Patients who required non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation (including ECMO) at baseline needed to worsen by at least 1 point on an 8-point ordinal scale to progress.</p><p>The proportion of patients who died by Day 29 was 4.7% (24/515) for baricitinib + remdesivir compared to 7.1% (37/518) for placebo + remdesivir [Kaplan Meier estimated difference in Day 29 probability of mortality: -2.6% (95% CI: -5.8%, 0.5%); hazard ratio = 0.65 (95% CI: 0.39, 1.09)].</p><p>COVID II</p><p>A randomized, double-blind, placebo-controlled clinical trial (NCT04421027) of hospitalized adults with confirmed SARS-CoV-2 infection compared treatment with baricitinib 4mg once daily (n = 764) with placebo (n = 761) for 14 days or hospital discharge, whichever came first. Patients could remain on background standard of care, as defined per local guidelines, including antimalarials, antivirals, corticosteroids, and/or azithromycin. In this study prophylaxis for venous thromboembolic event (VTE) was required for all patients unless contraindicated.</p><p>The most frequently used therapies at baseline were:</p><ul><li>corticosteroids (79% of patients, mostly dexamethasone)</li><li>remdesivir (19% of patients)</li></ul><p>Patients had to have laboratory-confirmed SARS-CoV-2 infection, at least one instance of elevation in at least one inflammatory marker above the upper limit of normal according to local laboratory ranges (CRP, D-dimer, LDH, ferritin), and at least one of the following to be enrolled in the trial: radiographic infiltrates by imaging, SpO2 &lt;94% on room air, evidence of active COVID infection (with clinical symptoms including any of the following: fever, vomiting, diarrhea, dry cough, tachypnea defined as respiratory rate &gt;24 breaths/min) or requirement for supplemental oxygen.</p><p>For the overall population (N = 1525 patients) at randomization, mean age was 58 years (with 33% of patients aged 65 or older); 63% of patients were male, 60% were White, 5% were Black or African American, 11% were Asian; 12% did not require supplemental oxygen (OS 4), 63% required supplemental oxygen (OS 5), 24% required non-invasive ventilation or high-flow oxygen (OS 6). The most common comorbidities were hypertension (48%), obesity (33%), and type 2 diabetes (29%). Demographics and disease characteristics were balanced across the baricitinib and placebo groups.</p><p>The primary endpoint was the proportion of patients who died or progressed to non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation within the first 28-days of the study. Patients who required non-invasive ventilation/high-flow oxygen at baseline needed to worsen by at least 1 point on an 8-point OS to progress (refer to the description of COVID I for the definition of the 8-point OS). A key secondary endpoint was all-cause mortality by Day 28.</p><p>The estimated proportion of patients who died or progressed to non-invasive ventilation/high-flow oxygen or invasive mechanical ventilation was lower in patients treated with baricitinib (27.8%) compared to placebo (30.5%), but this effect was not statistically significant [odds ratio: 0.85 (95% CI 0.67, 1.08); p = 0.180].</p><p>The proportion of patients who died by Day 28 was 8.1% (62/764) for baricitinib compared to 13.3% (101/761) for placebo [estimated difference in Day 28 probability of mortality = -4.9% (95% CI: -8.0%, -1.9%); hazard ratio = 0.56 (95% CI: 0.41, 0.77)].</p><p>COVID II Exploratory Sub-Study</p><p>In a separate group of patients requiring invasive mechanical ventilation or ECMO at baseline and enrolled in an addendum to COVID II, a pre-specified exploratory analysis showed that the proportion who died by Day 28 was 39.2% (20/51) for baricitinib compared to 58.0% (29/50) for placebo [estimated difference in Day 28 risk of mortality = -18.8% (95% CI: -36.3%, 0.6%); hazard ratio = 0.54 (95% CI: 0.31, 0.96)].</p><h2>14.3 Alopecia Areata</h2><p>Two randomized, double-blind, placebo-controlled trials [Trials AA-1 (NCT03570749) and AA-2 (NCT03899259)] enrolled a total of 1200 patients, with alopecia areata (AA), who had at least 50% scalp hair loss as measured by the Severity of Alopecia Tool (SALT) for more than 6 months. The trials enrolled males 18 to 60 years of age and females 18 to 70 years of age. Among the patients enrolled, 61% were female, 2% were 65 years of age or older, and 52% were White, 36% were Asian, and 8% were Black. At baseline, 53% of patients had at least 95% scalp hair loss, 34% had their current episode lasting at least 4 years, 69% had significant gaps in eyebrow hair or no notable eyebrow hair, and 58% had significant gaps in eyelashes or no notable eyelashes.</p><p>In the Phase 3 portion of Trial AA-1 and in Trial AA-2, patients received OLUMIANT 2 mg, OLUMIANT 4mg, or placebo once daily.</p><p>Both trials assessed the proportion of patients who achieved at least 80% scalp hair coverage (SALT score of 20) at Week 36 as the primary endpoint. Other outcomes at Week 36 included the proportion of patients who achieved at least 90% scalp hair coverage (SALT score of 10), patients with Scalp Hair Assessment PRO score of 0 or 1 with at least 2-point reduction on the 5-point scale, and assessments of eyebrow and eyelash hair loss.</p><p>Clinical Response</p><p>The results of the OLUMIANT trials (AA-1 and AA-2) are provided in Table 14 and Figure 5.</p><table><caption>Table 14: Clinical Response at Week 36 in Patients with Severe AA</caption><tfoot><tr><td colspan=\"7\"><p>a Not statistically significant under the multiplicity control plan</p></td></tr><tr><td colspan=\"7\"><p>b Patients evaluated scalp hair coverage on a 5-point scale where 0 = No missing hair (0% of scalp hair missing; full head of hair), 1 = A limited area of scalp hair loss (1% to 20%), 2 = moderate scalp hair loss (21% to 49%), 3 = a large area of scalp hair loss (50% to 94%), and 4 = nearly all or all scalp hair loss (95% to 100%).</p></td></tr></tfoot><tbody><tr><td colspan=\"3\">Trial AA-1</td><td colspan=\"3\">Trial AA-2</td></tr><tr><td>Placebo</td><td>OLUMIANT2 mg/day</td><td>OLUMIANT4 mg/day</td><td>Placebo</td><td>OLUMIANT2 mg/day</td><td>OLUMIANT4 mg/day</td></tr><tr><td colspan=\"7\">Number of subjects with at least 50% scalp hair loss at baseline</td></tr><tr><td>N</td><td>189</td><td>184</td><td>281</td><td>156</td><td>156</td><td>234</td></tr><tr><td>SALT 20 Difference from Placebo (95% CI)</td><td>5%</td><td>22%16%(10, 23)</td><td>35%30%(23, 36)</td><td>3%</td><td>17%15%(8, 22)</td><td>32%30%(23, 36)</td></tr><tr><td>SALT 10 Difference from Placebo (95% CI)</td><td>4%</td><td>13%9%(3, 15)</td><td>26%22%(16, 28)</td><td>1%</td><td>11%10%(5, 16)a</td><td>24%23%(17, 29)</td></tr><tr><td colspan=\"7\">Number of subjects reporting Scalp Hair Assessment PRO score 3 at baseline</td></tr><tr><td>N</td><td>181</td><td>175</td><td>275</td><td>151</td><td>149</td><td>215</td></tr><tr><td>Scalp Hair Assessment PRO score of 0 or 1b Difference from Placebo (95% CI)</td><td>5%</td><td>16%11%(5, 18)</td><td>33%28%(21, 34)</td><td>4%</td><td>16%12%(5, 19)</td><td>34%30%(23, 37)</td></tr></tbody></table><p>Among patients with substantial eyebrow and eyelash hair loss at baseline, an improvement in eyebrow and eyelash coverage was observed on OLUMIANT 4 mg once daily dosage at Week 36.</p><p>Figure 5: Percent of Patients Achieving SALT 20</p><p>Analyses by age, gender, race, and body weight did not identify differences in response to 36-weeks of treatment with OLUMIANT among these subgroups. SALT 20 response rates were higher in all dose groups in patients with baseline SALT 50 to 94 versus SALT 95 to 100. See Table 15.</p><table><caption>Table 15: SALT 20 at Week 36 by Baseline SALT Severity in AA</caption><tbody><tr><td colspan=\"3\">Trials AA-1 and AA-2</td></tr><tr><td>Placebo</td><td>OLUMIANT2 mg/day</td><td>OLUMIANT4 mg/day</td></tr><tr><td>50 % to 94% Scalp Hair Loss N SALT 20</td><td>1668%</td><td>14733%</td><td>24848%</td></tr><tr><td>95 % to 100% Scalp Hair Loss N SALT 20</td><td>1781%</td><td>19310%</td><td>26721%</td></tr></tbody></table><p>In AA-2, patients who achieved adequate response (SALT20) to OLUMIANT 4 mg once daily at 52 weeks of treatment entered a randomized down-titration period and received OLUMIANT 2 mg once daily or remained on OLUMIANT 4 mg once daily. After an additional 24 weeks of treatment (76 weeks total), 75% (30/40) of patients randomized to OLUMIANT 2mg once daily maintained response and 98% (41/42) of patients who remained on OLUMIANT 4 mg once daily maintained response.</p>",
      "howSupplied": "<h2>16.1 How Supplied</h2><p>OLUMIANT for oral administration is available as debossed, film-coated, tablets. Each tablet contains a recessed area on each face of the tablet surface.</p><table><tbody><tr><td>OLUMIANT Tablets</td><td>1 mg</td><td>2 mg</td><td>4 mg</td></tr><tr><td>Color</td><td>Very Light Pink</td><td>Light Pink</td><td>Medium Pink</td></tr><tr><td>Shape</td><td>Round</td><td>Oblong</td><td>Round</td></tr><tr><td rowspan=\"2\">Identification</td><td>Lilly</td><td>Lilly</td><td>Lilly</td></tr><tr><td>1</td><td>2</td><td>4</td></tr><tr><td colspan=\"4\">NDC Codes</td></tr><tr><td>Bottle of 30</td><td>0002-4732-30</td><td>0002-4182-30</td><td>0002-4479-30</td></tr></tbody></table>",
      "useInSpecificPopulations": "<h1>8 USE IN SPECIFIC POPULATIONS</h1><h2>8.1 Pregnancy</h2><p>Risk Summary</p><p>Based on the findings from animal reproduction studies, OLUMIANT may cause fetal harm during pregnancy. Available data from clinical trials and postmarketing case reports with OLUMIANT exposure in pregnancy are insufficient to inform a drug-associated risk for major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are no human data on chronic baricitinib exposure throughout pregnancy. There are risks to the mother and the fetus associated with rheumatoid arthritis in pregnancy (see Clinical Considerations). Consider the risks and benefits with chronic use of OLUMIANT during pregnancy.</p><p>In animal embryo-fetal development studies, oral baricitinib administration to pregnant rats and rabbits at exposures equal to and greater than approximately 11 and 46 times the maximum recommended human dose (MRHD) of 4 mg/day, respectively, resulted in reduced fetal body weights, increased embryolethality (rabbits only), and dose-related increases in skeletal malformations. No developmental toxicity was observed in pregnant rats and rabbits treated with oral baricitinib during organogenesis at approximately 2 and 7 times the exposure at the MRHD, respectively. In a pre- and post-natal development study in pregnant female rats, oral baricitinib administration at exposures approximately 24 times the MRHD resulted in reduction in pup viability (increased incidence of stillborn pups and early neonatal deaths), decreased fetal birth weight, reduced fetal body weight gain, decreased cytotoxic T cells on post-natal day (PND) 35 with evidence of recovery by PND 65, and developmental delays that might be attributable to decreased body weight gain. No developmental toxicity was observed at an exposure approximately 5times the exposure at the MRHD (see Data).</p><p>The background risks of major birth defects and miscarriage for the indicated population(s) are unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.</p><p>Report pregnancies to Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).</p><p>Clinical Considerations</p><p>Disease-Associated Maternal and/or Embryo/Fetal Risk</p><p>Published data suggest that increased disease activity is associated with the risk of developing adverse pregnancy outcomes in women with rheumatoid arthritis. Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2500 g) infants, and small for gestational age at birth.</p><p>Data</p><p>Animal Data</p><p>In an embryofetal development study in pregnant rats, dosed orally during the period of organogenesis from gestation days 6 to 17, baricitinib was teratogenic (skeletal malformations that consisted of bent limb bones and rib anomalies) at exposures equal to or greater than approximately 11 times the MRHD (on an AUC basis at maternal oral doses of 10mg/kg/day and higher). No developmental toxicity was observed in rats at an exposure approximately 2times the MRHD (on an AUC basis at a maternal oral dose of 2mg/kg/day).</p><p>In an embryofetal development study in pregnant rabbits, dosed orally during the period of organogenesis from gestation days 7 to 20, embryolethality, decreased fetal body weights, and skeletal malformations (rib anomalies) were observed in the presence of maternal toxicity at an exposure approximately 46times the MRHD (on an AUC basis at a maternal oral dose of 30mg/kg/day). Embryolethality consisted of increased post-implantation loss that was due to elevated incidences of both early and late resorptions. No developmental toxicity was observed in rabbits at an exposure approximately 7times the MRHD (on an AUC basis at a maternal oral dose of 10mg/kg/day).</p><p>In a pre- and post-natal development study in pregnant female rats dosed orally from gestation day 6 through lactation day 20, adverse findings observed in pups included decreased survival from birth to post-natal day 4 (due to increased stillbirths and early neonatal deaths), decreased birth weight, decreased body weight gain during the pre-weaning phase, increased incidence of malrotated forelimbs during the pre-weaning phase, and decreased cytotoxic Tcells on PND 35 with recovery by PND 65 at exposures approximately 24 times the MRHD (on an AUC basis at a maternal oral dose of 25mg/kg/day). Developmental delays (that may be secondary to decreased body weight gain) were observed in males and females at exposures approximately 24 times the MRHD (on an AUC basis at a maternal oral dose of 25mg/kg/day). These findings included decreased forelimb and hindlimb grip strengths, and delayed mean age of sexual maturity. No developmental toxicity was observed in rats at an exposure approximately 5times the MRHD (on an AUC basis at a maternal oral dose of 5mg/kg/day).</p><h2>8.2 Lactation</h2><p>Risk Summary</p><p>No information is available on the presence of OLUMIANT in human milk, the effects of the drug on the breastfed infant, or the effects of the drug on milk production. Baricitinib is present in the milk of lactating rats (see Data). Because of the potential for serious adverse reactions in nursing infants advise women not to breastfeed during treatment with OLUMIANT and for 4 days after the last dose (approximately 5 to 6 elimination half-lives).</p><p>Data</p><p>A single oral dose of 25mg/kg radiolabeled baricitinib was administered to lactating female Sprague-Dawley rats on post-partum day 13. Drug exposure was approximately 45-fold greater in milk than in plasma based on AUC0-t values.</p><h2>8.3 Females and Males of Reproductive Potential</h2><p>Contraception</p><p>Based on animal studies, OLUMIANT may cause fetal harm when administered during pregnancy [see Use in Specific Populations (8.1)]. Consider pregnancy planning and prevention for females of reproductive potential.</p><h2>8.4 Pediatric Use</h2><p>The safety and effectiveness of OLUMIANT in pediatric patients have not been established.</p><h2>8.5 Geriatric Use</h2><p>Of the 3100 patients treated in the rheumatoid arthritis clinical trials, a total of 537patients were 65years of age and older, including 71patients 75years of age and older. Of the 2558 patients treated in the COVID-19 clinical trials, a total of 791 were 65 years of age and older, including 295 patients 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects, and other reported clinical experience has not identified differences in responses between the elderly and younger patients, but greater sensitivity of some older individuals cannot be ruled out [see Clinical Pharmacology (12.3)].</p><p>Of the 1200 patients in the alopecia areata clinical trials, a total of 29 patients were 65 years of age or older. The number of patients aged 65 years and older was not sufficient to determine whether they respond differently from younger patients.</p><p>OLUMIANT is known to be substantially excreted by the kidney, and the risk of adverse reactions to this drug may be greater in patients with impaired renal function. Because geriatric patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function [see Dosage and Administration (2.6)].</p><h2>8.6 Hepatic Impairment</h2><p>No dose adjustment is necessary in patients with mild or moderate hepatic impairment.</p><p>The use of OLUMIANT has not been studied in patients with rheumatoid arthritis or alopecia areata and severe hepatic impairment and is therefore not recommended. OLUMIANT has not been studied in patients with COVID-19 and severe hepatic impairment. OLUMIANT should only be used in patients with COVID-19 and severe hepatic impairment if the potential benefit outweighs the potential risk [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].</p><h2>8.7 Renal Impairment</h2><p>Renal function was found to significantly affect baricitinib exposure.</p><p>Rheumatoid Arthritis and Alopecia Areata- The recommended dosage of OLUMIANT in patients with moderate renal impairment (estimated glomerular filtration rate (GFR) between 30 and &lt;60mL/min/1.73m2) should be reduced by half the recommended dose. OLUMIANT is not recommended for use in patients with rheumatoid arthritis or alopecia areata and severe renal impairment (estimated GFR of less than 30mL/min/1.73m2) [see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].</p><p>COVID-19- The recommended dosage of OLUMIANT in patients with moderate renal impairment (estimated GFR between 30 and &lt;60mL/min/1.732) or severe renal impairment (estimated GFR between 15 and &lt;30mL/min/1.73 m2) is 2mg once daily and 1 mg once daily, respectively. OLUMIANT is not recommended for use in patients who are on dialysis, have end-stage renal disease (ESRD), or with estimated GFR of &lt;15 mL/min/1.73 m2[see Dosage and Administration (2.6) and Clinical Pharmacology (12.3)].</p>",
      "description": "<p>OLUMIANT (baricitinib) is a Janus kinase (JAK) inhibitor with the chemical name {1-(ethylsulfonyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]azetidin-3-yl}acetonitrile. It has an empirical formula of C16H17N7O2S and a molecular weight of 371.42. OLUMIANT tablets are available for oral administration as debossed, film-coated tablets. The 1 mg tablet is very light pink, round, debossed with Lilly on one side and 1 on the other. The 2 mg tablet is light pink, oblong, debossed with Lilly on one side and 2 on the other. The 4 mg tablet is medium pink, round, debossed with Lilly on one side and 4 on the other. Each tablet contains 1, 2, or 4 mg of baricitinib and the following inactive ingredients: croscarmellose sodium, ferric oxide, lecithin (soya), magnesium stearate, mannitol, microcrystalline cellulose, polyethylene glycol, polyvinyl alcohol, talc, and titanium dioxide.</p>",
      "nonclinicalToxicology": "<h1>13 NONCLINICAL TOXICOLOGY</h1><h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><p>The carcinogenic potential of baricitinib was evaluated in Sprague-Dawley rats and Tg.rasH2 mice. No evidence of tumorigenicity was observed in male or female rats that received baricitinib for 91 to 94 weeks at oral doses up to 8 or 25mg/kg/day, respectively (approximately 7 and 30 times the MRHD on an AUC basis). No evidence of tumorigenicity was observed in Tg.rasH2 mice that received baricitinib for 26 weeks at oral doses up to 300 and 150mg/kg/day in male and female mice, respectively.</p><p>Baricitinib tested negative in the following genotoxicity assays: the in vitro bacterial mutagenicity assay (Ames assay), in vitro chromosome aberration assay in human peripheral blood lymphocytes, and in vivo rat bone marrow micronucleus assay.</p><p>Fertility (achievement of pregnancy) was reduced in male and female rats that received baricitinib at oral doses of 50 and 100mg/kg/day respectively (approximately 62 and 93 times the MRHD in males and females, respectively, on an AUC basis) based upon findings that 7 of 19 (36.8%) drug-treated females with evidence of mating were not gravid compared to 1 of 19 (5.3%) control females. It could not be determined from the study design if these findings were attributable to toxicities in one sex or both. Fertility was unaffected in male and female rats at oral doses of 15mg/kg and 25mg/kg, respectively (approximately 13 and 26 times the MRHD on an AUC basis). However, maintenance of pregnancy was adversely affected at these doses based upon findings of increased post-implantation losses (early resorptions) and decreased numbers of mean viable embryos per litter. The number of viable embryos was unaffected in female rats that received baricitinib at an oral dose of 5mg/kg/day and were mated to males that received the same dose (approximately 6 times the MRHD on an AUC basis). Reproductive performance was unaffected in male and female rats that received baricitinib at oral doses up to 50 and 100mg/kg/day respectively (approximately 62 and 93 times the MRHD in males and females, respectively, on an AUC basis).</p>",
      "mechanismOfAction": "<h2>12.1 Mechanism of Action</h2><p>Baricitinib is a Janus kinase (JAK) inhibitor. JAKs are intracellular enzymes which transmit signals arising from cytokine or growth factor-receptor interactions on the cellular membrane to influence cellular processes of hematopoiesis and immune cell function. Within the signaling pathway, JAKs phosphorylate and activate Signal Transducers and Activators of Transcription (STATs) which modulate intracellular activity including gene expression. Baricitinib modulates the signaling pathway at the point of JAKs, preventing the phosphorylation and activation of STATs.</p><p>JAK enzymes transmit cytokine signaling through their pairing (e.g., JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, JAK2/JAK2, JAK2/TYK2). In cell-free isolated enzyme assays, baricitinib had greater inhibitory potency at JAK1, JAK2 and TYK2 relative to JAK3. In human leukocytes, baricitinib inhibited cytokine induced STAT phosphorylation mediated by JAK1/JAK2, JAK1/JAK3, JAK1/TYK2, or JAK2/TYK2 with comparable potencies. However, the relevance of inhibition of specific JAK enzymes to therapeutic effectiveness is not currently known.</p>",
      "contraindications": "<p>None.</p>",
      "highlights": {
        "dosageAndAdministration": "<p>Administration Instructions: </p><ul><li>See the full prescribing information for recommended evaluations and immunizations prior to treatment. (2.1)</li><li>Rheumatoid Arthritis and Alopecia Areata: Avoid initiation or interrupt OLUMIANT in patients with anemia (hemoglobin &lt;8g/dL), lymphopenia (ALC&lt;500cells/mm3) or neutropenia (ANC&lt;1000cells/mm3). (2.1, 2.5, 5.8)</li><li>COVID-19: Avoid initiation or interrupt OLUMIANT in patients with lymphopenia (ALC&lt;200 cells/mm3) or neutropenia (ANC&lt;500cells/mm3). (2.1, 2.5, 5.8)</li></ul><p>Recommended Dosage: </p><p>Rheumatoid Arthritis: </p><ul><li>2mg once daily. (2.2)</li><li>OLUMIANT may be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs. (2.2)</li></ul><p>COVID-19: </p><ul><li>4 mg once daily for up to 14 days. (2.3)</li></ul><p>Alopecia Areata: </p><ul><li>2mg once daily. Increase to 4 mg once daily, if the response to treatment is not adequate. (2.4)</li><li>For patients with nearly complete or complete scalp hair loss, with or without substantial eyelash or eyebrow hair loss, consider treating with 4mg once daily. (2.4)</li><li>Reduce the dose to 2mg once daily when an adequate response has been achieved. (2.4)</li></ul><p>Dosage Modifications in Patients with Renal or Hepatic Impairment, or Cytopenias </p><ul><li>See the full prescribing information for dosage modifications by indication. (2.5, 2.6, 5.8)</li></ul>"
      },
      "metaDescription": "<p>OLUMIANT is a JAK inhibitor with baricitinib. Tablets are 1, 2, or 4 mg, debossed, film-coated, with inactive ingredients like croscarmellose sodium.</p>",
      "useAndConditions": "<p><h3>Approved Indications</h3></p>\n<ul>\n<li>Rheumatoid Arthritis: OLUMIANT is indicated for the treatment of adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response to one or more tumor necrosis factor (TNF) blockers.</li>\n<li>Coronavirus Disease 2019 (COVID-19): OLUMIANT is indicated for the treatment of COVID-19 in hospitalized adults requiring supplemental oxygen, non-invasive or invasive mechanical ventilation, or extracorporeal membrane oxygenation (ECMO).</li>\n<li>Alopecia Areata: OLUMIANT is indicated for the treatment of adult patients with severe alopecia areata.</li>\n</ul>",
      "contraIndications": "<p>No contraindications</p>",
      "warnings": "<h3>Warnings and Precautions</h3>\n<ul>\n<li>Serious Infections: Serious and sometimes fatal infections have been reported. Avoid use in patients with active, serious infections. Monitor for signs of infection during and after treatment.</li>\n<li>Tuberculosis: Evaluate for active infection prior to administration. Do not give to patients with active TB. Test for latent TB and treat before initiating OLUMIANT.</li>\n<li>Viral Reactivation: Cases of herpes virus reactivation reported. Interrupt treatment if herpes zoster develops. Monitor for hepatitis B virus DNA if applicable.</li>\n<li>Mortality: Higher rate of all-cause mortality observed in patients treated with JAK inhibitors compared to TNF blockers. Consider risks and benefits.</li>\n<li>Malignancy and Lymphoproliferative Disorders: Higher rates of malignancies observed. Consider risks, especially in patients with a known malignancy or who are smokers.</li>\n<li>Non-melanoma Skin Cancers: Reported in patients treated with OLUMIANT. Periodic skin examination recommended.</li>\n<li>Major Adverse Cardiovascular Events: Higher rate observed with JAK inhibitors. Consider risks, especially in smokers and those with cardiovascular risk factors.</li>\n<li>Thrombosis: Increased incidence of thrombosis, including DVT and PE. Discontinue if symptoms occur and avoid in patients at risk.</li>\n<li>Hypersensitivity: Reactions such as angioedema and rash reported. Discontinue if serious hypersensitivity occurs.</li>\n<li>Gastrointestinal Perforations: Reported in clinical studies. Monitor patients at risk and evaluate new abdominal symptoms promptly.</li>\n<li>Laboratory Abnormalities: Includes neutropenia, lymphopenia, anemia, liver enzyme elevations, and lipid elevations. Monitor and adjust dosing as necessary.</li>\n<li>Vaccinations: Avoid live vaccines. Update immunizations prior to initiating therapy.</li>\n</ul>",
      "dosing": "<p><h3>Adult Dosing</h3></p>\n<ul>\n<li>Rheumatoid Arthritis: 2 mg once daily orally, with or without food. May be used as monotherapy or in combination with methotrexate or other non-biologic DMARDs.</li>\n<li>COVID-19: 4 mg once daily orally, with or without food, for 14 days or until hospital discharge, whichever occurs first.</li>\n<li>Alopecia Areata: 2 mg once daily orally, with or without food. Increase to 4 mg once daily if the response is not adequate. For patients with nearly complete or complete scalp hair loss, consider 4 mg once daily. Once an adequate response is achieved, decrease to 2 mg once daily.</li>\n</ul>\n\n<p><h3>Dosage Modifications Due to Infections, Cytopenias, and Anemia</h3></p>\n<ul>\n<li>Rheumatoid Arthritis and Alopecia Areata: Avoid use in patients with active, serious, or opportunistic infection. If a serious infection develops, hold treatment until controlled.</li>\n<li>COVID-19: Monitor for new infections. Consider risks and benefits in patients with concurrent infections.</li>\n</ul>\n\n<p><h3>Renal Impairment</h3></p>\n<ul>\n<li>Rheumatoid Arthritis: \n  <ul>\n    <li>Mild (eGFR 60-90 mL/min/1.73 m): 2 mg once daily.</li>\n    <li>Moderate (eGFR 30-60 mL/min/1.73 m): 1 mg once daily.</li>\n    <li>Severe (eGFR <30 mL/min/1.73 m): Not recommended.</li>\n  </ul>\n</li>\n<li>COVID-19:\n  <ul>\n    <li>Mild (eGFR 60-90 mL/min/1.73 m): 4 mg once daily.</li>\n    <li>Moderate (eGFR 30-60 mL/min/1.73 m): 2 mg once daily.</li>\n    <li>Severe (eGFR 15-30 mL/min/1.73 m): 1 mg once daily.</li>\n    <li>End Stage Renal Disease or Acute Kidney Injury (eGFR <15 mL/min/1.73 m): Not recommended.</li>\n  </ul>\n</li>\n<li>Alopecia Areata:\n  <ul>\n    <li>Mild (eGFR 60-90 mL/min/1.73 m): Maintain dosage.</li>\n    <li>Moderate (eGFR 30-60 mL/min/1.73 m): Reduce to 1 mg once daily if the recommended dosage is 2 mg, or to 2 mg once daily if the recommended dosage is 4 mg.</li>\n    <li>Severe (eGFR <30 mL/min/1.73 m): Not recommended.</li>\n  </ul>\n</li>\n</ul>\n\n<p><h3>Hepatic Impairment</h3></p>\n<ul>\n<li>OLUMIANT is not recommended for use in patients with severe hepatic impairment.</"
    }
  },
  {
    "drugName": "Mounjaro",
    "setId": "d2d7da5d-ad07-4228-955f-cf7e355c8cc0",
    "slug": "mounjaro-d2d7da5",
    "labeler": "Eli Lilly and Company",
    "label": {
      "boxedWarning": "<h2>WARNING: RISK OF THYROID C-CELL TUMORS</h2><h2>See full prescribing information for complete boxed warning.</h2><ul><li>Tirzepatide causes thyroid C-cell tumors in rats. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as the human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined (5.1, 13.1).</li><li>MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with Multiple Endocrine Neoplasia syndrome type2 (MEN2). Counsel patients regarding the potential risk of MTC and symptoms of thyroid tumors (4, 5.1).</li></ul>",
      "genericName": "tirzepatide",
      "labelerName": "Eli Lilly and Company",
      "productType": "HUMAN PRESCRIPTION DRUG LABEL",
      "effectiveTime": "20250114",
      "title": "MOUNJARO",
      "indicationsAndUsage": "\n<p>MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p>\n<p>Limitations of Use</p>\n<ul>\n<li>MOUNJARO has not been studied in patients with a history of pancreatitis. Refer to Warnings and Precautions section 5.2 for more information.</li>\n<li>MOUNJARO is not indicated for use in patients with type 1 diabetes mellitus.</li>\n</ul>",
      "dosageAndAdministration": "\n<h3>2.1 Dosage</h3>\n<ul>\n<li>The recommended starting dosage of MOUNJARO is 2.5 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions. Refer to Warnings and Precautions section 5.6 and Adverse Reactions section 6.1. The 2.5 mg dosage is for treatment initiation and is not intended for glycemic control.</li>\n<li>After 4 weeks, increase the dosage to 5 mg injected subcutaneously once weekly.</li>\n<li>If additional glycemic control is needed, increase the dosage in 2.5 mg increments after at least 4 weeks on the current dose.</li>\n<li>The maximum dosage of MOUNJARO is 15 mg injected subcutaneously once weekly.</li>\n<li>If a dose is missed, instruct patients to administer MOUNJARO as soon as possible within 4 days (96 hours) after the missed dose. If more than 4 days have passed, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.</li>\n<li>The day of weekly administration can be changed, if necessary, as long as the time between the two doses is at least 3 days (72 hours).</li>\n</ul>\n<h3>2.2 Important Administration Instructions</h3>\n<ul>\n<li>Prior to initiation, train patients and caregivers on proper injection technique. Refer to Instructions for Use.</li>\n<li>Instruct patients using the single-dose vial to use a syringe appropriate for dose administration, such as a 1 mL syringe capable of measuring a 0.5 mL dose.</li>\n<li>Administer MOUNJARO once weekly, any time of day, with or without meals.</li>\n<li>Inject MOUNJARO subcutaneously in the abdomen, thigh, or upper arm.</li>\n<li>Rotate injection sites with each dose.</li>\n<li>Inspect MOUNJARO visually before use. It should appear clear and colorless to slightly yellow. Do not use MOUNJARO if particulate matter or discoloration is seen.</li>\n<li>When using MOUNJARO with insulin, administer as separate injections and never mix. It is acceptable to inject MOUNJARO and insulin in the same body region, but the injections should not be adjacent to each other.</li>\n</ul>",
      "dosageFormsAndStrengths": "\n<p>Injection: Clear, colorless to slightly yellow solution in pre-filled single-dose pens or single-dose vials, each available in the following strengths:</p>\n<ul>\n<li>2.5 mg per 0.5 mL</li>\n<li>5 mg per 0.5 mL</li>\n<li>7.5 mg per 0.5 mL</li>\n<li>10 mg per 0.5 mL</li>\n<li>12.5 mg per 0.5 mL</li>\n<li>15 mg per 0.5 mL</li>\n</ul>",
      "warningsAndPrecautions": "\n<h3>5.1 Risk of Thyroid C-Cell Tumors</h3>\n<p>In both sexes of rats, tirzepatide caused a dose-dependent and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) in a 2-year study at clinically relevant plasma exposures. It is unknown whether MOUNJARO causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of tirzepatide-induced rodent thyroid C-cell tumors has not been determined.</p>\n<p>MOUNJARO is contraindicated in patients with a personal or family history of MTC or in patients with MEN2. Counsel patients regarding the potential risk for MTC with the use of MOUNJARO and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).</p>\n<p>Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with MOUNJARO. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values greater than 50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.</p>\n<h3>5.2 Pancreatitis</h3>\n<p>Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed in patients treated with GLP-1 receptor agonists.</p>\n<p>In clinical studies, 14 events of acute pancreatitis were confirmed by adjudication in 13 MOUNJARO-treated patients (0.23 patients per 100 years of exposure) versus 3 events in 3 comparator-treated patients (0.11 patients per 100 years of exposure). MOUNJARO has not been studied in patients with a prior history of pancreatitis. It is unknown if patients with a history of pancreatitis are at higher risk for development of pancreatitis on MOUNJARO.</p>\n<p>After initiation of MOUNJARO, observe patients carefully for signs and symptoms of pancreatitis (including persistent severe abdominal pain, sometimes radiating to the back and which may or may not be accompanied by vomiting). If pancreatitis is suspected, discontinue MOUNJARO and initiate appropriate management.</p>\n<h3>5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin</h3>\n<p>Patients receiving MOUNJARO in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.</p>\n<p>The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.</p>\n<h3>5.4 Hypersensitivity Reactions</h3>\n<p>Serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with MOUNJARO. If hypersensitivity reactions occur, discontinue use of MOUNJARO; treat promptly per standard of care, and monitor until signs and symptoms resolve. Do not use in patients with a previous serious hypersensitivity reaction to tirzepatide or any of the excipients in MOUNJARO.</p>\n<p>Anaphylaxis and angioedema have been reported with GLP-1 receptor agonists. Use caution in patients with a history of angioedema or anaphylaxis with a GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to these reactions with MOUNJARO.</p>\n<h3>5.5 Acute Kidney Injury</h3>\n<p>MOUNJARO has been associated with gastrointestinal adverse reactions, which include nausea, vomiting, and diarrhea. These events may lead to dehydration, which if severe could cause acute kidney injury.</p>\n<p>In patients treated with GLP-1 receptor agonists, there have been postmarketing reports of acute kidney injury and worsening of chronic renal failure, which may sometimes require hemodialysis. Some of these events have been reported in patients without known underlying renal disease. A majority of the reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Monitor renal function when initiating or escalating doses of MOUNJARO in patients with renal impairment reporting severe gastrointestinal adverse reactions.</p>\n<h3>5.6 Severe Gastrointestinal Adverse Reactions</h3>\n<p>Use of MOUNJARO has been associated with gastrointestinal adverse reactions, sometimes severe. In the pool of placebo-controlled trials, severe gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO (5 mg 1.3%, 10 mg 0.4%, 15 mg 1.2%) than placebo (0.9%).</p>\n<p>MOUNJARO has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.</p>\n<h3>5.7 Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy</h3>\n<p>Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. MOUNJARO has not been studied in patients with non-proliferative diabetic retinopathy requiring acute therapy, proliferative diabetic retinopathy, or diabetic macular edema. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.</p>\n<h3>5.8 Acute Gallbladder Disease</h3>\n<p>Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing.</p>\n<p>In MOUNJARO placebo-controlled clinical trials, acute gallbladder disease (cholelithiasis, biliary colic, and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients. If cholelithiasis is suspected, gallbladder diagnostic studies and appropriate clinical follow-up are indicated.</p>\n<h3>5.9 Pulmonary Aspiration During General Anesthesia or Deep Sedation</h3>\n<p>MOUNJARO delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.</p>\n<p>Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking MOUNJARO, including whether modifying preoperative fasting recommendations or temporarily discontinuing MOUNJARO could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking MOUNJARO.</p>",
      "adverseReactions": "\n<p>The following serious adverse reactions are described below or elsewhere in the prescribing information:</p>\n<ul>\n<li>Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]</li>\n<li>Pancreatitis [see Warnings and Precautions (5.2)]</li>\n<li>Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]</li>\n<li>Hypersensitivity Reactions [see Warnings and Precautions (5.4)]</li>\n<li>Acute Kidney Injury [see Warnings and Precautions (5.5)]</li>\n<li>Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.6)]</li>\n<li>Diabetic Retinopathy Complications [see Warnings and Precautions (5.7)]</li>\n<li>Acute Gallbladder Disease [see Warnings and Precautions (5.8)]</li>\n<li>Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions (5.9)]</li>\n</ul>\n<h3>6.1 Clinical Trials Experience</h3>\n<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>\n<p>Pool of Two Placebo-Controlled Clinical Trials</p>\n<p>The data in Table 1 are derived from 2 placebo-controlled trials [1 monotherapy trial (SURPASS-1) and 1 trial in combination with basal insulin with or without metformin (SURPASS-5)] in adult patients with type 2 diabetes mellitus [see Clinical Studies (14.2, 14.4)]. These data reflect exposure of 718 patients to MOUNJARO and a mean duration of exposure to MOUNJARO of 36.6 weeks. The mean age of patients was 58 years, 4% were 75 years or older and 54% were male. The population was 57% White, 27% Asian, 13% American Indian or Alaska Native, and 3% Black or African American; 25% identified as Hispanic or Latino ethnicity. At baseline, patients had type 2 diabetes mellitus for an average of 9.1 years with a mean HbA1c of 8.1%. As assessed by baseline fundoscopic examination, 13% of the population had retinopathy. At baseline, eGFR was 90 mL/min/1.73 m<sup>2</sup> in 53%, 60 to 90 mL/min/1.73 m<sup>2</sup> in 39%, 45 to 60 mL/min/1.73 m<sup>2</sup> in 7%, and 30 to 45 mL/min/1.73 m<sup>2</sup> in 1% of patients.</p>\n<p>Pool of Seven Controlled Clinical Trials</p>\n<p>Adverse reactions were also evaluated in a larger pool of adult patients with type 2 diabetes mellitus participating in seven controlled clinical trials which included two placebo-controlled trials (SURPASS-1 and -5), three trials of MOUNJARO in combination with metformin, sulfonylureas, and/or SGLT2 Inhibitors (SURPASS-2, -3, -4) [see Clinical Studies (14.3)] and two additional trials conducted in Japan. In this pool, a total of 5119 adult patients with type 2 diabetes mellitus were treated with MOUNJARO for a mean duration of 48.1 weeks. The mean age of patients was 58 years, 4% were 75 years or older and 58% were male. The population was 65% White, 24% Asian, 7% American Indian or Alaska Native, and 3% Black or African American; 38% identified as Hispanic or Latino ethnicity. At baseline, patients had type 2 diabetes mellitus for an average of 9.1 years with a mean HbA1c of 8.3%. As assessed by baseline fundoscopic examination, 15% of the population had retinopathy. At baseline, eGFR was 90 mL/min/1.73 m<sup>2</sup> in 52%, 60 to 90 mL/min/1.73 m<sup>2</sup> in 40%, 45 to 60 mL/min/1.73 m<sup>2</sup> in 6%, and 30 to 45 mL/min/1.73 m<sup>2</sup> in 1% of patients.</p>\n<p>Common Adverse Reactions</p>\n<p>Table 1 shows common adverse reactions, not including hypoglycemia, associated with the use of MOUNJARO in the pool of placebo-controlled trials. These adverse reactions occurred more commonly on MOUNJARO than on placebo and occurred in at least 5% of patients treated with MOUNJARO.</p>\n<table>\n<caption>Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials Reported in 5% of MOUNJARO-treated Adult Patients with Type 2 Diabetes Mellitus</caption>\n<thead>\n<tr>\n<th>Adverse Reaction</th>\n<th>Placebo (N=235) %</th>\n<th>MOUNJARO 5 mg (N=237) %</th>\n<th>MOUNJARO 10 mg (N=240) %</th>\n<th>MOUNJARO 15 mg (N=241) %</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Nausea</td>\n<td>4</td>\n<td>12</td>\n<td>15</td>\n<td>18</td>\n</tr>\n<tr>\n<td>Diarrhea</td>\n<td>9</td>\n<td>12</td>\n<td>13</td>\n<td>17</td>\n</tr>\n<tr>\n<td>Decreased Appetite</td>\n<td>1</td>\n<td>5</td>\n<td>10</td>\n<td>11</td>\n</tr>\n<tr>\n<td>Vomiting</td>\n<td>2</td>\n<td>5</td>\n<td>5</td>\n<td>9</td>\n</tr>\n<tr>\n<td>Constipation</td>\n<td>1</td>\n<td>6</td>\n<td>6</td>\n<td>7</td>\n</tr>\n<tr>\n<td>Dyspepsia</td>\n<td>3</td>\n<td>8</td>\n<td>8</td>\n<td>5</td>\n</tr>\n<tr>\n<td>Abdominal Pain</td>\n<td>4</td>\n<td>6</td>\n<td>5</td>\n<td>5</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"5\">\n<p>Note: Percentages reflect the number of patients who reported at least 1 occurrence of the adverse reaction.</p>\n</td>\n</tr>\n</tfoot>\n</table>\n<p>In the pool of seven clinical trials, the types and frequency of common adverse reactions, not including hypoglycemia, were similar to those listed in Table 1.</p>\n<p>Gastrointestinal Adverse Reactions</p>\n<p>In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving MOUNJARO than placebo (placebo 20.4%, MOUNJARO 5 mg 37.1%, MOUNJARO 10 mg 39.6%, MOUNJARO 15 mg 43.6%). More patients receiving MOUNJARO 5 mg (3.0%), MOUNJARO 10 mg (5.4%), and MOUNJARO 15 mg (6.6%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation and decreased over time.</p>\n<p>The following gastrointestinal adverse reactions were reported more frequently in MOUNJARO-treated patients than placebo-treated patients (frequencies listed, respectively, as: placebo; 5 mg; 10 mg; 15 mg): eructation (0.4%, 3.0%, 2.5%, 3.3%), flatulence (0%, 1.3%, 2.5%, 2.9%), gastroesophageal reflux disease (0.4%, 1.7%, 2.5%, 1.7%), abdominal distension (0.4%, 0.4%, 2.9%, 0.8%).</p>\n<p>Other Adverse Reactions</p>\n<p>Hypoglycemia</p>\n<p>Table 2 summarizes the incidence of hypoglycemic events in the placebo-controlled trials.</p>\n<table>\n<caption>Table 2: Hypoglycemia Adverse Reactions in Placebo-Controlled Trials in Adult Patients with Type 2 Diabetes Mellitus</caption>\n<thead>\n<tr>\n<th></th>\n<th>Placebo %</th>\n<th>MOUNJARO 5 mg %</th>\n<th>MOUNJARO 10 mg %</th>\n<th>MOUNJARO 15 mg %</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Monotherapy</td>\n<td></td>\n<td></td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>(40 weeks)*</td>\n<td>N=115</td>\n<td>N=121</td>\n<td>N=119</td>\n<td>N=120</td>\n</tr>\n<tr>\n<td>Blood glucose &lt;54 mg/dL</td>\n<td>1</td>\n<td>0</td>\n<td>0</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Severe hypoglycemia**</td>\n<td>0</td>\n<td>0</td>\n<td>0</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Add-on to Basal Insulin with or without Metformin</td>\n<td></td>\n<td></td>\n<td></td>\n<td></td>\n</tr>\n<tr>\n<td>(40 weeks)*</td>\n<td>N=120</td>\n<td>N=116</td>\n<td>N=119</td>\n<td>N=120</td>\n</tr>\n<tr>\n<td>Blood glucose &lt;54 mg/dL</td>\n<td>13</td>\n<td>16</td>\n<td>19</td>\n<td>14</td>\n</tr>\n<tr>\n<td>Severe hypoglycemia**</td>\n<td>0</td>\n<td>0</td>\n<td>2</td>\n<td>1</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"5\">\n<p>* Reflects the study treatment period. Data include events occurring during 4 weeks of treatment-free safety follow up. Events after introduction of a new glucose-lowering treatment are excluded.</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"5\">\n<p>** Episodes requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.</p>\n</td>\n</tr>\n</tfoot>\n</table>\n<p>Hypoglycemia was more frequent when MOUNJARO was used in combination with a sulfonylurea [see Clinical Studies (14)]. In a clinical trial up to 104 weeks of treatment, when administered with a sulfonylurea, hypoglycemia (glucose level &lt;54 mg/dL) occurred in 13.8%, 9.9%, and 12.8%, and severe hypoglycemia occurred in 0.5%, 0%, and 0.6% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively.</p>\n<p>Heart Rate Increase</p>\n<p>In the pool of placebo-controlled trials, treatment with MOUNJARO resulted in a mean increase in heart rate of 2 to 4 beats per minute compared to a mean increase of 1 beat per minute in placebo-treated patients. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of 15 beats per minute, also were reported in 4.3%, 4.6%, 5.9% and 10% of subjects treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. For patients enrolled in Japan, these episodes were reported in 7% (3/43), 7.1% (3/42), 9.3% (4/43), and 23% (10/43) of patients treated with placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. The clinical relevance of heart rate increases is uncertain.</p>\n<p>Hypersensitivity Reactions</p>\n<p>Hypersensitivity reactions have been reported with MOUNJARO in the pool of placebo-controlled trials, sometimes severe (e.g., urticaria and eczema); hypersensitivity reactions were reported in 3.2% of MOUNJARO-treated patients compared to 1.7% of placebo-treated patients.</p>\n<p>In the pool of seven clinical trials, hypersensitivity reactions occurred in 106/2,570 (4.1%) of MOUNJARO-treated patients with anti-tirzepatide antibodies and in 73/2,455 (3.0%) of MOUNJARO-treated patients who did not develop anti-tirzepatide antibodies [see Clinical Pharmacology (12.6)].</p>\n<p>Injection Site Reactions</p>\n<p>In the pool of placebo-controlled trials, injection site reactions were reported in 3.2% of MOUNJARO-treated patients compared to 0.4% of placebo-treated patients.</p>\n<p>In the pool of seven clinical trials, injection site reactions occurred in 119/2,570 (4.6%) of MOUNJARO-treated patients with anti-tirzepatide antibodies and in 18/2,455 (0.7%) of MOUNJARO-treated patients who did not develop anti-tirzepatide antibodies [see Clinical Pharmacology (12.6)].</p>\n<p>Acute Gallbladder Disease</p>\n<p>In the pool of placebo-controlled clinical trials, acute gallbladder disease (cholelithiasis, biliary colic and cholecystectomy) was reported by 0.6% of MOUNJARO-treated patients and 0% of placebo-treated patients.</p>\n<p>Dysesthesia</p>\n<p>In the pool of placebo-controlled clinical trials, dysesthesia was reported by 0.4%, 0.4%, and 0.4% of patients treated with MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. No events were reported by patients receiving placebo.</p>\n<p>Dysgeusia</p>\n<p>In the pool of placebo-controlled clinical trials, dysgeusia was reported by 0.1% of MOUNJARO-treated patients and 0% of placebo-treated patients.</p>\n<p>Laboratory Abnormalities</p>\n<p>Amylase and Lipase Increase</p>\n<p>In the pool of placebo-controlled clinical trials, treatment with MOUNJARO resulted in mean increases from baseline in serum pancreatic amylase concentrations of 33% to 38% and serum lipase concentrations of 31% to 42%. Placebo-treated patients had a mean increase from baseline in pancreatic amylase of 4% and no changes were observed in lipase. The clinical significance of elevations in lipase or amylase with MOUNJARO is unknown in the absence of other signs and symptoms of pancreatitis.</p>\n<h3>6.2 Postmarketing Experience</h3>\n<p>The following adverse reactions have been reported during post-approval use of MOUNJARO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</p>\n<p>Hypersensitivity: anaphylaxis, angioedema</p>\n<p>Gastrointestinal: ileus</p>\n<p>Pulmonary: Pulmonary aspiration has occurred in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation.</p>",
      "drugInteractions": "<h1>7 DRUG INTERACTIONS</h1><h2>7.1 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin</h2><p>When initiating MOUNJARO, consider reducing the dose of concomitantly administered insulin secretagogues (e.g., sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3)].</p><h2>7.2 Oral Medications</h2><p>MOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications. Caution should be exercised when oral medications are concomitantly administered with MOUNJARO.</p><p>Monitor patients on oral medications dependent on threshold concentrations for efficacy and those with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with MOUNJARO.</p><p>Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO. Hormonal contraceptives that are not administered orally should not be affected [see Use in Specific Populations (8.3) and Clinical Pharmacology (12.2, 12.3)].</p>",
      "clinicalPharmacology": "<h1>12 CLINICAL PHARMACOLOGY</h1><h2>12.1 Mechanism of Action</h2><p>Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is an amino-acid sequence including a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.</p><p>Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.</p><h2>12.2 Pharmacodynamics</h2><p>Tirzepatide lowers fasting and postprandial glucose concentration, decreases food intake, and reduces body weight in patients with type2 diabetes mellitus.</p><p>First and Second-Phase Insulin Secretion</p><p>Tirzepatide enhances the first- and second-phase insulin secretion. (Figure1)</p><p>Figure 1: Mean insulin concentration at 0-120 minutes during hyperglycemic clamp at baseline and Week 28</p><p>Insulin Sensitivity</p><p>Tirzepatide increases insulin sensitivity, as demonstrated in a hyperinsulinemic euglycemic clamp study after 28 weeks of treatment.</p><p>Glucagon Secretion</p><p>Tirzepatide reduces fasting and postprandial glucagon concentrations. Tirzepatide 15mg reduced fasting glucagon concentration by 28% and glucagon AUC after a mixed meal by 43%, compared with no change for placebo after 28 weeks of treatment.</p><p>Gastric Emptying</p><p>Tirzepatide delays gastric emptying. The delay is largest after the first dose and this effect diminishes over time. Tirzepatide slows post-meal glucose absorption, reducing postprandial glucose.</p><h2>12.3 Pharmacokinetics</h2><p>The pharmacokinetics of tirzepatide is similar between healthy subjects and patients with type2 diabetes mellitus. Steady-state plasma tirzepatide concentrations were achieved following 4 weeks of once weekly administration. Tirzepatide exposure increases in a dose-proportional manner.</p><p>Absorption</p><p>Following subcutaneous administration, the time to maximum plasma concentration of tirzepatide ranges from 8 to 72 hours. The mean absolute bioavailability of tirzepatide following subcutaneous administration is 80%. Similar exposure was achieved with subcutaneous administration of tirzepatide in the abdomen, thigh, or upper arm.</p><p>Distribution</p><p>The mean apparent steady-state volume of distribution of tirzepatide following subcutaneous administration in patients with type2 diabetes mellitus is approximately 10.3L. Tirzepatide is highly bound to plasma albumin (99%).</p><p>Elimination</p><p>The apparent population mean clearance of tirzepatide is 0.061L/h with an elimination half-life of approximately 5 days, enabling once-weekly dosing.</p><p>Metabolism</p><p>Tirzepatide is metabolized by proteolytic cleavage of the peptide backbone, beta-oxidation of the C20 fatty diacid and amide hydrolysis.</p><p>Excretion</p><p>The primary excretion routes of tirzepatide metabolites are via urine and feces. Intact tirzepatide is not observed in urine or feces.</p><p>Specific Populations</p><p>The intrinsic factors of age, gender, race, ethnicity, or body weight do not have a clinically relevant effect on the PK of tirzepatide.</p><p>Patients with Renal Impairment</p><p>Renal impairment does not impact the pharmacokinetics of tirzepatide. The pharmacokinetics of tirzepatide after a single 5mg dose was evaluated in patients with different degrees of renal impairment (mild, moderate, severe, ESRD) compared with subjects with normal renal function. This was also shown for patients with both type2 diabetes mellitus and renal impairment based on data from clinical studies [see Use in Specific Populations (8.6)].</p><p>Patients with Hepatic Impairment</p><p>Hepatic impairment does not impact the pharmacokinetics of tirzepatide. The pharmacokinetics of tirzepatide after a single 5mg dose was evaluated in patients with different degrees of hepatic impairment (mild, moderate, severe) compared with subjects with normal hepatic function [see Use in Specific Populations (8.7)].</p><p>Drug Interactions Studies</p><p>Potential for Tirzepatide to Influence the Pharmacokinetics of Other Drugs</p><p>In vitro studies have shown low potential for tirzepatide to inhibit or induce CYP enzymes, and to inhibit drug transporters.</p><p>MOUNJARO delays gastric emptying, and thereby has the potential to impact the absorption of concomitantly administered oral medications [see Drug Interactions (7.2)].</p><p>The impact of tirzepatide on gastric emptying was greatest after a single dose of 5mg and diminished after subsequent doses.</p><p>Following a first dose of tirzepatide 5mg, acetaminophen maximum concentration (Cmax) was reduced by 50%, and the median peak plasma concentration (tmax) occurred 1 hour later. After coadministration at week 4, there was no meaningful impact on acetaminophen Cmax and tmax. Overall acetaminophen exposure (AUC0-24hr) was not influenced.</p><p>Following administration of a combined oral contraceptive (0.035mg ethinyl estradiol and 0.25mg norgestimate) in the presence of a single dose of tirzepatide 5mg, mean Cmax of ethinyl estradiol, norgestimate, and norelgestromin was reduced by 59%,66%, and 55%, while mean AUC was reduced by 20%, 21%, and 23%, respectively. A delay in tmax of 2.5 to 4.5hours was observed.</p><h2>12.6 Immunogenicity</h2><p>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the trials described below with the incidence of anti-drug antibodies in other trials.</p><p>During the 40- to 104-week treatment periods with ADA sampling conducted up to 44 to 108 weeks in seven clinical trials in adults with type 2 diabetes mellitus [see Clinical Studies (14)], 51% (2,570/5,025) of MOUNJARO-treated patients developed anti-tirzepatide antibodies. In these trials, anti-tirzepatide antibody formation in 34% and 14% of MOUNJARO-treated patients showed cross-reactivity to native GIP or native GLP-1, respectively.</p><p>Of the 2,570 MOUNJARO-treated patients who developed anti-tirzepatide antibodies during the treatment periods in these seven trials, 2% and 2% developed neutralizing antibodies against tirzepatide activity on the GIP or GLP-1 receptors, respectively, and 0.9% and 0.4% developed neutralizing antibodies against native GIP or GLP-1, respectively.</p><p>There was no identified clinically significant effect of anti-tirzepatide antibodies on pharmacokinetics or effectiveness of MOUNJARO. More MOUNJARO-treated patients who developed anti-tirzepatide antibodies experienced hypersensitivity reactions or injection site reactions than those who did not develop these antibodies [see Adverse Reactions (6.1)].</p>",
      "clinicalStudies": "<h1>14 CLINICAL STUDIES</h1><h2>14.1 Overview of Clinical Studies</h2><p>The effectiveness of MOUNJARO as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus was established in five trials. In these trials, MOUNJARO was studied as monotherapy (SURPASS-1); as an add-on to metformin, sulfonylureas, and/or sodium-glucose co-transporter 2 inhibitors (SGLT2 inhibitors) (SURPASS-2, -3, and -4); and in combination with basal insulin with or without metformin (SURPASS-5). In these trials, MOUNJARO (5mg, 10mg, and 15mg given subcutaneously once weekly) was compared with placebo, semaglutide 1mg, insulin degludec, and/or insulin glargine.</p><p>In adult patients with type2 diabetes mellitus, treatment with MOUNJARO produced a statistically significant reduction from baseline in HbA1c compared to placebo. The effectiveness of MOUNJARO was not impacted by age, gender, race, ethnicity, region, or by baseline BMI, HbA1c, diabetes duration, or renal function.</p><h2>14.2 Monotherapy Use of MOUNJARO in Adult Patients with Type2 Diabetes Mellitus</h2><p>SURPASS-1 (NCT03954834) was a 40-week double-blind trial that randomized 478 adult patients with type2 diabetes mellitus with inadequate glycemic control with diet and exercise to MOUNJARO 5mg, MOUNJARO 10mg, MOUNJARO 15mg, or placebo once weekly.</p><p>Patients had a mean age of 54 years, and 52% were men. The mean duration of type2 diabetes mellitus was 4.7 years, and the mean BMI was 32kg/m2. Overall, 36% were White, 35% were Asian, 25% were American Indians/Alaska Natives, and 5% were Black or African American; 43% identified as Hispanic or Latino ethnicity.</p><p>Monotherapy with MOUNJARO 5mg, 10mg and 15mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with placebo (see Table3).</p><table><caption>Table3: Results at Week 40 in a Trial of MOUNJARO as Monotherapy in Adult Patients with Type2 Diabetes Mellitus with Inadequate Glycemic Control with Diet and Exercise</caption><tfoot><tr><td colspan=\"5\"><p>a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 25%, 2%, 3%, and 2% of patients randomized to placebo, MOUNJARO 5mg, 10mg, and 15mg, respectively. At Week 40 the HbA1c data were missing for 12%, 6%, 7%, and 14% of patients randomized to placebo, MOUNJARO 5 mg, 10 mg, and 15 mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation.</p></td></tr><tr><td colspan=\"5\"><p>b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td colspan=\"5\"><p>c p&lt;0.001 (two-sided) for superiority vs. placebo, adjusted for multiplicity.</p></td></tr><tr><td colspan=\"5\"><p>d Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody><tr><td>Placebo</td><td>MOUNJARO5mg</td><td>MOUNJARO10mg</td><td>MOUNJARO15mg</td></tr><tr><td>Modified Intent-to-Treat (mITT) Population (N)a</td><td>113</td><td>121</td><td>121</td><td>120</td></tr><tr><td>HbA1c (%)</td></tr><tr><td> Baseline (mean)</td><td>8.1</td><td>8.0</td><td>7.9</td><td>7.9</td></tr><tr><td> Change at Week 40b</td><td>-0.1</td><td>-1.8</td><td>-1.7</td><td>-1.7</td></tr><tr><td> Difference from placebob (95% CI)</td><td>--</td><td>-1.7c(-2.0, -1.4)</td><td>-1.6c(-1.9, -1.3)</td><td>-1.6c(-1.9, -1.3)</td></tr><tr><td>Patients (%) achieving HbA1c &lt;7%d</td><td>23</td><td>82c</td><td>85c</td><td>78c</td></tr><tr><td>Fasting Serum Glucose (mg/dL)</td></tr><tr><td> Baseline (mean)</td><td>155</td><td>154</td><td>153</td><td>154</td></tr><tr><td> Change at Week 40b</td><td>4</td><td>-40</td><td>-40</td><td>-39</td></tr><tr><td> Difference from placebob (95% CI)</td><td>--</td><td>-43c(-55, -32)</td><td>-43c(-55, -32)</td><td>-42c(-54, -30)</td></tr><tr><td>Body Weight (kg)</td></tr><tr><td> Baseline (mean)</td><td>84.5</td><td>87.0</td><td>86.2</td><td>85.5</td></tr><tr><td> Change at Week 40b</td><td>-1.0</td><td>-6.3</td><td>-7.0</td><td>-7.8</td></tr><tr><td> Difference from placebob (95% CI)</td><td>--</td><td>-5.3c(-6.8, -3.9)</td><td>-6.0c(-7.4, -4.6)</td><td>-6.8c(-8.3, -5.4)</td></tr></tbody></table><h2>14.3 MOUNJARO Use in Combination with Metformin, Sulfonylureas, and/or SGLT2 Inhibitors in Adult Patients with Type2 Diabetes Mellitus</h2><p>Add-on to metformin</p><p>SURPASS-2 (NCT03987919) was a 40-week open-label trial (double-blind with respect to MOUNJARO dose assignment) that randomized 1879 adult patients with type2 diabetes mellitus with inadequate glycemic control on stable doses of metformin alone to the addition of MOUNJARO 5mg, MOUNJARO 10mg, or MOUNJARO 15mg once weekly or subcutaneous semaglutide 1mg once weekly.</p><p>Patients had a mean age of 57 years and 47% were men. The mean duration of type2 diabetes mellitus was 8.6 years, and the mean BMI was 34kg/m2. Overall, 83% were White, 4% were Black or African American, and 1% were Asian; 70% identified as Hispanic or Latino ethnicity.</p><p>Treatment with MOUNJARO 10mg and 15mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with semaglutide 1mg once weekly (see Table4 and Figure 2).</p><table><caption>Table4: Results at Week 40 in a Trial of MOUNJARO versus Semaglutide 1mg in Adult Patients with Type2 Diabetes Mellitus Added to Metformin</caption><tfoot><tr><td colspan=\"5\"><p>a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 3%, 2%, 1%, and 1% of patients randomized to semaglutide 1mg, MOUNJARO 5mg, 10mg, and 15mg, respectively. At Week 40 the HbA1c endpoint was missing for 5%, 4%, 5%, and 5% of patients randomized to semaglutide 1mg, MOUNJARO 5mg, 10mg, and 15mg, respectively. Missing Week 40 data were imputed using multiple imputation with retrieved dropout.</p></td></tr><tr><td colspan=\"5\"><p>b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td colspan=\"5\"><p>c p&lt;0.05 (two-sided) for superiority vs. semaglutide, adjusted for multiplicity.</p></td></tr><tr><td colspan=\"5\"><p>d p&lt;0.001 (two-sided) for superiority vs. semaglutide, adjusted for multiplicity.</p></td></tr><tr><td colspan=\"5\"><p>e Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr><tr><td colspan=\"5\"><p>f p&lt;0.01 (two-sided) for superiority vs. semaglutide, adjusted for multiplicity.</p></td></tr></tfoot><tbody><tr><td>Semaglutide 1mg</td><td>MOUNJARO5mg</td><td>MOUNJARO10mg</td><td>MOUNJARO15mg</td></tr><tr><td>Modified Intent-to-Treat (mITT) Population (N)a</td><td>468</td><td>470</td><td>469</td><td>469</td></tr><tr><td>HbA1c (%)</td></tr><tr><td> Baseline (mean)</td><td>8.3</td><td>8.3</td><td>8.3</td><td>8.3</td></tr><tr><td> Change at Week 40b</td><td>-1.9</td><td>-2.0</td><td>-2.2</td><td>-2.3</td></tr><tr><td> Difference from semaglutideb (95% CI)</td><td>--</td><td>-0.2c(-0.3, -0.0)</td><td>-0.4d(-0.5, -0.3)</td><td>-0.5d(-0.6, -0.3)</td></tr><tr><td>Patients (%) achieving HbA1c &lt;7%e</td><td>79</td><td>82</td><td>86f</td><td>86f</td></tr><tr><td>Fasting Serum Glucose (mg/dL)</td></tr><tr><td> Baseline (mean)</td><td>171</td><td>174</td><td>174</td><td>172</td></tr><tr><td> Change at Week 40b</td><td>-49</td><td>-55</td><td>-59</td><td>-60</td></tr><tr><td>Body Weight (kg)</td></tr><tr><td> Baseline (mean)</td><td>93.7</td><td>92.5</td><td>94.8</td><td>93.8</td></tr><tr><td> Change at Week 40b</td><td>-5.7</td><td>-7.6</td><td>-9.3</td><td>-11.2</td></tr><tr><td> Difference from semaglutideb (95% CI)</td><td>--</td><td>-1.9c(-2.8, -1.0)</td><td>-3.6d(-4.5, -2.7)</td><td>-5.5d(-6.4, -4.6)</td></tr></tbody></table><p>Figure2. Mean HbA1c (%) Over Time - Baseline to Week 40</p><table><tbody><tr><td>Numberofpatients</td></tr><tr><td>MOUNJARO5mg</td><td>470</td><td>451</td><td>470</td></tr><tr><td>MOUNJARO10mg</td><td>469</td><td>445</td><td>469</td></tr><tr><td>MOUNJARO15mg</td><td>469</td><td>447</td><td>469</td></tr><tr><td>Semaglutide1mg</td><td>468</td><td>443</td><td>468</td></tr></tbody></table><p>Note: Displayed results are from modified Intent-to-Treat Full Analysis Set. (1) Observed mean value from Week 0 to Week 40, and (2) least-squares mean standard error at Week 40 multiple imputation (MI).</p><p>Add-on to metformin with or without SGLT2 inhibitor</p><p>SURPASS-3 (NCT03882970) was a 52-week open-label trial that randomized 1444 adult patients with type2 diabetes mellitus with inadequate glycemic control on stable doses of metformin with or without SGLT2 inhibitor to the addition of MOUNJARO 5mg, MOUNJARO 10mg, MOUNJARO 15mg once weekly, or insulin degludec 100units/mL once daily. In this trial, 32% of patients were on SGLT2 inhibitor. Insulin degludec was initiated at 10units once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 26% of patients randomized to insulin degludec achieved the fasting serum glucose target of &lt;90mg/dL, and the mean daily insulin degludec dose was 49 U (0.5U per kilogram).</p><p>Patients had a mean age of 57 years, and 56% were men. The mean duration of type2 diabetes mellitus was 8.4 years, and the mean baseline BMI was 34kg/m2. Overall, 91% were White, 3% were Black or African American, and 5% were Asian; 29% identified as Hispanic or Latino ethnicity.</p><p>Treatment with MOUNJARO 10mg and 15mg once weekly for 52 weeks resulted in a statistically significant reduction in HbA1c compared with daily insulin degludec (see Table5).</p><table><caption>Table 5: Results at Week 52 in a Trial of MOUNJARO versus Insulin Degludec in Adult Patients with Type2 Diabetes Mellitus Added to Metformin with or without SGLT2 Inhibitor</caption><tfoot><tr><td colspan=\"5\"><p>a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%,1%, 1%, and 2% of patients randomized to insulin degludec, MOUNJARO 5mg, 10mg, and 15mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 6%, 10%, and 5% of patients randomized to insulin degludec, MOUNJARO 5mg, 10mg, and 15mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout.</p></td></tr><tr><td colspan=\"5\"><p>b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td colspan=\"5\"><p>c p&lt;0.001 (two-sided) for superiority vs. insulin degludec, adjusted for multiplicity.</p></td></tr><tr><td colspan=\"5\"><p>d Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody><tr><td>Insulin Degludec</td><td>MOUNJARO5mg</td><td>MOUNJARO10mg</td><td>MOUNJARO15mg</td></tr><tr><td>Modified Intent-to-Treat (mITT)a Population (N)</td><td>359</td><td>358</td><td>360</td><td>358</td></tr><tr><td>HbA1c (%)</td></tr><tr><td> Baseline (mean)</td><td>8.1</td><td>8.2</td><td>8.2</td><td>8.2</td></tr><tr><td> Change at Week 52b</td><td>-1.3</td><td>-1.9</td><td>-2.0</td><td>-2.1</td></tr><tr><td> Difference from insulin degludecb (95% CI)</td><td>--</td><td>-0.6c(-0.7, -0.5)</td><td>-0.8c(-0.9, -0.6)</td><td>-0.9c(-1.0, -0.7)</td></tr><tr><td>Patients (%) achieving HbA1c &lt;7%d</td><td>58</td><td>79c</td><td>82c</td><td>83c</td></tr><tr><td>Fasting Serum Glucose (mg/dL)</td></tr><tr><td> Baseline (mean)</td><td>167</td><td>172</td><td>170</td><td>168</td></tr><tr><td> Change at Week 52b</td><td>-51</td><td>-47</td><td>-50</td><td>-54</td></tr><tr><td>Body Weight (kg)</td></tr><tr><td> Baseline (mean)</td><td>94.0</td><td>94.4</td><td>93.8</td><td>94.9</td></tr><tr><td> Change at Week 52b</td><td>1.9</td><td>-7.0</td><td>-9.6</td><td>-11.3</td></tr><tr><td> Difference from insulin degludecb (95% CI)</td><td>--</td><td>-8.9c(-10.0, -7.8)</td><td>-11.5c(-12.6, -10.4)</td><td>-13.2c(-14.3, -12.1)</td></tr></tbody></table><p>Add-on to 1-3 oral anti-hyperglycemic agents (metformin, sulfonylurea or SGLT-2 inhibitor)</p><p>SURPASS-4 (NCT03730662) was a 104-week open-label trial (52-week primary endpoint) that randomized 2002 adult patients with type2 diabetes mellitus with increased cardiovascular risk to MOUNJARO 5mg, MOUNJARO 10mg, MOUNJARO 15mg once weekly, or insulin glargine 100units/mL once daily (1:1:1:3 ratio) on a background of metformin (95%) and/or sulfonylureas (54%) and/or SGLT2 inhibitors (25%).</p><p>Patients had a mean age of 64 years, and 63% were men. The mean duration of type2 diabetes mellitus was 11.8 years, and the mean baseline BMI was 33 kg/m2. Overall, 82% were White, 4% were Black or African American, and 4% were Asian; 48% identified as Hispanic or Latino ethnicity. Across all treatment groups, 87% had a history of cardiovascular disease. At baseline, eGFR was 90mL/min/1.73m2 in 43%, 60 to 90mL/min/1.73m2 in 40%, 45 to 60mL/min/1.73m2 in 10%, and 30 to 45mL/min/1.73m2 in 6% of patients.</p><p>Insulin glargine was initiated at 10U once daily and adjusted weekly throughout the trial using a treat-to-target algorithm based on self-measured fasting blood glucose values. At Week 52, 30% of patients randomized to insulin glargine achieved the fasting serum glucose target of &lt;100mg/dL, and the mean daily insulin glargine dose was 44U (0.5U per kilogram).</p><p>Treatment with MOUNJARO 10mg and 15mg once weekly for 52 weeks resulted in a statistically significant reduction in HbA1c compared with insulin glargine once daily (see Table6).</p><table><caption>Table6: Results at Week 52 in a Trial of MOUNJARO versus Insulin Glargine in Adult Patients with Type2 Diabetes Mellitus Added to Metformin and/or Sulfonylurea and/or SGLT2 Inhibitor</caption><tfoot><tr><td colspan=\"5\"><p>a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 1%, 0%, 0%, and 1% of patients randomized to insulin glargine, MOUNJARO 5mg, 10mg, and 15mg, respectively. At Week 52 the HbA1c endpoint was missing for 9%, 9%, 6%, and 4% of patients randomized to insulin glargine, MOUNJARO 5mg, 10mg, and 15mg, respectively. Missing Week 52 data were imputed using multiple imputation with retrieved dropout.</p></td></tr><tr><td colspan=\"5\"><p>b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td colspan=\"5\"><p>c p&lt;0.001 (two-sided) for superiority vs. insulin glargine, adjusted for multiplicity.</p></td></tr><tr><td colspan=\"5\"><p>d Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody><tr><td>Insulin Glargine</td><td>MOUNJARO5mg</td><td>MOUNJARO10mg</td><td>MOUNJARO15mg</td></tr><tr><td>Modified Intent-to-Treat (mITT) Population (N)a</td><td>998</td><td>328</td><td>326</td><td>337</td></tr><tr><td>HbA1c (%)</td></tr><tr><td> Baseline (mean)</td><td>8.5</td><td>8.5</td><td>8.6</td><td>8.5</td></tr><tr><td> Change at Week 52b</td><td>-1.4</td><td>-2.1</td><td>-2.3</td><td>-2.4</td></tr><tr><td> Difference from insulin glargineb (95% CI)</td><td>--</td><td>-0.7c(-0.9, -0.6)</td><td>-0.9c(-1.1, -0.8)</td><td>-1.0c(-1.2, -0.9)</td></tr><tr><td>Patients (%) achieving HbA1c &lt;7%d</td><td>49</td><td>75c</td><td>83c</td><td>85c</td></tr><tr><td>Fasting Serum Glucose (mg/dL)</td></tr><tr><td> Baseline (mean)</td><td>168</td><td>172</td><td>176</td><td>174</td></tr><tr><td> Change at Week 52b</td><td>-49</td><td>-44</td><td>-50</td><td>-55</td></tr><tr><td>Body Weight (kg)</td></tr><tr><td> Baseline (mean)</td><td>90.2</td><td>90.3</td><td>90.6</td><td>90.0</td></tr><tr><td> Change at Week 52b</td><td>1.7</td><td>-6.4</td><td>-8.9</td><td>-10.6</td></tr><tr><td> Difference from insulin glargineb (95% CI)</td><td>--</td><td>-8.1c(-8.9, -7.3)</td><td>-10.6c(-11.4, -9.8)</td><td>-12.2c(-13.0, -11.5)</td></tr></tbody></table><h2>14.4 MOUNJARO Use in Combination with Basal Insulin with or without Metformin in Adult Patients with Type 2 Diabetes Mellitus</h2><p>SURPASS-5 (NCT04039503) was a 40-week double-blind trial that randomized 475 patients with type2 diabetes mellitus with inadequate glycemic control on insulin glargine 100units/mL, with or without metformin, to MOUNJARO 5mg, MOUNJARO 10mg, MOUNJARO 15mg once weekly, or placebo. The dose of background insulin glargine was adjusted using a treat-to-target algorithm based on self-measured fasting blood glucose values, targeting &lt;100mg/dL.</p><p>Patients had a mean age of 61 years, and 56% were men. The mean duration of type2 diabetes mellitus was 13.3 years, and the mean baseline BMI was 33kg/m2. Overall, 80% were White, 1% were Black or African American, and 18% were Asian; 5% identified as Hispanic or Latino ethnicity.</p><p>The mean dose of insulin glargine at baseline was 34, 32, 35, and 33units/day for patients receiving MOUNJARO 5mg, 10mg, 15mg, and placebo, respectively. At randomization, the initial insulin glargine dose in patients with HbA1c 8.0% was reduced by 20%. At week 40, mean dose of insulin glargine was 38, 36, 29, and 59units/day for patients receiving MOUNJARO 5mg, 10mg, 15mg, and placebo, respectively.</p><p>Treatment with MOUNJARO 5mg once weekly, 10mg once weekly and 15mg once weekly for 40 weeks resulted in a statistically significant reduction in HbA1c compared with placebo (see Table7).</p><table><caption>Table 7: Results at Week 40 in a Trial of MOUNJARO Added to Basal Insulin with or without Metformin in Adult Patients with Type2 Diabetes Mellitus</caption><tfoot><tr><td colspan=\"5\"><p>a The modified intent-to-treat population consists of all randomly assigned participants who were exposed to at least 1 dose of study drug. Patients who discontinued study treatment because they did not meet study enrollment criteria were excluded. During the trial, rescue medication (additional antihyperglycemic medication) was initiated by 4%, 1%, 0%, and 1% of patients randomized to placebo, MOUNJARO 5mg, 10mg, and 15mg, respectively. At Week 40 the HbA1c endpoint was missing for 2%, 6%, 3%, and 7% of patients randomized to placebo, MOUNJARO 5mg, 10mg, and 15mg, respectively. Missing Week 40 data were imputed using placebo-based multiple imputation.</p></td></tr><tr><td colspan=\"5\"><p>b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors.</p></td></tr><tr><td colspan=\"5\"><p>c p&lt;0.001 (two-sided) for superiority vs. placebo, adjusted for multiplicity.</p></td></tr><tr><td colspan=\"5\"><p>d Analyzed using logistic regression adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody><tr><td>Placebo</td><td>MOUNJARO5mg</td><td>MOUNJARO10mg</td><td>MOUNJARO15mg</td></tr><tr><td>Modified Intent-to-Treat (mITT) Population (N)a</td><td>119</td><td>116</td><td>118</td><td>118</td></tr><tr><td>HbA1c (%)</td></tr><tr><td> Baseline (mean)</td><td>8.4</td><td>8.3</td><td>8.4</td><td>8.2</td></tr><tr><td> Change at Week 40b</td><td>-0.9</td><td>-2.1</td><td>-2.4</td><td>-2.3</td></tr><tr><td> Difference from placebob (95% CI)</td><td>--</td><td>-1.2c(-1.5, -1.0)</td><td>-1.5c(-1.8, -1.3)</td><td>-1.5c(-1.7, -1.2)</td></tr><tr><td>Patients (%) achieving HbA1c &lt;7%d</td><td>35</td><td>87c</td><td>90c</td><td>85c</td></tr><tr><td>Fasting Serum Glucose (mg/dL)</td></tr><tr><td> Baseline (mean)</td><td>164</td><td>163</td><td>163</td><td>160</td></tr><tr><td> Change at Week 40b</td><td>-39</td><td>-58</td><td>-64</td><td>-63</td></tr><tr><td> Difference from placebob (95% CI)</td><td>--</td><td>-19c(-27, -11)</td><td>-25c(-32, -17)</td><td>-23c(-31, -16)</td></tr><tr><td>Body Weight (kg)</td></tr><tr><td> Baseline (mean)</td><td>94.2</td><td>95.8</td><td>94.6</td><td>96.0</td></tr><tr><td> Change at Week 40b</td><td>1.6</td><td>-5.4</td><td>-7.5</td><td>-8.8</td></tr><tr><td> Difference from placebob (95% CI)</td><td>--</td><td>-7.1c(-8.7, -5.4)</td><td>-9.1c(-10.7, -7.5)</td><td>-10.5c(-12.1, -8.8)</td></tr></tbody></table>",
      "howSupplied": "<h2>16.1 How Supplied</h2><p>MOUNJARO is a clear, colorless to slightly yellow solution available in cartons containing 4 pre-filled single-dose pens or 1 single-dose vial as follows:</p><table><tbody><tr><td>Total Strength per Total Volume</td><td>Pen NDC</td><td>Vial NDC</td></tr><tr><td>2.5mg/0.5mL</td><td>0002-1506-80</td><td>0002-1152-01</td></tr><tr><td>5mg/0.5mL</td><td>0002-1495-80</td><td>0002-1243-01</td></tr><tr><td>7.5mg/0.5mL</td><td>0002-1484-80</td><td>0002-2214-01</td></tr><tr><td>10mg/0.5 mL</td><td>0002-1471-80</td><td>0002-2340-01</td></tr><tr><td>12.5mg/0.5mL</td><td>0002-1460-80</td><td>0002-2423-01</td></tr><tr><td>15mg/0.5mL</td><td>0002-1457-80</td><td>0002-3002-01</td></tr></tbody></table>",
      "useInSpecificPopulations": "<h1>8 USE IN SPECIFIC POPULATIONS</h1><h2>8.1 Pregnancy</h2><p>Risk Summary</p><p>Available data with MOUNJARO use in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. There are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see Clinical Considerations). Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy. MOUNJARO should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p><p>In pregnant rats administered tirzepatide during organogenesis, fetal growth reductions and fetal abnormalities occurred at clinical exposure in maternal rats based on AUC. In rabbits administered tirzepatide during organogenesis, fetal growth reductions were observed at clinically relevant exposures based on AUC. These adverse embryo/fetal effects in animals coincided with pharmacological effects on maternal weight and food consumption (see Data).</p><p>The estimated background risk of major birth defects is 610% in women with pre-gestational diabetes with an HbA1c &gt;7% and has been reported to be as high as 2025% in women with an HbA1c &gt;10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 24% and 1520%, respectively.</p><p>Clinical Considerations</p><p>Disease-Associated Maternal and/or Embryo/Fetal Risk</p><p>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.</p><p>Data</p><p>Animal Data</p><p>In pregnant rats given twice weekly subcutaneous doses of 0.02, 0.1, and 0.5mg/kg tirzepatide (0.03-, 0.07-, and 0.5-fold the MRHD of 15mg once weekly based on AUC) during organogenesis, increased incidences of external, visceral, and skeletal malformations, increased incidences of visceral and skeletal developmental variations, and decreased fetal weights coincided with pharmacologically-mediated reductions in maternal body weights and food consumption at 0.5mg/kg. In pregnant rabbits given once weekly subcutaneous doses of 0.01, 0.03, or 0.1mg/kg tirzepatide (0.01-, 0.06-, and 0.2-fold the MRHD) during organogenesis, pharmacologically-mediated effects on the gastrointestinal system resulting in maternal mortality or abortion in a few rabbits occurred at all dose levels. Reduced fetal weights associated with decreased maternal food consumption and body weights were observed at 0.1mg/kg. In a pre- and post-natal study in rats administered subcutaneous doses of 0.02, 0.10, or 0.25 mg/kg tirzepatide twice weekly from implantation through lactation, F1 pups from F0 maternal rats given 0.25mg/kg tirzepatide had statistically significant lower mean body weight when compared to controls from post-natal day 7 through post-natal day 126 for males and post-natal day 56 for females.</p><h2>8.2 Lactation</h2><p>Risk Summary</p><p>There are no data on the presence of tirzepatide in animal or human milk, the effects on the breastfed infant, or the effects on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for MOUNJARO and any potential adverse effects on the breastfed infant from MOUNJARO or from the underlying maternal condition.</p><h2>8.3 Females and Males of Reproductive Potential</h2><p>Contraception</p><p>Use of MOUNJARO may reduce the efficacy of oral hormonal contraceptives due to delayed gastric emptying. This delay is largest after the first dose and diminishes over time. Advise patients using oral hormonal contraceptives to switch to a non-oral contraceptive method, or add a barrier method of contraception for 4 weeks after initiation and for 4 weeks after each dose escalation with MOUNJARO [see Drug Interactions (7.2) and Clinical Pharmacology (12.2, 12.3)].</p><h2>8.4 Pediatric Use</h2><p>Safety and effectiveness of MOUNJARO have not been established in pediatric patients.</p><h2>8.5 Geriatric Use</h2><p>In the pool of seven clinical trials, 1539 (30.1%) MOUNJARO-treated patients were 65 years of age or older, and 212 (4.1%) MOUNJARO-treated patients were 75 years of age or older at baseline.</p><p>No overall differences in safety or efficacy were detected between these patients and younger patients, but greater sensitivity of some older individuals cannot be ruled out.</p><h2>8.6 Renal Impairment</h2><p>No dosage adjustment of MOUNJARO is recommended for patients with renal impairment. In subjects with renal impairment including end-stage renal disease (ESRD), no change in tirzepatide pharmacokinetics (PK) was observed [see Clinical Pharmacology (12.3)]. Monitor renal function when initiating or escalating doses of MOUNJARO in patients with renal impairment reporting severe adverse gastrointestinal reactions [see Warnings and Precautions (5.5)].</p><h2>8.7 Hepatic Impairment</h2><p>No dosage adjustment of MOUNJARO is recommended for patients with hepatic impairment. In a clinical pharmacology study in subjects with varying degrees of hepatic impairment, no change in tirzepatide PK was observed [see Clinical Pharmacology (12.3)].</p>",
      "description": "<p>MOUNJARO (tirzepatide) injection is a once weekly GIP receptor and GLP-1 receptor agonist for subcutaneous use. It contains tirzepatide, based on the GIP sequence, with aminoisobutyric acid in positions 2 and 13, a C-terminal amide, and a Lys residue at position 20 attached to 1,20-eicosanedioic acid via a linker. The molecular weight is 4813.53 Da and the empirical formula is C225H348N48O68. MOUNJARO is a clear, colorless to slightly yellow, sterile, preservative-free solution. Each single-dose pen or vial contains a 0.5mL solution of 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, or 15mg of tirzepatide with excipients: sodium chloride (4.1mg), sodium phosphate dibasic heptahydrate (0.7mg), and water for injection. Hydrochloric acid solution and/or sodium hydroxide solution may be added to adjust the pH, which ranges from 6.5 to 7.5.</p>",
      "nonclinicalToxicology": "<h1>13 NONCLINICAL TOXICOLOGY</h1><h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><p>A 2-year carcinogenicity study was conducted with tirzepatide in male and female rats at doses of 0.15, 0.50, and 1.5mg/kg (0.1-, 0.4-, and 1-fold the MRHD of 15mg once weekly based on AUC) administered by subcutaneous injection twice weekly. A statistically significant increase in thyroid C-cell adenomas was observed in males (0.5mg/kg) and females (0.15mg/kg), and a statistically significant increase in thyroid C-cell adenomas and carcinomas combined was observed in males and females at all doses examined. In a 6-month carcinogenicity study in rasH2 transgenic mice, tirzepatide at doses of 1, 3, and 10mg/kg administered by subcutaneous injection twice weekly was not tumorigenic.</p><p>Tirzepatide was not genotoxic in a rat bone marrow micronucleus assay.</p><p>In fertility and early embryonic development studies, male and female rats were administered twice weekly subcutaneous doses of 0.5, 1.5, or 3mg/kg (0.3-, 1-, and 2-fold and 0.3-, 0.9-, and 2-fold, respectively, the MRHD of 15mg once weekly based on AUC). No effects of tirzepatide were observed on sperm morphology, mating, fertility, and conception. In female rats, an increase in the number of females with prolonged diestrus and a decrease in the mean number of corpora lutea resulting in a decrease in the mean number of implantation sites and viable embryos was observed at all dose levels. These effects were considered secondary to the pharmacological effects of tirzepatide on food consumption and body weight.</p>",
      "instructionsForUse": "<h1>Mounjaro Single-Dose Vial Instructions for Use</h1><table><tbody><tr><td>INSTRUCTIONS FOR USEMOUNJARO [mown-JAHR-OH](tirzepatide)injection, for subcutaneous use2.5mg/0.5mL single-dose vial5mg/0.5mL single-dose vial7.5mg/0.5mL single-dose vial10mg/0.5mL single-dose vial12.5mg/0.5mL single-dose vial15mg/0.5mL single-dose vial</td></tr></tbody></table><p>Important information you need to know before injecting MOUNJARO</p><p>Read this Instructions for Use before you start taking MOUNJARO and each time you get a new vial. There may be new information. This information does not take the place of talking to your healthcare provider about your medical condition or your treatment.</p><p>Do not share your needles or syringes with other people. You may give other people a serious infection or get a serious infection from them.</p><p>Talk to your healthcare provider about how to inject MOUNJARO the right way.</p><ul><li>MOUNJARO is a single-dose vial.</li><li>MOUNJARO is used 1 time each week.</li><li>Inject under the skin (subcutaneously) only.</li><li>You or another person may inject into your stomach (abdomen) or thigh.</li><li>Another person can inject into the back of your upper arm.</li></ul><p>Gather supplies needed to give your injection</p><ul><li>1 single-dose MOUNJARO vial</li><li>1 syringe and 1 needle, supplied separately (for example, use a 1 mL syringe and needle as recommended by your healthcare provider)</li><li>1 alcohol swab</li><li>gauze</li><li>1 sharps container for throwing away used needles and syringes. See Disposing of used needles and syringes at the end of these instructions.</li></ul><table><tbody><tr><td>Guide to partsVial</td><td>Needle and Syringe (not included)</td></tr></tbody></table><p>Note: The needle and syringe are not included. The needle and syringe recommended by your healthcare provider may look different than the needle and syringe in this Instructions for Use.</p><p>Preparing to inject MOUNJARO</p><p>Remove the vial from the refrigerator.</p><p>Check the vial label to make sure you have the right medicine and dose, and that it has not expired.</p><p>Make sure the medicine:</p><table><tbody><tr><td><ul><li>is not frozen</li><li>is not cloudy</li></ul></td><td><ul><li>is colorless to slightly yellow</li><li>does not have particles</li></ul></td></tr></tbody></table><p>Always use a new syringe and needle for each injection to prevent infections and blocked needles. Do not reuse or share your syringes or needles with other people. You may give other people a serious infection or get a serious infection from them.</p><p>Wash your hands with soap and water.</p><table><tbody><tr><td>Step 1:Pull off the plastic protective cap. Do not remove the rubber stopper.</td></tr><tr><td>Step 2:Wipe the rubber stopper with an alcohol swab.</td></tr><tr><td>Step 3:Remove the outer wrapping from the syringe.</td></tr><tr><td>Step 4:Remove the outer wrapping from the needle.The syringe that your healthcare provider recommended may have a pre-attached needle. If the needle is attached, skip to step 6.</td></tr><tr><td>Step 5:Place the needle on top of the syringe and turn until it is tight and firmly attached.</td></tr><tr><td>Step 6:Remove the needle shield by pulling straight off.</td></tr><tr><td>Step 7:Hold the syringe in one hand with the needle pointing up. With the other hand pull down on the plunger until the plunger tip reaches the line on the syringe indicating that 0.5mL of air has been drawn into the syringe.</td></tr><tr><td>Step 8:Push the needle through the rubber stopper of the vial.</td></tr><tr><td>Step 9:Push the plunger all the way in. This puts air into the vial and makes it easier to pull the solution from the vial.</td></tr><tr><td>Step 10: Turn the vial and syringe upside down. Make sure that the tip of the needle is in the liquid and slowly pull the plunger down until the plunger tip is past the 0.5 mL line. If there are air bubbles, tap the syringe gently a few times to let any air bubbles rise to the top.</td></tr><tr><td>Step 11:Slowly push the plunger up until the plunger tip reaches the 0.5 mL line.</td></tr><tr><td>Step 12:Pull the syringe out of the rubber stopper of the vial.</td></tr></tbody></table><p>Injecting MOUNJARO </p><ul><li>Inject exactly as your healthcare provider has shown you. Your healthcare provider should tell you if you should pinch the skin before injecting.</li><li>Change (rotate) your injection site within the area you choose for each dose to reduce your risk of getting lipodystrophy (pits in skin or thickened skin) and localized cutaneous amyloidosis (skin with lumps) at the injection sites.</li><li>Do not inject where the skin has pits, is thickened, or has lumps.</li><li>Do not inject where the skin is tender, bruised, scaly or hard, or into scars or damaged skin.</li><li>Do not mix MOUNJARO with any other medicine.</li><li>Do not inject MOUNJARO in the same injection site used for other medicines.</li></ul><table><tbody><tr><td>Step 13: Choose your injection site. You can inject MOUNJARO under the skin (subcutaneously) of your stomach area (abdomen) or thighs. Someone else can inject in your stomach area, thighs, or the back of the upper arms.</td></tr><tr><td>Step 14:Insert the needle into your skin.</td></tr><tr><td>Step 15:Push down on the plunger to inject your dose.The needle should stay in your skin for at least 5 seconds to make sure you have injected all of your dose.</td></tr><tr><td>Step 16:Pull the needle out of your skin.<ul><li>If you see blood after you take the needle out of your skin, press the injection site with a piece of gauze or an alcohol swab. Do not rub the area.</li><li>Do not recap the needle. Recapping the needle can lead to a needle stick injury.</li></ul></td></tr></tbody></table><p>Disposing of used needles and syringes</p><ul><li>Put your used needle and syringe in an FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) loose needles and syringes in your household trash.</li><li>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:<dl><dt>-</dt><dd> made of a heavy-duty plastic,</dd><dt>-</dt><dd> can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</dd><dt>-</dt><dd> upright and stable during use,</dd><dt>-</dt><dd> leak-resistant, and</dd><dt>-</dt><dd> properly labeled to warn of hazardous waste inside the container.</dd></dl></li><li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDAs website at: http://www.fda.gov/safesharpsdisposal.</li><li>Do not dispose of your used sharps disposal container in your household trash unless your community guidelines permit this. Do not recycle your used sharps disposal container.</li></ul><p>Storing MOUNJARO</p><ul><li>Store all unopened vials in the refrigerator at 36F to 46F (2C to 8C).</li><li>You may store the unopened vial at room temperature up to 86F (30C) for up to 21 days.</li><li>Do not freeze. Do not use if MOUNJARO has been frozen.</li><li>Store the vial in the original carton to protect from light.</li><li>Throw away all opened vials after use, even if there is medicine left in the vial.</li></ul><p>Keep MOUNJARO vials, syringes, needles, and all medicines out of the reach of children.</p><p>If you have any questions or problems with your MOUNJARO, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider for help.</p><p>Marketed by: Lilly USA, LLC Indianapolis, IN 46285, USA</p><p>MOUNJARO is a registered trademark of Eli Lilly and Company.</p><p>Copyright 2023, 2024, Eli Lilly and Company. All rights reserved.</p><p>MON-VL-0002-IFU-20240229</p><p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p><p>Revised: February 2024</p>",
      "mechanismOfAction": "<h2>12.1 Mechanism of Action</h2><p>Tirzepatide is a GIP receptor and GLP-1 receptor agonist. It is an amino-acid sequence including a C20 fatty diacid that enables albumin binding and prolongs the half-life. Tirzepatide selectively binds to and activates both the GIP and GLP-1 receptors, the targets for native GIP and GLP-1.</p><p>Tirzepatide enhances first- and second-phase insulin secretion, and reduces glucagon levels, both in a glucose-dependent manner.</p>",
      "contraindications": "\n<p>MOUNJARO is contraindicated in patients with:</p>\n<ul>\n<li>A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [see Warnings and Precautions (5.1)].</li>\n<li>Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported with MOUNJARO [see Warnings and Precautions (5.4)].</li>\n</ul>",
      "highlights": {
        "dosageAndAdministration": "<ul><li>The recommended starting dosage is 2.5mg injected subcutaneously once weekly (2.1)</li><li>After 4 weeks, increase to 5mg injected subcutaneously once weekly (2.1)</li><li>If additional glycemic control is needed, increase the dosage in 2.5mg increments after at least 4 weeks on the current dose.</li><li>The maximum dosage is 15mg subcutaneously once weekly (2.1).</li><li>Administer once weekly at any time of day, with or without meals. (2.2)</li><li>Inject subcutaneously in the abdomen, thigh, or upper arm. (2.2)</li><li>Rotate injection sites with each dose.</li></ul>"
      },
      "metaDescription": "<p>MOUNJARO is a tirzepatide injection for subcutaneous use, available in doses of 2.5mg to 15mg, with a pH of 6.5 to 7.5.</p>",
      "useAndConditions": "<p><h3>Approved Indications</h3></p>\n<ul>\n<li>MOUNJARO is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</li>\n</ul>",
      "contraIndications": "<h3>Contraindications</h3>\n<ul>\n<li>A personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).</li>\n<li>Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO, including reactions such as anaphylaxis and angioedema.</li>\n</ul>",
      "warnings": "<h3>Warnings and Precautions</h3>\n<ul>\n<li>Risk of Thyroid C-Cell Tumors: MOUNJARO is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Counsel patients about the potential risk for MTC and inform them of symptoms of thyroid tumors.</li>\n<li>Pancreatitis: Acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing pancreatitis, has been observed. Monitor patients for signs and symptoms of pancreatitis and discontinue MOUNJARO if suspected.</li>\n<li>Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Increased risk of hypoglycemia when used with insulin secretagogues or insulin. Consider dose reduction of these agents and educate patients on hypoglycemia signs and symptoms.</li>\n<li>Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylaxis and angioedema, have been reported. Discontinue MOUNJARO if such reactions occur and do not use in patients with previous serious hypersensitivity to tirzepatide.</li>\n<li>Acute Kidney Injury: Gastrointestinal adverse reactions may lead to dehydration and acute kidney injury. Monitor renal function in patients with renal impairment experiencing severe gastrointestinal reactions.</li>\n<li>Severe Gastrointestinal Adverse Reactions: Severe gastrointestinal reactions have been reported. MOUNJARO is not recommended in patients with severe gastrointestinal disease, including severe gastroparesis.</li>\n<li>Diabetic Retinopathy Complications: Rapid glucose control improvement may worsen diabetic retinopathy. Monitor patients with a history of diabetic retinopathy for progression.</li>\n<li>Acute Gallbladder Disease: Acute gallbladder disease events have been reported. If cholelithiasis is suspected, conduct diagnostic studies and follow-up.</li>\n<li>Pulmonary Aspiration During General Anesthesia or Deep Sedation: MOUNJARO delays gastric emptying, increasing the risk of pulmonary aspiration. Instruct patients to inform healthcare providers before surgeries or procedures.</li>\n</ul>",
      "dosing": "<p><h3>Adult Dosing</h3></p>\n<ul>\n<li>Starting dose: 2.5 mg injected subcutaneously once weekly.</li>\n<li>After 4 weeks, increase to 5 mg injected subcutaneously once weekly.</li>\n<li>If additional glycemic control is needed, increase in 2.5 mg increments after at least 4 weeks on the current dose.</li>\n<li>Maximum dose: 15 mg injected subcutaneously once weekly.</li>\n<li>If a dose is missed, administer as soon as possible within 4 days (96 hours). If more than 4 days have passed, skip the missed dose and continue with the next scheduled dose.</li>\n<li>The day of weekly administration can be changed if necessary, ensuring at least 3 days (72 hours) between doses.</li>\n</ul>\n\n<p><h3>Administration Instructions</h3></p>\n<ul>\n<li>Train patients and caregivers on proper injection technique.</li>\n<li>Use a syringe appropriate for dose administration, such as a 1 mL syringe capable of measuring a 0.5 mL dose.</li>\n<li>Administer once weekly, any time of day, with or without meals.</li>\n<li>Inject subcutaneously in the abdomen, thigh, or upper arm.</li>\n<li>Rotate injection sites with each dose.</li>\n<li>Inspect visually before use; should appear clear and colorless to slightly yellow. Do not use if particulate matter or discoloration is seen.</li>\n<li>When using with insulin, administer as separate injections and do not mix. Injections can be in the same body region but not adjacent.</li>\n</ul>\n\n<p><h3>Available Strengths</h3></p>\n<ul>\n<li>2.5 mg per 0.5 mL</li>\n<li>5 mg per 0.5 mL</li>\n<li>7.5 mg per 0.5 mL</li>\n<li>10 mg per 0.5 mL</li>\n<li>12.5 mg per 0.5 mL</li>\n<li>15 mg per 0.5 mL</li>\n</ul>"
    }
  },
  {
    "drugName": "Jaypirca",
    "setId": "bd551845-0878-49a4-860f-839b83f6b801",
    "slug": "jaypirca-bd55184",
    "labeler": "Lilly",
    "label": {
      "genericName": "pirtobrutinib",
      "labelerName": "Eli Lilly and Company",
      "productType": "HUMAN PRESCRIPTION DRUG LABEL",
      "effectiveTime": "20241113",
      "title": "JAYPIRCA",
      "indicationsAndUsage": "\n<h3>1.1 Mantle Cell Lymphoma</h3>\n<p>JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL) after at least two lines of systemic therapy, including a BTK inhibitor.</p>\n<p>This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.</p>\n<h3>1.2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</h3>\n<p>JAYPIRCA is indicated for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL) who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor.</p>\n<p>This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.</p>",
      "dosageAndAdministration": "\n<h3>2.1 Recommended Dosage</h3>\n<p>The recommended dosage of JAYPIRCA is 200 mg orally once daily until disease progression or unacceptable toxicity.</p>\n<p>Advise patients of the following:</p>\n<ul>\n<li>Swallow tablets whole with water. Do not cut, crush, or chew tablets.</li>\n<li>Take JAYPIRCA at the same time each day. JAYPIRCA may be taken with or without food.</li>\n<li>If a dose of JAYPIRCA is missed by more than 12 hours, do not make up the dose and take the next dose as scheduled.</li>\n</ul>\n<h3>2.2 Dosage Modifications for Adverse Reactions</h3>\n<p>Recommended dosage modifications of JAYPIRCA for adverse reactions are presented in Table 1 [see Warnings and Precautions (5.1, 5.2, 5.3, and 5.4)].</p>\n<table>\n<thead>\n<tr>\n<th>Adverse Reaction</th>\n<th>Occurrences Requiring Dosage Modification</th>\n<th>Modification (Starting Dosage: 200 mg once daily)</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td rowspan=\"4\">\n<ul>\n<li>Grade 3 or greater non-hematologic toxicity</li>\n<li>Absolute neutrophil count &lt; 1 to 0.5 x 10<sup>9</sup>/L with fever and/or infection</li>\n<li>Absolute neutrophil count &lt; 0.5 x 10<sup>9</sup>/L lasting 7 or more days</li>\n<li>Platelet count &lt; 50 to 25 x 10<sup>9</sup>/L with bleeding</li>\n<li>Platelet count &lt; 25 x 10<sup>9</sup>/L</li>\n</ul>\n</td>\n<td>First occurrence</td>\n<td>Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at original dosage (200 mg once daily).</td>\n</tr>\n<tr>\n<td>Second occurrence</td>\n<td>Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 100 mg once daily.</td>\n</tr>\n<tr>\n<td>Third occurrence</td>\n<td>Interrupt JAYPIRCA until recovery to Grade 1 or baseline; restart at 50 mg once daily.</td>\n</tr>\n<tr>\n<td>Fourth occurrence</td>\n<td>Discontinue JAYPIRCA.</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"3\">\n<p>Dose modification is not recommended for asymptomatic lymphocytosis. Asymptomatic lipase increase may not necessarily warrant dose modification.</p>\n</td>\n</tr>\n<tr>\n<td colspan=\"3\">\n<p>Evaluate the benefit-risk before resuming treatment at the same dose for a Grade 4 non-hematological toxicity.</p>\n</td>\n</tr>\n</tfoot>\n</table>\n<h3>2.3 Dosage Modifications for Patients with Severe Renal Impairment</h3>\n<p>For patients with severe renal impairment (eGFR 15-29 mL/min), reduce the JAYPIRCA dose to 100 mg once daily if the current dose is 200 mg once daily otherwise reduce the dose by 50 mg. If the current dosage is 50 mg once daily, discontinue JAYPIRCA [see Use in Specific Populations (8.7), Clinical Pharmacology (12.3)]. No dosage adjustment of JAYPIRCA is recommended in patients with mild to moderate renal impairment (eGFR 30-89 mL/min).</p>\n<h3>2.4 Dosage Modifications for Concomitant Use with Strong CYP3A Inhibitors</h3>\n<p>Avoid concomitant use of strong CYP3A inhibitors with JAYPIRCA [see Drug Interactions (7.1), Clinical Pharmacology (12.3)]. If concomitant use of a strong CYP3A inhibitor is unavoidable, reduce the JAYPIRCA dose by 50 mg. If the current dosage is 50 mg once daily, interrupt JAYPIRCA treatment for the duration of strong CYP3A inhibitor use. After discontinuation of a strong CYP3A inhibitor for 5 half-lives, resume the JAYPIRCA dose that was taken prior to initiating the strong CYP3A inhibitor.</p>\n<h3>2.5 Dosage Modifications for Concomitant Use with CYP3A Inducers</h3>\n<p>Avoid concomitant use of strong or moderate CYP3A inducers with JAYPIRCA [see Drug Interactions (7.1), Clinical Pharmacology (12.3)]. If concomitant use with moderate CYP3A inducers is unavoidable and the current dosage of JAYPIRCA is 200 mg once daily, increase the dose to 300 mg. If the current dosage is 50 mg or 100 mg once daily, increase the dose by 50 mg.</p>",
      "dosageFormsAndStrengths": "\n<p>Tablets:</p>\n<p>Each 50 mg tablet is blue, arc-triangle shaped, film-coated, and debossed with Lilly 50 on one side and 6902 on the other side.</p>\n<p>Each 100 mg tablet is blue, round, film-coated, and debossed with Lilly 100 on one side and 7026 on the other side.</p>",
      "warningsAndPrecautions": "\n<h3>5.1 Infections</h3>\n<p>Fatal and serious infections, including bacterial, viral, or fungal infections, and opportunistic infections have occurred in patients treated with JAYPIRCA. In the clinical trial, Grade 3 or higher infections occurred in 24% of 593 patients, most commonly pneumonia (14%), with fatal infections occurring in 4.4% of patients. Sepsis occurred in 6% of patients and febrile neutropenia in 4%. In patients with CLL/SLL, Grade 3 or higher infections occurred in 32% of patients, with fatal infections occurring in 8%. Opportunistic infections after treatment with JAYPIRCA have included, but are not limited to, Pneumocystis jirovecii pneumonia and fungal infection [see Adverse Reactions (6.1)].</p>\n<p>Consider prophylaxis, including vaccinations and antimicrobial prophylaxis, in patients who are at increased risk for infections, including opportunistic infections. Monitor patients for signs and symptoms of infection, evaluate promptly, and treat appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA [see Dosage and Administration (2.2)].</p>\n<h3>5.2 Hemorrhage</h3>\n<p>Fatal and serious hemorrhage has occurred with JAYPIRCA. Major hemorrhage, defined as Grade 3 or higher bleeding or any central nervous system bleeding, occurred in 3% of 593 patients treated with JAYPIRCA, including gastrointestinal hemorrhage; fatal hemorrhage occurred in 0.3% of patients. Bleeding of any grade, excluding bruising and petechiae, occurred in 17% of patients [see Adverse Reactions (6.1)].</p>\n<p>Major hemorrhage occurred in 2.3% of patients taking JAYPIRCA without antithrombotic agents and 0.7% of patients taking JAYPIRCA with antithrombotic agents. Consider the risks and benefits of antithrombotic agents when co-administered with JAYPIRCA. Monitor patients for signs of bleeding. Based on severity of bleeding, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA [see Dosage and Administration (2.2)].</p>\n<p>Consider the benefit-risk of withholding JAYPIRCA for 3 to 7 days pre- and post-surgery depending upon the type of surgery and risk of bleeding.</p>\n<h3>5.3 Cytopenias</h3>\n<p>JAYPIRCA can cause cytopenias, including neutropenia, thrombocytopenia, and anemia.</p>\n<p>In the clinical trial, Grade 3 or 4 cytopenias, including decreased neutrophils (26%), decreased platelets (12%), and decreased hemoglobin (12%) developed in patients treated with JAYPIRCA. Grade 4 decreased neutrophils developed in 14% of patients and Grade 4 decreased platelets developed in 6% of patients [see Adverse Reactions (6.1)].</p>\n<p>Monitor complete blood counts regularly during treatment. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA [see Dosage and Administration (2.2)].</p>\n<h3>5.4 Cardiac Arrhythmias</h3>\n<p>Cardiac arrhythmias, including atrial fibrillation and atrial flutter, were reported in recipients of JAYPIRCA. Atrial fibrillation or flutter were reported in 3.2% of patients, with Grade 3 or 4 atrial fibrillation or flutter reported in 1.5% of 593 patients in the clinical trial [see Adverse Reactions (6.1)]. Other serious cardiac arrhythmias such as supraventricular tachycardia and cardiac arrest occurred in 0.5% of patients. Patients with cardiac risk factors, such as hypertension, or previous arrhythmias may be at increased risk.</p>\n<p>Monitor for signs and symptoms of arrhythmias (e.g., palpitations, dizziness, syncope, dyspnea) and manage appropriately. Based on severity, reduce dose, temporarily withhold, or permanently discontinue JAYPIRCA [see Dosage and Administration (2.2)].</p>\n<h3>5.5 Second Primary Malignancies</h3>\n<p>Second primary malignancies, including non-skin carcinomas, developed in 9% of 593 patients treated with JAYPIRCA monotherapy. The most frequent malignancy was non-melanoma skin cancer, reported in 4.6% of 593 patients. Other second primary malignancies included solid tumors (including genitourinary and breast cancers) and melanoma. Advise patients to use sun protection and monitor patients for the development of second primary malignancies.</p>\n<h3>5.6 Hepatotoxicity, Including Drug-Induced Liver Injury</h3>\n<p>Hepatotoxicity, including severe, life-threatening, and potentially fatal cases of drug-induced liver injury (DILI), has occurred in patients treated with Bruton tyrosine kinase inhibitors, including JAYPIRCA.</p>\n<p>Evaluate bilirubin and transaminases at baseline and throughout treatment with JAYPIRCA. For patients who develop abnormal liver tests after JAYPIRCA, monitor more frequently for liver test abnormalities and clinical signs and symptoms of hepatic toxicity. If DILI is suspected, withhold JAYPIRCA. Upon confirmation of DILI, discontinue JAYPIRCA.</p>\n<h3>5.7 Embryo-Fetal Toxicity</h3>\n<p>Based on findings in animals, JAYPIRCA can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of pirtobrutinib to pregnant rats during the period of organogenesis caused embryo-fetal toxicity including embryo-fetal mortality and malformations at maternal exposures (AUC) approximately 3-times the recommended dose of 200 mg once daily. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with JAYPIRCA and for one week after the last dose [see Use in Specific Populations (8.1, 8.3)].</p>",
      "adverseReactions": "\n<p>The following clinically significant adverse reactions are described elsewhere in the labeling:</p>\n<ul>\n<li>Infections [see Warnings and Precautions (5.1)]</li>\n<li>Hemorrhage [see Warnings and Precautions (5.2)]</li>\n<li>Cytopenias [see Warnings and Precautions (5.3)]</li>\n<li>Atrial Fibrillation and Atrial Flutter [see Warnings and Precautions (5.4)]</li>\n<li>Second Primary Malignancies [see Warnings and Precautions (5.5)]</li>\n<li>Hepatotoxicity, including DILI [see Warnings and Precautions (5.6)]</li>\n</ul>\n<h3>6.1 Clinical Trials Experience</h3>\n<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be compared to rates in the clinical trials of another drug and may not reflect the rates observed in the general patient population.</p>\n<p>The data in the WARNINGS AND PRECAUTIONS reflect exposure to JAYPIRCA as a single-agent, administered at 200 mg once daily in 593 patients with hematologic malignancies in the BRUIN study. Among these 593 patients, the median duration of exposure was 10 months, 62% were exposed for at least 6 months and 45% were exposed for at least one year.</p>\n<p>In this pooled safety population, the most common ( 20%) adverse reactions, including laboratory abnormalities, were decreased neutrophil count (46%), decreased hemoglobin (39%), fatigue (32%), decreased lymphocyte count (31%), musculoskeletal pain (30%), decreased platelet count (29%), diarrhea (24%), COVID-19 (22%), bruising (21%), and cough (20%).</p>\n<p>Mantle Cell Lymphoma</p>\n<p>BRUIN</p>\n<p>The safety of JAYPIRCA was evaluated in the BRUIN trial in patients with MCL who received a prior BTK inhibitor [see Clinical Studies (14.1)]. The trial required a platelet count  50 x 10<sup>9</sup>/L, absolute neutrophil count  0.75 x 10<sup>9</sup>/L, hepatic transaminases  2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. The trial excluded patients with active central nervous system (CNS) involvement by lymphoma, significant cardiovascular disease, major bleeding or grade 3 arrhythmia with a prior BTK inhibitor, prolonged QTc interval, or need for a strong CYP3A inhibitor or inducer or strong P-gp inhibitor.</p>\n<p>Patients received JAYPIRCA 200 mg orally once daily until disease progression or unacceptable toxicity (n = 128); 36% were exposed for 6 months or longer and 10% were exposed for at least one year. The median number of prior therapies was 3 (range: 1-9). The median age was 71 years (range: 46 to 88 years) and 80% of patients were male. Race was reported for all patients; 78% were White, 14% were Asian, 2.3% were Black, and 2.3% were Hispanic or Latino.</p>\n<p>Serious adverse reactions occurred in 38% of patients who received JAYPIRCA. Serious adverse reactions that occurred in  2% of patients were pneumonia (14%), COVID-19 (4.7%), musculoskeletal pain (3.9%), hemorrhage (2.3%), pleural effusion (2.3%), and sepsis (2.3%). Fatal adverse reactions within 28 days of the last dose of JAYPIRCA occurred in 7% of patients, most commonly due to infections (4.7%) including COVID-19 (3.1% of all patients).</p>\n<p>Adverse reactions led to dose reductions in 4.7%, treatment interruption in 32%, and permanent discontinuation of JAYPIRCA in 9%. Adverse reactions that resulted in dosage modification in &gt; 5% of patients included pneumonia and neutropenia. Adverse reactions which resulted in permanent discontinuation of JAYPIRCA in &gt; 1% of patients included pneumonia.</p>\n<p>The most common adverse reactions ( 15%), excluding laboratory terms, were fatigue, musculoskeletal pain, diarrhea, edema, dyspnea, pneumonia, and bruising.</p>\n<table>\n<caption>Table 2: Adverse Reactions ( 10%) in Patients with MCL Who Received JAYPIRCA</caption>\n<thead>\n<tr>\n<th colspan=\"2\">JAYPIRCA 200 mg once daily</th>\n</tr>\n<tr>\n<th colspan=\"2\">N = 128</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Adverse Reactions<sup>a</sup></td>\n<td>All Grades (%)</td>\n<td>Grade 3-4 (%)</td>\n</tr>\n<tr>\n<td colspan=\"3\">General Disorders</td>\n</tr>\n<tr>\n<td>Fatigue</td>\n<td>29</td>\n<td>1.6</td>\n</tr>\n<tr>\n<td>Edema</td>\n<td>18</td>\n<td>0.8</td>\n</tr>\n<tr>\n<td>Fever</td>\n<td>13</td>\n<td>-</td>\n</tr>\n<tr>\n<td colspan=\"3\">Musculoskeletal and Connective Tissue Disorders</td>\n</tr>\n<tr>\n<td>Musculoskeletal pain</td>\n<td>27</td>\n<td>3.9</td>\n</tr>\n<tr>\n<td>Arthritis or arthralgia</td>\n<td>12</td>\n<td>0.8</td>\n</tr>\n<tr>\n<td colspan=\"3\">Gastrointestinal Disorders</td>\n</tr>\n<tr>\n<td>Diarrhea</td>\n<td>19</td>\n<td>-</td>\n</tr>\n<tr>\n<td>Constipation</td>\n<td>13</td>\n<td>-</td>\n</tr>\n<tr>\n<td>Abdominal pain</td>\n<td>11</td>\n<td>0.8</td>\n</tr>\n<tr>\n<td>Nausea</td>\n<td>11</td>\n<td>-</td>\n</tr>\n<tr>\n<td colspan=\"3\">Respiratory, thoracic, and mediastinal disorders</td>\n</tr>\n<tr>\n<td>Dyspnea</td>\n<td>17</td>\n<td>2.3</td>\n</tr>\n<tr>\n<td>Cough</td>\n<td>14</td>\n<td>-</td>\n</tr>\n<tr>\n<td colspan=\"3\">Injury</td>\n</tr>\n<tr>\n<td>Bruising</td>\n<td>16</td>\n<td>-</td>\n</tr>\n<tr>\n<td colspan=\"3\">Infections</td>\n</tr>\n<tr>\n<td>Pneumonia</td>\n<td>16<sup>b</sup></td>\n<td>14</td>\n</tr>\n<tr>\n<td>Upper respiratory tract infections</td>\n<td>10</td>\n<td>0.8</td>\n</tr>\n<tr>\n<td colspan=\"3\">Nervous system disorders</td>\n</tr>\n<tr>\n<td>Peripheral neuropathy</td>\n<td>14</td>\n<td>0.8</td>\n</tr>\n<tr>\n<td>Dizziness</td>\n<td>10</td>\n<td>-</td>\n</tr>\n<tr>\n<td colspan=\"3\">Skin and subcutaneous disorders</td>\n</tr>\n<tr>\n<td>Rash</td>\n<td>14</td>\n<td>-</td>\n</tr>\n<tr>\n<td colspan=\"3\">Vascular disorders</td>\n</tr>\n<tr>\n<td>Hemorrhage</td>\n<td>11<sup>c</sup></td>\n<td>3.1</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"3\"><p>a Each term listed includes other related terms.</p></td>\n</tr>\n<tr>\n<td colspan=\"3\"><p>b includes 1 fatality from COVID-19 pneumonia</p></td>\n</tr>\n<tr>\n<td colspan=\"3\"><p>c includes 1 fatality from hemorrhage</p></td>\n</tr>\n</tfoot>\n</table>\n<p>Clinically relevant adverse reactions in &lt; 10% include vision changes, memory changes, headache, urinary tract infection, herpesvirus infection, and tumor lysis syndrome.</p>\n<p>Table 3 summarizes laboratory abnormalities in BRUIN.</p>\n<table>\n<caption>Table 3: Select Laboratory Abnormalities ( 10%) That Worsened from Baseline in Patients with MCL Who Received JAYPIRCA</caption>\n<thead>\n<tr>\n<th rowspan=\"2\">Laboratory Abnormality</th>\n<th colspan=\"2\">JAYPIRCA<sup>a</sup> 200 mg once daily</th>\n</tr>\n<tr>\n<th>All Grades (%)</th>\n<th>Grade 3 or 4 (%)</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Hematology</td>\n</tr>\n<tr>\n<td>Hemoglobin decreased</td>\n<td>42</td>\n<td>9</td>\n</tr>\n<tr>\n<td>Platelet count decreased</td>\n<td>39</td>\n<td>14</td>\n</tr>\n<tr>\n<td>Neutrophil count decreased</td>\n<td>36</td>\n<td>16</td>\n</tr>\n<tr>\n<td>Lymphocyte count decreased</td>\n<td>32</td>\n<td>15</td>\n</tr>\n<tr>\n<td>Chemistry</td>\n</tr>\n<tr>\n<td>Creatinine increased</td>\n<td>30</td>\n<td>1.6</td>\n</tr>\n<tr>\n<td>Calcium decreased</td>\n<td>19</td>\n<td>1.6</td>\n</tr>\n<tr>\n<td>AST increased</td>\n<td>17</td>\n<td>1.6</td>\n</tr>\n<tr>\n<td>Potassium decreased</td>\n<td>13</td>\n<td>1.6</td>\n</tr>\n<tr>\n<td>Sodium decreased</td>\n<td>13</td>\n<td>-</td>\n</tr>\n<tr>\n<td>Lipase increased</td>\n<td>12</td>\n<td>4.4</td>\n</tr>\n<tr>\n<td>Alkaline phosphatase increased</td>\n<td>11</td>\n<td>-</td>\n</tr>\n<tr>\n<td>ALT increased</td>\n<td>11</td>\n<td>1.6</td>\n</tr>\n<tr>\n<td>Potassium increased</td>\n<td>11</td>\n<td>0.8</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"3\"><p>a The denominator used to calculate the rate varied from 90 to 127 based on the number of patients with a baseline value and at least one post-treatment value.</p></td>\n</tr>\n</tfoot>\n</table>\n<p>Grade 4 laboratory abnormalities in &gt; 5% of patients included neutrophils decreased (10%), platelets decreased (7%), and lymphocytes decreased (6%).</p>\n<p>Lymphocytosis: Upon initiation of JAYPIRCA, a temporary increase in lymphocyte counts (defined as absolute lymphocyte count increased 50% from baseline and a post-baseline value  5,000/L) occurred in 34% of MCL patients in BRUIN. The median time to onset of lymphocytosis was 1.1 weeks, with 75% of cases occurring within 2.1 weeks, and the median duration was 11 weeks.</p>\n<p>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</p>\n<p>BRUIN</p>\n<p>The safety of JAYPIRCA was evaluated in the BRUIN trial in 110 patients with CLL/SLL, with 98% receiving at least two prior lines of systemic therapy including a BTK inhibitor and a BCL-2 inhibitor [see Clinical Studies (14.2)]. The trial required a platelet count  50 x 10<sup>9</sup>/L, absolute neutrophil count  0.75 x 10<sup>9</sup>/L, hepatic transaminases  2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. The trial excluded patients with active central nervous system (CNS) involvement by lymphoma, significant cardiovascular disease, major bleeding, uncontrolled or symptomatic arrhythmias, prolonged QTc interval, or need for a strong CYP3A inhibitor or inducer or strong P-gp inhibitor.</p>\n<p>Patients received JAYPIRCA 200 mg orally once daily until disease progression or unacceptable toxicity (N = 110); 60% were exposed for at least 1 year and 14% were exposed for at least two years. The median age was 68 years (range: 41 to 88 years) and 67% of patients were male. Race was reported in 110 (100%) patients; of these patients, 89% were White, 4.5% were Black, 1.8% were Asian, and 1.8% were Hispanic or Latino. The median number of prior therapies was 5 (range: 1-11).</p>\n<p>Serious adverse reactions occurred in 56% of patients who received JAYPIRCA. Serious adverse reactions that occurred in  5% of patients were pneumonia (18%), COVID-19 (9%), sepsis (7%), and febrile neutropenia (7%). Fatal adverse reactions within 28 days of the last dose of JAYPIRCA occurred in 11% of patients, most commonly due to infections (10%), including sepsis (5%) and COVID-19 (2.7%).</p>\n<p>Adverse reactions led to dose reductions in 3.6%, treatment interruption in 42%, and permanent discontinuation of JAYPIRCA in 9%. Adverse reactions which resulted in dose reductions of JAYPIRCA in &gt; 1% of patients included neutropenia. Adverse reactions which resulted in treatment interruptions of JAYPIRCA in &gt; 5% of patients included pneumonia, neutropenia, febrile neutropenia, and COVID-19. Adverse reactions which resulted in permanent discontinuation of JAYPIRCA in &gt; 1% of patients included second primary malignancy, COVID-19, and sepsis.</p>\n<p>The most common adverse reactions ( 20%), excluding laboratory terms, were fatigue, bruising, cough, musculoskeletal pain, COVID-19, diarrhea, pneumonia, abdominal pain, dyspnea, hemorrhage, edema, nausea, pyrexia, and headache. Table 4 summarizes select adverse reactions for patients treated on BRUIN.</p>\n<table>\n<caption>Table 4: Adverse Reactions ( 10%) in Patients with CLL/SLL Who Received JAYPIRCA</caption>\n<thead>\n<tr>\n<th colspan=\"2\">JAYPIRCA 200 mg once daily</th>\n</tr>\n<tr>\n<th colspan=\"2\">N = 110</th>\n</tr>\n<tr>\n<th>Adverse Reactions<sup>a</sup></th>\n<th>All Grades (%)</th>\n<th>Grade 3-4 (%)</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td colspan=\"3\">General Disorders</td>\n</tr>\n<tr>\n<td>Fatigue</td>\n<td>36</td>\n<td>2.7</td>\n</tr>\n<tr>\n<td>Edema</td>\n<td>21</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Pyrexia</td>\n<td>20</td>\n<td>2.7</td>\n</tr>\n<tr>\n<td colspan=\"3\">Injury</td>\n</tr>\n<tr>\n<td>Bruising</td>\n<td>36</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Fall</td>\n<td>14</td>\n<td>0.9</td>\n</tr>\n<tr>\n<td colspan=\"3\">Respiratory, thoracic, and mediastinal disorders</td>\n</tr>\n<tr>\n<td>Cough</td>\n<td>33</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Dyspnea</td>\n<td>22</td>\n<td>2.7</td>\n</tr>\n<tr>\n<td>Mucositis</td>\n<td>12</td>\n<td>0.9</td>\n</tr>\n<tr>\n<td colspan=\"3\">Musculoskeletal and Connective Tissue Disorders</td>\n</tr>\n<tr>\n<td>Musculoskeletal pain</td>\n<td>32</td>\n<td>0.9</td>\n</tr>\n<tr>\n<td>Arthritis or arthralgia</td>\n<td>19</td>\n<td>1.8</td>\n</tr>\n<tr>\n<td colspan=\"3\">Infections</td>\n</tr>\n<tr>\n<td>COVID-19</td>\n<td>28<sup>b</sup></td>\n<td>7</td>\n</tr>\n<tr>\n<td>Pneumonia</td>\n<td>27<sup>c</sup></td>\n<td>16</td>\n</tr>\n<tr>\n<td>Upper respiratory tract infections</td>\n<td>13</td>\n<td>2.7</td>\n</tr>\n<tr>\n<td>Respiratory tract infection</td>\n<td>11</td>\n<td>1.8</td>\n</tr>\n<tr>\n<td colspan=\"3\">Gastrointestinal Disorders</td>\n</tr>\n<tr>\n<td>Diarrhea</td>\n<td>26</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Abdominal pain</td>\n<td>25</td>\n<td>2.7</td>\n</tr>\n<tr>\n<td>Nausea</td>\n<td>21</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Constipation</td>\n<td>14</td>\n<td>0</td>\n</tr>\n<tr>\n<td colspan=\"3\">Vascular disorders</td>\n</tr>\n<tr>\n<td>Hemorrhage</td>\n<td>22<sup>d</sup></td>\n<td>2.7</td>\n</tr>\n<tr>\n<td>Hypertension</td>\n<td>12</td></tr></tbody></table>",
      "drugInteractions": "<h1>7 DRUG INTERACTIONS</h1><h2>7.1 Effect of Other Drugs on JAYPIRCA</h2><p>Strong CYP3A Inhibitors</p><p>Pirtobrutinib is a CYP3A substrate. Concomitant use of JAYPIRCA with a strong CYP3A inhibitor increased pirtobrutinib systemic exposure [see Clinical Pharmacology (12.3)], which may increase the risk of JAYPIRCA adverse reactions. Avoid concomitant use of strong CYP3A inhibitors during treatment with JAYPIRCA. If concomitant use of strong CYP3A inhibitors is unavoidable, reduce the JAYPIRCA dosage [see Dosage and Administration (2.4)].</p><p>Strong or Moderate CYP3A Inducers</p><p>Concomitant use of JAYPIRCA with a strong or moderate CYP3A inducer decreased pirtobrutinib systemic exposure [see Clinical Pharmacology (12.3)], which may reduce JAYPIRCA efficacy. Avoid concomitant use of JAYPIRCA with strong or moderate CYP3A inducers. If concomitant use of moderate CYP3A inducers is unavoidable, increase the JAYPIRCA dosage [see Dosage and Administration (2.5)].</p><h2>7.2 Effect of JAYPIRCA on Other Drugs</h2><p>Sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP Substrates</p><p>JAYPIRCA is a P-gp inhibitor, a moderate CYP2C8 and BCRP inhibitor, and a weak CYP2C19 and CYP3A inhibitor. Concomitant use of JAYPIRCA with sensitive P-gp, CYP2C8, BCRP, CYP2C19, or CYP3A substrates increased their plasma concentrations [see Clinical Pharmacology (12.3)], which may increase the risk of adverse reactions related to these substrates for drugs which are sensitive to minimal concentration changes. Follow recommendations for sensitive CYP2C8, CYP2C19, CYP3A, P-gp, or BCRP substrates provided in their approved product labeling.</p>",
      "clinicalPharmacology": "<h1>12 CLINICAL PHARMACOLOGY</h1><h2>12.1 Mechanism of action</h2><p>Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK and BTK harboring C481 mutations, leading to inhibition of BTK kinase activity. In nonclinical studies, pirtobrutinib inhibited BTK-mediated B-cell CD69 expression and inhibited malignant B-cell proliferation. Pirtobrutinib showed dose-dependent anti-tumor activities in BTK wild type and BTK C481S mutant mouse xenograft models.</p><h2>12.2 Pharmacodynamics</h2><p>At the recommended dosage of 200 mg once daily, pirtobrutinib trough concentrations exceeded the BTK IC96. BTK occupancy is maintained throughout the dosing interval, regardless of the intrinsic rate of BTK turnover.</p><p>Cardiac Electrophysiology</p><p>The effect of a single 900 mg dose of pirtobrutinib (equivalent to approximately 2 times higher than the concentrations achieved at steady state at the recommended dosage of 200 mg once daily) on the QTc interval was evaluated in a placebo-controlled and positive-controlled study in 30 healthy subjects. Pirtobrutinib had no clinically meaningful effect on the change in QTcF interval (i.e., &gt; 10 ms) and there was no relationship between pirtobrutinib exposure and change in QTc interval.</p><h2>12.3 Pharmacokinetics</h2><p>The pharmacokinetics of pirtobrutinib were characterized in healthy subjects and in patients with cancer. Pirtobrutinib exposure (AUC) and Cmax increases proportionally following single oral doses ranging from 300 mg to 800 mg (1.5 to 4times the approved recommended dosage) and once daily doses ranging from 25 300 mg (0.125 to 1.5 times the recommended dosage). Steady state was achieved within 5 days of once daily dosing, and the mean (CV%) accumulation ratio was 1.63 (26.7%) based on AUC after administration of 200 mg dosages.</p><p>Following administration of the recommended dosage, the geometric mean (CV%) steady-state AUC and Cmax of pirtobrutinib were 90300 h*ng/mL (40%) and 6380 ng/mL (26%), respectively. The geometric mean (CV%) AUC0-24 and Cmax of pirtobrutinib on Cycle 1 Day 8 were 81800 h*ng/mL (66.6%) and 3670 ng/mL (89.5%), respectively.</p><p>Absorption</p><p>The absolute bioavailability of pirtobrutinib after a single oral 200 mg dose is 85.5% (range 75.9% to 90.9%). The median time (range) to reach peak plasma concentration (tmax) is approximately 2 hours (0.833 to 4.15 hours).</p><p>Effect of Food</p><p>No clinically significant differences in the pharmacokinetics of pirtobrutinib were observed following administration of a high-fat, high-calorie meal (approximately 800 to 1000 calories with 150 calories from protein, 250 calories from carbohydrate, and 500 to 600 calories from fat) to healthy subjects. A high-fat meal decreased the Cmax of pirtobrutinib by 23% and delayed tmax by 1 hour. There was no effect on pirtobrutinib AUC.</p><p>Distribution</p><p>The mean apparent central volume of distribution of pirtobrutinib is 34.1 L. Human protein binding of pirtobrutinib is 96%and is independent of concentration in vitro. Mean blood-to-plasma ratio is 0.79.</p><p>Elimination</p><p>The effective half-life of pirtobrutinib is approximately 19 hours and the mean (CV%) apparent clearance is 2.05 L/h (37.2%).</p><p>Metabolism</p><p>Pirtobrutinib is primarily metabolized by CYP3A4 and direct glucuronidation by UGT1A8 and UGT1A9, in vitro.</p><p>Excretion</p><p>Following a single radiolabeled dose of pirtobrutinib 200 mg to healthy subjects, 37% of the dose was recovered in feces (18% unchanged) and 57% in urine (10% unchanged).</p><p>Specific Populations</p><p>There were no clinically significant differences in the pharmacokinetics of pirtobrutinib based on age (range 2295years), sex, race/ethnicity (White 84%, Asian 7%), body weight (range 35.7 152 kg), mild (total bilirubin upper limit of normal (ULN) and aspartate aminotransferase (AST) &gt; ULN or total bilirubin &gt; 1 to 1.5 ULN and any AST), moderate (total bilirubin &gt; 1.5 to 3 ULN and any AST), or severe (total bilirubin &gt; 3 ULN and any AST) hepatic impairment. The effect of other races/ethnicities on the pharmacokinetics of pirtobrutinib is unknown.</p><p>Patients with Renal Impairment</p><p>Following a single 200 mg oral dose, the AUC of pirtobrutinib in subjects with severe renal impairment (eGFR 15-29mL/min) increased by 62% and mean unbound AUC increased by 68% compared to healthy subjects with normal renal function. There were no clinically significant differences in the pharmacokinetics of pirtobrutinib in subjects with mild (eGFR 60-89 mL/min) or moderate renal impairment (eGFR 30-59 mL/min). The effect of renal impairment requiring dialysis on the pharmacokinetics of pirtobrutinib is unknown.</p><p>Drug Interaction Studies</p><p>Clinical Studies and Model-Informed Approaches</p><p>Strong CYP3A Inhibitors: Co-administration of a single 200 mg dose of pirtobrutinib with itraconazole (strong CYP3A inhibitor) increased AUC of pirtobrutinib by 49%.</p><p>Moderate CYP3A Inhibitors: Verapamil and diltiazem (moderate CYP3A inhibitors) are predicted to increase the AUC of pirtobrutinib by 30% and 20%, respectively.</p><p>Strong CYP3A inducers: Coadministration of a single 200 mg dose of pirtobrutinib with rifampin (strong CYP3A inducer) decreased the AUC of pirtobrutinib by 71%.</p><p>Moderate CYP3A Inducers: Efavirenz and bosentan (moderate CYP3A inducers) are predicted to decrease the AUC of pirtobrutinib by 49% and 27%, respectively.</p><p>Gastric Reducing Agents: No clinically significant differences in pirtobrutinib pharmacokinetics were observed when co-administered with omeprazole (a proton pump inhibitor).</p><p>P-glycoprotein (P-gp) inhibitors: No clinically significant differences in pirtobrutinib pharmacokinetics were observed when co-administered with itraconazole (P-gp inhibitor).</p><p>CYP3A Substrates: Pirtobrutinib increased the AUC and Cmax of orally administered midazolam (sensitive CYP3A substrate) by 70% and 58%, respectively. Pirtobrutinib did not have a clinically meaningful effect on the exposure of intravenously administered midazolam.</p><p>CYP2C8 Substrates: Pirtobrutinib increased the AUC and Cmax of repaglinide (sensitive CYP2C8 substrate) by 130% and 98%, respectively.</p><p>CYP2C19 Substrates: Pirtobrutinib increased the AUC and Cmax of omeprazole (sensitive CYP2C19 substrate) by 56% and 49%, respectively.</p><p>P-gp Substrates: A single 200 mg dose of pirtobrutinib increased the AUC and Cmax of digoxin (sensitive P-gp substrate) by 17% and 51%, respectively. Multiple doses of pirtobrutinib (200 mg daily) further increased the AUC and Cmax of digoxin (sensitive P-gp substrate) up to 35% and 55%, respectively.</p><p>BCRP Substrates: Multiple doses of pirtobrutinib (200 mg daily) increased the AUC and Cmax of rosuvastatin (sensitive BCRP substrate) by 140% and 146%, respectively.</p><p>CYP1A2 and CYP2C9 Substrates: Pirtobrutinib did not have a clinically meaningful effect on the exposures of caffeine (sensitive CYP1A2 substrate) or S-warfarin (moderate sensitive CYP2C9 substrate).</p><p>In Vitro Studies</p><p>Cytochrome P450 (CYP) Enzymes: Pirtobrutinib inhibits CYP2C8, CYP2C9, CYP3A, CYP1A2, CYP2B6, CYP2C19, and CYP2D6. Pirtobrutinib induces CYP3A4, CYP3A5, CYP2B6, and CYP2C19.</p><p>Transporter Systems: Pirtobrutinib inhibits P-gp and BCRP, but not OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, or MATE2-K. Pirtobrutinib is not a substrate of the hepatic transporters. Pirtobrutinib is a substrate of P-gp and BCRP, but not OCT1, OATP1B1, OATP1B3, or BSEP.</p>",
      "clinicalStudies": "<h1>14 CLINICAL STUDIES</h1><h2>14.1 Mantle Cell Lymphoma</h2><p>The efficacy of JAYPIRCA in patients with MCL was evaluated in BRUIN [NCT03740529], an open-label, international, multicohort, single-arm study of JAYPIRCA as monotherapy. Efficacy was based on 120 patients with MCL treated with JAYPIRCA who were previously treated with a BTK inhibitor. JAYPIRCA was given orally at a dose of 200 mg once daily and was continued until disease progression or unacceptable toxicity. Patients with active central nervous system lymphoma or allogeneic hematopoietic stem cell transplantation (HSCT) or CAR-T cell therapy within 60 days were excluded.</p><p>The median age was 71 years (range: 46 to 88 years); 79% were male; 78% were White, 14% Asian, 1.7% Black or African American. Seventy-eight percent of patients had the classic/leukemic variant of MCL, 12% had pleomorphic MCL, and 11% had blastoid MCL. The simplified Mantle Cell Lymphoma International Prognostic Index (sMIPI) score was low in 15%, intermediate in 59%, and high in 26% of patients. Patients received a median number of 3 prior lines of therapy (range: 1 to 9) with 93% having received 2 or more prior lines. All received 1 or more prior lines of therapy containing a BTK inhibitor; other prior therapies included chemoimmunotherapy in 88%, HSCT in 20%, lenalidomide in 18%, and CAR-T therapy in 9%. The most common prior BTK inhibitors received were ibrutinib (67%), acalabrutinib (30%), and zanubrutinib (8%). Patients may have received more than one prior BTK inhibitor; 83% of patients discontinued the last BTK inhibitor for refractory or progressive disease, 10% discontinued for toxicity, and 5% discontinued for other reasons.</p><p>Efficacy was based on overall response rate (ORR) and duration of response (DOR), as assessed by an independent review committee (IRC) using 2014 Lugano criteria. Efficacy results are shown in Table 6. Additionally, the Kaplan-Meier estimate for the DOR rate at 6 months was 65.3% (95% CI: 49.8, 77.1).</p><table><caption>Table 6: Efficacy Results per IRC in Patients with MCL Previously Treated with a BTK Inhibitor</caption><tfoot><tr><td colspan=\"2\"><p>CI, confidence interval; CR, complete response; DOR, duration of response; PR, partial response; NE, not estimable.</p></td></tr><tr><td colspan=\"2\"><p>a PET-CT scans were utilized in response assessments (in 41% of patients), with the remainder being assessed by CT scans only.</p></td></tr><tr><td colspan=\"2\"><p>b ORR using CT scan-based assessments in all patients was 48% (95% CI: 38, 57) and CR rate was 13%.</p></td></tr><tr><td colspan=\"2\"><p>c Based on Kaplan-Meier estimation. Estimated median follow-up was 7.3 months.</p></td></tr></tfoot><tbody><tr><td>Outcome</td><td>JAYPIRCA 200 mg once daily(N = 120)</td></tr><tr><td>Overall Response Ratea,b</td></tr><tr><td> ORR, n</td><td>60 (50%)</td></tr><tr><td> (95% CI, %)</td><td>41, 59</td></tr><tr><td>CR, n</td><td>15 (13%)</td></tr><tr><td>PR, n</td><td>45 (38%)</td></tr><tr><td>Time to Response</td></tr><tr><td>Median (range), months</td><td>1.8 (0.8, 4.2)</td></tr><tr><td>Duration of Responsec</td></tr><tr><td> Number censored, n</td><td>36</td></tr><tr><td> Median DOR, months (95% CI)</td><td>8.3 (5.7, NE)</td></tr></tbody></table><h2>14.2 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma</h2><p>The efficacy of JAYPIRCA in patients with CLL/SLL was evaluated in BRUIN [NCT03740529], an open-label, international, single-arm, multicohort study of JAYPIRCA as monotherapy. Efficacy was based on 108 patients with CLL/SLL treated with JAYPIRCA who were previously treated with at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. JAYPIRCA was given orally at a dose of 200 mg once daily and was continued until disease progression or unacceptable toxicity. The trial required a platelet count 50 x 109/L, absolute neutrophil count 0.75 x 109/L, hepatic transaminases 2.5 times upper limit of normal (ULN), and an ECOG performance status of 0 to 2. The trial excluded patients with significant cardiovascular disease, major bleeding, uncontrolled or symptomatic arrhythmias, prolonged QTc interval, or need for a strong CYP3A inhibitor or inducer or strong P-gp inhibitor. Patients with active central nervous system (CNS) involvement by lymphoma or allogeneic hematopoietic stem cell transplantation (HSCT) within 60 days were excluded.</p><p>The median age was 68 years (range: 41 to 88 years); 69% were male; 89% were White, 4.6% Black or African American, 1.9% Asian and 1.9% were Hispanic or Latino. Baseline ECOG performance status was 0 or 1 in 91% of patients and 48% of patients had Rai stage III or IV disease. Among those patients with central testing available, 42% (37 of 88 patients) had a C481 BTK mutation, 54% (43 of 79 patients) had 17p deletion and/or TP53 mutation, 93% (77 of 83 patients) had unmutated IGHV, and 22% (16 of 72 patients) had 11q deletion. Patients received a median number of 5 prior lines of therapy (range: 2 to 11). The most common prior BTK inhibitors received were ibrutinib (97%), acalabrutinib (9%), and zanubrutinib (0.9%). Seventy-seven percent of patients discontinued the last BTK inhibitor for refractory or progressive disease, 13% discontinued for toxicity, and 10% discontinued for other reasons.</p><p>Efficacy was established based on overall response rate (ORR) and duration of response (DOR), as assessed by an independent review committee (IRC) using 2018 iwCLL criteria. Efficacy results are shown in Table 7. The median time to response was 3.7 months (range: 1.7, 27.9 months).</p><table><caption>Table 7: Efficacy Results per IRC in Patients with CLL/SLL Previously Treated with a BTK Inhibitor and a BCL-2 inhibitor</caption><tfoot><tr><td colspan=\"2\"><p>CI, confidence interval; PR, partial response.</p></td></tr><tr><td colspan=\"2\"><p>a Based on Kaplan-Meier estimation. Estimated median follow-up was 15.7 months.</p></td></tr></tfoot><tbody><tr><td>Outcome</td><td>JAYPIRCA 200 mg once daily(N = 108)</td></tr><tr><td>Overall Response Rate</td></tr><tr><td>ORR, n</td><td>78 (72%)</td></tr><tr><td> (95% CI, %)</td><td>63, 80</td></tr><tr><td>PR, n</td><td>78 (72%)</td></tr><tr><td>Duration of Responsea</td></tr><tr><td>Median DOR, months (95% CI)</td><td>12.2 (9.3, 14.7)</td></tr></tbody></table>",
      "howSupplied": "<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1><p>How Supplied</p><p>JAYPIRCA tablets are supplied as follows:</p><table><tbody><tr><td>Tablet Strength</td><td>Description</td><td>Package Configuration</td><td>NDC Number</td></tr><tr><td>50 mg</td><td>Blue, film coated, arc-triangle shaped tablets debossed with Lilly 50 on one side and 6902 on the other side.</td><td>Bottle with child-resistant closure.Each bottle contains 30 tablets.</td><td>0002-6902-30</td></tr><tr><td>100 mg</td><td>Blue, film coated, round tablets debossed with Lilly 100 on one side and 7026 on the other side.</td><td>Bottle with child-resistant closure.Each bottle contains 60 tablets.</td><td>0002-7026-60</td></tr></tbody></table><p>Storage and Handling</p><p>Store JAYPIRCA tablets at room temperature 20C to 25C (68F to 77F); excursions permitted between 15C and 30C (59F and 86F) ([see USP Controlled Room Temperature]).</p>",
      "useInSpecificPopulations": "<h1>8 USE IN SPECIFIC POPULATIONS</h1><h2>8.1 Pregnancy</h2><p>Risk Summary</p><p>Based on findings from animal studies, JAYPIRCA can cause fetal harm when administered to a pregnant woman. There are no available data on JAYPIRCA use in pregnant women to evaluate for a drug-associated risk. In an animal reproduction study, administration of pirtobrutinib to pregnant rats during organogenesis resulted in adverse developmental outcomes, including structural abnormalities, altered fetal growth, and embryo-fetal mortality, at maternal exposures approximately 3-times those in patients at the recommended daily dose of 200 mg (see Data). Advise pregnant women of the potential risk to a fetus.</p><p>The background risk in the U.S. general population of major birth defects is 2% to 4% and of miscarriage is 15% to 20% of clinically recognized pregnancies.</p><p>Data</p><p>Animal Data</p><p>In an embryo-fetal development study in rats, pregnant animals were administered oral doses of pirtobrutinib at up to 500mg/kg twice daily during the period of organogenesis. Doses 375 mg/kg twice daily caused decreased fetal body weights and increased incidence of malformations and variations in the urinary tract (including absent or abnormal ureters and kidneys), reproductive tract (malpositioned ovaries and misshapen uterus), and bone (misshapen sternebrae). At 500mg/kg twice daily, total resorption was observed. At 375 mg/kg twice daily in rats, the maternal systemic exposures (AUC) were approximately 3 times the human exposure at 200 mg once daily.</p><h2>8.2 Lactation</h2><p>Risk Summary</p><p>There are no data on the presence of pirtobrutinib in human milk or the effects on the breastfed child or milk production. Because of the potential for serious adverse reactions in the breastfed child, advise women not to breastfeed during treatment with JAYPIRCA and for one week after the last dose.</p><h2>8.3 Females and Males of Reproductive Potential</h2><p>Based on findings from animal studies, JAYPIRCA can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].</p><p>Pregnancy Testing</p><p>Verify pregnancy status in females of reproductive potential prior to initiating JAYPIRCA.</p><p>Contraception</p><p>Females</p><p>Advise females of reproductive potential to use effective contraception during treatment with JAYPIRCA and for one week after the last dose.</p><h2>8.4 Pediatric Use</h2><p>Safety and effectiveness of JAYPIRCA have not been established in pediatric patients.</p><h2>8.5 Geriatric Use</h2><p>Of the patients with MCL who received the 200 mg dose of JAYPIRCA in BRUIN, 93 (78%) were 65 years of age and older and 39 (33%) were 75 years and older [see Clinical Studies (14.1)]. Clinical studies of JAYPIRCA did not include sufficient numbers of patients with MCL who were less than 65 years of age to determine whether older patients respond differently from younger adult patients. Of the patients with CLL/SLL who received the 200 mg once daily dose of JAYPIRCA in BRUIN, 68 (63%) were 65 years of age and older and 21 (19%) were 75 years and older [see Clinical Studies (14.2)]. No overall differences in effectiveness were observed between younger and older patients.</p><p>In the pooled safety population in patients with hematologic malignancies, 401 (68%) were 65 years of age and older, while 154 (26%) were 75 years of age and older. Patients aged 65 years and older experienced higher rates of Grade 3 and higher adverse reactions and serious adverse reactions compared to patients who were less than 65 years of age.</p><h2>8.6 Renal Impairment</h2><p>Severe renal impairment (eGFR15-29 mL/min) increases pirtobrutinib exposure [see Clinical Pharmacology (12.3)]. Reduce the JAYPIRCA dosage in patients with severe renal impairment [see Dosage and Administration (2.3)]. No dosage adjustment of JAYPIRCA is recommended in patients with mild (60-89 mL/min) or moderate (30-59 mL/min) renal impairment.</p><h2>8.7 Hepatic Impairment</h2><p>No dosage adjustment of JAYPIRCA is recommended in patients with mild hepatic impairment (total bilirubin upper limit of normal (ULN) and aspartate aminotransferase (AST) &gt; ULN or total bilirubin &gt; 1 to 1.5 ULN and any AST), moderate hepatic impairment (total bilirubin &gt; 1.5 to 3 ULN and any AST), or severe hepatic impairment (total bilirubin &gt; 3 ULN and any AST) [see Clinical Pharmacology (12.3)].</p>",
      "description": "<p>Pirtobrutinib is a kinase inhibitor and an orally available, small molecule ATP-competitive inhibitor of BTK. The active pharmaceutical ingredient is pirtobrutinib with the molecular formula C22H21F4N5O3 and a molecular weight of 479.44 g/mol. The chemical name is 5-amino-3-{4-[(5-fluoro-2-methoxybenzamido)methyl]phenyl}-1-[(2S)-1,1,1-trifluoropropan-2-yl]-1H-pyrazole-4-carboxamide. Pirtobrutinib is a white to practically white to yellow to brown solid and is practically insoluble in water across the pH 1 to pH 7 range. Pirtobrutinib tablets are supplied as 50 mg or 100 mg film-coated, debossed tablets for oral administration. Each tablet contains inactive ingredients of croscarmellose sodium, hypromellose acetate succinate, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and silicon dioxide. The tablet film coating material contains FD&C Blue #2, hypromellose, titanium dioxide, and triacetin.</p>",
      "nonclinicalToxicology": "<h1>13 NONCLINICAL TOXICOLOGY</h1><h2>13.1 Carcinogenesis, mutagenesis, impairment of fertility</h2><p>Carcinogenicity studies have not been conducted with pirtobrutinib.</p><p>Pirtobrutinib was not mutagenic in a bacterial mutagenicity (Ames) assay. Pirtobrutinib was aneugenic in in vitro micronucleus assays using human peripheral blood lymphocytes. Pirtobrutinib was not genotoxic in an in vivo rat bone marrow micronucleus assay at doses up to 2000 mg/kg.</p><p>Studies to assess the effects of pirtobrutinib on fertility have not been conducted. In repeat-dose toxicity studies of up to 3-months duration conducted with pirtobrutinib in rats and dogs, no effects on male or female reproductive organs were identified.</p>",
      "mechanismOfAction": "<h2>12.1 Mechanism of action</h2><p>Pirtobrutinib is a small molecule, noncovalent inhibitor of BTK. BTK is a signaling protein of the B-cell antigen receptor (BCR) and cytokine receptor pathways. In B-cells, BTK signaling results in activation of pathways necessary for B-cell proliferation, trafficking, chemotaxis, and adhesion. Pirtobrutinib binds to wild type BTK and BTK harboring C481 mutations, leading to inhibition of BTK kinase activity. In nonclinical studies, pirtobrutinib inhibited BTK-mediated B-cell CD69 expression and inhibited malignant B-cell proliferation. Pirtobrutinib showed dose-dependent anti-tumor activities in BTK wild type and BTK C481S mutant mouse xenograft models.</p>",
      "contraindications": "<p>None.</p>",
      "highlights": {
        "dosageAndAdministration": "<ul><li>Recommended dosage: 200 mg orally once daily; swallow whole with water, with or without food. Do not cut, crush, or chew tablets. (2.1)</li><li>Manage toxicity using treatment interruption, dosage reduction, or discontinuation. (2.2)</li><li>Reduce dose in patients with severe renal impairment. (2.3, 8.6)</li></ul>"
      },
      "metaDescription": "<p>Pirtobrutinib is a kinase inhibitor, orally available, with formula C22H21F4N5O3. Tablets are 50 mg or 100 mg, with various inactive ingredients.</p>",
      "useAndConditions": "<p><h3>Approved Indications</h3></p>\n<ul>\n<li>Mantle Cell Lymphoma (MCL): JAYPIRCA is indicated for the treatment of adult patients with relapsed or refractory MCL after at least two lines of systemic therapy, including a BTK inhibitor. This indication is approved under accelerated approval based on response rate.</li>\n<li>Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): JAYPIRCA is indicated for the treatment of adult patients with CLL/SLL who have received at least two prior lines of therapy, including a BTK inhibitor and a BCL-2 inhibitor. This indication is approved under accelerated approval based on response rate.</li>\n</ul>",
      "contraIndications": "<p>No contraindications</p>",
      "warnings": "<h3>Warnings and Precautions</h3>\n<ul>\n<li>Fatal and serious infections, including bacterial, viral, fungal, and opportunistic infections, have occurred. Grade 3 or higher infections occurred in 24% of patients, with fatal infections in 4.4%. Consider prophylaxis and monitor for signs of infection.</li>\n<li>Fatal and serious hemorrhage has occurred. Major hemorrhage occurred in 3% of patients, with fatal hemorrhage in 0.3%. Monitor for signs of bleeding and consider risks of antithrombotic agents.</li>\n<li>Cytopenias, including neutropenia, thrombocytopenia, and anemia, have been reported. Grade 3 or 4 cytopenias occurred in patients. Monitor complete blood counts regularly.</li>\n<li>Cardiac arrhythmias, including atrial fibrillation and flutter, were reported in 3.2% of patients. Monitor for signs of arrhythmias and manage appropriately.</li>\n<li>Second primary malignancies, including non-skin carcinomas, developed in 9% of patients. Advise sun protection and monitor for malignancies.</li>\n<li>Hepatotoxicity, including drug-induced liver injury, has occurred. Evaluate liver function tests at baseline and throughout treatment. Withhold or discontinue if DILI is suspected or confirmed.</li>\n<li>Embryo-fetal toxicity: JAYPIRCA can cause fetal harm. Advise pregnant women of potential risks and recommend effective contraception for females of reproductive potential during treatment and for one week after the last dose.</li>\n</ul>",
      "dosing": "<h3>Recommended Dosage</h3>\n<ul>\n    <li>200 mg orally once daily until disease progression or unacceptable toxicity.</li>\n    <li>Swallow tablets whole with water. Do not cut, crush, or chew tablets.</li>\n    <li>Take at the same time each day, with or without food.</li>\n    <li>If a dose is missed by more than 12 hours, do not make up the dose and take the next dose as scheduled.</li>\n</ul>\n\n<h3>Dosage Modifications for Adverse Reactions</h3>\n<ul>\n    <li>First occurrence: Interrupt until recovery to Grade 1 or baseline; restart at 200 mg once daily.</li>\n    <li>Second occurrence: Interrupt until recovery to Grade 1 or baseline; restart at 100 mg once daily.</li>\n    <li>Third occurrence: Interrupt until recovery to Grade 1 or baseline; restart at 50 mg once daily.</li>\n    <li>Fourth occurrence: Discontinue JAYPIRCA.</li>\n    <li>Dose modification is not recommended for asymptomatic lymphocytosis or asymptomatic lipase increase.</li>\n    <li>Evaluate benefit-risk before resuming treatment at the same dose for Grade 4 non-hematological toxicity.</li>\n</ul>\n\n<h3>Dosage Modifications for Patients with Severe Renal Impairment</h3>\n<ul>\n    <li>For eGFR 15-29 mL/min: Reduce dose to 100 mg once daily if current dose is 200 mg once daily; otherwise, reduce by 50 mg.</li>\n    <li>If current dosage is 50 mg once daily, discontinue JAYPIRCA.</li>\n    <li>No adjustment recommended for mild to moderate renal impairment (eGFR 30-89 mL/min).</li>\n</ul>\n\n<h3>Dosage Modifications for Concomitant Use with Strong CYP3A Inhibitors</h3>\n<ul>\n    <li>Avoid concomitant use with strong CYP3A inhibitors.</li>\n    <li>If unavoidable, reduce dose by 50 mg.</li>\n    <li>If current dosage is 50 mg once daily, interrupt treatment during inhibitor use.</li>\n    <li>After discontinuation of inhibitor for 5 half-lives, resume prior dose.</li>\n</ul>\n\n<h3>Dosage Modifications for Concomitant Use with CYP3A Inducers</h3>\n<ul>\n    <li>Avoid concomitant use with strong or moderate CYP3A inducers.</li>\n    <li>If unavoidable with moderate inducers and current dose is 200 mg once daily, increase to 300 mg.</li>\n    <li>If current dosage is 50 mg or 100 mg once daily, increase by 50 mg.</li>\n</ul>"
    }
  },
  {
    "drugName": "Ebglyss",
    "setId": "7a774ea2-acde-4aaa-9a8f-ccba5a5b1d5f",
    "slug": "ebglyss-7a774ea",
    "labeler": "Lilly",
    "label": {
      "genericName": "lebrikizumab-lbkz",
      "labelerName": "Eli Lilly and Company",
      "productType": "HUMAN PRESCRIPTION DRUG LABEL",
      "effectiveTime": "20250207",
      "title": "EBGLYSS",
      "indicationsAndUsage": "\n<p>EBGLYSS is indicated for the treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. EBGLYSS can be used with or without topical corticosteroids.</p>",
      "dosageAndAdministration": "\n<h3>2.1 Vaccination Prior to Administration of EBGLYSS</h3>\n<p>Complete all age-appropriate vaccinations according to current immunization guidelines [see Warnings and Precautions (5.4)].</p>\n<h3>2.2 Recommended Dosage</h3>\n<p>The recommended dosage of EBGLYSS is an initial dose of 500 mg (two 250 mg injections) at Week 0 and Week 2, followed by 250 mg every two weeks until Week 16 or later, when adequate clinical response is achieved. The maintenance dosage is 250 mg every four weeks [see Clinical Studies (14.1)].</p>\n<h3>2.3 Concomitant Topical Therapies</h3>\n<p>EBGLYSS can be used with or without topical corticosteroids (TCS). Topical calcineurin inhibitors (TCI) may be used, but reserved for sensitive areas only, such as the face, neck, intertriginous and genital areas.</p>\n<h3>2.4 Important Administration Instructions</h3>\n<ul>\n<li>EBGLYSS is for subcutaneous administration.</li>\n<li>EBGLYSS is intended for use under the guidance of a healthcare professional. Provide proper training to patients and/or caregivers on the subcutaneous injection technique of EBGLYSS. Adult patients may self-inject, or caregivers may give EBGLYSS after training in subcutaneous injection technique. For pediatric patients, caregivers may give injections after training in subcutaneous injection technique.</li>\n<li>Sites for injection include the abdomen, thigh, and back of the upper arm. Administration of EBGLYSS in the back of the upper arm may be performed by a caregiver or healthcare provider.</li>\n<li>Alternate the injection site with each injection. Do not inject EBGLYSS within 2 inches (5 cm) of the navel or into areas where the skin is tender, bruised, red, hard, or in an area of skin that is affected by atopic dermatitis or skin lesions.</li>\n<li>Before injection, remove EBGLYSS prefilled pen or EBGLYSS prefilled syringe from the refrigerator. If using:\n        <ul>\n<li>EBGLYSS prefilled pen, it is not necessary to warm up to room temperature before use.</li>\n<li>EBGLYSS prefilled syringe, leave at room temperature for 45 minutes without removing the needle cap. Do not warm EBGLYSS by using a heat source such as hot water, microwave, or direct sunlight. Protect EBGLYSS from light until use [see How Supplied/Storage and Handling (16)].</li>\n</ul>\n</li>\n<li>Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. EBGLYSS is a clear to opalescent, colorless to slightly yellow to slightly brown solution. Do not use if the liquid contains visible particles, is discolored or cloudy [see Dosage Forms and Strengths (3), How Supplied/Storage and Handling (16)].</li>\n<li>Refer to the Instructions for Use for complete administration instructions with illustrations [see Instructions for Use].</li>\n</ul>\n<h3>2.5 Missed Dose</h3>\n<p>If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.</p>",
      "dosageFormsAndStrengths": "\n<p>EBGLYSS is a clear to opalescent, colorless to slightly yellow to slightly brown solution available as follows:</p>\n<ul>\n<li>Injection: 250 mg/2 mL in a single-dose prefilled pen</li>\n<li>Injection: 250 mg/2 mL in a single-dose prefilled syringe with needle shield</li>\n</ul>",
      "warningsAndPrecautions": "\n<h3>5.1 Hypersensitivity</h3>\n<p>Hypersensitivity reactions, including angioedema and urticaria, have been reported with use of EBGLYSS. If a serious hypersensitivity reaction occurs, discontinue EBGLYSS and institute appropriate therapy.</p>\n<h3>5.2 Conjunctivitis and Keratitis</h3>\n<p>Conjunctivitis and keratitis adverse reactions have been reported in clinical trials.</p>\n<p>Conjunctivitis and keratitis occurred more frequently in atopic dermatitis subjects who received EBGLYSS compared to those who received placebo. Conjunctivitis was the most frequently reported eye disorder. Most subjects with conjunctivitis or keratitis recovered during the treatment period.</p>\n<p>Advise patients to report new onset or worsening eye symptoms to their healthcare provider.</p>\n<h3>5.3 Parasitic (Helminth) Infections</h3>\n<p>Patients with known helminth infections were excluded from participation in clinical studies. It is unknown if EBGLYSS will influence the immune response against helminth infections by inhibiting IL-13 signaling.</p>\n<p>Treat patients with pre-existing helminth infections before initiating treatment with EBGLYSS. If patients become infected while receiving EBGLYSS and do not respond to antihelminth treatment, discontinue treatment with EBGLYSS until the infection resolves.</p>\n<h3>5.4 Vaccinations</h3>\n<p>EBGLYSS may alter a patient's immunity and increase the risk of infection following administration of live vaccines. Prior to therapy with EBGLYSS, complete all age-appropriate vaccinations according to current immunization guidelines. Avoid use of live vaccines immediately prior to or during treatment with EBGLYSS. No data are available on the response to live vaccines.</p>",
      "adverseReactions": "\n<p>The following adverse reactions are described elsewhere in the labeling:</p>\n<ul>\n<li>Hypersensitivity [see Warnings and Precautions (5.1)]</li>\n<li>Conjunctivitis and Keratitis [see Warnings and Precautions (5.2)]</li>\n</ul>\n<h3>6.1 Clinical Trials Experience</h3>\n<p>Because clinical trials are conducted under widely varying and controlled conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>\n<p>Atopic Dermatitis</p>\n<p>The safety of EBGLYSS was evaluated across 4 randomized, double-blind, placebo-controlled, multicenter trials in subjects with moderate-to-severe atopic dermatitis including 3 phase 3 trials (ADvocate 1, ADvocate 2, ADhere) and 1 phase 2 dose ranging trial (KGAF). In these 4 trials, mean age was 37 years; 50% of subjects were male; 62% were White, 13% were Black, and 20% were Asian. In terms of co-morbid conditions, in the phase 3 trials, 30% of the subjects had asthma, 50% had allergic rhinitis, 31% had food allergy, and 14% had allergic conjunctivitis at baseline.</p>\n<p>A total of 891 subjects were treated with EBGLYSS for at least 1 year in the atopic dermatitis development program.</p>\n<p>ADvocate 1, ADvocate 2, and KGAF compared the safety of EBGLYSS monotherapy to placebo. ADhere compared the safety of EBGLYSS + TCS to placebo + TCS through 16 weeks. All subjects from the phase 3 trials were allowed to enroll in the long-term extension study.</p>\n<p>Weeks 0 to 16</p>\n<p>Table 1 summarizes the adverse reactions that occurred at a rate of at least 1% in the EBGLYSS 250 mg every 2 weeks monotherapy group, or in the EBGLYSS 250 mg every 2 weeks + TCS group, all at a higher rate than placebo during the first 16 weeks of treatment.</p>\n<table>\n<caption>Table 1: Adverse Reactions Occurring in 1% of the EBGLYSS Monotherapy Group or the EBGLYSS+TCS Group in the Atopic Dermatitis Trials through Week 16</caption>\n<thead>\n<tr>\n<th rowspan=\"2\">Adverse Reactions</th>\n<th colspan=\"2\">EBGLYSS Monotherapy<sup>a</sup></th>\n<th colspan=\"2\">EBGLYSS + TCS<sup>b</sup></th>\n</tr>\n<tr>\n<th>EBGLYSS 250 mg Q2W<sup>c</sup> N = 638 n (%)</th>\n<th>Placebo N = 338 n (%)</th>\n<th>EBGLYSS 250 mg Q2W<sup>c</sup> + TCS N = 145 n (%)</th>\n<th>Placebo + TCS N = 66 n (%)</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Conjunctivitis<sup>d</sup></td>\n<td>61 (10)</td>\n<td>10 (3)</td>\n<td>7 (5)</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Injection Site Reactions<sup>e</sup></td>\n<td>16 (3)</td>\n<td>4 (1)</td>\n<td>4 (3)</td>\n<td>1 (2)</td>\n</tr>\n<tr>\n<td>Herpes Zoster</td>\n<td>3 (&lt;1)</td>\n<td>0</td>\n<td>2 (1)</td>\n<td>0</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"5\"><p>a Integrated analysis of ADvocate 1, ADvocate 2, and the phase 2 dose finding trial (KGAF)</p></td>\n</tr>\n<tr>\n<td colspan=\"5\"><p>b Analysis of TCS concomitant therapy trial ADhere</p></td>\n</tr>\n<tr>\n<td colspan=\"5\"><p>c EBGLYSS 500mg at Week 0 and Week 2, followed by 250mg every two weeks</p></td>\n</tr>\n<tr>\n<td colspan=\"5\"><p>d Conjunctivitis cluster includes conjunctivitis, conjunctivitis allergic, and conjunctivitis bacterial</p></td>\n</tr>\n<tr>\n<td colspan=\"5\"><p>e Injection Site Reactions cluster includes injection site-related: pain, erythema, reaction, discomfort, dermatitis, pruritus, swelling, and rash</p></td>\n</tr>\n</tfoot>\n</table>\n<p>In the monotherapy trials (ADvocate 1, ADvocate 2, and KGAF) through Week 16, the proportion of subjects who discontinued treatment due to adverse events was 2.4% in the EBGLYSS 250mg every 2 weeks group and 1.8% in the placebo group. In the TCS trial (ADhere) through Week 16, the proportion of subjects who discontinued treatment due to adverse events was 2.1% in the EBGLYSS 250mg every 2 weeks + TCS group and 0% in the placebo + TCS group. The most common adverse reactions leading to discontinuation of EBGLYSS compared to the placebo group were conjunctivitis and keratitis (0.6% vs. 0.3%), and injection site reactions (0.2% vs. 0) in the monotherapy trials; and conjunctivitis (0.7% vs. 0), and injection site reactions (0.7% vs. 0) in the TCS trial.</p>\n<p>Eosinophilia</p>\n<p>Increased post-baseline blood eosinophils were observed at a higher frequency in EBGLYSS-treated subjects compared to placebo. During the first 16 weeks, eosinophilia (&gt;5000 cells/mcL) was observed in 0.4% in the EBGLYSS-treated subjects and 0% in subjects receiving placebo. Blood eosinophil elevations were generally transient and did not result in discontinuation.</p>\n<p>Safety Weeks 16 to 52</p>\n<p>Among those EBGLYSS-treated subjects who responded at Week 16 and who were re-randomized in the maintenance period of the monotherapy trials ADvocate 1 and ADvocate 2, a total of 113 and 118 subjects received EBGLYSS 250 mg every 2 weeks or every 4 weeks, respectively. The safety profile of EBGLYSS 250 mg every 4 weeks was generally consistent with EBGLYSS every 2 weeks during Weeks 16 to 52. The safety profile of EBGLYSS during maintenance treatment was generally consistent with the safety profile observed through Week 16.</p>\n<p>Specific Adverse Drug Reactions</p>\n<p>Conjunctivitis and Keratitis</p>\n<p>Conjunctivitis was the most frequently reported eye disorder. Most cases of conjunctivitis and keratitis were mild or moderate in severity and recovered or resolved without treatment interruption or discontinuation.</p>\n<p>During the initial 16-week treatment period of the monotherapy trials, conjunctivitis, including allergic conjunctivitis, was reported by 61 subjects (10%) in the EBGLYSS 250mg every 2 weeks group and 10 subjects (3%) in the placebo group. In the TCS concomitant therapy trial, conjunctivitis was reported by 7 subjects (5%) in the EBGLYSS 250mg every 2 weeks + TCS group compared to 0% in the placebo + TCS group. During the 16-week placebo-controlled induction period, 68 subjects reported 73 events of conjunctivitis. All events were nonserious and mild or moderate in severity. Conjunctivitis led to treatment discontinuation in 3 subjects. The exposure adjusted incidence rate of conjunctivitis for subjects treated with EBGLYSS 250mg every 2 weeks was 30.6 events per 100 patient years through Week 16 (KGAF, ADvocate 1, ADvocate 2, ADhere).</p>\n<p>During the maintenance treatment period of the monotherapy trials (ADvocate 1 and ADvocate 2) from 16 to 52 weeks, conjunctivitis, including allergic conjunctivitis, was reported by 2 subjects (1.8%) in the EBGLYSS 250mg every 2 weeks group and 12 subjects (10.1%) in the EBGLYSS 250 mg every 4 weeks group, compared to 5 subjects (8.3%) in the placebo group. During the maintenance treatment period, 14 subjects treated with EBGLYSS reported 18 events of conjunctivitis. All events were mild or moderate in severity. Conjunctivitis led to treatment discontinuation in 2 subjects in the EBGLYSS 250mg every 4 weeks group. The exposure adjusted incidence rate of conjunctivitis for subjects treated with EBGLYSS 250mg every 2 weeks was 18.3 events per 100 patient years and for those treated with EBGLYSS 250 mg every 4 weeks was 20.6 events per 100 patient years through Week 52 (ADvocate 1, ADvocate 2, ADhere + the long-term extension study).</p>\n<p>During the initial 16-week treatment period of the monotherapy trials, keratitis, including atopic and vernal keratoconjunctivitis, was reported by 4 subjects (0.6%) in the EBGLYSS 250 mg every 2 weeks group and 1 subject (0.3%) in the placebo group. In the TCS concomitant therapy trial, vernal keratoconjunctivitis was reported by 1 subject (0.7%) in the EBGLYSS 250mg every 2 weeks + TCS group, compared to 0% in the placebo + TCS group. During the 16-week placebo-controlled induction period, 5 subjects reported 7 events of keratitis. All events were nonserious and mild or moderate in severity. Keratitis led to treatment discontinuation in 2 subjects. The exposure adjusted incidence rate of keratitis for subjects treated with EBGLYSS 250mg every 2 weeks was 2.2 events per 100 patient years through Week 16 (KGAF, ADvocate 1, ADvocate 2, ADhere).</p>\n<p>During the maintenance treatment period of the monotherapy trials (ADvocate 1 and ADvocate 2) from 16 to 52 weeks, atopic keratoconjunctivitis was reported by 1 subject (0.8%) in the EBGLYSS 250mg every 4 weeks group, and vernal keratoconjunctivitis was reported by 1 subject (0.9%) in the EBGLYSS 250mg every 2 weeks group, compared to 0% in the placebo group. One (0.9%) event of severe vernal keratoconjunctivitis in an EBGLYSS 250mg every 2 weeks subject led to treatment discontinuation. The exposure adjusted incidence rate of keratitis for subjects treated with EBGLYSS 250mg every 2 weeks was 1.0 event per 100 patient years and for those treated with EBGLYSS 250 mg every 4 weeks was 0.7 events per 100 patient years through Week 52 (ADvocate 1, ADvocate 2, ADhere + the long-term extension study).</p>\n<p>Injection Site Reactions</p>\n<p>Injection site reactions were reported by 3% of the EBGLYSS group and 1% of the placebo group in the first 16 weeks of the monotherapy trials. Incidence of injection site reactions declined with continued treatment. Most events were mild or moderate and recovered without treatment discontinuation.</p>",
      "clinicalPharmacology": "<h1>12 CLINICAL PHARMACOLOGY</h1><h2>12.1 Mechanism of Action</h2><p>Lebrikizumab-lbkz is an IgG4 monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13 and allows IL-13 to bind to IL-13R1 but inhibits human IL-13 signaling through the IL-4R/IL-13R1 receptor complex. IL-13 is a naturally occurring cytokine that is involved in Type 2 inflammation, which is an important component in the pathogenesis of atopic dermatitis. Lebrikizumab-lbkz inhibits IL-13-induced responses including the release of proinflammatory cytokines, chemokines and IgE. Lebrikizumab-lbkz-bound IL-13 can still bind IL-13R2 allowing subsequent internalization and natural clearance of IL-13.</p><h2>12.2 Pharmacodynamics</h2><p>In clinical studies, lebrikizumab-lbkz reduced the levels of serum periostin, total immunoglobulin E (IgE), CCchemokine ligand (CCL)17 [thymus and activation-regulated chemokine (TARC)], CCL18 [pulmonary and activation-regulated chemokine (PARC)], and CCL13 [monocyte chemotactic protein-4 (MCP-4)]. The clinical relevance of these biomarkers is not completely understood.</p><h2>12.3 Pharmacokinetics</h2><p>Lebrikizumab-lbkz steady-state exposure following either a subcutaneous dose of 250mg every 2 weeks or every 4weeks in patients with atopic dermatitis are presented in Table 2. Lebrikizumab-lbkz exposure increases dose-proportionally over a subcutaneous dose range of 37.5 to 500mg. Lebrikizumab-lbkz steady state is achieved at Week4 following the approved recommended loading doses.</p><table><caption>Table 2: Lebrikizumab-lbkz Steady-State Exposure Following Subcutaneous Administration in Patients with Atopic Dermatitis</caption><tfoot><tr><td colspan=\"4\"><p>Cmax = Maximum concentration, Cavg = Average concentration, Ctrough = Trough concentration</p></td></tr><tr><td colspan=\"4\"><p>a Following approved recommended loading doses</p></td></tr></tfoot><tbody><tr><td>Lebrikizumab-lbkz Dosagea</td><td>Cmax</td><td>Cavg</td><td>Ctrough</td></tr><tr><td>250 mg every 2 weeks</td><td>108 mcg/mL</td><td>100 mcg/mL</td><td>87 mcg/mL</td></tr><tr><td>250 mg every 4 weeks</td><td>63 mcg/mL</td><td>51 mcg/mL</td><td>36 mcg/mL</td></tr></tbody></table><p>Absorption</p><p>Following a single subcutaneous 250mg dose of lebrikizumab-lbkz, peak serum concentrations were achieved approximately 7 to 8 days post dose. The absolute bioavailability for a subcutaneous dose was approximately 86%.</p><p>Injection site locations did not influence the absorption of lebrikizumab-lbkz.</p><p>Distribution</p><p>The lebrikizumab-lbkz steady-state volume of distribution is 5.14L.</p><p>Metabolism/Elimination</p><p>Lebrikizumab-lbkz is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.</p><p>The lebrikizumab-lbkz half-life is 24.5days and clearance is 0.154L/day. Lebrikizumab-lbkz exhibits linear elimination that is independent of dose.</p><p>Specific Populations</p><p>Age, Sex, Race</p><p>Age, sex, or race did not have a significant effect on the pharmacokinetics of lebrikizumab-lbkz.</p><p>Weight</p><p>Lebrikizumab-lbkz trough concentrations were lower in subjects with higher body weight.</p><p>Patients with Renal or Hepatic Impairment</p><p>Specific clinical pharmacology studies to evaluate the effects of renal impairment and hepatic impairment on the pharmacokinetics of lebrikizumab-lbkz have not been conducted. Lebrikizumab-lbkz, as a monoclonal antibody, is not expected to undergo significant hepatic or renal elimination. No clinically significant differences in the pharmacokinetics of lebrikizumab-lbkz were observed in patients with mild or moderate renal impairment.</p><p>Drug Interaction Studies</p><p>The effect of lebrikizumab-lbkz on the PK of co-administered medications has not been studied.</p><h2>12.6 Immunogenicity</h2><p>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies, including those of EBGLYSS or of other drug products.</p><p>Antibodies to lebrikizumab-lbkz developed in 4/145 (2.8%) of subjects treated with EBGLYSS 250 mg every 2weeks followed by 250mg every four weeks during the 12-month treatment period in EBGLYSS studies. Most of these antibodies were neutralizing and of low titer. Similar results were observed in pediatric subjects who received EBGLYSS up to 12months. The presence of anti-drug antibodies was not associated with changes to pharmacokinetics, efficacy, or safety of lebrikizumab-lbkz. The clinical relevance of these findings is unknown because of the low occurrence of ADA.</p>",
      "clinicalStudies": "<h1>14 CLINICAL STUDIES</h1><h2>14.1 Atopic Dermatitis</h2><p>Three multicenter, randomized, double-blind, placebo-controlled trials, ADvocate 1, ADvocate 2 and ADhere (NCT04146363, NCT04178967, NCT04250337) enrolled a total of 1062 subjects 12 years of age and older with moderate-to-severe atopic dermatitis not adequately controlled by topical medication(s) and who were candidates for systemic therapy. A total of 148 subjects (14%) were 12 to &lt;18 years who weighed at least 40kg and 914 (86%) were adult subjects. Disease severity was defined by an Investigator's Global Assessment (IGA) score 3 in the overall assessment of AD lesions on a severity scale of 0 to 4, an Eczema Area and Severity Index (EASI) score 16 on a scale of 0 to 72, and a minimum body surface area involvement of 10%.</p><p>At baseline, 50% of subjects were male, 63% were White, 11% were Black or African American, and 21% were Asian; 12.8% identified as Hispanic or Latino, 63% of subjects had a baseline IGA score of 3 (moderate AD) and 37% of subjects had a baseline IGA of 4 (severe AD). The baseline mean EASI was 29, and the baseline Pruritus Numeric Rating Scale (NRS) was 7 on a scale of 0-10. Of all subjects, 99% had received prior treatment for AD.</p><p>In all three trials, subjects in the EBGLYSS group received subcutaneous injections of EBGLYSS 500mg at Week0 and at Week2, followed by 250mg every other week (Q2W) through Week 16.</p><p>To evaluate the maintenance and durability of response in the monotherapy trials (ADvocate 1 and ADvocate 2), subjects originally randomized to EBGLYSS who achieved an IGA score of 0 or 1, or at least a 75% reduction in EASI from baseline [EASI-75] at Week16 and did not require rescue therapy were re-randomized to an additional 36 weeks of either a maintenance dose of EBGLYSS 250mg Q2W (every 2 weeks), EBGLYSS 250mg Q4W (every 4 weeks), or placebo.</p><p>Subjects who did not achieve IGA 0 or 1 or EASI-75 at Week 16 or subjects who required rescue therapy during the first 16weeks were treated with open-label EBGLYSS 250mg Q2W.</p><p>In the concomitant therapy trial (ADhere), subjects received EBGLYSS + TCS or placebo + TCS. Topical calcineurin inhibitors (TCI) were permitted for sensitive areas only, such as the face, neck, intertriginous and genital areas. </p><p>All three trials assessed the primary endpoint, the proportion of subjects who achieved an IGA score of 0 (clear) or 1(almost clear) and at least a 2-point improvement from baseline at Week16. Other evaluated outcomes at Week16 included the proportion of subjects with EASI-75 and EASI-90, and improvement in itch severity as defined by a reduction of at least 4 points on an 11-point Pruritus NRS. ADvocate 1 and ADvocate 2 also evaluated the maintenance and durability of response through Week52.</p><p>The results of the EBGLYSS monotherapy trials (ADvocate 1 and ADvocate 2) are presented in Table 3.</p><table><caption>Table 3: Efficacy Results of EBGLYSS Monotherapy at Week 16a in ADvocate 1 and ADvocate 2 in Subjects with Moderate-to-Severe Atopic Dermatitis</caption><tfoot><tr><td colspan=\"7\"><p>a Subjects who received rescue therapy or discontinued treatment due to lack of efficacy were analyzed as non-responders. Data after treatment discontinuation due to any other reason were considered missing. Any missing data was imputed using MCMC-MI.</p></td></tr><tr><td colspan=\"7\"><p>b Subjects received 500mg of EBGLYSS at Week 0 and Week 2, and 250mg Q2W up to Week16</p></td></tr><tr><td colspan=\"7\"><p>c Primary endpoint. Responder was defined as a subject with an IGA 0 or 1 (clear or almost clear) and a reduction of 2points on a 0-4 IGA scale</p></td></tr></tfoot><tbody><tr><td colspan=\"3\">ADvocate 1</td><td colspan=\"3\">ADvocate 2</td></tr><tr><td>EBGLYSS250mgQ2Wb</td><td>Placebo</td><td>Difference from Placebo (95% CI)</td><td>EBGLYSS250 mgQ2Wb</td><td>Placebo</td><td>Difference from Placebo (95% CI)</td></tr><tr><td>Number of subjects</td><td>283</td><td>141</td><td>--</td><td>281</td><td>146</td><td>--</td></tr><tr><td> IGA 0 or 1c</td><td>43%</td><td>13%</td><td>30%(22%, 38%)</td><td>33%</td><td>11%</td><td>22%(14%, 30%)</td></tr><tr><td> EASI-75</td><td>59%</td><td>16%</td><td>42%(33%, 51%)</td><td>52%</td><td>18%</td><td>33%(24%, 42%)</td></tr><tr><td> EASI-90</td><td>38%</td><td>9%</td><td>29%(21%, 36%)</td><td>31%</td><td>10%</td><td>21%(13%, 28%)</td></tr><tr><td>Number of subjects with baseline Pruritus NRS score 4</td><td>263</td><td>130</td><td>--</td><td>253</td><td>134</td><td>--</td></tr><tr><td> Pruritus NRS 4 point improvement</td><td>46%</td><td>13%</td><td>33%(25%, 41%)</td><td>40%</td><td>12%</td><td>28%(20%, 37%)</td></tr></tbody></table><p>The proportion of EBGLYSS-treated subjects who achieved IGA 0 or 1 (with 2-point improvement from baseline) by visit in ADvocate 1 and ADvocate 2 are presented in Figure 1.</p><p>Figure 1: Proportion of Subjects with Moderate-to-Severe Atopic Dermatitis achieving IGA 0 or 1, with a 2-point improvement from baseline through Week 16 in ADvocate 1 and ADvocate 2</p><p>The proportion of EBGLYSS-treated subjects who achieved at least a 4-point improvement from baseline in Pruritus NRS by visit in ADvocate 1 and ADvocate 2 are presented in Figure 2.</p><p>Figure 2: Proportion of Subjects with Moderate-to-Severe Atopic Dermatitis with 4-point improvement in Pruritus NRS through Week 16 in ADvocate 1 or ADvocate 2</p><p>Examination of age, sex, and White, Asian, Black or African American race subgroups did not identify differences in response to EBGLYSS among these subgroups. The database was not large enough to adequately assess differences in effects in other races. </p><p>The results in the concomitant therapy trial (ADhere) at Week 16, where subjects received EBGLYSS + TCS or placebo + TCS were consistent with the results in the monotherapy trials (ADvocate 1 and ADvocate 2).</p><p>Maintenance and Durability of Response (Week 16 to Week 52)</p><p>EBGLYSS-treated subjects achieving IGA 0 or 1 or EASI-75, and who did not receive rescue therapy at Week16 were re-randomized to 36 weeks of maintenance treatment with EBGLYSS 250mg Q2W, EBGLYSS 250mg Q4W, or placebo in ADvocate 1 and ADvocate 2. The results are presented in Table 4.</p><table><caption>Table 4: Efficacy Results of EBGLYSS at Week 52 in ADvocate 1 and ADvocate 2a in Subjects with Moderate-to-Severe Atopic Dermatitis</caption><tfoot><tr><td colspan=\"7\"><p>a Subjects who received systemic rescue therapy, discontinued treatment due to lack of efficacy were analyzed as non-responders. Data after topical rescue medication or treatment discontinuation due to any other reason were considered missing. Any missing data were imputed using MCMC-MI.</p></td></tr><tr><td colspan=\"7\"><p>b Responder was defined as a subject with an IGA 0 or 1 (clear or almost clear) and a reduction of 2 points on a 0-4 IGA scale</p></td></tr></tfoot><tbody><tr><td colspan=\"3\">ADvocate 1</td><td colspan=\"3\">ADvocate 2</td></tr><tr><td>EBGLYSS 250mgQ2W</td><td>EBGLYSS 250 mg Q4W</td><td>Placebo</td><td>EBGLYSS 250mgQ2W</td><td>EBGLYSS 250 mgQ4W</td><td>Placebo</td></tr><tr><td>Number of subjects who were IGA of 0 or 1 Responders at Week16b</td><td>45</td><td>45</td><td>22</td><td>32</td><td>32</td><td>16</td></tr><tr><td> IGA of 0 or 1b at Week 52</td><td>76%</td><td>74%</td><td>47%</td><td>65%</td><td>81%</td><td>50%</td></tr><tr><td>Number of subjects who were EASI-75 Responders at Week16</td><td>61</td><td>62</td><td>30</td><td>51</td><td>53</td><td>27</td></tr><tr><td> EASI-75 at Week52</td><td>79%</td><td>79%</td><td>61%</td><td>77%</td><td>85%</td><td>72%</td></tr></tbody></table>",
      "howSupplied": "<p>How Supplied</p><p>EBGLYSS (lebrikizumab-lbkz) injection is a sterile, preservative free, clear to opalescent, colorless to slightly yellow to slightly brown solution, available in a single-dose prefilled pen or a single-dose prefilled syringe with needle shield. Each prefilled pen and prefilled syringe with needle shield is designed to deliver 250mg of EBGLYSS in 2mL.</p><p>EBGLYSS is supplied as:</p><table><tbody><tr><td>Pack Size</td><td>NDC</td></tr><tr><td colspan=\"3\">Prefilled Pen</td></tr><tr><td> 250mg/2 mL single-dose</td><td>Carton of 1</td><td>0002-7772-11</td></tr><tr><td colspan=\"3\">Prefilled syringe with needle shield</td></tr><tr><td> 250mg/2 mL single-dose</td><td>Carton of 1</td><td>0002-7797-11</td></tr></tbody></table>",
      "useInSpecificPopulations": "<h1>8 USE IN SPECIFIC POPULATIONS</h1><h2>8.1 Pregnancy</h2><p>Risk Summary</p><p>Available data on lebrikizumab-lbkz use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes. Transport of human IgG antibody across the placenta increases as pregnancy progresses and peaks during the third trimester; therefore, lebrikizumab-lbkz may be transmitted from the mother to the developing fetus. In animal reproduction studies, no effects on embryo-fetal development were observed after subcutaneous administration of lebrikizumab-lbkz to cynomolgus monkeys during organogenesis at doses up to 18 times the human exposure at the maximum recommended human dose (MRHD) (see Data).</p><p>All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</p><p>Report pregnancies to Eli Lilly and Company at 1-800-LillyRx (1-800-545-5979).</p><p>Data</p><p>Animal Data</p><p>In an embryofetal development study, no malformations or embryofetal toxicity were observed in fetuses from pregnant cynomolgus monkeys administered lebrikizumab-lbkz during organogenesis at doses up to 150mg/kg initial dose followed by 50mg/kg per week by subcutaneous injection, which was associated with plasma exposure (Cavg,ss) approximately 18 times the human exposure at the MRHD. Lebrikizumab-lbkz crossed the placenta in monkeys.</p><p>In a prenatal and postnatal development study, pregnant cynomolgus monkeys were administered lebrikizumab-lbkz during organogenesis to parturition at doses up to 150mg/kg initial dose followed by 50mg/kg per week by subcutaneous injection, which was associated with plasma exposure (Cavg,ss) approximately 18 times the human exposure at the MRHD. No embryofetal toxicity or malformations, or effects on morphological, functional, or immunological development were observed in the infants from birth through 6 months of age.</p><h2>8.2 Lactation</h2><p>Risk Summary</p><p>There are no data on the presence of lebrikizumab-lbkz in human milk, the effects on the breastfed infant, or the effects on milk production. Endogenous IgG and monoclonal antibodies are transferred in human milk. The effects of local gastrointestinal exposure and limited systemic exposure in the breastfed infant to lebrikizumab-lbkz are unknown. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for EBGLYSS and any potential adverse effects on the breastfed infant from EBGLYSS or from the underlying maternal condition.</p><h2>8.4 Pediatric Use</h2><p>The safety and effectiveness of EBGLYSS have been established in pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. A total of 372 pediatric subjects were exposed to EBGLYSS with 270 subjects exposed to EBGLYSS for at least one year. The safety and effectiveness were generally consistent between pediatric and adult subjects [see Adverse Reactions (6.1), Clinical Studies (14.1)].</p><p>The safety and effectiveness of EBGLYSS have not been established in pediatric patients younger than 12 years of age and pediatric patients 12 years and older who weigh less than 40 kg.</p><h2>8.5 Geriatric Use</h2><p>Of the 1348 adult subjects with moderate-to-severe atopic dermatitis exposed to EBGLYSS, a total of 123 were 65years or older, and 29 subjects were 75 years or older. Clinical studies of EBGLYSS did not include sufficient numbers of subjects 65years of age and older to determine whether they respond differently from younger adult subjects [see Clinical Pharmacology (12.3)].</p>",
      "description": "<p>Lebrikizumab-lbkz is an interleukin-13 antagonist and an IgG4 monoclonal antibody that binds to IL-13 and inhibits its signaling. It is produced in CHO cells by recombinant DNA technology and has a molecular weight of approximately 145 kDa. EBGLYSS (lebrikizumab-lbkz) injection is a sterile, preservative-free solution for subcutaneous use, available as a 250 mg/2 mL single-dose prefilled pen or syringe, not made with natural rubber latex. Each delivers 250 mg lebrikizumab-lbkz in 2 mL solution containing glacial acetic acid, histidine, polysorbate 20, sucrose, and Water for Injection, with a pH of 5.4 to 6.0.</p>",
      "nonclinicalToxicology": "<h1>13 NONCLINICAL TOXICOLOGY</h1><h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><p>Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of lebrikizumab-lbkz.</p><p>No effects on fertility parameters such as reproductive organs, reproductive hormones or menstrual cycle length were observed in sexually mature female cynomolgus monkeys that were administered intravenous doses of lebrikizumab-lbkz up to 25mg/kg/week for 37 weeks, which was associated with plasma exposure (Cavg,ss) approximately 15times the human exposure at the MRHD. No effects on reproductive organs or sperm analysis were observed in sexually mature male cynomolgus monkeys that were administered subcutaneous doses of lebrikizumab-lbkz up to 25mg/kg/week for 13weeks, which was associated with plasma exposure (Cavg,ss) approximately 11 times the human exposure at the MRHD.</p>",
      "instructionsForUse": "<h1>PREFILLED SYRINGE INSTRUCTIONS FOR USE</h1><p>INSTRUCTIONS FOR USE</p><p>EBGLYSS[EHB-glihs]</p><p>(lebrikizumab-lbkz)</p><p>injection, for subcutaneous use</p><p>Single-Dose Prefilled Syringe with Needle Shield</p><p>This Instructions for Use contains information on how to inject EBGLYSS.</p><p>Before you use the EBGLYSS Prefilled Syringe with Needle Shield (Prefilled Syringe), read and carefully follow all the step-by-step instructions.</p><p>Important information you need to know before injecting EBGLYSS</p><ul><li>Your healthcare provider should show you how to prepare and inject EBGLYSS using the Prefilled Syringe. Do not inject yourself or someone else until you have been shown how to inject EBGLYSS.</li><li>Keep these Instructions for Use and read it as needed.</li><li>Each EBGLYSS Prefilled Syringe contains 1 dose of EBGLYSS. The Prefilled Syringe is for one-time use only.</li><li>The EBGLYSS Prefilled Syringe contains glass parts. Handle it carefully. If you drop it on a hard surface, do not use it. Use a new EBGLYSS Prefilled Syringe for your injection.</li><li>Your healthcare provider may help you decide where on your body to inject your dose. You can also read the Choose and clean your injection site section of these instructions to help you choose which area can work best for you.</li><li>If you have vision problems, do not use the EBGLYSS Prefilled Syringe without help from a caregiver.</li><li>See Storing EBGLYSS for important storage information.</li></ul><p>INSTRUCTIONS FOR USE</p><p>Before you use the EBGLYSS Prefilled Syringe, read and carefully follow all the step-by-step instructions.</p><p>Parts of the EBGLYSS Prefilled Syringe with Needle Shield</p><table><tbody><tr><td colspan=\"3\">Preparing to inject EBGLYSS</td></tr><tr><td colspan=\"3\">Gather Supplies and EBGLYSS Prefilled Syringe</td></tr><tr><td colspan=\"3\"><ul><li>EBGLYSS Prefilled Syringe from the refrigerator</li><li>1 alcohol wipe</li><li>1 cotton ball or piece of gauze</li><li>1 sharps disposal container (see Disposing of EBGLYSS)</li></ul></td></tr><tr><td colspan=\"2\">Remove Prefilled Syringe from carton</td><td>Remove the EBGLYSS Prefilled Syringe from the carton by holding the middle of the Syringe Body and then place the EBGLYSS Prefilled Syringe on a clean flat surface.Leave the needle cap on the syringe until you are ready to inject.Do not pull back on the Plunger Rod at any time.</td></tr><tr><td colspan=\"2\">Wait 45 minutes</td></tr><tr><td colspan=\"3\">With the Needle Cap on, allow the Prefilled Syringe to warm up to room temperature for 45 minutes before injecting.<ul><li>Do not warm up the EBGLYSS Prefilled Syringe with a microwave, or hot water, or direct sunlight.</li><li>Do not use the Prefilled Syringe if the medicine is frozen.</li></ul></td></tr><tr><td colspan=\"3\">Inspect the Prefilled Syringe and the medicineMake sure you have the right medicine. The medicine inside should be clear. It may be colorless to slightly yellow to slightly brown. Some air bubbles are normal.</td></tr><tr><td>Note: You may gently rotate the plunger rod to view the syringe label if needed.Do not use the Prefilled Syringe (see Disposing of EBGLYSS) if the:<ul><li>Needle Cap is missing or not securely attached</li><li>Prefilled Syringe looks damaged</li><li>medicine is cloudy, is discolored, or has particles</li><li>expiration date printed on the label has passed.</li></ul></td></tr><tr><td colspan=\"3\">Wash your hands with soap and water</td></tr><tr><td colspan=\"3\">Choose and clean your injection siteYour healthcare provider can help you choose the injection site that is best for you. Clean the injection site with an alcohol wipe and let dry.</td></tr><tr><td>You or another person may inject into these areas.</td><td><ul><li>Stomach area (abdomen) <dl><dt>-</dt><dd>At least 2 inches away from the belly button (navel).</dd></dl></li><li>Front of thigh <dl><dt>-</dt><dd>At least 2 inches above the knee and 2 inches below the groin.</dd></dl></li></ul></td></tr><tr><td>Another person should inject into this area.</td><td><ul><li>Back of upper arm <dl><dt>-</dt><dd>Another person should inject into the back of your upper arm.</dd></dl>Do not inject in the exact same spot every time.Do not inject into areas where the skin is tender, bruised, red, hard, or in an area of the skin that is affected by eczema (atopic dermatitis) or other skin lesions.</li></ul></td></tr></tbody></table><table><tbody><tr><td colspan=\"3\">Injecting EBGLYSS</td></tr><tr><td rowspan=\"2\">1</td><td>Remove Needle Cap</td></tr><tr><td>Hold the EBGLYSS Prefilled Syringe in the middle of the Syringe Body and pull the Needle Cap straight off.Do not put the Needle Cap back on; this could damage the needle.Do not touch the Needle.</td></tr><tr><td>2</td><td colspan=\"2\">Pinch the injection site and insert the Needle</td></tr><tr><td>Gently pinch a fold of skin at the injection site with one hand.Insert the Needle completely into the fold of skin at about a 45 angle with your other hand.</td></tr><tr><td rowspan=\"2\">3</td><td>Push in the Plunger Rod</td></tr><tr><td>Gently relax the pinch while keeping the needle in place. Push the Plunger Rod all the way down as far as it will go to inject all of the medicine.Note: It is normal to feel some resistance.You have to give the full dose to activate the Needle Shield.</td></tr><tr><td>4</td><td>Release the Plunger Rod</td></tr><tr><td>Lift your thumb to release the Plunger Rod until the Needle is covered by the Needle Shield.Lightly press a cotton ball or gauze on the injection site if you see any blood.Do not rub your skin after the injection.</td></tr></tbody></table><table><tbody><tr><td colspan=\"2\">Disposing of EBGLYSS</td></tr><tr><td>Dispose of (throw away) the used Prefilled Syringe</td><td>Put the used EBGLYSS Prefilled Syringe and Needle Cap in an FDA-cleared sharps disposal container right away after use.</td></tr><tr><td colspan=\"2\">Do not throw away (dispose of) the EBGLYSS Prefilled Syringe in your household trash.If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:<ul><li>made of a heavy-duty plastic,</li><li>able to be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</li><li>upright and stable during use,</li><li>leak-resistant, and</li><li>properly labeled to warn of hazardous waste inside the container.</li></ul>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container.There may be local laws about how you should throw away needles and syringes.For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA website at: http://www.fda.gov/safesharpsdisposalDo not recycle your used sharps disposal container.</td></tr></tbody></table><p>Storing EBGLYSS</p><ul><li>Store your Prefilled Syringe in a refrigerator between 36F to 46F (2C to 8C).</li><li>EBGLYSS can be stored at room temperature up to 7 days in the original carton. Do not store above 86F (30C). Throw away (dispose of) EBGLYSS that has been left at room temperature for longer than 7days.</li><li>Store your Prefilled Syringe in the original carton to protect from light until use.</li><li>Do not freeze your Prefilled Syringe. Do not shake your Prefilled Syringe.</li><li>Do not microwave your Prefilled Syringe, or run hot water over it, or leave it in direct sunlight.</li><li>Throw away (dispose of) your Prefilled Syringe if any of the above conditions are not followed.</li></ul><p>Keep your Prefilled Syringes and all medicines out of the reach of children.</p><table><tbody><tr><td colspan=\"3\">If you have more questions about how to use the EBGLYSS Prefilled Syringe:</td></tr><tr><td><ul><li>Call your healthcare provider</li></ul></td><td rowspan=\"3\">Scan this code to launch www.ebglyss.com</td></tr><tr><td><ul><li>Call 1-800-Lilly-Rx (1-800-545-5979)</li></ul></td></tr><tr><td><ul><li>Visit www.ebglyss.com</li></ul></td></tr></tbody></table><p>Read the Patient Information insert for EBGLYSS inside this box to learn more about your medicine.</p><p>Eli Lilly and Company</p><p>Indianapolis, IN 46285, USA</p><p>US License Number 1891</p><p>EBGLYSS is a trademark of Eli Lilly and Company.</p><p>Copyright 2024, Eli Lilly and Company. All rights reserved.</p><p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.</p><p>Issued: September 2024</p><p>EBG-0001-PFS-IFU-202409</p>",
      "mechanismOfAction": "<h2>12.1 Mechanism of Action</h2><p>Lebrikizumab-lbkz is an IgG4 monoclonal antibody that binds with high affinity and slow off-rate to interleukin (IL)-13 and allows IL-13 to bind to IL-13R1 but inhibits human IL-13 signaling through the IL-4R/IL-13R1 receptor complex. IL-13 is a naturally occurring cytokine that is involved in Type 2 inflammation, which is an important component in the pathogenesis of atopic dermatitis. Lebrikizumab-lbkz inhibits IL-13-induced responses including the release of proinflammatory cytokines, chemokines and IgE. Lebrikizumab-lbkz-bound IL-13 can still bind IL-13R2 allowing subsequent internalization and natural clearance of IL-13.</p>",
      "contraindications": "\n<p>EBGLYSS is contraindicated in patients with prior serious hypersensitivity to lebrikizumab-lbkz or any excipients of EBGLYSS. See Warnings and Precautions section 5.1.</p>",
      "highlights": {
        "dosageAndAdministration": "<ul><li>Prior to EBGLYSS treatment, complete all age-appropriate vaccinations according to current immunization guidelines. (2.1)</li><li>The recommended dosage of EBGLYSS is 500mg (two 250mg injections) at Week 0 and Week 2, followed by 250mg (one injection) every 2 weeks until Week 16 or later, when adequate clinical response is achieved. The maintenance dose is EBGLYSS 250 mg every 4 weeks. (2.2)</li><li>Administer by subcutaneous injection. (2.4)</li></ul>"
      },
      "metaDescription": "<p>Lebrikizumab-lbkz is an IgG4 monoclonal antibody for subcutaneous use, available in 250 mg/2 mL prefilled pens or syringes, pH 5.4-6.0.</p>",
      "useAndConditions": "<p><h3>Approved Indications</h3></p>\n<ul>\n<li>Treatment of adults and pediatric patients 12 years of age and older who weigh at least 40 kg with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable.</li>\n</ul>",
      "contraIndications": "<h3>Contraindications</h3>\n<ul>\n<li>Prior serious hypersensitivity to lebrikizumab-lbkz or any excipients of EBGLYSS</li>\n</ul>",
      "warnings": "<h3>Warnings and Precautions</h3>\n<ul>\n<li>Hypersensitivity reactions, including angioedema and urticaria, have been reported. If a serious hypersensitivity reaction occurs, discontinue EBGLYSS and institute appropriate therapy.</li>\n<li>Conjunctivitis and keratitis adverse reactions have been reported, occurring more frequently in atopic dermatitis subjects receiving EBGLYSS compared to placebo. Advise patients to report new onset or worsening eye symptoms.</li>\n<li>Patients with known helminth infections were excluded from clinical studies. Treat pre-existing helminth infections before initiating EBGLYSS. If infection occurs during treatment and does not respond to antihelminth treatment, discontinue EBGLYSS until resolution.</li>\n<li>EBGLYSS may alter immunity and increase infection risk following live vaccines. Complete all age-appropriate vaccinations prior to therapy. Avoid live vaccines immediately prior to or during treatment with EBGLYSS.</li>\n</ul>",
      "dosing": "<p>2.2 Recommended Dosage</p>\n<ul>\n    <li>Initial dose: 500 mg (two 250 mg injections) at Week 0 and Week 2.</li>\n    <li>Followed by: 250 mg every two weeks until Week 16 or later, when adequate clinical response is achieved.</li>\n    <li>Maintenance dosage: 250 mg every four weeks.</li>\n</ul>\n\n<p>2.4 Important Administration Instructions</p>\n<ul>\n    <li>EBGLYSS is for subcutaneous administration.</li>\n    <li>Sites for injection include the abdomen, thigh, and back of the upper arm.</li>\n    <li>Alternate the injection site with each injection.</li>\n    <li>Do not inject within 2 inches (5 cm) of the navel or into areas where the skin is tender, bruised, red, hard, or affected by atopic dermatitis or skin lesions.</li>\n    <li>Before injection, remove EBGLYSS prefilled pen or syringe from the refrigerator.</li>\n    <li>If using the prefilled pen, it is not necessary to warm up to room temperature before use.</li>\n    <li>If using the prefilled syringe, leave at room temperature for 45 minutes without removing the needle cap.</li>\n    <li>Do not warm EBGLYSS using a heat source such as hot water, microwave, or direct sunlight.</li>\n    <li>Inspect visually for particulate matter and discoloration prior to administration.</li>\n    <li>Do not use if the liquid contains visible particles, is discolored or cloudy.</li>\n</ul>\n\n<p>2.5 Missed Dose</p>\n<ul>\n    <li>If a dose is missed, administer the dose as soon as possible.</li>\n    <li>Thereafter, resume dosing at the regular scheduled time.</li>\n</ul>"
    }
  },
  {
    "drugName": "Taltz",
    "setId": "ac96658a-d7dc-4c7c-8928-2adcdf4318b2",
    "slug": "taltz-ac96658",
    "labeler": "Lilly",
    "label": {
      "genericName": "ixekizumab",
      "labelerName": "Eli Lilly and Company",
      "productType": "HUMAN PRESCRIPTION DRUG LABEL",
      "effectiveTime": "20241113",
      "title": "TALTZ",
      "indicationsAndUsage": "\n<h3>1.1 Plaque Psoriasis</h3>\n<p>TALTZ is indicated for the treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.</p>\n<h3>1.2 Psoriatic Arthritis</h3>\n<p>TALTZ is indicated for the treatment of adult patients with active psoriatic arthritis.</p>\n<h3>1.3 Ankylosing Spondylitis</h3>\n<p>TALTZ is indicated for the treatment of adult patients with active ankylosing spondylitis.</p>\n<h3>1.4 Non-radiographic Axial Spondyloarthritis</h3>\n<p>TALTZ is indicated for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.</p>",
      "dosageAndAdministration": "\n<h3>2.1 Testing and Procedures Prior to Treatment Initiation</h3>\n<p>Perform the following evaluations prior to TALTZ initiation:</p>\n<ul>\n<li>Evaluate patients for tuberculosis (TB) infection. TALTZ initiation is not recommended in patients with active TB infection. Initiate treatment of latent TB prior to initiation of TALTZ [see Warnings and Precautions (5.2)].</li>\n<li>Complete all age-appropriate vaccinations as recommended by current immunization guidelines prior to initiating treatment with TALTZ [see Warnings and Precautions (5.6)].</li>\n</ul>\n<h3>2.2 Recommended Dosage in Adult Plaque Psoriasis</h3>\n<p>TALTZ is administered by subcutaneous injection. The recommended dosage in adults with moderate-to-severe plaque psoriasis is 160mg (two 80mg injections) at Week 0, followed by 80mg at Weeks 2, 4, 6, 8, 10, and 12, then 80mg every 4 weeks.</p>\n<h3>2.3 Recommended Dosage in Pediatric Plaque Psoriasis</h3>\n<p>TALTZ is administered by subcutaneous injection every 4 weeks (Q4W). The recommended dosage in pediatric patients from 6 to less than 18 years of age with moderate-to-severe plaque psoriasis is based on the following weight categories.</p>\n<table>\n<thead>\n<tr>\n<th>Pediatric Patient's Weight</th>\n<th>Starting Dose (Week 0)</th>\n<th>Dose every 4 weeks (Q4W) Thereafter</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Greater than 50kg</td>\n<td>160mg (two 80mg injections)</td>\n<td>80mg</td>\n</tr>\n<tr>\n<td>25 to 50kg</td>\n<td>80mg</td>\n<td>40mg</td>\n</tr>\n<tr>\n<td>Less than 25kg</td>\n<td>40mg</td>\n<td>20mg</td>\n</tr>\n</tbody>\n</table>\n<h3>2.4 Recommended Dosage in Psoriatic Arthritis</h3>\n<p>The recommended dosage is 160mg by subcutaneous injection (two 80mg injections) at Week 0, followed by 80mg every 4 weeks.</p>\n<p>For psoriatic arthritis patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for adult plaque psoriasis [see Dosage and Administration (2.2)].</p>\n<p>TALTZ may be administered alone or in combination with a conventional disease-modifying antirheumatic drug (cDMARD) (e.g., methotrexate).</p>\n<h3>2.5 Recommended Dosage in Ankylosing Spondylitis</h3>\n<p>The recommended dosage is 160mg by subcutaneous injection (two 80mg injections) at Week 0, followed by 80mg every 4 weeks.</p>\n<h3>2.6 Recommended Dosage in Non-radiographic Axial Spondyloarthritis</h3>\n<p>The recommended dosage is 80 mg by subcutaneous injection every 4 weeks.</p>\n<h3>2.7 Preparation and Administration Instructions</h3>\n<p>TALTZ is intended for use under the guidance and supervision of a healthcare provider. Adult patients may self-inject or caregivers may give injections of TALTZ after training in subcutaneous injection technique using the autoinjector or prefilled syringe. Safety and effectiveness of pediatric self-administration has not been established. Therefore, TALTZ should be administered to pediatric patients by a healthcare provider or by a caregiver who has received training and demonstrated proper subcutaneous injection technique.</p>\n<p>TALTZ 20 mg and 40 mg doses prepared from the TALTZ 80 mg/mL prefilled syringe should only be administered by a qualified healthcare professional [see Dosage and Administration (2.8)].</p>\n<p>The TALTZ Instructions for Use contains more detailed instructions on the preparation and administration of TALTZ [see Instructions for Use].</p>\n<p>Before injection, remove TALTZ autoinjector or TALTZ prefilled syringe from the refrigerator and allow TALTZ to reach room temperature (30 minutes) without removing the needle cap. Inspect TALTZ visually for particulate matter and discoloration prior to administration. TALTZ is a clear and colorless to slightly yellow solution. Do not use if the liquid contains visible particles, is discolored or cloudy (other than clear and colorless to slightly yellow).</p>\n<p>Administer each injection at a different anatomic location (such as upper arms, thighs or any quadrant of abdomen) than the previous injection, and not into areas where the skin is tender, bruised, erythematous, indurated or affected by psoriasis. Administration of TALTZ in the upper, outer arm may be performed by a caregiver or healthcare provider [see Instructions for Use].</p>\n<p>TALTZ does not contain preservatives, therefore discard any unused product.</p>\n<p>If a dose is missed, administer the dose as soon as possible. Thereafter, resume dosing at the regular scheduled time.</p>\n<h3>2.8 Alternative Preparation Instructions of TALTZ Doses for Pediatric Patients with Plaque Psoriasis Weighing 50 kg or Less</h3>\n<p>If the 20 mg/0.25 mL or 40 mg/0.5 mL prefilled syringe is unavailable, TALTZ doses of 20mg or 40mg for pediatric patients with plaque psoriasis [see Dosage and Administration (2.3)] must be manually prepared according to the steps below using only the TALTZ 80 mg/mL prefilled syringe. The preparation and administration of the 20mg and 40mg doses should only be performed by a qualified healthcare professional. For additional preparation and administration instructions, [see Dosage and Administration (2.7)].</p>\n<ol>\n<li>Gather the following necessary supplies for preparation:\n        <ul>\n<li>0.5mL or 1mL disposable syringe</li>\n<li>Sterile needle for withdrawal</li>\n<li>27-gauge sterile needle for administration</li>\n<li>Sterile, clear glass vial.</li>\n</ul>\n</li>\n<li>Expel the entire contents of the prefilled syringe into the sterile vial. DO NOT shake or swirl the vial. Do not add other medications to solutions containing TALTZ.</li>\n<li>Using the 0.5mL or 1mL disposable syringe and sterile needle, withdraw the prescribed dose from the vial (0.25mL for 20mg; 0.5mL for 40mg).</li>\n<li>Remove the needle from the syringe and replace it with a 27-gauge needle prior to administering TALTZ.</li>\n</ol>\n<p>Storage of Prepared TALTZ</p>\n<p>If necessary, TALTZ 20 mg or 40 mg doses prepared from an 80 mg/mL prefilled syringe may be stored at room temperature for up to 4 hours from first puncturing the sterile vial.</p>",
      "dosageFormsAndStrengths": "\n<p>TALTZ is a clear and colorless to slightly yellow solution available as:</p>\n<ul>\n<li>Injection: 80 mg/mL solution of TALTZ in a single-dose prefilled autoinjector</li>\n<li>Injection: 80 mg/mL solution of TALTZ in a single-dose prefilled syringe</li>\n<li>Injection: 40 mg/0.5 mL solution of TALTZ in a single-dose prefilled syringe</li>\n<li>Injection: 20 mg/0.25 mL solution of TALTZ in a single-dose prefilled syringe</li>\n</ul>",
      "warningsAndPrecautions": "\n<h3>5.1 Infections</h3>\n<p>TALTZ may increase the risk of infection. In clinical trials in adult patients with plaque psoriasis, the TALTZ group had a higher rate of infections than the placebo group, with 27% in the TALTZ group compared to 23% in the placebo group. Upper respiratory tract infections, oral candidiasis, conjunctivitis, and tinea infections occurred more frequently in the TALTZ group than in the placebo group. A similar increase in risk of infection was seen in placebo-controlled trials in patients with pediatric psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis [see Adverse Reactions (6.1)].</p>\n<p>In the postmarketing setting, serious bacterial, viral, and fungal opportunistic infections have been reported in patients receiving IL-17 inhibitors, including TALTZ. Instruct patients treated with TALTZ to seek medical advice if signs or symptoms of clinically important chronic or acute infection occur. If a patient develops a serious infection or is not responding to standard therapy, monitor the patient closely and discontinue TALTZ until the infection resolves.</p>\n<h3>5.2 Pre-treatment Evaluation for Tuberculosis</h3>\n<p>Evaluate patients for tuberculosis (TB) infection prior to initiating treatment with TALTZ. Do not administer to patients with active TB infection. Initiate treatment of latent TB prior to administering TALTZ. Consider anti-TB therapy prior to initiating TALTZ in patients with a past history of latent or active TB in whom an adequate course of treatment cannot be confirmed. Patients receiving TALTZ should be monitored closely for signs and symptoms of active TB during and after treatment.</p>\n<h3>5.3 Hypersensitivity</h3>\n<p>Serious hypersensitivity reactions, including angioedema and urticaria, each occurring at a rate of 0.1%, occurred in the TALTZ group in clinical trials. Anaphylaxis, including cases leading to hospitalization, has been reported in postmarketing use with TALTZ [see Adverse Reactions (6.1, 6.3)]. If a serious hypersensitivity reaction occurs, discontinue TALTZ immediately and initiate appropriate therapy.</p>\n<h3>5.4 Eczematous Eruptions</h3>\n<p>In the postmarketing setting, cases of severe eczematous eruptions, including atopic dermatitis-like eruptions, dyshidrotic eczema, and erythroderma, were reported in patients receiving TALTZ; some cases resulted in hospitalization. The onset of eczematous eruptions was variable, ranging from days to months after the first dose of TALTZ. Treatment may need to be discontinued to resolve the eczematous eruption. Some patients with limited psoriasis treatment options were successfully treated for eczema while continuing TALTZ.</p>\n<h3>5.5 Inflammatory Bowel Disease</h3>\n<p>Patients treated with TALTZ may be at increased risk of inflammatory bowel disease. In clinical trials, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the TALTZ group than the placebo control group [see Adverse Reactions (6.1)]. During TALTZ treatment, monitor for onset or exacerbation of inflammatory bowel disease, and if IBD occurs, discontinue TALTZ and initiate appropriate medical management.</p>\n<h3>5.6 Immunizations</h3>\n<p>Prior to initiating therapy with TALTZ, consider completion of all age-appropriate immunizations according to current immunization guidelines. Avoid use of live vaccines in patients treated with TALTZ. No data are available on the response to live vaccines.</p>",
      "adverseReactions": "\n<p>The following adverse drug reactions are discussed in greater detail in other sections of the label:</p>\n<ul>\n<li>Infections [see Warnings and Precautions (5.1)]</li>\n<li>Hypersensitivity Reactions [see Contraindications (4) and Warnings and Precautions (5.3)]</li>\n<li>Eczematous Eruptions [see Warnings and Precautions (5.4)]</li>\n<li>Inflammatory Bowel Disease [see Warnings and Precautions (5.5)]</li>\n</ul>\n<h3>6.1 Clinical Trials Experience</h3>\n<p>Because clinical trials are conducted under widely varying and controlled conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>\n<p>Adult Plaque Psoriasis</p>\n<p>Weeks 0 to 12:</p>\n<p>Three placebo-controlled trials in subjects with plaque psoriasis were integrated to evaluate the safety of TALTZ compared to placebo for up to 12 weeks. A total of 1167 subjects (mean age 45 years; 66% men; 94% White) with plaque psoriasis received TALTZ (160mg at Week 0, 80mg every 2 weeks [Q2W] for 12 weeks) subcutaneously. In two of the trials, the safety of TALTZ (use up to 12 weeks) was also compared with an active comparator, U.S. approved etanercept [see Clinical Studies (14)].</p>\n<p>In the 12-week, placebo-controlled period, adverse events occurred in 58% of the TALTZ Q2W group (2.5 per subject-year of follow-up) compared with 47% of the placebo group (2.1 per subject-year of follow-up). Serious adverse events occurred in 2% of the TALTZ group (0.07 per subject-year of follow-up), and in 2% of the placebo group (0.07 per subject-year of follow-up).</p>\n<p>Table 2 summarizes the adverse reactions that occurred at a rate of at least 1% and at a higher rate in the TALTZ group than in the placebo group during the 12-week placebo-controlled period of the pooled clinical trials.</p>\n<table>\n<thead>\n<tr>\n<th>Adverse Reactions</th>\n<th>TALTZ 80mg Q2W (N=1167) n (%)</th>\n<th>Etanercept (N=287) n (%)</th>\n<th>Placebo (N=791) n (%)</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Injection site reactions</td>\n<td>196 (17)</td>\n<td>32 (11)</td>\n<td>26 (3)</td>\n</tr>\n<tr>\n<td>Upper respiratory tract infections</td>\n<td>163 (14)</td>\n<td>23 (8)</td>\n<td>101 (13)</td>\n</tr>\n<tr>\n<td>Nausea</td>\n<td>23 (2)</td>\n<td>1 (&lt;1)</td>\n<td>5 (1)</td>\n</tr>\n<tr>\n<td>Tinea infections</td>\n<td>17 (2)</td>\n<td>0</td>\n<td>1 (&lt;1)</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"4\">a Upper respiratory tract infections cluster includes nasopharyngitis and rhinovirus infection.</td>\n</tr>\n<tr>\n<td colspan=\"4\">b U.S. approved etanercept.</td>\n</tr>\n</tfoot>\n</table>\n<p>Adverse reactions that occurred at rates less than 1% in the TALTZ group and more frequently than in the placebo group during the 12-week induction period included rhinitis, oral candidiasis, urticaria, influenza, conjunctivitis, inflammatory bowel disease, and angioedema.</p>\n<p>Weeks 13 to 60:</p>\n<p>A total of 332 subjects received the recommended maintenance regimen of TALTZ 80mg dosed every 4 weeks.</p>\n<p>During the maintenance period (Weeks 13 to 60), adverse events occurred in 80% of subjects treated with TALTZ (1.0 per subject-year of follow-up) compared to 58% of subjects treated with placebo (1.1 per subject-year of follow-up). Serious adverse events were reported in 4% of subjects treated with TALTZ (0.05 per subject-year of follow-up) and none in the subjects treated with placebo.</p>\n<p>Weeks 0 to 60:</p>\n<p>Over the entire treatment period (Weeks 0 to 60), adverse events were reported in 67% of subjects treated with TALTZ (1.4 per subject-year of follow-up) compared to 48% of subjects treated with placebo (2.0 per subject-year of follow-up). Serious adverse events were reported in 3% of subjects treated with TALTZ (0.06 per subject-year of follow-up), and in 2% of subjects treated with placebo (0.06 per subject-year of follow-up).</p>\n<p>Specific Adverse Drug Reactions</p>\n<p>Injection Site Reactions</p>\n<p>The most frequent injection site reactions were erythema and pain. Most injection site reactions were mild-to-moderate in severity and did not lead to discontinuation of TALTZ.</p>\n<p>Infections</p>\n<p>In the 12-week, placebo-controlled period of the clinical trials in plaque psoriasis, infections occurred in 27% of subjects treated with TALTZ (1.2 per subject-year of follow-up) compared to 23% of subjects treated with placebo (1.0 per subject-year of follow-up). Serious infections occurred in 0.4% of subjects treated with TALTZ (0.02 per subject-year of follow-up) and in 0.4% of subjects treated with placebo (0.02 per subject-year of follow-up) [see Warnings and Precautions (5.1)].</p>\n<p>During the maintenance treatment period (Weeks 13 to 60), infections occurred in 57% of subjects treated with TALTZ (0.70 per subject-year of follow-up) compared to 32% of subjects treated with placebo (0.61 per subject-year of follow-up). Serious infections occurred in 0.9% of subjects treated with TALTZ (0.01 per subject-year of follow-up) and none in the subjects treated with placebo.</p>\n<p>Over the entire treatment period (Weeks 0 to 60), infections were reported in 38% of subjects treated with TALTZ (0.83 per subject-year of follow-up) compared to 23% of subjects treated with placebo (1.0 per subject-year of follow-up). Serious infections occurred in 0.7% of subjects treated with TALTZ (0.02 per subject-year of follow-up), and in 0.4% of subjects treated with placebo (0.02 per subject-year of follow-up).</p>\n<p>Inflammatory Bowel Disease</p>\n<p>In adult subjects with plaque psoriasis, Crohn's disease and ulcerative colitis, including exacerbations, occurred at a greater frequency in the TALTZ 80mg Q2W group (Crohn's disease 0.1%, ulcerative colitis 0.2%) than the placebo group (0%) during the 12-week, placebo-controlled period in clinical trials [see Warnings and Precautions (5.5)].</p>\n<p>Laboratory Assessment of Cytopenia</p>\n<p>Neutropenia</p>\n<p>Over the entire treatment period (Weeks 0 to 60), neutropenia occurred in 11% of subjects treated with TALTZ (0.24 per subject-year of follow-up) compared to 3% of subjects treated with placebo (0.14 per subject-year of follow-up). In subjects treated with TALTZ, the incidence rate of neutropenia during Weeks 13 to 60 was lower than the incidence rate during Weeks 0 to 12.</p>\n<p>In the 12-week, placebo-controlled period, neutropenia Grade 3 (&lt;1,000 cells/mm3) occurred in 0.2% of the TALTZ group (0.007 per subject-year of follow-up) compared to 0.1% of the placebo group (0.006 per subject-year of follow-up). The majority of cases of neutropenia were either Grade 2 (2% for TALTZ 80mg Q2W versus 0.3% for placebo; 1,000 to &lt;1,500 cells/mm3) or Grade 1 (7% for TALTZ 80mg Q2W versus 3% for placebo; 1,500 cells/mm3 to 2,000 cells/mm3). Neutropenia in the TALTZ group was not associated with an increased rate of infection compared to the placebo group.</p>\n<p>Thrombocytopenia</p>\n<p>Ninety eight percent of cases of thrombocytopenia were Grade 1 (3% for TALTZ 80mg Q2W versus 1% for placebo; 75,000 cells/mm3 to &lt;150,000 cells/mm3). Thrombocytopenia in subjects treated with TALTZ was not associated with an increased rate of bleeding compared to subjects treated with placebo.</p>\n<p>Active Comparator Trials</p>\n<p>In the two clinical trials that included an active comparator, the rate of serious adverse events during weeks zero to twelve was 0.7% for U.S. approved etanercept and 2% for TALTZ 80mg Q2W, and the rate of discontinuation from adverse events was 0.7% for U.S. approved etanercept and 2% for TALTZ 80mg Q2W. The incidence of infections was 18% for U.S. approved etanercept and 26% for TALTZ 80mg Q2W. The rate of serious infections was 0.3% for both TALTZ 80mg Q2W and U.S. approved etanercept.</p>\n<p>Pediatric Plaque Psoriasis</p>\n<p>TALTZ was evaluated in a placebo-controlled trial in pediatric subjects with moderate-to-severe psoriasis 6 to less than 18 years of age. A total of 171 subjects were studied (115 subjects on TALTZ and 56 subjects on placebo). Overall, the safety profile observed in pediatric subjects with plaque psoriasis treated with TALTZ every 4 weeks is consistent with the safety profile in adult subjects with plaque psoriasis with the exception of the frequencies of conjunctivitis (2.6%), influenza (1.7%), and urticaria (1.7%).</p>\n<p>In this clinical trial, Crohn's disease occurred at a greater frequency in the TALTZ group (0.9%) than the placebo group (0%) during the 12-week, placebo-controlled period. Crohn's disease occurred in a total of 4 TALTZ treated subjects (2.0%) in the clinical trial [see Warnings and Precautions (5.5)].</p>\n<p>Psoriatic Arthritis</p>\n<p>TALTZ was studied in two placebo-controlled trials in patients with psoriatic arthritis. A total of 678 patients were studied (454 patients on TALTZ and 224 on placebo). A total of 229 patients in these trials received TALTZ 160mg at Week 0, followed by 80mg every 4 weeks (Q4W). Overall, the safety profile observed in patients with psoriatic arthritis treated with TALTZ Q4W is consistent with the safety profile in adult patients with plaque psoriasis with the exception of the frequencies of influenza (1.3%) and conjunctivitis (1.3%).</p>\n<p>Ankylosing Spondylitis</p>\n<p>TALTZ was studied in two placebo-controlled trials in patients with ankylosing spondylitis. A total of 566 patients were studied (376 patients on TALTZ and 190 on placebo). A total of 195 patients in these trials received TALTZ 80 or 160mg at Week 0, followed by 80mg every 4 weeks (Q4W). Overall, the safety profile observed in patients with ankylosing spondylitis treated with TALTZ Q4W is consistent with the safety profile in adult patients with plaque psoriasis.</p>\n<p>In adult patients with ankylosing spondylitis, Crohn's disease and ulcerative colitis, including exacerbations, occurred in 2 patients (1.0%) and 1 patient (0.5%), respectively, in the TALTZ 80mg Q4W group and 1 patient (0.5%) and 0%, respectively, in the placebo group during the 16-week, placebo-controlled period in clinical trials. Of these patients, serious events occurred in 1 patient in the TALTZ 80mg Q4W group and 1 patient in the placebo group [see Warnings and Precautions (5.5)].</p>\n<p>Non-radiographic Axial Spondyloarthritis</p>\n<p>TALTZ was studied in a placebo-controlled trial in patients with non-radiographic axial spondyloarthritis. A total of 303 patients were studied (198 patients on TALTZ and 105 on placebo). A total of 96 patients in this trial received TALTZ 80 or 160mg at Week 0, followed by 80 mg every 4 weeks (Q4W). Overall, the safety profile observed in patients with non-radiographic axial spondyloarthritis treated with TALTZ 80mg Q4W up to Week 16 is consistent with the previous experience of TALTZ in other indications.</p>\n<h3>6.2 Immunogenicity</h3>\n<p>As with all therapeutic proteins there is the potential for immunogenicity with TALTZ. The assay to test for neutralizing antibodies has limitations detecting neutralizing antibodies in the presence of ixekizumab; therefore, the incidence of neutralizing antibodies development could be underestimated.</p>\n<p>Plaque Psoriasis Population</p>\n<p>By Week 12, approximately 9% of adult subjects treated with TALTZ every 2 weeks developed antibodies to ixekizumab. Approximately 22% of subjects treated with TALTZ at the recommended dosing regimen developed antibodies to ixekizumab during the 60-week treatment period. The clinical effects of antibodies to ixekizumab are dependent on the antibody titer; higher antibody titers were associated with decreasing drug concentration and clinical response.</p>\n<p>Of the adult subjects who developed antibodies to ixekizumab during the 60-week treatment period, approximately 10%, which equates to 2% of subjects treated with TALTZ at the recommended dosing regimen, had antibodies that were classified as neutralizing. Neutralizing antibodies were associated with reduced drug concentrations and loss of efficacy.</p>\n<p>In pediatric psoriasis subjects treated with ixekizumab at the recommended dosing regimen up to 12 weeks, 21 subjects (18%) developed anti-drug antibodies, 5 subjects (4%) had confirmed neutralizing antibodies associated with low drug concentrations. No conclusive evidence could be obtained on the potential association of neutralizing antibodies and clinical response and/or adverse events due to small number of pediatric subjects in the study.</p>\n<p>Psoriatic Arthritis Population</p>\n<p>For subjects treated with TALTZ 80mg every 4 weeks for up to 52 weeks (PsA1), 11% developed anti-drug antibodies, and 8% had confirmed neutralizing antibodies.</p>\n<p>Ankylosing Spondylitis Population</p>\n<p>For patients treated with TALTZ 80mg every 4 weeks for up to 16 weeks (AS1, AS2), 5.2% developed anti-drug antibodies, and 1.5% had neutralizing antibodies.</p>\n<p>Non-radiographic Axial Spondyloarthritis Population</p>\n<p>Of patients treated with TALTZ 80mg every 4 weeks for up to 52 weeks (nr-axSpA1), 8.9% developed anti-drug antibodies, all of which were low titer. No patient had neutralizing antibodies.</p>\n<p>The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies to TALTZ across indications or with the incidences of antibodies to other products may be misleading.</p>\n<h3>6.3 Postmarketing Experience</h3>\n<p>The following adverse reactions have been identified during post-approval use of TALTZ. Because the reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to TALTZ exposure.</p>\n<p>Immune system disorders: anaphylaxis [see Contraindications (4)].</p>\n<p>Infections: bacterial, viral, and fungal opportunistic infections, including cryptococcal meningoencephalitis, esophageal and disseminated mucocutaneous candidiasis, pulmonary tuberculosis, toxoplasmosis, varicella zoster virus reactivation, cytomegalovirus colitis, pulmonary aspergillosis.</p>\n<p>Skin and subcutaneous tissue disorders: Eczematous eruptions (erythroderma, atopic dermatitis-like eruptions, and dyshidrotic eczema).</p>",
      "clinicalPharmacology": "<h1>12 CLINICAL PHARMACOLOGY</h1><h2>12.1 Mechanism of Action</h2><p>Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.</p><h2>12.2 Pharmacodynamics</h2><p>No formal pharmacodynamic studies have been conducted with TALTZ.</p><h2>12.3 Pharmacokinetics</h2><p>The pharmacokinetic (PK) properties of ixekizumab were similar across the adult plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis indications.</p><p>Absorption</p><p>Following a single subcutaneous dose of 160mg in subjects with plaque psoriasis, ixekizumab reached peak mean (SD) serum concentrations (Cmax) of 16.2 6.6 mcg/mL by approximately 4 days post dose.</p><p>Steady-state concentrations were achieved by Week 8 following the 160mg starting dose and 80mg every 2weeks dosing regimen; the mean SD steady-state trough concentration was 9.3 5.3mcg/mL. Steady-state concentrations were achieved approximately 10weeks after switching from the 80mg every 2weeks dosing regimen to the 80 mg every 4 weeks dosing regimen at Week 12. The mean SD steady-state trough concentration was 3.5 2.5mcg/mL.</p><p>In studies of subjects with plaque psoriasis, ixekizumab bioavailability ranged from 60% to 81% following subcutaneous injection. Administration of ixekizumab via injection in the thigh achieved a higher bioavailability relative to that achieved using other injection sites including the arm and abdomen.</p><p>Distribution</p><p>The mean (geometric CV%) volume of distribution at steady-state was 7.11L (29%) in subjects with plaque psoriasis.</p><p>Elimination</p><p>The metabolic pathway of ixekizumab has not been characterized. As a humanized IgG4 monoclonal antibody ixekizumab is expected to be degraded into small peptides and amino acids via catabolic pathways in the same manner as endogenous IgG.</p><p>The mean systemic clearance was 0.39L/day (37%) and the mean (geometric CV%) half-life was 13 days (40%) in subjects with plaque psoriasis.</p><p>Weight</p><p>Ixekizumab clearance and volume of distribution increase as body weight increases.</p><p>Dose Linearity</p><p>Ixekizumab exhibited dose-proportional pharmacokinetics in subjects with plaque psoriasis over a dose range from 5mg (not the recommended dose) to 160mg following subcutaneous administration.</p><p>Specific Populations</p><p>Age: </p><p>Geriatric Population</p><p>Population pharmacokinetic analysis indicated that age did not significantly influence the clearance of ixekizumab in adult subjects with plaque psoriasis. Subjects who are 65 years or older had a similar ixekizumab clearance as compared to subjects less than 65 years old.</p><p>Pediatric Population</p><p>Pediatric psoriasis subjects (6 to less than 18 years of age) were administered ixekizumab at the recommended pediatric dosing regimen for 12 weeks. Subjects weighing &gt;50kg and 25 to 50kg had a mean SD steady-state trough concentration of 3.8 2.2mcg/mL and 3.9 2.4mcg/mL at Week 12, respectively. There were limited PK data (n=2) in subjects weighing &lt;25kg at Week 12.</p><p>Drug Interaction Studies</p><p>Population PK data analyses indicated that the clearance of ixekizumab was not impacted by concomitant administration of methotrexate, or by prior exposure to methotrexate or adalimumab in patients with psoriatic arthritis.</p><p>Population PK data analyses indicated that the clearance of ixekizumab was not impacted by concomitant administration of oral corticosteroids, NSAIDs, or cDMARDs (sulfasalazine and methotrexate) in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis.</p><p>Cytochrome P450 Substrates</p><p>No clinically significant changes in exposure of caffeine (CYP1A2 substrate), warfarin (CYP2C9 substrate), omeprazole (CYP2C19 substrate) or midazolam (CYP3A substrate) were observed in subjects with plaque psoriasis when used concomitantly with a single 160 mg dose of ixekizumab, or multiple doses of 80 mg every 2 weeks. The potential effect of ixekizumab on the CYP2D6 activity cannot be ruled out due to high variability in exposure (approximately 2-fold) of dextromethorphan and its CYP2D6 metabolite dextrorphan in psoriasis subjects.</p>",
      "clinicalStudies": "<h1>14 CLINICAL STUDIES</h1><h2>14.1 Adult Plaque Psoriasis</h2><p>Three multicenter, randomized, double-blind, placebo-controlled trials, Trials 1, 2, and 3 (NCT01474512, NCT01597245, NCT01646177), enrolled a total of 3866 subjects 18 years of age and older with plaque psoriasis who had a minimum body surface area involvement of 10%, a static Physician Global Assessment (sPGA) score of 3 in the overall assessment (plaque thickness/induration, erythema, and scaling) of psoriasis on a severity scale of 0 to 5, a Psoriasis Area and Severity Index (PASI) score 12, and who were candidates for phototherapy or systemic therapy.</p><p>In all three trials, subjects were randomized to either placebo or TALTZ (80mg every 2 weeks [Q2W]) for 12weeks, following a 160mg starting dose. In the two active comparator trials (Trials 2 and 3), subjects were also randomized to receive U.S. approved etanercept 50mg twice weekly for 12weeks.</p><p>All three trials assessed the changes from baseline to Week 12 in the two co-primary endpoints: 1) PASI 75, the proportion of subjects who achieved at least a 75% reduction in the PASI composite score that takes into consideration both the percentage of body surface area affected and the nature and severity of psoriatic changes (induration, erythema and scaling) within the affected regions, and 2) sPGA of 0 (clear) or 1 (minimal), the proportion of subjects with an sPGA 0 or 1 and at least a 2-point improvement.</p><p>Other evaluated outcomes included the proportion of subjects with an sPGA score of 0 (clear), a reduction of at least 90% in PASI (PASI 90), a reduction of 100% in PASI (PASI 100), and an improvement of itch severity as measured by a reduction of at least 4 points on an 11-point itch Numeric Rating Scale.</p><p>Subjects in all treatment groups had a median baseline PASI score ranging from approximately 17 to 18. Baseline sPGA score was severe or very severe in 51% of subjects in Trial 1, 50% in Trial 2, and 48% in Trial 3.</p><p>Of all subjects, 44% had received prior phototherapy, 49% had received prior conventional systemic therapy, and 26% had received prior biologic therapy for the treatment of psoriasis. Of the subjects who had received prior biologic therapy, 15% had received at least one anti-TNF alpha agent, and 9% had received an anti-IL 12/IL23. A total of 23% of study subjects had a history of psoriatic arthritis.</p><p>Clinical Response at Week 12</p><p>The results of Trials 1, 2, and 3 are presented in Table 3.</p><table><caption>Table 3: Efficacy Results at Week 12 in Adults with Plaque Psoriasis in Trials 1, 2, and 3; NRIa</caption><tfoot><tr><td colspan=\"7\"><p>a Abbreviations: N = number of patients in the intent-to-treat population; NRI = Non-Responder Imputation.</p></td></tr><tr><td colspan=\"7\"><p>b At Week 0, subjects received 160mg of TALTZ.</p></td></tr><tr><td colspan=\"7\"><p>c Co-primary endpoints.</p></td></tr><tr><td colspan=\"7\"><p>d Itch NRS (4 improvement) in subjects with baseline Itch NRS 4. The number of ITT subjects with baseline Itch NRS Score 4 are as follows: Trial 1, TALTZ n=391, PBO n=374; Trial 2, TALTZ n=303, PBO n=135; Trial 3, TALTZ n=320, PBO n=158.</p></td></tr></tfoot><tbody><tr><td colspan=\"2\">Trial 1</td><td colspan=\"2\">Trial 2</td><td colspan=\"2\">Trial 3</td></tr><tr><td>TALTZ 80mgbQ2W (N=433)n (%)</td><td>Placebo(N=431)n (%)</td><td>TALTZ 80mgbQ2W (N=351)n (%)</td><td>Placebo(N=168)n (%)</td><td>TALTZ 80mgbQ2W (N=385)n (%)</td><td>Placebo(N=193)n (%)</td></tr><tr><td>sPGA of 0 (clear) or 1 (minimal)c</td><td>354 (82)</td><td>14 (3)</td><td>292 (83)</td><td>4 (2)</td><td>310 (81)</td><td>13 (7)</td></tr><tr><td>sPGA of 0 (clear)</td><td>160 (37)</td><td>0</td><td>147 (42)</td><td>1 (1)</td><td>155 (40)</td><td>0</td></tr><tr><td>PASI 75c</td><td>386 (89)</td><td>17 (4)</td><td>315 (90)</td><td>4 (2)</td><td>336 (87)</td><td>14 (7)</td></tr><tr><td>PASI 90</td><td>307 (71)</td><td>2 (1)</td><td>248 (71)</td><td>1 (1)</td><td>262 (68)</td><td>6 (3)</td></tr><tr><td>PASI 100</td><td>153 (35)</td><td>0</td><td>142 (40)</td><td>1 (1)</td><td>145 (38)</td><td>0</td></tr><tr><td>Itch NRS (4 point improvement)d</td><td>336 (86)</td><td>58 (16)</td><td>258 (85)</td><td>19 (14)</td><td>264 (83)</td><td>33 (21)</td></tr></tbody></table><p>Examination of age, gender, race, body weight, and previous treatment with a biologic did not identify differences in response to TALTZ among these subgroups at Week 12.</p><p>An integrated analysis of the U.S. sites in the two active comparator studies using U.S. approved etanercept, TALTZ demonstrated superiority to U.S. approved etanercept (50mg twice weekly) on sPGA and PASI scores during the 12-week treatment period. The respective response rates for TALTZ 80mg Q2W and U.S. approved etanercept 50mg twice weekly were: sPGA of 0 or 1 (73% and 27%); PASI 75 (87% and 41%); sPGA of 0 (34% and 5%); PASI 90 (64% and 18%), and PASI 100 (34% and 4%).</p><p>Maintenance and Durability of Response</p><p>To evaluate the maintenance and durability of response, subjects originally randomized to TALTZ and who were responders at Week 12 (i.e., sPGA of 0 or 1) in Trial 1 and Trial 2 were re-randomized to an additional 48 weeks of either a maintenance dose of TALTZ 80mg Q4W (every 4 weeks) or placebo. Non-responders (sPGA &gt;1) at Week 12 and subjects who relapsed (sPGA 3) during the maintenance period were placed on TALTZ 80mg Q4W.</p><p>For responders at Week 12, the percentage of subjects who maintained this response (sPGA 0 or 1) at Week 60 (48 weeks following re-randomization) in the integrated trials (Trial 1 and Trial 2) was higher for subjects treated with TALTZ 80mg Q4W (75%) compared to those treated with placebo (7%).</p><p>For responders at Week 12 who were re-randomized to treatment withdrawal (i.e., placebo), the median time to relapse (sPGA 3) was 164 days in the integrated trials. Among these subjects, 66% regained a response of at least 0 or 1 on the sPGA within 12 weeks of restarting treatment with TALTZ 80mg Q4W.</p><p>Psoriasis Involving the Genital Area</p><p>A randomized, double-blind, placebo-controlled trial (Trial 4) was conducted in 149 adult subjects with plaque psoriasis who had a minimum body surface area (BSA) involvement of 1%, a sPGA score of 3 (moderate psoriasis), a sPGA of Genitalia score of 3 (moderate psoriasis involving the genital area), who failed to respond to or were intolerant of at least one topical therapy used for treatment of psoriasis affecting the genital area, and who were candidates for phototherapy and/or systemic therapy.</p><p>Subjects had a median baseline PASI score of approximately 12. Baseline BSA involvement was at least 10% for approximately 60% of the enrolled subjects. Baseline sPGA of Genitalia score was severe or very severe in approximately 42% of the subjects; baseline sPGA score was severe or very severe in approximately 47% of the subjects.</p><p>Subjects randomized to TALTZ received an initial dose of 160mg followed by 80mg every 2 weeks for 12 weeks. The trial evaluated the primary endpoint of the proportion of subjects who achieved a 0 (clear) or 1 (minimal) response at Week 12 on sPGA of Genitalia. Other evaluated outcomes at Week 12 included the proportion of subjects who achieved a sPGA score of 0 (clear) or 1 (minimal), improvement of genital itch severity as measured by a reduction of at least 4 points in the 11-point Genital Psoriasis Symptoms Scale (GPSS) score Itch numeric rating scale (NRS), and the patient-perceived impact of psoriasis affecting the genital area on limiting frequency of sexual activity (intercourse or other activities) as measured by the Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 (In the past week how often did your genital psoriasis limit the frequency of your sexual activity?). SFQ Item 2 score ranges from 0 to 4 (0=never, 1=rarely, 2=sometimes, 3=often, 4=always); where higher scores indicate greater limitations on the frequency of sexual activity in the past week.</p><p>The results of Trial 4 are presented in Table 4.</p><table><caption>Table 4: Efficacy Results at Week 12 in Adults with Genital Psoriasis in Trial 4; NRIa</caption><tfoot><tr><td colspan=\"3\"><p>a Abbreviations: NRI = Non-Responder Imputation; GPSS = Genital Psoriasis Symptoms Scale; GenPs-SFQ = Genital Psoriasis Sexual Frequency Questionnaire.</p></td></tr><tr><td colspan=\"3\"><p>b At Week 0, subjects received 160mg of TALTZ, followed by 80mg every 2 weeks for 12 weeks.</p></td></tr></tfoot><tbody><tr><td>Endpoints</td><td>TALTZ 80mg Q2Wbn (%)</td><td>Placebon (%)</td></tr><tr><td>Number of subjects randomized</td><td>N=75</td><td>N=74</td></tr><tr><td> sPGA of Genitalia 0 (clear) or 1 (minimal)</td><td>55 (73%)</td><td>6 (8%)</td></tr><tr><td> sPGA 0 (clear) or 1 (minimal)</td><td>55 (73%)</td><td>2 (3%)</td></tr><tr><td>Number of subjects with baseline GPSSaItch NRS Score 4</td><td>N=56</td><td>N=51</td></tr><tr><td> GPSS Genital Itch (4 point improvement)</td><td>31 (55%)</td><td>3 (6%)</td></tr><tr><td>Number of subjects with baseline GenPs-SFQaItem 2 Score 2</td><td>N=37</td><td>N=42</td></tr><tr><td> GenPs-SFQ Item 2 score 0 (never) or 1 (rarely)</td><td>29 (78%)</td><td>9 (21%)</td></tr></tbody></table><h2>14.2 Pediatric Plaque Psoriasis</h2><p>A randomized, double-blind, multicenter, placebo-controlled trial (IXORA-Peds, NCT03073200) enrolled 171 pediatric subjects 6 to less than 18 years of age, with moderate-to-severe plaque psoriasis (as defined by a sPGA score 3, involving 10% of the body surface area, and a PASI score 12) who were candidates for phototherapy or systemic therapy or were inadequately controlled on topical therapy.</p><p>Subjects were randomized to placebo or TALTZ with dosing stratified by weight.</p><ul><li>&lt;25kg: 40mg at Week 0 followed by 20mg Q4W</li><li>25kg to 50kg: 80mg at Week 0 followed by 40mg Q4W</li><li>&gt;50kg: 160mg at Week 0 followed by 80mg Q4W</li></ul><p>Response to treatment was assessed at 12 weeks of therapy and was defined by the proportion of subjects who achieved an sPGA score of 0 (clear) or 1 (almost clear) with at least a 2-point improvement from baseline and the proportion of subjects that achieved a reduction in PASI score of at least 75% (PASI 75) from baseline.</p><p>Other evaluated outcomes included the proportion of subjects who achieved PASI 90, PASI 100, sPGA of 0 and an improvement of itch severity as measured by a reduction of at least 4 points on an 11-point itch Numeric Rating Scale.</p><p>Subjects had a median baseline PASI score of 17 (range 12-49). Baseline sPGA score was severe or very severe in 49%. Of all subjects, 22% had received prior phototherapy and 32% had received prior conventional systemic therapy for the treatment of psoriasis.</p><p>Clinical Response</p><p>The efficacy results of IXORA-Peds are presented in Table 5.</p><table><caption>Table 5: Efficacy Results in Pediatric Subjects with Plaque Psoriasis in IXORA-Peds, NRIa</caption><tfoot><tr><td colspan=\"3\"><p>a Abbreviations: N = Number of subjects in the intent-to-treat population; NRI = Non-Responder Imputation.</p></td></tr><tr><td colspan=\"3\"><p>b At Week 0, subjects received 160mg, 80mg, or 40mg of TALTZ, followed by 80mg, 40mg, or 20mg every 4 weeks, depending on weight category, for 12 weeks.</p></td></tr><tr><td colspan=\"3\"><p>c Co-primary endpoints.</p></td></tr><tr><td colspan=\"3\"><p>d Itch NRS (4 improvement) in subjects with baseline Itch NRS 4. The number of ITT subjects with baseline Itch NRS Score 4 are as follows: TALTZ, n = 83; PBO, n = 40.</p></td></tr></tfoot><tbody><tr><td>TALTZb(N=115)n (%)</td><td>Placebo(N=56)n (%)</td></tr><tr><td>Week 12</td></tr><tr><td> sPGA 0 (clear) or 1 (minimal)c</td><td>93 (81%)</td><td>6 (11%)</td></tr><tr><td> sPGA 0 (clear)</td><td>60 (52%)</td><td>1 (2%)</td></tr><tr><td> PASI 75c</td><td>102 (89%)</td><td>14 (25%)</td></tr><tr><td> PASI 90</td><td>90 (78%)</td><td>3 (5%)</td></tr><tr><td> PASI 100</td><td>57 (50%)</td><td>1 (2%)</td></tr><tr><td> Itch NRS (4 point improvement)d</td><td>59 (71%)</td><td>8 (20%)</td></tr><tr><td>Week 4</td></tr><tr><td> sPGA 0 (clear) or 1 (minimal)</td><td>55 (48%)</td><td>4 (7%)</td></tr><tr><td> PASI 75</td><td>62 (54%)</td><td>5 (9%)</td></tr></tbody></table><h2>14.3 Psoriatic Arthritis</h2><p>The safety and efficacy of TALTZ were assessed in 679 patients, in 2 randomized, double-blind, placebo-controlled studies (PsA1 and PsA2) in adult patients, age 18 years and older with active psoriatic arthritis (at least 3 swollen and at least 3 tender joints) despite non-steroidal anti-inflammatory drug (NSAID), corticosteroid or disease modifying anti-rheumatic drug (DMARD) therapy. Patients in these studies had a diagnosis of PsA for at least 6 months across both studies. At baseline, 60% and 23% of the patients had enthesitis and dactylitis, respectively. In PsA2, all patients discontinued previous treatment with anti-TNF agents due to either inadequate response or intolerance. In addition, approximately 47% of patients from both studies had concomitant methotrexate (MTX) use.</p><p>PsA1 Study (NCT01695239) evaluated 417 biologic-naive patients, who were treated with either TALTZ 160mg at Week0 followed by 80mg every 2weeks (Q2W) or 4weeks (Q4W), adalimumab 40mg every 2weeks, or placebo. PsA2 Study (NCT02349295) evaluated 363 anti-TNF experienced patients, who were treated with TALTZ 160 mg at Week 0 followed by 80mg every 2 or 4weeks, or placebo. Patients receiving placebo were re-randomized to receive TALTZ (80mg every 2 or 4weeks) at Week16 or Week24 based on responder status. The primary endpoint was the percentage of patients achieving an ACR20 response at Week24.</p><p>Clinical Response</p><p>In both studies, patients treated with TALTZ 80mg Q4W demonstrated a greater clinical response including ACR20, ACR50, and ACR70 compared to placebo at Week 24 (Table 6). In PsA2, responses were seen regardless of prior anti-TNF exposure.</p><table><caption>Table 6: Responsesa at Week 12 and 24; NRIb</caption><tfoot><tr><td colspan=\"7\"><p>a Patients who met escape criteria (less than 20% improvement in tender and swollen joint counts) at Week 16 or had missing data at Week 24 were considered non-responders at Week 24.</p></td></tr><tr><td colspan=\"7\"><p>b Abbreviations: N = number of patients in the intent-to-treat population; NRI = Non-Responder Imputation.</p></td></tr><tr><td colspan=\"7\"><p>c At Week 0, patients received 160mg of TALTZ.</p></td></tr></tfoot><tbody><tr><td colspan=\"3\">PsA1 anti-TNF naive</td><td colspan=\"3\">PsA2 anti-TNF experienced</td></tr><tr><td>TALTZ80mgcQ4W(N=107)</td><td>Placebo (N=106)</td><td>Difference from placebo (95% CI)</td><td>TALTZ80mgcQ4W(N=122)</td><td>Placebo (N=118)</td><td>Difference from placebo (95% CI)</td></tr><tr><td colspan=\"7\">ACR20 response</td></tr><tr><td>Week 12 (%)</td><td>57</td><td>31</td><td>26 (13, 39)</td><td>50</td><td>22</td><td>28 (16, 40)</td></tr><tr><td>Week 24 (%)</td><td>58</td><td>30</td><td>28 (15, 41)</td><td>53</td><td>20</td><td>34 (22, 45)</td></tr><tr><td colspan=\"7\">ACR50 response</td></tr><tr><td>Week 12 (%)</td><td>34</td><td>5</td><td>29 (19, 39)</td><td>31</td><td>3</td><td>28 (19, 37)</td></tr><tr><td>Week 24 (%)</td><td>40</td><td>15</td><td>25 (14, 37)</td><td>35</td><td>5</td><td>30 (21, 40)</td></tr><tr><td colspan=\"7\">ACR70 response</td></tr><tr><td>Week 12 (%)</td><td>15</td><td>0</td><td>15 (8, 22)</td><td>15</td><td>2</td><td>13 (6, 20)</td></tr><tr><td>Week 24 (%)</td><td>23</td><td>6</td><td>18 (9, 27)</td><td>22</td><td>0</td><td>22 (15, 30)</td></tr></tbody></table><p>The percentage of patients achieving ACR20 response by visit is shown in Figure 1.</p><p>Figure 1: Percent of Patients Achieving ACR20 Responseain PsA1 Through Week 24</p><p>a Patients who met escape criteria (less than 20% improvement in tender and swollen joint counts) at Week16 or had missing data at Week 24 were considered non-responders at Week24.</p><p>The improvements in the components of the ACR response criteria are shown in Table7.</p><table><caption>Table 7: Efficacy results in ACR Components at Week 12 and 16</caption><tfoot><tr><td colspan=\"5\"><p>a At Week 0, subjects received 160mg of TALTZ.</p></td></tr><tr><td colspan=\"5\"><p>b Disability Index of the Health Assessment Questionnaire; 0 = best, 3 = worst, measures the patient's ability to perform the following: dress/groom, arise, eat, walk, reach, grip, maintain hygiene, and maintain daily activity.</p></td></tr></tfoot><tbody><tr><td colspan=\"2\">PsA1</td><td colspan=\"2\">PsA2</td></tr><tr><td>TALTZ 80mgaQ4W (N=107)</td><td>Placebo(N=106)</td><td>TALTZ 80mgaQ4W (N=122)</td><td>Placebo(N=118)</td></tr><tr><td>No. of Swollen Joints</td></tr><tr><td> Baseline</td><td>11.4</td><td>10.6</td><td>13.1</td><td>10.3</td></tr><tr><td> Mean Change at Week 12</td><td>-6.2</td><td>-3.2</td><td>-5.8</td><td>-2.6</td></tr><tr><td> Mean Change at Week 16</td><td>-6.2</td><td>-3.0</td><td>-7.4</td><td>-2.6</td></tr><tr><td>No. of Tender Joints</td></tr><tr><td> Baseline</td><td>20.5</td><td>19.2</td><td>22.0</td><td>23.0</td></tr><tr><td> Mean Change at Week 12</td><td>-10.3</td><td>-3.5</td><td>-9.4</td><td>-5.4</td></tr><tr><td> Mean Change at Week 16</td><td>-9.7</td><td>-4.0</td><td>-10.1</td><td>-3.0</td></tr><tr><td>Patient's Assessment of Pain</td></tr><tr><td> Baseline</td><td>60.1</td><td>58.5</td><td>63.9</td><td>63.9</td></tr><tr><td> Mean Change at Week 12</td><td>-26.6</td><td>-9.1</td><td>-29.8</td><td>-11.9</td></tr><tr><td> Mean Change at Week 16</td><td>-26.1</td><td>-10.6</td><td>-30.1</td><td>-12.3</td></tr><tr><td>Patient Global Assessment</td></tr><tr><td> Baseline</td><td>62.7</td><td>61.1</td><td>66.4</td><td>64.1</td></tr><tr><td> Mean Change at Week 12</td><td>-29.7</td><td>-11.1</td><td>-34.5</td><td>-10.7</td></tr><tr><td> Mean Change at Week 16</td><td>-30.4</td><td>-13.2</td><td>-35.3</td><td>-15.7</td></tr><tr><td>Physician Global Assessment</td></tr><tr><td> Baseline</td><td>57.6</td><td>55.9</td><td>60.3</td><td>58.9</td></tr><tr><td> Mean Change at Week 12</td><td>-34.0</td><td>-16.6</td><td>-34.4</td><td>-15.9</td></tr><tr><td> Mean Change at Week 16</td><td>-35.5</td><td>-16.5</td><td>-32.9</td><td>-9.7</td></tr><tr><td>Disability Index (HAQ-DI)b</td></tr><tr><td> Baseline</td><td>1.2</td><td>1.2</td><td>1.2</td><td>1.2</td></tr><tr><td> Mean Change at Week 12</td><td>-0.4</td><td>-0.1</td><td>-0.4</td><td>-0.1</td></tr><tr><td> Mean Change at Week 16</td><td>-0.4</td><td>-0.1</td><td>-0.5</td><td>-0.1</td></tr><tr><td>CRP (mg/L)</td></tr><tr><td> Baseline</td><td>12.8</td><td>15.1</td><td>17.0</td><td>12.1</td></tr><tr><td> Mean Change at Week 12</td><td>-8.8</td><td>-3.2</td><td>-11.4</td><td>-4.3</td></tr><tr><td> Mean Change at Week 16</td><td>-9.3</td><td>-3.2</td><td>-11.2</td><td>-5.9</td></tr></tbody></table><p>Treatment with TALTZ resulted in improvement in dactylitis and enthesitis in patients with pre-existing dactylitis or enthesitis.</p><p>Treatment with TALTZ 80mg Q4W resulted in an improvement in psoriatic skin lesions in patients with PsA.</p><p>Radiographic Response</p><p>Radiographic changes were assessed in PsA1. Inhibition of progression of structural damage was assessed radiographically and expressed as the change in modified total Sharp score (mTSS) at Week16, compared to baseline. The total Sharp score was modified for psoriatic arthritis by addition of hand distal interphalangeal (DIP) joints.</p><p>TALTZ 80mg Q4W inhibited the progression of structural joint damage (mTSS) compared to placebo at Week16. The adjusted mean change from baseline in the mTSS was 0.13 for TALTZ 80mg Q4W and 0.36 for placebo (difference in means TALTZ minus placebo: -0.23, 95% CI: (-0.42, -0.04)).</p><p>Physical Function</p><p>TALTZ treated patients showed improvement in physical function compared to patients treated with placebo as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI) at Week 12 and 24. In both studies, the proportion of HAQ-DI responders (0.35 improvement in HAQ-DI score) was greater in the TALTZ 80mg Q4W groups compared to placebo at week 12 and 24.</p><p>Other Health-Related Outcomes</p><p>General health status was assessed by the Short Form health survey (SF-36). At Week 12 in PsA1 and PsA2, patients treated with TALTZ showed greater improvement from baseline in the SF-36 physical component summary (PCS) score compared to patients treated with placebo but this improvement was not consistent in both studies for the SF-36 mental component summary (MCS) score. At Week 12, there was consistent evidence of effect in the physical-functioning, role-physical, bodily-pain, and general health domains but not in the social-functioning, role-emotional, vitality, and mental health domains.</p><h2>14.4 Ankylosing Spondylitis</h2><p>The safety and efficacy of TALTZ were assessed in 567 patients, in 2 randomized, double-blind, placebo-controlled studies (AS1 and AS2) in adult patients, age 18 years and older with active ankylosing spondylitis. Patients had active disease as defined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 4 despite non-steroidal anti-inflammatory drug (NSAID), corticosteroid, or disease modifying anti-rheumatic drug (DMARD) therapy. At baseline, patients had symptoms of AS for an average of 17 years across both studies. At baseline, approximately 32% of the patients were on a concomitant cDMARD. In AS2, all patients discontinued previous treatment with 1 or 2 TNF inhibitors due to either inadequate response or intolerance.</p><p>AS1 Study (NCT02696785) evaluated 341 biologic-naive patients, who were treated with either TALTZ 80mg or 160mg at Week0 followed by 80mg every 2weeks (Q2W) or 4weeks (Q4W), adalimumab 40mg every 2weeks, or with placebo. Patients receiving placebo were re-randomized at Week 16 to receive TALTZ (160mg starting dose, followed by 80mg Q2W or Q4W). Patients receiving adalimumab were re-randomized at Week 16 to receive TALTZ (80mg Q2W or Q4W). AS2 Study (NCT02696798) evaluated 316 TNF-inhibitor experienced patients (90% were inadequate responders and 10% were intolerant to TNF inhibitors). All patients were treated with TALTZ 80 or 160mg at Week 0 followed by 80mg Q2W or Q4W, or with placebo. Patients receiving placebo were re-randomized at Week 16 to receive TALTZ (160mg initial dose, followed by 80mg Q2W or Q4W). The primary endpoint in both studies was the percentage of patients achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) response at Week16.</p><p>Clinical Response</p><p>In both studies, patients treated with TALTZ 80mg Q4W demonstrated greater improvements in ASAS40 and ASAS20 responses compared to placebo at Week 16 (Table 8). Responses were seen regardless of concomitant therapies. In AS2, responses were seen regardless of prior TNF-inhibitor exposure.</p><table><caption>Table 8: ASAS20 and ASAS40 Responses at Week 16, NRIa,b</caption><tfoot><tr><td colspan=\"7\"><p>a Abbreviations: N = number of patients in the intent-to-treat population; NRI = Non-responder Imputation.</p></td></tr><tr><td colspan=\"7\"><p>b Patients with missing data were counted as non-responders.</p></td></tr><tr><td colspan=\"7\"><p>c At Week 0, patients received 80mg or 160mg of TALTZ.</p></td></tr><tr><td colspan=\"7\"><p>d An ASAS20 response is defined as a 20% improvement and an absolute improvement from baseline of 1 units (range 0 to 10) in 3of 4 domains (Patient Global, Spinal Pain, Function, and Inflammation), and no worsening of 20% and 1 unit (range 0 to 10) in the remaining domain. An ASAS40 response is defined as a 40% improvement and an absolute improvement from baseline of 2 units in 3 of 4 domains without any worsening in the remaining domain.</p></td></tr><tr><td colspan=\"7\"><p>e Primary endpoint.</p></td></tr></tfoot><tbody><tr><td colspan=\"3\">AS1 biologic-naive</td><td colspan=\"3\">AS2 TNF-inhibitor experienced</td></tr><tr><td>TALTZ80mgQ4Wc(N=81)</td><td>Placebo (N=87)</td><td>Difference from placebo (95% CI)</td><td>TALTZ80mgQ4Wc(N=114)</td><td>Placebo (N=104)</td><td>Difference from placebo (95% CI)</td></tr><tr><td>ASAS20 responsed, %</td><td>64</td><td>40</td><td>24 (9, 39)</td><td>48</td><td>30</td><td>18 (6, 31)</td></tr><tr><td>ASAS40 responsed,e, %</td><td>48</td><td>18</td><td>30 (16, 43)</td><td>25</td><td>13</td><td>13 (3, 23)</td></tr></tbody></table><p>The percent of patients achieving ASAS40 response by visit in AS1 is shown in Figure 2.</p><p>Figure 2: ASAS40 Response through Week 16, NRIa</p><p>a Patients with missing data were counted as non-responders.</p><p>The improvement in the main components of the ASAS40 response criteria and other measures of disease activity are shown in Table 9.</p><table><caption>Table 9: ASAS Components and Other Measures of Disease Activity at Week 16a,b</caption><tfoot><tr><td colspan=\"5\"><p>a Abbreviations: ASDAS = Ankylosing Spondylitis Disease Activity Score; BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; hsCRP = High sensitivity C-reactive protein.</p></td></tr><tr><td colspan=\"5\"><p>b Mean changes are least-squares mean changes from baseline at Week 16.</p></td></tr><tr><td colspan=\"5\"><p>c At Week 0, patients received 80 or 160mg of TALTZ.</p></td></tr><tr><td colspan=\"5\"><p>d Inflammation is the mean of patient-reported stiffness self-assessments (questions 5 and 6) in BASDAI.</p></td></tr></tfoot><tbody><tr><td colspan=\"2\">AS1 biologic-naive</td><td colspan=\"2\">AS2 TNF-inhibitor experienced</td></tr><tr><td>TALTZ 80mgQ4Wc(N=81)</td><td>Placebo(N=87)</td><td>TALTZ 80mgQ4Wc(N=114)</td><td>Placebo(N=104)</td></tr><tr><td colspan=\"5\">ASAS Components</td></tr><tr><td colspan=\"5\"> Patient Global Assessment (0-10)</td></tr><tr><td> Baseline</td><td>6.9</td><td>7.1</td><td>8.0</td><td>7.8</td></tr><tr><td> Mean Change from Baseline</td><td>-2.5</td><td>-1.4</td><td>-2.4</td><td>-0.7</td></tr><tr><td colspan=\"5\"> Total Spinal Pain (0-10)</td></tr><tr><td> Baseline</td><td>7.2</td><td>7.4</td><td>7.9</td><td>7.8</td></tr><tr><td> Mean Change from Baseline</td><td>-3.2</td><td>-1.7</td><td>-2.4</td><td>-1.0</td></tr><tr><td colspan=\"5\"> BASFI (0-10)</td></tr><tr><td> Baseline</td><td>6.1</td><td>6.4</td><td>7.4</td><td>7.0</td></tr><tr><td> Mean Change from Baseline</td><td>-2.4</td><td>-1.2</td><td>-1.7</td><td>-0.6</td></tr><tr><td colspan=\"5\"> Inflammation (0-10)d</td></tr><tr><td> Baseline</td><td>6.5</td><td>6.8</td><td>7.2</td><td>7.2</td></tr><tr><td> Mean Change from Baseline</td><td>-3.2</td><td>-1.3</td><td>-2.4</td><td>-0.7</td></tr><tr><td colspan=\"5\">Other Measures of Disease Activity</td></tr><tr><td colspan=\"5\"> BASDAI Score</td></tr><tr><td> Baseline</td><td>6.8</td><td>6.8</td><td>7.5</td><td>7.3</td></tr><tr><td> Mean Change from Baseline</td><td>-2.9</td><td>-1.4</td><td>-2.2</td><td>-0.9</td></tr><tr><td colspan=\"5\"> BASMI</td></tr><tr><td> Baseline</td><td>3.9</td><td>4.5</td><td>4.7</td><td>4.9</td></tr><tr><td> Mean Change from Baseline</td><td>-0.5</td><td>-0.1</td><td>-0.3</td><td>-0.0</td></tr><tr><td colspan=\"5\"> hsCRP (mg/L)</td></tr><tr><td> Baseline</td><td>12.2</td><td>16.0</td><td>20.2</td><td>16.0</td></tr><tr><td> Mean Change from Baseline</td><td>-5.2</td><td>1.4</td><td>-11.1</td><td>9.7</td></tr></tbody></table><p>Health-Related Outcomes</p><p>General health status and quality of life was assessed by the Short Form health survey (SF-36). At Week 16, in AS1 and AS2, compared to placebo, patients treated with TALTZ showed greater improvement from baseline in the SF-36 physical component summary (PCS) score and the physical functioning, role physical, bodily pain, vitality, and general health domains, with no consistent improvements in the mental component summary (MCS), social functioning, role emotional, and mental health domains.</p><h2>14.5 Non-radiographic Axial Spondyloarthritis</h2><p>The efficacy and safety of TALTZ were assessed in a randomized, double-blind, 52-week placebo-controlled study (nr-axSpA1) (NCT02757352) in patients 18years of age with active axial spondyloarthritis for at least 3months. Patients must have had objective signs of inflammation indicated by elevated C-reactive protein (CRP) (defined as greater than 5mg/L), and/or sacroiliitis on magnetic resonance imaging (MRI), and no definitive radiographic evidence of structural damage on sacroiliac joints. Patients had active disease as defined by the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 4, and spinal pain 4 on a 0 to 10 Numerical Rating Scale (NRS). Patients must have been intolerant to or had an inadequate response to at least two NSAIDs. Patients were treated with either placebo or TALTZ 80mg or 160mg at Week 0, followed by either 80mg every 2weeks (Q2W) or 80mg every 4weeks (Q4W). Initiation and/or dose adjustment of concomitant medications (NSAIDs, cDMARDs, corticosteroids, analgesics) were permitted starting at Week 16. Patients were allowed to transition to use of open-label TALTZ 80mg Q2W starting at Week 16 up to Week 44 at the discretion of the investigator.</p><p>At baseline, patients had symptoms of nr-axSpA for an average of 11years. Approximately 39% of the patients were on a concomitant cDMARD.</p><p>The primary endpoint was the percentage of patients achieving an Assessment of Spondyloarthritis International Society 40 (ASAS40) response at Week 52. The ASAS40 response was also evaluated at Week 16 as a major secondary endpoint.</p><p>Clinical Response</p><p>At both Weeks 16 and 52, a greater proportion of patients treated with TALTZ 80mg Q4W had ASAS40 response compared to patients treated with placebo (Table 10). The components of ASAS response criteria and CRP are shown in Table 11.</p><table><caption>Table 10: ASAS40 Responses at Week 16 and Week 52, NRIa,b</caption><tfoot><tr><td colspan=\"7\"><p>a Abbreviations: N = number of patients in the intent-to-treat population; NRI = Non-responder Imputation.</p></td></tr><tr><td colspan=\"7\"><p>b Patients who initiated open-label TALTZ 80mg Q2W, or discontinued initially randomized treatment and remained in the study, or were missing Week 16 or Week 52 data were counted as non-responders.</p></td></tr><tr><td colspan=\"7\"><p>c Starting at Week 16 and up to Week 44, patients who were determined as inadequate responders by investigators were given the option to make changes in their background therapy and/or transition to open label TALTZ 80mg Q2W.</p></td></tr><tr><td colspan=\"7\"><p>d At Week 0, patients received 80mg or 160mg of TALTZ.</p></td></tr><tr><td colspan=\"7\"><p>e An ASAS40 response is defined as a 40% improvement and an absolute improvement from baseline of 2 units in 3 of 4 domains without any worsening in the remaining domain.</p></td></tr></tfoot><tbody><tr><td colspan=\"3\">Week 16</td><td colspan=\"3\">Week 52</td></tr><tr><td>TALTZ80mgQ4Wc,d(N=96)</td><td>Placebo (N=105)</td><td>Difference from placebo (95% CI)</td><td>TALTZ80mgQ4Wc,d(N=96)</td><td>Placebo (N=105)</td><td>Difference from placebo (95% CI)</td></tr><tr><td>ASAS40 responsee, %</td><td>35.4</td><td>19.0</td><td>16.4 (4.2, 28.5)</td><td>30.2</td><td>13.3</td><td>16.9 (5.6, 28.1)</td></tr></tbody></table><p>The improvement in the main components of the ASAS40 response criteria and other measures of disease activity at Week 16 are shown in Table 11.</p><table><caption>Table 11: ASAS Components and Other Measures of Disease Activity at Week 16a</caption><tfoot><tr><td colspan=\"3\"><p>a Abbreviations: BASDAI = Bath Ankylosing Spondylitis Disease Activity Index; BASFI = Bath Ankylosing Spondylitis Functional Index; BASMI = Bath Ankylosing Spondylitis Metrology Index; hsCRP = High sensitivity C-reactive protein; NRI = Non-responder Imputation.</p></td></tr><tr><td colspan=\"3\"><p>b At Week 0, patients received 80 or 160mg of TALTZ.</p></td></tr><tr><td colspan=\"3\"><p>c Mean changes are least-squares mean changes from baseline at Week 16 using a mixed model for repeated measures adjusting for treatment group, screening MRI/CRP classification, visit, continuous baseline, interaction of visit with treatment, interaction of continuous baseline with visit.</p></td></tr><tr><td colspan=\"3\"><p>d Inflammation is the mean of patient-reported stiffness self-assessments (questions 5 and 6) in BASDAI questionnaire.</p></td></tr></tfoot><tbody><tr><td>TALTZ 80mgQ4Wb(N=96)</td><td>Placebo(N=105)</td></tr><tr><td colspan=\"3\">ASAS Components</td></tr><tr><td colspan=\"3\"> Patient Global Assessment (0-10)</td></tr><tr><td> Baseline</td><td>7.1</td><td>7.4</td></tr><tr><td> Mean Change from Baselinec</td><td>-2.3</td><td>-1.3</td></tr><tr><td colspan=\"3\"> Total Spinal Pain (0-10)</td></tr><tr><td> Baseline</td><td>7.3</td><td>7.4</td></tr><tr><td> Mean Change from Baselinec</td><td>-2.4</td><td>-1.5</td></tr><tr><td colspan=\"3\"> BASFI (0-10)</td></tr><tr><td> Baseline</td><td>6.4</td><td>6.7</td></tr><tr><td> Mean Change from Baselinec</td><td>-2.0</td><td>-1.3</td></tr><tr><td colspan=\"3\"> Inflammation (0-10)d</td></tr><tr><td> Baseline</td><td>6.8</td><td>7.0</td></tr><tr><td> Mean Change from Baselinec</td><td>-2.5</td><td>-1.5</td></tr><tr><td colspan=\"3\">Other Measures of Disease Activity</td></tr><tr><td colspan=\"3\"> BASDAI Score (0-10)</td></tr><tr><td> Baseline</td><td>7.0</td><td>7.2</td></tr><tr><td> Mean Change from Baselinec</td><td>-2.2</td><td>-1.5</td></tr><tr><td colspan=\"3\"> BASMI (0-10)</td></tr><tr><td> Baseline</td><td>3.2</td><td>3.2</td></tr><tr><td> Mean Change from Baselinec</td><td>-0.4</td><td>-0.2</td></tr><tr><td colspan=\"3\"> hsCRP (mg/L)</td></tr><tr><td> Baseline</td><td>12.4</td><td>14.3</td></tr><tr><td> Mean Change from Baselinec</td><td>-8.0</td><td>-3.0</td></tr></tbody></table><p>The percent of patients achieving ASAS40 responses by visit is shown in Figure 3.</p><p>Figure 3: ASAS40 Responses through Week 16, NRIa</p><p>a Patients with missing data were counted as non-responders.</p><p>Health-Related Outcomes</p><p>General health status and quality of life was assessed by the Short Form health survey (SF-36). At Week 16, compared to placebo, nr-axSpA patients treated with TALTZ 80mg Q4W showed greater improvement from baseline in the SF-36 physical component summary (PCS) score and physical functioning, bodily pain, vitality, and social functioning domains, with no consistent improvements in the mental component summary (MCS), role physical, general health, role emotional, and mental health domains.</p>",
      "howSupplied": "<p>How Supplied</p><p>TALTZ injection is a sterile, preservative free, clear and colorless to slightly yellow solution available in:</p><ul><li>a single-dose prefilled autoinjector or a single-dose prefilled syringe to deliver 80mg ixekizumab.</li><li>a single-dose prefilled syringe to deliver 40 mg ixekizumab.</li><li>a single-dose prefilled syringe to deliver 20 mg ixekizumab.</li></ul><p>TALTZ is supplied as:</p><table><tbody><tr><td>Pack Size</td><td>NDC Code</td></tr><tr><td>Autoinjector</td></tr><tr><td>Carton of 1</td><td>0002-1445-11</td></tr><tr><td> 80mg single-dose</td><td>Carton of 2</td><td>0002-1445-27</td></tr><tr><td>Carton of 3</td><td>0002-1445-09</td></tr><tr><td>Prefilled syringe</td></tr><tr><td> 80mg single-dose</td><td>Carton of 1</td><td>0002-7724-11</td></tr><tr><td> 40mg single-dose</td><td>Carton of 1</td><td>0002-8905-11</td></tr><tr><td> 20mg single-dose</td><td>Carton of 1</td><td>0002-8900-11</td></tr></tbody></table>",
      "useInSpecificPopulations": "<h1>8 USE IN SPECIFIC POPULATIONS</h1><h2>8.1 Pregnancy</h2><p>Pregnancy Exposure Registry</p><p>There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to TALTZ during pregnancy. Pregnant women exposed to TALTZ are encouraged to enroll in the TALTZ Pregnancy Registry by calling 1-800-284-1695. Contact information for the registry is also available on http://www.pregnancyregistry.lilly.com.</p><p>Risk Summary</p><p>Available data from the published literature and the pharmacovigilance database with TALTZ use in pregnant women are insufficient to evaluate for a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. </p><p>Human IgG is known to cross the placental barrier; therefore, TALTZ may be transmitted from the mother to the developing fetus. An embryofetal development study conducted in pregnant monkeys during organogenesis at doses up to 19 times the maximum recommended human dose (MRHD) revealed no evidence of harm to the developing fetus. When dosing was continued until parturition, neonatal deaths were observed at 1.9 times the MRHD [see Data]. The clinical significance of these nonclinical findings is unknown.</p><p>The background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</p><p>Data</p><p>Animal Data</p><p>An embryofetal development study was conducted in cynomolgus monkeys administered ixekizumab. No malformations or embryofetal toxicity were observed in fetuses from pregnant monkeys administered ixekizumab weekly by subcutaneous injection during organogenesis to near parturition at doses up to 19 times the MRHD (on a mg/kg basis of 50mg/kg/week). Ixekizumab crossed the placenta in monkeys.</p><p>In a pre- and post-natal development toxicity study, pregnant cynomolgus monkeys were administered weekly subcutaneous doses of ixekizumab up to 19 times the MRHD from the beginning of organogenesis to parturition. Neonatal deaths occurred in the offspring of two monkeys administered ixekizumab at 1.9 times the MRHD (on a mg/kg basis of 5mg/kg/week) and two monkeys administered ixekizumab at 19 times the MRHD (on a mg/kg basis of 50mg/kg/week). These neonatal deaths were attributed to early delivery, trauma, or congenital defect. The clinical significance of these findings is unknown. No ixekizumab-related effects on functional or immunological development were observed in the surviving infants from birth through 6 months of age.</p><h2>8.2 Lactation</h2><p>Risk Summary</p><p>There are no available data on the presence of ixekizumab in human milk, the effects on the breastfed infant, or the effects on milk production. Ixekizumab was detected in the milk of lactating cynomolgus monkeys. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TALTZ and any potential adverse effects on the breastfed infant from TALTZ or from the underlying maternal condition.</p><h2>8.4 Pediatric Use</h2><p>The safety and effectiveness of TALTZ have been established in pediatric subjects aged 6 years to less than 18 years with moderate-to-severe plaque psoriasis. The safety and effectiveness of TALTZ in other pediatric indications and for pediatric subjects less than 6 years of age have not been established.</p><h2>8.5 Geriatric Use</h2><p>Of the 4204 adult psoriasis subjects exposed to TALTZ, a total of 301 were 65 years or older, and 36 subjects were 75 years or older. Although no differences in safety or efficacy were observed between older and younger subjects, the number of subjects aged 65 and over is not sufficient to determine whether they respond differently from younger subjects [see Clinical Pharmacology (12.3)].</p>",
      "description": "<p>Ixekizumab is a humanized IgG4 monoclonal antibody with neutralizing activity against IL-17A, produced by recombinant DNA technology. It consists of two identical light chain polypeptides of 219 amino acids each and two identical heavy chain polypeptides of 445 amino acids each, with a molecular weight of 146,158 Daltons. TALTZ injection is a sterile, preservative-free solution for subcutaneous use, available in various dosages: 80 mg in a 1 mL prefilled autoinjector or syringe, 40 mg in a 0.5 mL syringe, and 20 mg in a 0.25 mL syringe. Each dosage form contains ixekizumab, Polysorbate 80, Sucrose, and Water for Injection, with a pH of 5.2 to 6.2. Sodium Hydroxide may be added to adjust pH.</p>",
      "nonclinicalToxicology": "<h1>13 NONCLINICAL TOXICOLOGY</h1><h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><p>Animal studies have not been conducted to evaluate the carcinogenic or mutagenic potential of TALTZ. Moreover published literature is mixed on potential effects on malignancy risk due to the inhibition of IL-17A activity, the pharmacological action of TALTZ. Some published literature suggests that IL-17A directly promotes cancer cell invasion, suggesting a potential beneficial effect by TALTZ, whereas other reports indicate IL-17A promotes T-cell mediated tumor rejection, suggesting a potential adverse effect by TALTZ. However, neutralization of IL-17A with TALTZ has not been studied in these models. Depletion of IL-17A with a neutralizing antibody inhibited tumor development in mice, suggesting a potential beneficial effect by TALTZ. The relevance of experimental findings in mouse models for malignancy risk in humans is unknown.</p><p>No effects on fertility parameters such as reproductive organs, menstrual cycle length, or sperm analysis were observed in sexually mature cynomolgus monkeys that were administered ixekizumab for 13 weeks at a subcutaneous dose of 50mg/kg/week (19 times the MRHD on a mg/kg basis). The monkeys were not mated to evaluate fertility.</p>",
      "instructionsForUse": "<h1>TALTZ 20 mg Prefilled Syringe</h1><table><tbody><tr><td>INSTRUCTIONS FOR USE</td></tr><tr><td>TALTZ [tol-t-s](ixekizumab)injection, for subcutaneous use20 mg/0.25 mL single-dose prefilled syringe</td></tr><tr><td>This Instructions for Use contains information on how to inject TALTZ. </td></tr><tr><td>Important Information You Need to Know Before Giving TALTZ Injection to Your Child</td></tr><tr><td><ul><li>Your child's healthcare provider or nurse should show you how to prepare and inject TALTZ using the prefilled syringe. Do not give the TALTZ prefilled syringe to your child until you have been shown how to inject TALTZ.</li><li>Children ages 6 to 17 years of age should not inject themselves with TALTZ. You or an adult caregiver should prepare and give TALTZ injections to your child.</li><li>You should read this Instructions for Use before injecting TALTZ and each time your child gets a refill. Keep the Instructions for Use and refer to them as needed.</li><li>Each TALTZ prefilled syringe contains 1 dose (20 mg) of TALTZ. The syringe is for one-time use only. Do not share or reuse the TALTZ prefilled syringe. Your child may give or get an infection.</li><li>Your child's healthcare provider may help you decide where on the body to inject the dose. Do not give an injection in an area of the skin that is tender, bruised, red or hard, or in an area of skin that is affected by psoriasis. Read the Choose the injection site section of these instructions to help you choose which area can work best.</li></ul></td></tr><tr><td><ul><li>If you have vision problems, do not use TALTZ prefilled syringe without help.</li></ul></td></tr></tbody></table><table><tbody><tr><td colspan=\"3\">Before you use the TALTZ prefilled syringe, read and carefully follow all the step-by-step instructions.</td></tr><tr><td colspan=\"3\">Parts of the TALTZ prefilled syringe</td></tr><tr><td colspan=\"1\">Step 1</td><td colspan=\"2\">Preparing to Inject TALTZ</td></tr><tr><td>Step 1a</td><td><ul><li>Take the TALTZ prefilled syringe from the refrigerator.</li><li>Remove the prefilled syringe from the package. </li><li>Leave the needle cap on the syringe until you are ready to inject.</li><li>Wait 30 minutes to let the prefilled syringe warm to room temperature before you use it.</li><li>Do not microwave the syringe, run hot water over it, or leave it in direct sunlight.</li><li>Do not shake the prefilled syringe.</li></ul></td></tr><tr><td>Step 1b</td><td colspan=\"2\">Gather the supplies needed for injection:<ul><li>1 alcohol wipe</li><li>1 cotton ball or piece of gauze</li><li>1 sharps disposal container. See Disposing of TALTZ</li></ul></td></tr><tr><td>Step 1c</td><td>Inspect the syringe. Leave the needle cap on the syringe until you are ready to inject.<ul><li>Make sure the name TALTZ appears on the label.</li><li>The medicine inside should be clear. Its color may be colorless to slightly yellow.</li></ul>Do not use the prefilled syringe, and dispose of as directed by your child's healthcare provider or pharmacist if:<ul><li>the expiration date printed on the label has passed (see Figure A).</li><li>it looks damaged.</li><li>the medicine is frozen.</li><li>the medicine is cloudy, discolored, or has small particles. The medicine should look clear and colorless to slightly yellow.</li></ul></td></tr><tr><td>Step 1d</td><td colspan=\"2\">Wash your hands with soap and water before you inject TALTZ.</td></tr><tr><td>Step 1e</td><td><p>Choose the injection site.</p>You may inject in the stomach area (abdomen) or in the thigh, or in the back of the arm (see Figure B). Do not give an injection into areas where the skin is tender, bruised, red or hard, or in an area of skin that is affected by psoriasis.Do not inject within 1 inch of the navel (belly button).Change (alternate) injection sites.<ul><li>Do not inject in the exact same spot every time. For example, if the last injection was in the left thigh, the next injection should be in the right thigh, the abdomen, or the back of either arm.</li><li>Talk with your child's healthcare provider about where on the body to best inject TALTZ.</li></ul></td></tr><tr><td>Step 1f</td><td colspan=\"2\">Prepare the skin. Clean the injection site with an alcohol wipe. Let the injection site dry before you inject TALTZ.</td></tr><tr><td>Step 2</td><td colspan=\"2\">Injecting TALTZ</td></tr><tr><td>Step 2a</td><td>Pull the needle cap off and throw it away (see Figure C).<ul><li>Do not put the needle cap back on. You could damage the needle or stick yourself by accident.</li><li>Do not touch the needle.</li></ul></td></tr><tr><td>Step 2b</td><td>Gently pinch and hold a fold of skin where you will inject (see Figure D).</td></tr><tr><td>Step 2c</td><td><p>Insert the needle at a 45-degree angle to inject under the skin (subcutaneous injection) (see Figure E). Then gently let go of the skin. Make sure to keep the needle in place.</p><p>Let go of the skin before you push the plunger in (see Figure F).</p></td></tr><tr><td>Step 2d</td><td>Push in the plunger.<ul><li>Slowly push on the thumb pad to push the plunger all the way in until all the medicine is injected (see Figure G).</li><li>The gray syringe plunger should be pushed all the way to the needle end of the syringe.</li><li>You should see the gray syringe plunger at the bottom of the syringe body when the injection is complete (see Figure H).</li><li>Gently remove the needle from the skin.</li><li>Press a cotton ball or gauze over the injection site. Do not rub the injection site, as this may cause bruising. There may be slight bleeding. This is normal.</li></ul>Do not put the needle cap back on the prefilled syringe.</td></tr><tr><td>Step 3</td><td colspan=\"2\"><p>Disposing of TALTZ</p></td></tr><tr><td colspan=\"2\">Step 3a</td></tr><tr><td colspan=\"3\"><ul><li>Put the used TALTZ prefilled syringe in an FDA-cleared sharps disposal container right away after use (see Figure I). Do not throw away (dispose of) the TALTZ prefilled syringe in your household trash.</li></ul></td></tr><tr><td colspan=\"3\"><ul><li>If you do not have an FDA-cleared sharps disposal container, you may use a household container that is:<ul><li>made of a heavy-duty plastic,</li><li>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</li><li>upright and stable during use,</li><li>leak-resistant, and</li><li>properly labeled to warn of hazardous waste inside the container.</li></ul></li></ul></td></tr><tr><td colspan=\"3\"><ul><li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal</li></ul></td></tr><tr><td colspan=\"3\"><ul><li>Do not recycle your used sharps disposal container.</li></ul></td></tr><tr><td colspan=\"3\">Commonly asked questions and answers.</td></tr><tr><td>Q.</td><td colspan=\"2\">What if I see air bubbles in the TALTZ prefilled syringe?</td></tr><tr><td>A.</td><td colspan=\"2\">It is normal to have air bubbles in the prefilled syringe.</td></tr><tr><td>Q.</td><td colspan=\"2\">What if there is a drop of liquid on the tip of the needle when I remove the needle cap?</td></tr><tr><td>A.</td><td colspan=\"2\">It is okay to see a drop of liquid on the tip of the needle.</td></tr><tr><td>Q.</td><td colspan=\"2\">What if I cannot push in the plunger?</td></tr><tr><td>A.</td><td colspan=\"2\">If the plunger is stuck or damaged:</td></tr><tr><td colspan=\"2\"><ul><li>Do not continue to use the syringe</li></ul></td></tr><tr><td colspan=\"2\"><ul><li>Remove the needle from the skin</li></ul></td></tr><tr><td colspan=\"2\"><ul><li>Dispose of the syringe and get a new one</li></ul></td></tr><tr><td>Q.</td><td colspan=\"2\">How can I tell if the injection is complete?</td></tr><tr><td>A.</td><td colspan=\"2\">When the injection is complete:</td></tr><tr><td colspan=\"2\"><ul><li>The gray syringe plunger should be pushed all the way to the needle end of the syringe.</li></ul></td></tr><tr><td>Q.</td><td colspan=\"2\">What if the syringe is left at room temperature for longer than 30 minutes?</td></tr><tr><td>A.</td><td colspan=\"2\">If needed, the syringe may be left out of the refrigerator at room temperature up to 86F (30C) for up to 5 days if protected from light. Throw away TALTZ if not used within the 5-day period at room temperature. See \"Storing TALTZ\" for more detail. </td></tr><tr><td colspan=\"3\">If you have more questions about how to use the TALTZ prefilled syringe:</td></tr><tr><td colspan=\"3\"><ul><li>Call your child's healthcare provider</li><li>Call Lilly at 1-800-545-5979 (1-800-Lilly-Rx)</li><li><p>Visit www.taltz.com </p></li></ul></td></tr><tr><td colspan=\"3\">Storing TALTZ</td></tr><tr><td colspan=\"3\"><ul><li>Protect TALTZ from light.</li><li>Store TALTZ in the refrigerator between 36F to 46F (2C to 8C). <ul><li>If needed, you may store TALTZ at room temperature up to 86F (30C) for up to 5 days in the original carton to protect from light. Once TALTZ has been stored at room temperature, do not return to the refrigerator. Throw away TALTZ if it is not used within 5 days at room temperature.</li><li>Record the date when TALTZ is first removed from the refrigerator in the spaces provided on the carton.</li></ul></li><li>Do not freeze TALTZ. Do not use if TALTZ has been frozen.</li><li>Do not shake TALTZ.</li></ul></td></tr><tr><td colspan=\"3\">Keep TALTZ and all medicines out of the reach of children.</td></tr><tr><td colspan=\"3\">Read the Medication Guide for TALTZ inside this box to learn more about the medicine.</td></tr><tr><td colspan=\"3\">Eli Lilly and CompanyIndianapolis, IN 46285, USAUS License Number 1891TALTZ is a trademark of Eli Lilly and Company.Copyright 2024 Eli Lilly and Company. All rights reserved. This Instructions for Use has been approved by the U.S. Food and Drug Administration.Approved: February 2024TAL-0.25ML-PFS-0001-IFU-20240202</td></tr></tbody></table>",
      "mechanismOfAction": "<h2>12.1 Mechanism of Action</h2><p>Ixekizumab is a humanized IgG4 monoclonal antibody that selectively binds with the interleukin 17A (IL-17A) cytokine and inhibits its interaction with the IL-17 receptor. IL-17A is a naturally occurring cytokine that is involved in normal inflammatory and immune responses. Ixekizumab inhibits the release of proinflammatory cytokines and chemokines.</p>",
      "contraindications": "<p>TALTZ is contraindicated in patients with a previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients. See Warnings and Precautions section 5.3 for more information.</p>",
      "highlights": {
        "dosageAndAdministration": "<p>Administer by subcutaneous injection. </p><p>Adult Plaque Psoriasis (2.2) </p><ul><li>Recommended dosage is 160mg (two 80mg injections) at Week 0, followed by 80mg at Weeks 2, 4, 6, 8, 10, and 12, then 80mg every 4 weeks.</li></ul><p>Pediatric Plaque Psoriasis (2.3) </p><ul><li>For patients weighing greater than 50kg, recommended dosage is 160mg (two 80mg injections) at Week 0, followed by 80mg every 4 weeks.</li><li>For patients weighing 25-50kg, recommended dosage is 80mg at Week 0, followed by 40mg every 4 weeks.</li><li>For patients weighing less than 25kg, recommended dosage is 40mg at Week 0, followed by 20mg every 4 weeks.</li></ul><p>Psoriatic Arthritis (2.4) </p><ul><li>Recommended dosage is 160mg by subcutaneous injection (two 80mg injections) at Week 0, followed by 80mg every 4 weeks.</li><li>For psoriatic arthritis patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for adult plaque psoriasis. (2.2)</li><li>TALTZ may be administered alone or in combination with a conventional DMARD (e.g., methotrexate).</li></ul><p>Ankylosing Spondylitis (2.5) </p><ul><li>Recommended dosage is 160mg by subcutaneous injection (two 80mg injections) at Week 0, followed by 80mg every 4 weeks.</li></ul><p>Non-radiographic Axial Spondyloarthritis (2.6) </p><ul><li>Recommended dosage is 80 mg by subcutaneous injection every 4 weeks.</li></ul>"
      },
      "metaDescription": "<p>Ixekizumab is a humanized IgG4 mAb against IL-17A, available as TALTZ injection in 80 mg, 40 mg, and 20 mg doses with a pH of 5.2 to 6.2.</p>",
      "useAndConditions": "<p><h3>Approved Indications</h3></p>\n<ul>\n<li>Treatment of patients 6 years of age and older with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.</li>\n<li>Treatment of adult patients with active psoriatic arthritis.</li>\n<li>Treatment of adult patients with active ankylosing spondylitis.</li>\n<li>Treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation.</li>\n</ul>",
      "contraIndications": "<h3>Contraindications</h3>\n<ul>\n<li>Previous serious hypersensitivity reaction, such as anaphylaxis, to ixekizumab or to any of the excipients.</li>\n</ul>",
      "warnings": "<h3>Warnings and Precautions</h3>\n<ul>\n<li>TALTZ may increase the risk of infection. In clinical trials, a higher rate of infections was observed in the TALTZ group compared to the placebo group. Serious bacterial, viral, and fungal opportunistic infections have been reported in the postmarketing setting. Patients should seek medical advice if signs of infection occur, and TALTZ should be discontinued if a serious infection develops.</li>\n<li>Evaluate patients for tuberculosis (TB) infection prior to initiating TALTZ. Do not administer to patients with active TB infection. Initiate treatment of latent TB before administering TALTZ, and monitor patients for signs of active TB during and after treatment.</li>\n<li>Serious hypersensitivity reactions, including angioedema, urticaria, and anaphylaxis, have been reported. If a serious hypersensitivity reaction occurs, discontinue TALTZ immediately and initiate appropriate therapy.</li>\n<li>Severe eczematous eruptions, including atopic dermatitis-like eruptions, dyshidrotic eczema, and erythroderma, have been reported. Treatment may need to be discontinued to resolve the eruptions.</li>\n<li>Patients treated with TALTZ may be at increased risk of inflammatory bowel disease. Monitor for onset or exacerbation of inflammatory bowel disease, and discontinue TALTZ if it occurs.</li>\n<li>Consider completion of all age-appropriate immunizations prior to initiating TALTZ. Avoid use of live vaccines in patients treated with TALTZ.</li>\n</ul>",
      "dosing": "<h3>Adult Dosing</h3>\n<ul>\n    <li>Plaque Psoriasis: 160mg (two 80mg injections) at Week 0, followed by 80mg at Weeks 2, 4, 6, 8, 10, and 12, then 80mg every 4 weeks.</li>\n    <li>Psoriatic Arthritis: 160mg (two 80mg injections) at Week 0, followed by 80mg every 4 weeks. For patients with coexistent moderate-to-severe plaque psoriasis, use the dosing regimen for adult plaque psoriasis.</li>\n    <li>Ankylosing Spondylitis: 160mg (two 80mg injections) at Week 0, followed by 80mg every 4 weeks.</li>\n    <li>Non-radiographic Axial Spondyloarthritis: 80mg every 4 weeks.</li>\n</ul>\n\n<h3>Pediatric Dosing</h3>\n<ul>\n    <li>Plaque Psoriasis (6 to less than 18 years): Administered every 4 weeks based on weight:\n        <ul>\n            <li>Greater than 50kg: 160mg (two 80mg injections) at Week 0, then 80mg every 4 weeks.</li>\n            <li>25 to 50kg: 80mg at Week 0, then 40mg every 4 weeks.</li>\n            <li>Less than 25kg: 40mg at Week 0, then 20mg every 4 weeks.</li>\n        </ul>\n    </li>\n</ul>"
    }
  },
  {
    "drugName": "Trulicity Demo Pen",
    "setId": "463050bd-2b1c-40f5-b3c3-0a04bb433309",
    "slug": "trulicity-463050b",
    "labeler": "Lilly",
    "label": {
      "boxedWarning": "<h1>WARNING: RISK OF THYROID C-CELL TUMORS</h1><ul><li>In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. It is unknown whether TRULICITY causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans as human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined[see Warnings and Precautions (5.1), and Nonclinical Toxicology (13.1)].</li><li>TRULICITY is contraindicated in patients with a personal or family history of MTC and in patients with Multiple Endocrine Neoplasia syndrome type2 (MEN2). Counsel patients regarding the potential risk of MTC with use of TRULICITY and inform them of symptoms of thyroid tumors (e.g., mass in the neck, dysphagia, dyspnea, persistent hoarseness). Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with TRULICITY[see Contraindications (4) and Warnings and Precautions (5.1)].</li></ul>",
      "genericName": "Dulaglutide",
      "labelerName": "Eli Lilly and Company",
      "productType": "HUMAN PRESCRIPTION DRUG LABEL",
      "effectiveTime": "20241101",
      "title": "Trulicity",
      "indicationsAndUsage": "\n<p>TRULICITY is indicated:</p>\n<ul>\n<li>As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.</li>\n<li>To reduce the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.</li>\n</ul>\n<p>Limitations of Use</p>\n<p>TRULICITY:</p>\n<ul>\n<li>Has not been studied in patients with a history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.</li>\n<li>Should not be used in patients with type 1 diabetes mellitus.</li>\n<li>Has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.</li>\n</ul>",
      "dosageAndAdministration": "\n<h3>2.1 Adult Dosage</h3>\n<ul>\n<li>The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly. Follow the dosage escalation below to reduce the risk of gastrointestinal adverse reactions. Refer to Warnings and Precautions section 5.6 and Adverse Reactions section 6.1.</li>\n<li>After 4 weeks, the dosage may be increased to 1.5 mg once weekly for additional glycemic control.</li>\n<li>If additional glycemic control is needed, increase the dosage in 1.5 mg increments after at least 4 weeks on the current dosage.</li>\n<li>The maximum recommended dosage is 4.5 mg injected subcutaneously once weekly.</li>\n</ul>\n<h3>2.2 Pediatric Dosage</h3>\n<ul>\n<li>The recommended starting dosage of TRULICITY is 0.75 mg injected subcutaneously once weekly.</li>\n<li>If additional glycemic control is needed, increase the dosage to the maximum recommended dosage of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage to reduce the risk of gastrointestinal adverse reactions. Refer to Warnings and Precautions section 5.6 and Adverse Reactions section 6.1.</li>\n</ul>\n<h3>2.3 Recommendations Regarding Missed Dose</h3>\n<ul>\n<li>If a dose is missed, instruct patients to administer the dose as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose. If less than 3 days remain before the next scheduled dose, skip the missed dose and administer the next dose on the regularly scheduled day. In each case, patients can then resume their regular once weekly dosing schedule.</li>\n<li>The day of weekly administration can be changed, if necessary, as long as the last dose was administered 3 or more days before the new day of administration.</li>\n</ul>\n<h3>2.4 Important Administration Instructions</h3>\n<ul>\n<li>Prior to initiation, train patients and caregivers on proper injection technique. Refer to Instructions for Use.</li>\n<li>Administer TRULICITY once weekly, any time of day, with or without food.</li>\n<li>Inject TRULICITY subcutaneously in the abdomen, thigh, or upper arm.</li>\n<li>Rotate injection sites with each dose.</li>\n<li>Inspect TRULICITY visually before use. It should appear clear and colorless. Do not use TRULICITY if particulate matter or coloration is seen.</li>\n<li>When using TRULICITY with insulin, administer as separate injections and never mix. It is acceptable to inject TRULICITY and insulin in the same body region, but the injections should not be adjacent to each other.</li>\n</ul>",
      "dosageFormsAndStrengths": "\n<p>Injection: TRULICITY is a clear and colorless solution available as:</p>\n<ul>\n<li>0.75 mg/0.5 mL solution in a single-dose pen</li>\n<li>1.5 mg/0.5 mL solution in a single-dose pen</li>\n<li>3 mg/0.5 mL solution in a single-dose pen</li>\n<li>4.5 mg/0.5 mL solution in a single-dose pen</li>\n</ul>",
      "warningsAndPrecautions": "\n<h3>5.1 Risk of Thyroid C-cell Tumors</h3>\n<p>In male and female rats, dulaglutide causes a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and carcinomas) after lifetime exposure. Glucagon-like peptide-1 (GLP-1) receptor agonists have induced thyroid C-cell adenomas and carcinomas in mice and rats at clinically relevant exposures. It is unknown whether TRULICITY will cause thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans, as the human relevance of dulaglutide-induced rodent thyroid C-cell tumors has not been determined.</p>\n<p>One case of MTC was reported in a patient treated with TRULICITY in a clinical trial. This patient had pretreatment calcitonin levels approximately 8 times the upper limit of normal (ULN). An additional case of C-cell hyperplasia with elevated calcitonin levels following treatment was reported in the cardiovascular outcomes trial (REWIND). Cases of MTC in patients treated with liraglutide, another GLP-1 receptor agonist, have been reported in the postmarketing period; the data in these reports are insufficient to establish or exclude a causal relationship between MTC and GLP-1 receptor agonist use in humans.</p>\n<p>TRULICITY is contraindicated in patients with a personal or family history of MTC or in patients with MEN2. Counsel patients regarding the potential risk for MTC with the use of TRULICITY and inform them of symptoms of thyroid tumors (e.g., a mass in the neck, dysphagia, dyspnea, persistent hoarseness).</p>\n<p>Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value for early detection of MTC in patients treated with TRULICITY. Such monitoring may increase the risk of unnecessary procedures, due to the low test specificity for serum calcitonin and a high background incidence of thyroid disease. Significantly elevated serum calcitonin values may indicate MTC and patients with MTC usually have calcitonin values greater than 50 ng/L. If serum calcitonin is measured and found to be elevated, the patient should be further evaluated. Patients with thyroid nodules noted on physical examination or neck imaging should also be further evaluated.</p>\n<h3>5.2 Pancreatitis</h3>\n<p>In a pooled analysis from the original registration studies, 12 pancreatitis-related adverse reactions (3.4 cases per 1000 patient years) were reported in patients exposed to TRULICITY versus 3 in non-incretin comparators (2.7 cases per 1000 patient years). An analysis of adjudicated events revealed 5 cases of confirmed pancreatitis in patients exposed to TRULICITY (1.4 cases per 1000 patient years) versus 1 case in non-incretin comparators (0.88 cases per 1000 patient years).</p>\n<p>Based on an analysis of adjudicated events in a clinical trial evaluating Trulicity 1.5 mg, 3 mg, or 4.5 mg once weekly, pancreatitis occurred in 1 patient exposed to TRULICITY 1.5 mg (0.2%), in 2 patients exposed to TRULICITY 3 mg (0.3%), and 3 patients exposed to TRULICITY 4.5 mg (0.5%).</p>\n<p>After initiation of TRULICITY, observe patients carefully for signs and symptoms of pancreatitis, including persistent severe abdominal pain, sometimes radiating to the back, which may or may not be accompanied by vomiting. If pancreatitis is suspected, promptly discontinue TRULICITY and initiate appropriate management. If pancreatitis is confirmed, TRULICITY should not be restarted. TRULICITY has not been evaluated in patients with a prior history of pancreatitis. Consider other antidiabetic therapies in patients with a history of pancreatitis.</p>\n<h3>5.3 Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin</h3>\n<p>Patients receiving TRULICITY in combination with an insulin secretagogue (e.g., sulfonylurea) or insulin may have an increased risk of hypoglycemia, including severe hypoglycemia.</p>\n<p>The risk of hypoglycemia may be lowered by a reduction in the dose of sulfonylurea (or other concomitantly administered insulin secretagogue) or insulin. Inform patients using these concomitant medications of the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia.</p>\n<h3>5.4 Hypersensitivity Reactions</h3>\n<p>There have been postmarketing reports of serious hypersensitivity reactions including anaphylactic reactions and angioedema in patients treated with TRULICITY. If a hypersensitivity reaction occurs, discontinue TRULICITY; treat promptly per standard of care, and monitor until signs and symptoms resolve. TRULICITY is contraindicated in patients with a previous serious hypersensitivity reaction to dulaglutide or to any of the components of TRULICITY.</p>\n<p>Anaphylaxis and angioedema have been reported with other GLP-1 receptor agonists. Use caution in a patient with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist because it is unknown whether such patients will be predisposed to anaphylaxis with TRULICITY.</p>\n<h3>5.5 Acute Kidney Injury</h3>\n<p>In patients treated with GLP-1 receptor agonists, including TRULICITY, there have been postmarketing reports of acute renal failure and worsening of chronic renal failure, which may sometimes require hemodialysis. Some of these events were reported in patients without known underlying renal disease. A majority of reported events occurred in patients who had experienced nausea, vomiting, diarrhea, or dehydration. Because these reactions may worsen renal function, use caution when initiating or escalating doses of TRULICITY in patients with renal impairment. Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions.</p>\n<h3>5.6 Severe Gastrointestinal Adverse Reactions</h3>\n<p>Use of TRULICITY has been associated with gastrointestinal adverse reactions, sometimes severe. In the pool of placebo-controlled trials, severe gastrointestinal adverse reactions were reported more frequently among patients receiving TRULICITY (0.75 mg 2.2%, 1.5 mg 4.3%) than placebo (1.4%).</p>\n<p>TRULICITY has not been studied in patients with severe gastrointestinal disease, including severe gastroparesis, and is therefore not recommended in these patients.</p>\n<h3>5.7 Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy</h3>\n<p>In a cardiovascular outcomes trial with a median follow-up of 5.4 years involving patients with type 2 diabetes with established cardiovascular disease or multiple cardiovascular risk factors, diabetic retinopathy complications occurred in patients treated with TRULICITY 1.5 mg (1.9%) and placebo (1.5%). These events were prospectively ascertained as a secondary composite endpoint. The proportion of patients with diabetic retinopathy complications was larger among patients with a history of diabetic retinopathy at baseline (TRULICITY 8.5%, placebo 6.2%) than among patients without a known history of diabetic retinopathy (TRULICITY 1%, placebo 1%).</p>\n<p>Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy.</p>\n<h3>5.8 Acute Gallbladder Disease</h3>\n<p>Acute events of gallbladder disease such as cholelithiasis or cholecystitis have been reported in GLP-1 receptor agonist trials and postmarketing. In a cardiovascular outcomes trial with a median follow-up of 5.4 years, cholelithiasis occurred at a rate of 0.62 per 100 patient-years in TRULICITY-treated patients and 0.56 per 100 patient-years in placebo-treated patients after adjusting for prior cholecystectomy. Serious events of acute cholecystitis were reported in 0.5% and 0.3% of patients on TRULICITY and placebo respectively. If cholelithiasis is suspected, gallbladder studies and appropriate clinical follow-up are indicated.</p>\n<h3>5.9 Pulmonary Aspiration During General Anesthesia or Deep Sedation</h3>\n<p>TRULICITY delays gastric emptying. There have been rare postmarketing reports of pulmonary aspiration in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures requiring general anesthesia or deep sedation who had residual gastric contents despite reported adherence to preoperative fasting recommendations.</p>\n<p>Available data are insufficient to inform recommendations to mitigate the risk of pulmonary aspiration during general anesthesia or deep sedation in patients taking TRULICITY, including whether modifying preoperative fasting recommendations or temporarily discontinuing TRULICITY could reduce the incidence of retained gastric contents. Instruct patients to inform healthcare providers prior to any planned surgeries or procedures if they are taking TRULICITY.</p>",
      "adverseReactions": "\n<p>The following serious reactions are described below or elsewhere in the prescribing information:</p>\n<ul>\n<li>Risk of Thyroid C-cell Tumors [see Warnings and Precautions (5.1)]</li>\n<li>Pancreatitis [see Warnings and Precautions (5.2)]</li>\n<li>Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin [see Warnings and Precautions (5.3)]</li>\n<li>Hypersensitivity Reactions [see Warnings and Precautions (5.4)]</li>\n<li>Acute Kidney Injury [see Warnings and Precautions (5.5)]</li>\n<li>Severe Gastrointestinal Adverse Reactions [see Warnings and Precautions (5.6)]</li>\n<li>Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy [see Warnings and Precautions (5.7)]</li>\n<li>Acute Gallbladder Disease [see Warnings and Precautions (5.8)]</li>\n<li>Pulmonary Aspiration During General Anesthesia or Deep Sedation [see Warnings and Precautions (5.9)]</li>\n</ul>\n<h3>6.1 Clinical Trials Experience</h3>\n<p>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>\n<p>Adverse Reactions in the Clinical Trials in Adults with Type 2 Diabetes Mellitus</p>\n<p>Pool of Adult Placebo-Controlled Trials for TRULICITY 0.75 mg and 1.5 mg Doses</p>\n<p>The data in Table 1 are derived from a pool of placebo-controlled trials and include 1,670 adult patients with type 2 diabetes mellitus exposed to TRULICITY with a mean duration of exposure of 23.8 weeks [see Clinical Studies (14)]. The mean age of patients was 56 years, 1% were 75 years or older and 53% were male. The population was 69% White, 7% Black or African American, 13% Asian; 30% were of Hispanic or Latino ethnicity. At baseline, the population had diabetes for an average of 8 years, a mean HbA1c of 8.0%, and 2.5% of the population reported retinopathy. Baseline estimated renal function was normal or mildly impaired (eGFR 60 mL/min/1.73 m<sup>2</sup>) in 96%.</p>\n<p>Table 1 shows adverse reactions, excluding hypoglycemia, occurring in 5% of TRULICITY treated adult patients and more commonly than placebo in a pool of placebo-controlled trials.</p>\n<table>\n<caption>Table 1: Adverse Reactions in Pool of Placebo-Controlled Trials That Occurred in 5% of TRULICITY-Treated Adult Patients with Type 2 Diabetes Mellitus</caption>\n<thead>\n<tr>\n<th>Adverse Reaction</th>\n<th>Placebo (N=568) %</th>\n<th>TRULICITY 0.75 mg (N=836) %</th>\n<th>TRULICITY 1.5 mg (N=834) %</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Nausea</td>\n<td>5.3</td>\n<td>12.4</td>\n<td>21.1</td>\n</tr>\n<tr>\n<td>Diarrhea<sup>a</sup></td>\n<td>6.7</td>\n<td>8.9</td>\n<td>12.6</td>\n</tr>\n<tr>\n<td>Vomiting<sup>b</sup></td>\n<td>2.3</td>\n<td>6.0</td>\n<td>12.7</td>\n</tr>\n<tr>\n<td>Abdominal Pain<sup>c</sup></td>\n<td>4.9</td>\n<td>6.5</td>\n<td>9.4</td>\n</tr>\n<tr>\n<td>Decreased Appetite</td>\n<td>1.6</td>\n<td>4.9</td>\n<td>8.6</td>\n</tr>\n<tr>\n<td>Dyspepsia</td>\n<td>2.3</td>\n<td>4.1</td>\n<td>5.8</td>\n</tr>\n<tr>\n<td>Fatigue<sup>d</sup></td>\n<td>2.6</td>\n<td>4.2</td>\n<td>5.6</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"4\"><p>a Includes diarrhea, fecal volume increased, frequent bowel movements.</p></td>\n</tr>\n<tr>\n<td colspan=\"4\"><p>b Includes retching, vomiting, vomiting projectile.</p></td>\n</tr>\n<tr>\n<td colspan=\"4\"><p>c Includes abdominal discomfort, abdominal pain, abdominal pain lower, abdominal pain upper, abdominal tenderness, gastrointestinal pain.</p></td>\n</tr>\n<tr>\n<td colspan=\"4\"><p>d Includes fatigue, asthenia, malaise.</p></td>\n</tr>\n<tr>\n<td colspan=\"4\"><p>Note: Percentages reflect the number of patients that reported at least 1 treatment-emergent occurrence of the adverse reaction.</p></td>\n</tr>\n</tfoot>\n</table>\n<p>Gastrointestinal Adverse Reactions</p>\n<p>In the pool of placebo-controlled trials, gastrointestinal (GI) adverse reactions occurred more frequently among patients who received TRULICITY compared to patients who received placebo (placebo 21%, 0.75 mg 32%, 1.5 mg 41%). A higher percentage of patients who received TRULICITY 0.75 mg (1.3%) and TRULICITY 1.5 mg (3.5%) discontinued treatment due to GI adverse reactions than patients who received placebo (0.2%). Investigators graded the severity of GI adverse reactions that occurred in those treated with 0.75 mg and 1.5 mg of TRULICITY as mild in 58% and 48% of cases, respectively, moderate in 35% and 42% of cases, respectively, or severe in 7% and 11% of cases, respectively.</p>\n<p>The following GI adverse reactions were reported more frequently in TRULICITY-treated patients than placebo-treated patients (frequencies listed, respectively, as: placebo; 0.75 mg; 1.5 mg): constipation (0.7%, 3.9%, 3.7%), flatulence (1.4%, 1.4%, 3.4%), abdominal distension (0.7%, 2.9%, 2.3%), gastroesophageal reflux disease (0.5%, 1.7%, 2.0%), and eructation (0.2%, 0.6%, 1.6%).</p>\n<p>Adult Dose Ranging Trial for TRULICITY 3 mg and 4.5 mg Doses</p>\n<p>Table 2 shows adverse reactions occurring 5% in any of the treatment groups through 36 weeks in a clinical trial with 1842 adult patients with type 2 diabetes mellitus treated with TRULICITY 1.5 mg, 3 mg, or 4.5 mg subcutaneously once weekly as an add-on to metformin [see Clinical Studies (14.3)]. The adverse reaction profile is consistent with previous clinical trials in adults.</p>\n<table>\n<caption>Table 2: Adverse Reactions That Occurred in 5% of TRULICITY-treated Adult Patients with Type 2 Diabetes Mellitus in a Clinical Trial through 36 Weeks<sup>a</sup></caption>\n<thead>\n<tr>\n<th>Adverse Reaction</th>\n<th>TRULICITY 1.5 mg (N=612) %</th>\n<th>TRULICITY 3 mg (N=616) %</th>\n<th>TRULICITY 4.5 mg (N=614) %</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Nausea</td>\n<td>13.4</td>\n<td>15.6</td>\n<td>16.4</td>\n</tr>\n<tr>\n<td>Diarrhea</td>\n<td>7.0</td>\n<td>11.4</td>\n<td>10.7</td>\n</tr>\n<tr>\n<td>Vomiting</td>\n<td>5.6</td>\n<td>8.3</td>\n<td>9.3</td>\n</tr>\n<tr>\n<td>Dyspepsia</td>\n<td>2.8</td>\n<td>5.0</td>\n<td>2.6</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"4\"><p>a Percentages reflect the number of patients that reported at least 1 treatment-emergent occurrence of the adverse reaction.</p></td>\n</tr>\n</tfoot>\n</table>\n<p>Other Adverse Reactions in Adults</p>\n<p>Hypoglycemia</p>\n<p>Table 3 summarizes the incidence of hypoglycemia in the placebo-controlled clinical studies in adult patients with type 2 diabetes mellitus: episodes with a glucose level &lt;54 mg/dL with or without symptoms, and severe hypoglycemia, defined as an episode requiring the assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions.</p>\n<table>\n<caption>Table 3: Incidence (%) of Hypoglycemia in Adult Patients with Type 2 Diabetes Mellitus in Placebo-Controlled Trials</caption>\n<thead>\n<tr>\n<th>Placebo</th>\n<th>TRULICITY 0.75 mg</th>\n<th>TRULICITY 1.5 mg</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td colspan=\"4\">Add-on to Metformin</td>\n</tr>\n<tr>\n<td>(26 weeks)</td>\n<td>N=177</td>\n<td>N=302</td>\n<td>N=304</td>\n</tr>\n<tr>\n<td>Hypoglycemia with a glucose level &lt;54 mg/dL</td>\n<td>0</td>\n<td>0.3</td>\n<td>0.7</td>\n</tr>\n<tr>\n<td>Severe hypoglycemia</td>\n<td>0</td>\n<td>0</td>\n<td>0</td>\n</tr>\n<tr>\n<td colspan=\"4\">Add-on to Metformin + Pioglitazone</td>\n</tr>\n<tr>\n<td>(26 weeks)</td>\n<td>N=141</td>\n<td>N=280</td>\n<td>N=279</td>\n</tr>\n<tr>\n<td>Hypoglycemia with a glucose level &lt;54 mg/dL</td>\n<td>1.4</td>\n<td>2.1</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Severe hypoglycemia</td>\n<td>0</td>\n<td>0</td>\n<td>0</td>\n</tr>\n<tr>\n<td colspan=\"4\">Add-on to Glimepiride</td>\n</tr>\n<tr>\n<td>(24 weeks)</td>\n<td>N=60</td>\n<td>-</td>\n<td>N=239</td>\n</tr>\n<tr>\n<td>Hypoglycemia with a glucose level &lt;54 mg/dL</td>\n<td>0</td>\n<td>-</td>\n<td>3.3</td>\n</tr>\n<tr>\n<td>Severe hypoglycemia</td>\n<td>0</td>\n<td>-</td>\n<td>0</td>\n</tr>\n<tr>\n<td colspan=\"4\">In Combination with Insulin Glargine Metformin</td>\n</tr>\n<tr>\n<td>(28 weeks)</td>\n<td>N=150</td>\n<td>-</td>\n<td>N=150</td>\n</tr>\n<tr>\n<td>Hypoglycemia with a glucose level &lt;54 mg/dL</td>\n<td>9.3</td>\n<td>-</td>\n<td>14.7</td>\n</tr>\n<tr>\n<td>Severe hypoglycemia</td>\n<td>0</td>\n<td>-</td>\n<td>0.7</td>\n</tr>\n<tr>\n<td colspan=\"4\">Add-on to SGLT2i Metformin</td>\n</tr>\n<tr>\n<td>(24 weeks)</td>\n<td>N=140</td>\n<td>N=141</td>\n<td>N=142</td>\n</tr>\n<tr>\n<td>Hypoglycemia with a glucose level &lt;54 mg/dL</td>\n<td>0.7</td>\n<td>0.7</td>\n<td>0.7</td>\n</tr>\n<tr>\n<td>Severe hypoglycemia</td>\n<td>0</td>\n<td>0.7</td>\n<td>0</td>\n</tr>\n</tbody>\n</table>\n<p>Hypoglycemia was more frequent when TRULICITY was used in combination with a sulfonylurea or insulin than when used with non-secretagogues. In a 78-week adult clinical trial, hypoglycemia (glucose level &lt;54 mg/dL) occurred in 20% and 21% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea. Severe hypoglycemia occurred in 0% and 0.7% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with a sulfonylurea. In a 52-week adult clinical trial, hypoglycemia (glucose level &lt;54 mg/dL) occurred in 77% and 69% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with prandial insulin. Severe hypoglycemia occurred in 2.7% and 3.4% of patients when TRULICITY 0.75 mg and 1.5 mg, respectively, were co-administered with prandial insulin. Refer to Table 3 for the incidence of hypoglycemia in patients treated in combination with basal insulin glargine.</p>\n<p>In the clinical trial with adult patients on TRULICITY 1.5 mg, TRULICITY 3 mg, or TRULICITY 4.5 mg once weekly, as add-on to metformin, incidences of hypoglycemia (glucose level &lt;54 mg/dL) through 36 weeks were 1.1%, 0.3%, and 1.1%, respectively, and incidences of severe hypoglycemia were 0.2%, 0%, and 0.2%, respectively.</p>\n<p>Cholelithiasis and Cholecystitis</p>\n<p>In a cardiovascular outcomes trial in adult patients with type 2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors with a median follow up of 5.4 years [see Clinical Studies 14.5], cholelithiasis occurred at a rate of 0.62/100 patient-years in TRULICITY-treated patients and 0.56/100 patient-years in placebo-treated patients after adjusting for prior cholecystectomy. Serious events of acute cholecystitis were reported in 0.5% and 0.3% of patients on TRULICITY and placebo respectively.</p>\n<p>Heart Rate Increase and Tachycardia-Related Adverse Reactions</p>\n<p>In adult patients, TRULICITY 0.75 mg and 1.5 mg resulted in a mean increase in heart rate (HR) of 2-4 beats per minute (bpm).</p>\n<p>Adverse reactions of sinus tachycardia were reported more frequently in patients exposed to TRULICITY. Sinus tachycardia was reported in 3.0%, 2.8%, and 5.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Persistence of sinus tachycardia (reported at more than 2 visits) was reported in 0.2%, 0.4% and 1.6% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively. Episodes of sinus tachycardia, associated with a concomitant increase from baseline in heart rate of 15 beats per minute, were reported in 0.7%, 1.3% and 2.2% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.</p>\n<p>Hypersensitivity</p>\n<p>Systemic hypersensitivity adverse reactions, sometimes severe (e.g., severe urticaria, systemic rash, facial edema, lip swelling), occurred in 0.5% of adult patients on TRULICITY in clinical studies.</p>\n<p>Injection-site Reactions</p>\n<p>In the placebo-controlled studies in adults, injection-site reactions (e.g., injection-site rash, erythema) were reported in 0.5% of TRULICITY-treated patients and in 0.0% of placebo-treated patients.</p>\n<p>PR Interval Prolongation and Adverse Reactions of First-Degree Atrioventricular (AV) Block</p>\n<p>A mean increase from baseline in PR interval of 2-3 milliseconds was observed in TRULICITY-treated adult patients in contrast to a mean decrease of 0.9 milliseconds in placebo-treated patients. The adverse reaction of first-degree AV block occurred more frequently in patients treated with TRULICITY than placebo (0.9%, 1.7% and 2.3% for placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively). On electrocardiograms, a PR interval increase to at least 220 milliseconds was observed in 0.7%, 2.5% and 3.2% of patients treated with placebo, TRULICITY 0.75 mg and TRULICITY 1.5 mg, respectively.</p>\n<p>Amylase and Lipase Increase</p>\n<p>Adult patients exposed to TRULICITY had mean increases from baseline in lip</p>",
      "drugInteractions": "<h1>7 DRUG INTERACTIONS</h1><h2>7.1 Oral Medications</h2><p>TRULICITY delays gastric emptying and thus has the potential to reduce the rate of absorption of concomitantly administered oral medications. The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of TRULICITY [see Dosage and Administration (2.1)]. The delay is largest after the first dose and diminishes with subsequent doses. In clinical pharmacology studies, TRULICITY 1.5mg did not affect the absorption of the tested orally administered medications to a clinically relevant degree [see Clinical Pharmacology (12.3)]. There is limited experience with the use of concomitant medications in clinical trials with TRULICITY doses of 3mg and 4.5mg.</p><p>Monitor drug levels of oral medications with a narrow therapeutic index (e.g., warfarin) when concomitantly administered with TRULICITY.</p><h2>7.2 Concomitant Use with an Insulin Secretagogue (e.g., Sulfonylurea) or with Insulin</h2><p>When initiating TRULICITY, consider reducing the dose of concomitantly administered insulin secretagogues (such as sulfonylureas) or insulin to reduce the risk of hypoglycemia [see Warnings and Precautions (5.3) and Adverse Reactions (6.1)].</p>",
      "clinicalPharmacology": "<h1>12 CLINICAL PHARMACOLOGY</h1><h2>12.1 Mechanism of Action</h2><p>TRULICITY contains dulaglutide, which is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37). Dulaglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying.</p><h2>12.2 Pharmacodynamics</h2><p>TRULICITY lowers fasting glucose and reduces postprandial glucose (PPG) concentrations in patients with type2 diabetes mellitus. The reduction in fasting and postprandial glucose can be observed after a single dose.</p><p>Fasting and Postprandial Glucose</p><p>In a clinical pharmacology study in patients with type2 diabetes mellitus, treatment with once weekly TRULICITY resulted in a reduction of fasting and 2-hour PPG concentrations, and postprandial serum glucose incremental AUC, when compared to placebo (-25.6mg/dL, -59.5mg/dL, and -197mg*h/dL, respectively); these effects were sustained after 6 weeks of dosing with the 1.5mg dose.</p><p>First- and Second-Phase Insulin Secretion</p><p>Both first- and second-phase insulin secretion were increased in patients with type2 diabetes treated with TRULICITY compared with placebo.</p><p>Insulin and Glucagon Secretion</p><p>TRULICITY stimulates glucose-dependent insulin secretion and reduces glucagon secretion. Treatment with TRULICITY 0.75mg and 1.5mg once weekly increased fasting insulin from baseline at Week 26 by 35.38 and 17.50pmol/L, respectively, and C-peptide concentration by 0.09 and 0.07nmol/L, respectively, in a monotherapy trial. In the same trial, fasting glucagon concentration was reduced by 1.71 and 2.05pmol/L from baseline with TRULICITY 0.75mg and 1.5mg, respectively.</p><p>Gastric Motility</p><p>Dulaglutide causes a delay of gastric emptying. The delay in gastric emptying is dose-dependent but is attenuated with adequate dose escalation to higher doses of TRULICITY. The delay is largest after the first dose and diminishes with subsequent doses.</p><p>Cardiac Electrophysiology (QTc)</p><p>The effect of dulaglutide on cardiac repolarization was tested in a thorough QTc study. Dulaglutide did not produce QTc prolongation at doses of 4 and 7mg. The maximum recommended dose is 4.5mg once weekly.</p><h2>12.3 Pharmacokinetics</h2><p>The pharmacokinetics of dulaglutide is similar between healthy subjects and patients with type2 diabetes mellitus. Following subcutaneous administration, the time to maximum plasma concentration of dulaglutide at steady state ranges from 24 to 72 hours, with a median of 48 hours. After reaching steady state, the accumulation ratio was approximately 1.56. Steady-state plasma dulaglutide concentrations were achieved between 2 and 4 weeks following once weekly administration. Site of subcutaneous administration (abdomen, upper arm, and thigh) had no statistically significant effect on the exposure to dulaglutide.</p><p>Absorption The mean absolute bioavailability of dulaglutide following subcutaneous administration of single 0.75mg and 1.5mg doses was 65% and 47%, respectively. Absolute subcutaneous bioavailability for 3mg and 4.5mg doses were estimated to be similar to 1.5mg although this has not been specifically studied. Dulaglutide concentrations increased approximately proportional to dose from 0.75mg to 4.5mg.</p><p>Distribution Apparent population mean central volume of distribution was 3.09L and the apparent population mean peripheral volume of distribution was 5.98L.</p><p>Elimination</p><p>The apparent population mean clearance of dulaglutide was 0.142L/h. The elimination half-life of dulaglutide was approximately 5 days.</p><p>Metabolism Dulaglutide is presumed to be degraded into its component amino acids by general protein catabolism pathways.</p><p>Specific Populations</p><p>The intrinsic factors of age ( 65 years), sex, race, ethnicity, body weight, or renal or hepatic impairment did not have a clinically relevant effect on the PK of dulaglutide as shown in Figure1.</p><p>Abbreviations: AUC = area under the time-concentration curve; CI = confidence interval; Cmax = maximum concentration; ESRD = end-stage renal disease; PK = pharmacokinetics.</p><p>Note: Reference values for weight, age, gender, and race comparisons are 93kg, 56 years old, male, and white, respectively; reference groups for renal and hepatic impairment data are subjects with normal renal and hepatic function from the respective clinical pharmacology studies. The weight values shown in the plot (70 and 120kg) are the 10th and 90th percentiles of weight in the PK population.</p><p>Figure1: Impact of intrinsic factors on dulaglutide pharmacokinetics.</p><p>Pediatric Patients</p><p>A population pharmacokinetic analysis was conducted for dulaglutide 0.75mg and 1.5mg using data from 128 pediatric patients 10 years of age and older with type2 diabetes mellitus. The AUC in pediatric patients was approximately 37% lower than that in adult patients. However, this difference was not determined to be clinically meaningful.</p><p>Patients with Renal Impairment</p><p>Dulaglutide systemic exposure was increased by 20, 28, 14 and 12% for mild, moderate, severe, and ESRD renal impairment sub-groups, respectively, compared to subjects with normal renal function. The corresponding values for increase in Cmax were 13, 23, 20 and 11%, respectively (Figure1). Additionally, in a 52 week clinical trial in patients with type2 diabetes mellitus and moderate to severe renal impairment, the PK behavior of TRULICITY 0.75mg and 1.5mg once weekly was similar to that demonstrated in previous clinical studies [see Warning and Precautions (5.5), Use in Specific Populations (8.6)].</p><p>Patients with Hepatic Impairment</p><p>Dulaglutide systemic exposure decreased by 23, 33 and 21% for mild, moderate and severe hepatic impairment groups, respectively, compared to subjects with normal hepatic function, and Cmax was decreased by a similar magnitude (Figure1) [see Use in Specific Populations (8.7)].</p><p>Drug Interaction Studies</p><p>The potential effect of co-administered medications on the PK of dulaglutide 1.5mg and vice versa was studied in several single- and multiple-dose studies in healthy subjects, patients with type2 diabetes mellitus, and patients with hypertension.</p><p>Potential for Dulaglutide to Influence the Pharmacokinetics of Other Drugs</p><p>Dulaglutide slows gastric emptying and, as a result, may reduce the extent and rate of absorption of orally co-administered medications. In clinical pharmacology studies, dulaglutide at a dose of 1.5mg did not affect the absorption of the tested orally administered medications to any clinically relevant degree. The delay in gastric emptying is dose-dependent but is attenuated with the recommended dose escalation to higher doses of TRULICITY [see Dosage and Administration (2.1), Drug Interactions (7.1)]. The delay is largest after the first dose and diminishes with subsequent doses. PK measures indicating the magnitude of these interactions are presented in Figure2.</p><p>Abbreviations: AUC = area under the time-concentration curve; CI = confidence interval; Cmax = maximum concentration; PK = pharmacokinetics.</p><p>Note: Reference group is co-administered medication given alone.</p><p>Figure2: Impact of dulaglutide 1.5mg on the pharmacokinetics of co-administered medications.</p><p>Potential for Co-administered Drugs to Influence the Pharmacokinetics of Dulaglutide</p><p>In a clinical pharmacology study, the co-administration of a single dose of 1.5mg dulaglutide with steady-state dose of 100mg sitagliptin caused an increase in dulaglutide AUC and Cmax of approximately 38% and 27%, which is not considered clinically relevant.</p><h2>12.6 Immunogenicity</h2><p>The observed incidence of anti-drug antibodies is highly dependent on the sensitivity and specificity of the assay. Differences in assay methods preclude meaningful comparisons of the incidence of anti-drug antibodies in the studies described below with the incidence of anti-drug antibodies in other studies.</p><p>In glycemic control trials in adults with type2 diabetes mellitus (monotherapy and combination therapy) [see Clinical Studies (14.2, 14.3)], during a treatment period ranging from 24 to 104 weeks, 64/3,907 (1.6%) of TRULICITY-treated patients developed anti-dulaglutide antibodies (referred to as anti-drug-antibodies (ADA)). Of the 64 TRULICITY-treated patients that developed ADA, 34 patients (0.9% of the overall population) developed dulaglutide-neutralizing antibodies, and 36 patients (0.9% of the overall population) developed antibodies against native GLP-1. There was no identified clinically significant effect of ADA on pharmacokinetics, pharmacodynamics, safety, or effectiveness of TRULICITY over the 24 to 104 week treatment duration in the trials in adults with type2 diabetes mellitus.</p><p>During the 26-week controlled period of the glycemic control trial in pediatric patients 10 years of age or older with type2 diabetes mellitus [see Clinical Studies (14.6)], 4/101 (4%) of TRULICITY-treated pediatric patients developed ADA. Of the 4 pediatric patients that developed ADA, 1 patient (1% of the overall population) developed dulaglutide-neutralizing antibodies and 3 patients (3% of the overall population) developed antibodies against native GLP-1. During the 52-week postbaseline period of the same trial (through safety follow-up), 6/103 (6%) of TRULICITY-treated patients developed ADA. Of the 6 patients that developed ADA, 1 patient (1% of the overall population) developed dulaglutide-neutralizing antibodies and 4 patients (4% of the overall population) developed antibodies against native GLP-1. Because of the low occurrence of ADA, the effect of these antibodies on the pharmacokinetics, pharmacodynamics, safety, and/or effectiveness of TRULICITY is unknown in pediatric patients.</p>",
      "clinicalStudies": "<h1>14 CLINICAL STUDIES</h1><h2>14.1 Overview of Clinical Trials</h2><p>TRULICITY has been studied in adults as monotherapy and in combination with metformin, sulfonylurea, metformin and sulfonylurea, metformin and thiazolidinedione, sodium-glucose co-transporter-2 inhibitors (SGLT2i) with or without metformin, basal insulin with or without metformin, and prandial insulin with or without metformin. TRULICITY has also been studied in patients with type2 diabetes mellitus and moderate to severe renal impairment.</p><p>Dose escalation was performed in one trial in adults with TRULICITY doses up to 4.5mg added to metformin. All other clinical studies in adults evaluated TRULICITY 0.75mg and 1.5mg without dose escalation; patients were initiated and maintained on either 0.75mg or 1.5mg for the duration of the trials [see Clinical Studies (14.2, 14.3, 14.4)].</p><p>TRULICITY 0.75mg and 1.5mg was studied in pediatric patients 10 years of age and older with type2 diabetes in combination with or without metformin and/or basal insulin treatment [see Clinical Studies (14.6)].</p><p>In patients with type2 diabetes mellitus, TRULICITY produced reductions from baseline in HbA1c compared to placebo. No overall differences in glycemic effectiveness were observed across demographic subgroups (age, gender, race/ethnicity, duration of diabetes).</p><p>A cardiovascular outcomes trial was conducted in adult patients with type2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors. Patients were randomized to TRULICITY 1.5mg or placebo both added to standard of care. TRULICITY significantly reduced the risk of first occurrence of primary composite endpoint of CV death, non-fatal MI, or non-fatal stroke [see Clinical Studies (14.5)].</p><h2>14.2 Glycemic Control Monotherapy Trials in Adults with Type2 Diabetes Mellitus</h2><p>In a double-blind trial with primary endpoint at 26 weeks, 807 adult patients inadequately treated with diet and exercise, or with diet and exercise and one antidiabetic agent used at submaximal dose, were randomized to TRULICITY 0.75mg once weekly, TRULICITY 1.5mg once weekly, or metformin 1500 to 2000mg/day following a two-week washout. Seventy-five percent (75%) of the randomized population were treated with one antidiabetic agent at the screening visit. Most patients previously treated with an antidiabetic agent were receiving metformin (~90%) at a median dose of 1000mg daily and approximately 10% were receiving a sulfonylurea.</p><p>Patients had a mean age of 56 years and a mean duration of type2 diabetes of 3 years. Forty-four percent were male. The White, Black and Asian race accounted for 74%, 7% and 8% of the population, respectively. Twenty-nine percent of the trial population were from the US.</p><p>Treatment with TRULICITY 0.75mg and 1.5mg once weekly resulted in reduction in HbA1c from baseline at 26-weeks (Table4). The difference in observed effect size between TRULICITY 0.75mg and 1.5mg, respectively, and metformin excluded the pre-specified non-inferiority margin of 0.4%.</p><table><caption>Table4: Results at Week 26 in a Trial of TRULICITY as Monotherapy in Adult Patients with Type2 Diabetes Mellitusa</caption><tfoot><tr><td colspan=\"4\"><p>Abbreviation: HbA1c = hemoglobin A1c.</p></td></tr><tr><td colspan=\"4\"><p>a Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 26, primary efficacy was missing for 10%, 12% and 14% of individuals randomized to TRULICITY 0.75mg, TRULICITY 1.5mg and metformin, respectively.</p></td></tr><tr><td colspan=\"4\"><p>b Least-squares mean adjusted for baseline value and other stratification factors.</p></td></tr><tr><td colspan=\"4\"><p> Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 265 individuals in each of the treatment arms.</p></td></tr></tfoot><tbody><tr><td colspan=\"3\">26-Week Primary Time Point</td></tr><tr><td>TRULICITY 0.75mg</td><td>TRULICITY 1.5mg</td><td>Metformin 1500-2000mg</td></tr><tr><td>Intent-to-Treat (ITT) Population (N)</td><td>270</td><td>269</td><td>268</td></tr><tr><td colspan=\"4\">HbA1c (%) (Mean)</td></tr><tr><td>Baseline</td><td>7.6</td><td>7.6</td><td>7.6</td></tr><tr><td>Change from baselineb</td><td>-0.7</td><td>-0.8</td><td>-0.6</td></tr><tr><td colspan=\"4\">Fasting Serum Glucose (mg/dL) (Mean)</td></tr><tr><td>Baseline</td><td>161</td><td>164</td><td>161</td></tr><tr><td>Change from baselineb</td><td>-26</td><td>-29</td><td>-24</td></tr><tr><td colspan=\"4\">Body Weight (kg) (Mean)</td></tr><tr><td>Baseline</td><td>91.8</td><td>92.7</td><td>92.4</td></tr><tr><td>Change from baselineb</td><td>-1.4</td><td>-2.3</td><td>-2.2</td></tr></tbody></table><h2>14.3 Glycemic Control Combination Therapy Trials in Adults with Type2 Diabetes Mellitus</h2><p>Sitagliptin-Controlled Trial (Add-on to Metformin)</p><p>In this placebo-controlled, double-blind trial with primary endpoint at 52 weeks, 972 adult patients were randomized to placebo, TRULICITY 0.75mg once weekly, TRULICITY 1.5mg once weekly, or sitagliptin 100mg/day (after 26 weeks, patients in the placebo treatment group received blinded sitagliptin 100mg/day for the remainder of the trial), all as add-on to metformin. Randomization occurred after an 11-week lead-in period to allow for a metformin titration period, followed by a 6-week glycemic stabilization period. Patients had a mean age of 54 years; mean duration of type2 diabetes of 7 years; 48% were male; race: White, Black and Asian were 53%, 4% and 27%, respectively; and 24% of the trial population were in the US.</p><p>At the 26-week placebo-controlled time point, the HbA1c change was 0.1%, -1.0%, -1.2%, and -0.6% for placebo, TRULICITY 0.75mg, TRULICITY 1.5mg, and sitagliptin, respectively. The percentage of patients who achieved HbA1c &lt;7.0% was 22%, 56%, 62% and 39% for placebo, TRULICITY 0.75mg, TRULICITY 1.5mg, and sitagliptin, respectively. At 26 weeks, there was a mean weight reduction of 1.4kg, 2.7kg, 3.0kg, and 1.4kg for placebo, TRULICITY 0.75mg, TRULICITY 1.5mg, and sitagliptin, respectively. There was a mean reduction of fasting glucose of 9mg/dL, 35mg/dL, 41mg/dL, and 18mg/dL for placebo, TRULICITY 0.75mg, TRULICITY 1.5mg, and sitagliptin, respectively.</p><p>Treatment with TRULICITY 0.75mg and 1.5mg once weekly resulted in a statistically significant reduction in HbA1c compared to placebo (at 26 weeks) and compared to sitagliptin (at 26 and 52 weeks), all in combination with metformin (Table5 and Figure3).</p><table><caption>Table5: Results at Week 52 of TRULICITY Compared to Sitagliptin used as Add-On to Metformin in Adult Patients with Type2 Diabetes Mellitusa</caption><tfoot><tr><td colspan=\"4\"><p>Abbreviations: HbA1c = hemoglobin A1c.</p></td></tr><tr><td colspan=\"4\"><p>a All ITT patients randomized after the dose-finding portion of the trial. Last observation carried forward (LOCF) was used to impute missing data. At Week 52 primary efficacy was missing for 15%, 19%, and 20% of individuals randomized to TRULICITY 0.75mg, TRULICITY 1.5mg and sitagliptin, respectively.</p></td></tr><tr><td colspan=\"4\"><p>b Least-squares (LS) mean adjusted for baseline value and other stratification factors.</p></td></tr><tr><td colspan=\"4\"><p> Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 276, 277, and 270 individuals randomized to TRULICITY 0.75mg, TRULICITY 1.5mg and sitagliptin, respectively.</p></td></tr><tr><td colspan=\"4\"><p> Multiplicity adjusted 1-sided p-value &lt;0.001, for superiority of TRULICITY compared to sitagliptin, assessed only for HbA1c.</p></td></tr><tr><td colspan=\"4\"><p>## p&lt;0.001 TRULICITY compared to sitagliptin, assessed only for HbA1c &lt;7.0%.</p></td></tr></tfoot><tbody><tr><td colspan=\"3\">52-Week Primary Time Point</td></tr><tr><td>TRULICITY0.75mg</td><td>TRULICITY1.5mg</td><td>Sitagliptin100mg</td></tr><tr><td>Intent-to-Treat (ITT) Population (N)</td><td>281</td><td>279</td><td>273</td></tr><tr><td colspan=\"4\">HbA1c (%) (Mean)</td></tr><tr><td>Baseline</td><td>8.2</td><td>8.1</td><td>8.0</td></tr><tr><td>Change from baselineb</td><td>-0.9</td><td>-1.1</td><td>-0.4</td></tr><tr><td>Difference from sitagliptinb (95% CI)</td><td>-0.5 (-0.7, -0.3)</td><td>-0.7 (-0.9, -0.5)</td><td>-</td></tr><tr><td>Percentage of patients HbA1c &lt;7.0%</td><td>49##</td><td>59##</td><td>33</td></tr><tr><td colspan=\"4\">Fasting Plasma Glucose (mg/dL) (Mean)</td></tr><tr><td>Baseline</td><td>174</td><td>173</td><td>171</td></tr><tr><td>Change from baselineb</td><td>-30</td><td>-41</td><td>-14</td></tr><tr><td>Difference from sitagliptinb (95% CI)</td><td>-15 (-22, -9)</td><td>-27 (-33, -20)</td><td>-</td></tr><tr><td colspan=\"4\">Body Weight (kg) (Mean)</td></tr><tr><td>Baseline</td><td>85.5</td><td>86.5</td><td>85.8</td></tr><tr><td>Change from baselineb</td><td>-2.7</td><td>-3.1</td><td>-1.5</td></tr><tr><td>Difference from sitagliptinb (95% CI)</td><td>-1.2 (-1.8, -0.6)</td><td>-1.5 (-2.1, -0.9)</td><td>-</td></tr></tbody></table><table><tfoot><tr><td colspan=\"4\"><p>Mean HbA1c adjusted for baseline HbA1c and country.</p></td></tr></tfoot><tbody><tr><td colspan=\"4\">Number of patients with observed data</td></tr><tr><td>Placebo</td><td>139</td><td>108</td></tr><tr><td>TRULICITY 0.75mg</td><td>281</td><td>258</td><td>238</td></tr><tr><td>TRULICITY 1.5mg</td><td>279</td><td>249</td><td>225</td></tr><tr><td>Sitagliptin</td><td>273</td><td>241</td><td>219</td></tr></tbody></table><p>Figure3: Adjusted Mean HbA1c at each Time Point (ITT, MMRM) and at Week 52 (ITT, LOCF) in Adult Patients with Type2 Diabetes Mellitus</p><p>Dosage Ranging Trial of TRULICITY 1.5, 3mg, and 4.5mg (Add-on to Metformin)</p><p>In this parallel-arm, double-blind trial with primary endpoint at 36 weeks, a total of 1842 adult patients were randomized 1:1:1 to TRULICITY 1.5mg, TRULICITY 3mg, or TRULICITY 4.5mg once weekly, all as add-on to metformin (NCT03495102).</p><p>Following randomization, all patients received TRULICITY 0.75mg once weekly. The dose was increased every 4 weeks to the next higher dose until the patients reached their assigned dose (1.5mg, 3mg, or 4.5mg). Patients were to remain on the assigned study dose for the duration of the trial.</p><p>Patients had a mean age of 57.1 years; a mean duration of type2 diabetes of 7.6 years; 51.2% were male; race: White, Black, and Asian were 85.8%, 4.5%, and 2.4%, respectively; and 27.6% of the trial population was in the US.</p><p>At 36 weeks, treatment with TRULICITY 4.5mg resulted in a statistically significant reduction in HbA1c and in body weight compared to TRULICITY 1.5mg (Table6 and Figure4).</p><table><caption>Table6. Results at Week 36 of TRULICITY 1.5mg Compared to 3mg and 4.5mg as Add-On to Metformin in Adult Patients with Type2 Diabetes Mellitusa</caption><tfoot><tr><td colspan=\"4\"><p>Abbreviations: HbA1c = hemoglobin A1c</p></td></tr><tr><td colspan=\"4\"><p>a Intent-to-treat population. At Week 36, primary efficacy was missing for 7%, 7%, and 6% of individuals treated with TRULICITY 1.5mg, TRULICITY 3mg, and TRULICITY 4.5mg, respectively.</p></td></tr><tr><td colspan=\"4\"><p>b Least-squares mean adjusted for baseline value and other stratification factors. Missing data were imputed using multiple imputation.</p></td></tr><tr><td colspan=\"4\"><p>c Patients with missing HbA1c data at Week 36 were considered as not achieving HbA1c target.</p></td></tr><tr><td colspan=\"4\"><p>^ p=0.0001 for superiority compared to TRULICITY 1.5mg, overall type I error controlled.</p></td></tr><tr><td colspan=\"4\"><p>^^ p&lt;0.0001 for superiority compared to TRULICITY 1.5mg, overall type I error controlled.</p></td></tr></tfoot><tbody><tr><td colspan=\"3\">36-Week Primary Time Point</td></tr><tr><td>TRULICITY 1.5mg</td><td>TRULICITY 3mg</td><td>TRULICITY 4.5mg</td></tr><tr><td>Intent-to-Treat (ITT) Population (N)</td><td>612</td><td>616</td><td>614</td></tr><tr><td colspan=\"4\">HbA1c (%) (Mean)</td></tr><tr><td>Baseline</td><td>8.6</td><td>8.6</td><td>8.6</td></tr><tr><td>Change from baselineb</td><td>-1.5</td><td>-1.6</td><td>-1.8</td></tr><tr><td>Difference from 1.5mgb (95% CI)</td><td>-0.1 (-0.2, 0.0)</td><td>-0.2 (-0.4, -0.1) ^</td></tr><tr><td>Percentage of patients HbA1c &lt;7.0%c</td><td>50</td><td>56</td><td>62</td></tr><tr><td colspan=\"4\">Fasting Serum Glucose (mg/dL) (Mean)</td></tr><tr><td>Baseline</td><td>185</td><td>184</td><td>183</td></tr><tr><td>Change from baselineb</td><td>-45</td><td>-46</td><td>-51</td></tr><tr><td>Difference from 1.5mgb (95% CI)</td><td>- 2 (-7, 3)</td><td>-6 (-11, -2)</td></tr><tr><td colspan=\"4\">Body Weight (kg) (Mean)</td></tr><tr><td>Baseline</td><td>95.5</td><td>96.3</td><td>95.4</td></tr><tr><td>Change from baselineb</td><td>-3.0</td><td>-3.8</td><td>-4.6</td></tr><tr><td>Difference from 1.5mgb (95% CI)</td><td>-0.9 (-1.4, -0.4)</td><td>-1.6 (-2.2, -1.1) ^^</td></tr></tbody></table><table><tbody><tr><td colspan=\"4\">Number of patients with observed data</td></tr><tr><td>TRULICITY 1.5mg</td><td>612</td><td>567</td></tr><tr><td>TRULICITY 3mg</td><td>616</td><td>572</td></tr><tr><td>TRULICITY 4.5mg</td><td>614</td><td>575</td></tr></tbody></table><p>Observed mean HbA1c at scheduled visits and retrieved dropout multiple imputation (MI) based estimate at week 36.</p><p>Figure4: Mean HbA1c at each Time Point (ITT) and at Week 36 (ITT, MI)</p><p>Placebo-Controlled Trial (Add-on to Sulfonylurea)</p><p>In this 24-week placebo-controlled, double-blind trial, 299 adult patients were randomized to and received placebo or once weekly TRULICITY 1.5mg, both as add-on to glimepiride. Patients had a mean age of 58 years; mean duration of type2 diabetes of 8 years; 44% were male; race: White, Black, and Asian were 83%, 4%, and 2%, respectively; and 24% of the trial population were in the US.</p><p>At 24 weeks, treatment with once weekly TRULICITY 1.5mg resulted in a statistically significant reduction in HbA1c compared to placebo (Table7).</p><table><caption>Table7: Results at Week 24 of TRULICITY Compared to Placebo as Add-On to Glimepiride in Adult Patients with Type2 Diabetes Mellitusa</caption><tfoot><tr><td colspan=\"3\"><p>Abbreviations: HbA1c = hemoglobin A1c.</p></td></tr><tr><td colspan=\"3\"><p>a Intent-to-treat population. Data post-onset of rescue therapy are treated as missing. At Week 24 primary efficacy was missing for 10% and 12% of individuals randomized to TRULICITY 1.5mg and placebo, respectively.</p></td></tr><tr><td colspan=\"3\"><p>b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. Placebo multiple imputation, with respect to the baseline values, was used to model a wash-out of the treatment effect for patients having missing Week 24 data.</p></td></tr><tr><td colspan=\"3\"><p>c Patients with missing HbA1c data at Week 24 were considered as non-responders.</p></td></tr><tr><td colspan=\"3\"><p> p&lt;0.001 for superiority of TRULICITY 1.5mg compared to placebo, overall type I error controlled.</p></td></tr></tfoot><tbody><tr><td colspan=\"2\">24-Week Primary Time Point</td></tr><tr><td>Placebo</td><td>TRULICITY1.5mg</td></tr><tr><td>Intent-to-Treat (ITT) Population (N)</td><td>60</td><td>239</td></tr><tr><td colspan=\"3\">HbA1c (%) (Mean)</td></tr><tr><td>Baseline</td><td>8.4</td><td>8.4</td></tr><tr><td>Change from baselineb</td><td>-0.3</td><td>-1.3</td></tr><tr><td>Difference from placebob (95% CI)</td><td>-1.1 (-1.4, -0.7)</td></tr><tr><td>Percentage of patients HbA1c &lt;7.0%c</td><td>17</td><td>50</td></tr><tr><td colspan=\"3\">Fasting Serum Glucose (mg/dL) (Mean)</td></tr><tr><td>Baseline</td><td>175</td><td>178</td></tr><tr><td>Change from baselineb</td><td>2</td><td>-28</td></tr><tr><td>Difference from placebob (95% CI)</td><td>-30 (-44, -15)</td></tr><tr><td colspan=\"3\">Body Weight (kg) (Mean)</td></tr><tr><td>Baseline</td><td>89.5</td><td>84.5</td></tr><tr><td>Change from baselineb</td><td>-0.2</td><td>-0.5</td></tr><tr><td>Difference from placebob (95% CI)</td><td>-0.4 (-1.2, 0.5)</td></tr></tbody></table><p>Placebo- and Exenatide-Controlled Trial (Add-on to Metformin and Thiazolidinedione)</p><p>In this placebo-controlled trial with primary endpoint at 26 weeks, 976 adult patients were randomized to and received placebo, TRULICITY 0.75mg once weekly, TRULICITY 1.5mg once weekly, or exenatide 10mcg BID, all as add-on to maximally tolerated doses of metformin (1500mg per day) and pioglitazone (up to 45mg per day). Exenatide treatment group assignment was open-label while the treatment assignments to placebo, TRULICITY 0.75mg, and TRULICITY 1.5mg were blinded. After 26 weeks, patients in the placebo treatment group were randomized to either TRULICITY 0.75mg once weekly or TRULICITY 1.5mg once weekly to maintain blinding. Randomization occurred after a 12-week lead-in period; during the initial 4 weeks of the lead-in period, patients were titrated to maximally tolerated doses of metformin and pioglitazone; this was followed by an 8-week glycemic stabilization period prior to randomization. Patients randomized to exenatide started at a dose of 5mcg BID for 4 weeks and then were escalated to 10mcg BID. Patients had a mean age of 56 years; mean duration of type2 diabetes of 9 years; 58% were male; race: White, Black and Asian were 74%, 8% and 3%, respectively; and 81% of the trial population were in the US.</p><p>Treatment with TRULICITY 0.75mg and 1.5mg once weekly resulted in a statistically significant reduction in HbA1c compared to placebo (at 26 weeks) and compared to exenatide at 26 weeks (Table8 and Figure5). Over the 52-week trial period, the percentage of patients who required glycemic rescue was 8.9% in the TRULICITY 0.75mg once weekly + metformin and pioglitazone treatment group, 3.2% in the TRULICITY 1.5mg once weekly + metformin and pioglitazone treatment group, and 8.7% in the exenatide BID + metformin and pioglitazone treatment group.</p><table><caption>Table8: Results at Week 26 of TRULICITY Compared to Placebo and Exenatide, All as Add-On to Metformin and Thiazolidinedione in Adult Patients with Type2 Diabetes Mellitusa</caption><tfoot><tr><td colspan=\"5\"><p>Abbreviations: BID = twice daily; HbA1c = hemoglobin A1c.</p></td></tr><tr><td colspan=\"5\"><p>a Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 26, primary efficacy was missing for 23%, 10%, 7% and 12% of individuals randomized to placebo, TRULICITY 0.75mg, TRULICITY 1.5mg, and exenatide, respectively.</p></td></tr><tr><td colspan=\"5\"><p>b Least-squares (LS) mean adjusted for baseline value and other stratification factors.</p></td></tr><tr><td colspan=\"5\"><p> Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 119, 269, 271 and 266 individuals randomized to placebo, TRULICITY 0.75mg, TRULICITY 1.5mg, and exenatide, respectively.</p></td></tr><tr><td colspan=\"5\"><p> Multiplicity adjusted 1-sided p-value &lt;0.001, for superiority of TRULICITY compared to placebo, assessed only for HbA1c.</p></td></tr><tr><td colspan=\"5\"><p> Multiplicity adjusted 1-sided p-value &lt;0.001, for superiority of TRULICITY compared to exenatide, assessed only for HbA1c.</p></td></tr><tr><td colspan=\"5\"><p>** p&lt;0.001 TRULICITY compared to placebo, assessed only for HbA1c &lt;7.0%.</p></td></tr><tr><td colspan=\"5\"><p>## p&lt;0.001 TRULICITY compared to exenatide, assessed only for HbA1c &lt;7.0%.</p></td></tr></tfoot><tbody><tr><td colspan=\"4\">26-Week Primary Time Point</td></tr><tr><td>Placebo</td><td>TRULICITY 0.75mg</td><td>TRULICITY 1.5mg</td><td>Exenatide 10mcg BID</td></tr><tr><td>Intent-to-Treat (ITT) Population (N)</td><td>141</td><td>280</td><td>279</td><td>276</td></tr><tr><td colspan=\"5\">HbA1c (%) (Mean)</td></tr><tr><td>Baseline</td><td>8.1</td><td>8.1</td><td>8.1</td><td>8.1</td></tr><tr><td>Change from baselineb</td><td>-0.5</td><td>-1.3</td><td>-1.5</td><td>-1.0</td></tr><tr><td>Difference from placebob (95% CI)</td><td>-</td><td>-0.8 (-1.0, -0.7)</td><td>-1.1 (-1.2, -0.9)</td><td>-</td></tr><tr><td>Difference from exenatideb (95% CI)</td><td>-</td><td>-0.3 (-0.4, -0.2)</td><td>-0.5 (-0.7, -0.4)</td><td>-</td></tr><tr><td>Percentage of patients HbA1c &lt;7.0%</td><td>43</td><td>66**, ##</td><td>78**, ##</td><td>52</td></tr><tr><td colspan=\"5\">Fasting Serum Glucose (mg/dL) (Mean)</td></tr><tr><td>Baseline</td><td>166</td><td>159</td><td>162</td><td>164</td></tr><tr><td>Change from baselineb</td><td>-5</td><td>-34</td><td>-42</td><td>-24</td></tr><tr><td>Difference from placebob (95% CI)</td><td>-</td><td>-30 (-36, -23)</td><td>-38 (-45, -31)</td><td>-</td></tr><tr><td>Difference from exenatideb (95% CI)</td><td>-</td><td>-10 (-15, -5)</td><td>-18 (-24, -13)</td><td>-</td></tr><tr><td colspan=\"5\">Body Weight (kg) (Mean)</td></tr><tr><td>Baseline</td><td>94.1</td><td>95.5</td><td>96.2</td><td>97.4</td></tr><tr><td>Change from baselineb</td><td>1.2</td><td>0.2</td><td>-1.3</td><td>-1.1</td></tr><tr><td>Difference from placebob (95% CI)</td><td>-</td><td>-1.0 (-1.8, -0.3)</td><td>-2.5 (-3.3, -1.8)</td><td>-</td></tr><tr><td>Difference from exenatideb (95% CI)</td><td>-</td><td>1.3 (0.6, 1.9)</td><td>-0.2 (-0.9, 0.4)</td><td>-</td></tr></tbody></table><table><tfoot><tr><td colspan=\"4\"><p>Mean HbA1c adjusted for baseline HbA1c and country.</p></td></tr></tfoot><tbody><tr><td colspan=\"4\">Number of patients with observed data</td></tr><tr><td>Placebo</td><td>141</td><td>108</td></tr><tr><td>TRULICITY 0.75mg</td><td>280</td><td>251</td></tr><tr><td>TRULICITY 1.5mg</td><td>279</td><td>259</td></tr><tr><td>Exenatide</td><td>276</td><td>242</td></tr></tbody></table><p>Figure5: Adjusted Mean HbA1c at Each Time Point (ITT, MMRM) and at Week 26 (ITT, LOCF)</p><p>Placebo-Controlled Trial (Add-on to SGLT2i, with or without Metformin)</p><p>In this 24-week placebo-controlled, double-blind trial, 423 adult patients were randomized to and received TRULICITY 0.75mg, TRULICITY 1.5mg, or placebo, as add-on to sodium-glucose co-transporter 2 inhibitor (SGLT2i) therapy (96% with and 4% without metformin). Trulicity was administered once weekly, and SGLT2i was administered according to the local country label. Patients had a mean age of 57 years; mean duration of type2 diabetes of 9.4 years; 50% were male; race: White, Black, and Asian were 89%, 3%, and 0.2%, respectively; and 21% of the trial population was in the US.</p><p>At 24 weeks, treatment with once weekly TRULICITY 0.75mg and 1.5mg resulted in a statistically significant reduction from baseline in HbA1c compared to placebo (Table9).</p><p>The mean baseline body weight was 90.5, 91.1, and 92.9kg in the placebo, TRULICITY 0.75mg, and TRULICITY 1.5mg groups, respectively. The mean changes from baseline in body weight at Week 24 were -2.0, -2.5, and -2.9kg for placebo, TRULICITY 0.75mg, and TRULICITY 1.5mg, respectively. The difference from placebo (95% CI) was -0.9kg (-1.7, -0.1) for TRULICITY 1.5mg.</p><table><caption>Table9: Results at Week 24 of TRULICITY as Add-on to SGLT2i in Adult Patients with Type2 Diabetes Mellitusa</caption><tfoot><tr><td colspan=\"4\"><p>Abbreviations: HbA1c = hemoglobin A1c; SGLT2i = sodium-glucose co-transporter-2 inhibitors.</p></td></tr><tr><td colspan=\"4\"><p>a Intent-to-treat population. At Week 24, primary efficacy was missing for 3%, 4%, and 6% of individuals treated with placebo, TRULICITY 0.75mg, and TRULICITY 1.5mg, respectively.</p></td></tr><tr><td colspan=\"4\"><p>b Least-squares mean adjusted for baseline value and other stratification factors. Placebo multiple imputation, using baseline and 24-week values from the placebo arm, was applied to model a washout of the treatment effect for patients missing 24-week values (HbA1c, fasting serum glucose, and body weight).</p></td></tr><tr><td colspan=\"4\"><p>c Patients with missing HbA1c data at Week 24 were considered as non-responders.</p></td></tr><tr><td colspan=\"4\"><p> p&lt;0.001 for superiority of TRULICITY compared to placebo, overall type I error controlled.</p></td></tr></tfoot><tbody><tr><td colspan=\"3\">24-Week Primary Time Point</td></tr><tr><td>Placebo</td><td>TRULICITY 0.75mg</td><td>TRULICITY 1.5mg</td></tr><tr><td>Intent-to-Treat (ITT) Population (N)</td><td>140</td><td>141</td><td>142</td></tr><tr><td colspan=\"4\">HbA1c (%) (Mean)</td></tr><tr><td>Baseline</td><td>8.1</td><td>8.1</td><td>8.0</td></tr><tr><td>Change from baselineb</td><td>-0.6</td><td>-1.2</td><td>-1.3</td></tr><tr><td>Difference from placebob (95% CI)</td><td>-</td><td>-0.7 (-0.8, -0.5)</td><td>-0.8 (-0.9, -0.6)</td></tr><tr><td>Percentage of patients HbA1c &lt;7.0%c</td><td>31</td><td>59</td><td>67</td></tr><tr><td colspan=\"4\">Fasting Serum Glucose (mg/dL) (Mean)</td></tr><tr><td>Baseline</td><td>153</td><td>162</td><td>161</td></tr><tr><td>Change from baselineb</td><td>-6</td><td>-25</td><td>-30</td></tr><tr><td>Difference from placebob (95% CI)</td><td>-</td><td>-19 (-25, -13)</td><td>-24 (-30, -18)</td></tr></tbody></table><p>Insulin Glargine Controlled Trial (Add-on to Metformin and Sulfonylurea)</p><p>In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 52 weeks, 807 adult patients were randomized to and received TRULICITY 0.75mg once weekly, TRULICITY 1.5mg once weekly, or insulin glargine once daily, all as add-on to maximally tolerated doses of metformin and glimepiride. Randomization occurred after a 10-week lead-in period; during the initial 2 weeks of the lead-in period, patients were titrated to maximally tolerated doses of metformin and glimepiride. This was followed by a 6- to 8-week glycemic stabilization period prior to randomization.</p><p>Patients randomized to insulin glargine were started on a dose of 10units once daily. Insulin glargine dose adjustments occurred twice weekly for the first 4 weeks of treatment based on self-measured fasting plasma glucose (FPG), followed by once weekly titration through Week 8 of treatment, utilizing an algorithm that targeted a fasting plasma glucose of &lt;100mg/dL. Only 24% of patients were titrated to goal at the 52-week primary endpoint. The dose of glimepiride could be reduced or discontinued after randomization (at the discretion of the investigator) in the event of persistent hypoglycemia. The dose of glimepiride was reduced or discontinued in 28%, 32%, and 29% of patients randomized to TRULICITY 0.75mg, TRULICITY 1.5mg, and glargine.</p><p>Patients had a mean age of 57 years; mean duration of type2 diabetes of 9 years; 51% were male; race: White, Black and Asian were 71%, 1% and 17%, respectively; and 0% of the trial population were in the US.</p><p>Treatment with TRULICITY once weekly resulted in a reduction in HbA1c from baseline at 52 weeks when used in combination with metformin and sulfonylurea (Table10). The difference in observed effect size between TRULICITY 0.75mg and 1.5mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4%.</p><table><caption>Table10: Results at Week 52 of TRULICITY Compared to Insulin Glargine, Both as Add-on to Metformin and Sulfonylurea in Adult Patients with Type2 Diabetes Mellitusa</caption><tfoot><tr><td colspan=\"4\"><p>Abbreviations: HbA1c = hemoglobin A1c.</p></td></tr><tr><td colspan=\"4\"><p>a Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 52, primary efficacy was missing for 17%, 13% and 12% of individuals randomized to TRULICITY 0.75mg, TRULICITY 1.5mg and glargine, respectively.</p></td></tr><tr><td colspan=\"4\"><p>b Least-squares (LS) mean adjusted for baseline value and other stratification factors.</p></td></tr><tr><td colspan=\"4\"><p> Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 267, 263 and 259 individuals randomized to TRULICITY 0.75mg, TRULICITY 1.5mg, and glargine, respectively.</p></td></tr></tfoot><tbody><tr><td colspan=\"3\">52-Week Primary Time Point</td></tr><tr><td>TRULICITY 0.75mg</td><td>TRULICITY 1.5mg</td><td>Insulin Glargine</td></tr><tr><td>Intent-to-Treat (ITT) Population (N)</td><td>272</td><td>273</td><td>262</td></tr><tr><td colspan=\"4\">HbA1c (%) (Mean)</td></tr><tr><td>Baseline</td><td>8.1</td><td>8.2</td><td>8.1</td></tr><tr><td>Change from baselineb</td><td>-0.8</td><td>-1.1</td><td>-0.6</td></tr><tr><td colspan=\"4\">Fasting Serum Glucose (mg/dL) (Mean)</td></tr><tr><td>Baseline</td><td>161</td><td>165</td><td>163</td></tr><tr><td>Change from baselineb</td><td>-16</td><td>-27</td><td>-32</td></tr><tr><td>Difference from insulin glargineb (95% CI)</td><td>16 (9, 23)</td><td>5 (-2, 12)</td><td>-</td></tr><tr><td colspan=\"4\">Body Weight (kg) (Mean)</td></tr><tr><td>Baseline</td><td>86.4</td><td>85.2</td><td>87.6</td></tr><tr><td>Change from baselineb</td><td>-1.3</td><td>-1.9</td><td>1.4</td></tr><tr><td>Difference from insulinb (95% CI)</td><td>-2.8 (-3.4, -2.2)</td><td>-3.3 (-3.9, -2.7)</td><td>-</td></tr></tbody></table><p>Placebo-Controlled Trial (Add-on to Basal Insulin, with or without Metformin)</p><p>In this 28-week placebo-controlled, double-blind trial, 300 adult patients were randomized to placebo or once weekly TRULICITY 1.5mg, as add-on to titrated basal insulin glargine (with or without metformin). Patients had a mean age of 60 years; mean duration of type2 diabetes of 13 years; 58% were male; race: White, Black, and Asian were 94%, 4%, and 0.3%, respectively; and 20% of the trial population was in the US.</p><p>The mean starting dose of insulin glargine was 37units/day for patients receiving placebo and 41units/day for patients receiving TRULICITY 1.5mg. At randomization, the initial insulin glargine dose in patients with HbA1c &lt;8.0% was reduced by 20%.</p><p>At 28 weeks, treatment with once weekly TRULICITY 1.5mg resulted in a statistically significant reduction in HbA1c compared to placebo (Table11).</p><table><caption>Table11: Results at Week 28 of TRULICITY Compared to Placebo as Add-On to Basal Insulin in Adult Patients with Type2 Diabetes Mellitusa</caption><tfoot><tr><td colspan=\"3\"><p>Abbreviations: HbA1c = hemoglobin A1c.</p></td></tr><tr><td colspan=\"3\"><p>a Intent-to-treat population. At Week 28, primary efficacy was missing for 12% and 8% of individuals randomized to placebo and TRULICITY 1.5mg, respectively.</p></td></tr><tr><td colspan=\"3\"><p>b Least-squares mean from ANCOVA adjusted for baseline value and other stratification factors. Placebo multiple imputation, with respect to baseline values, was used to model a wash-out of the treatment effect for patients having missing Week 28 data.</p></td></tr><tr><td colspan=\"3\"><p>c Patients with missing HbA1c data at Week 28 were considered as non-responders.</p></td></tr><tr><td colspan=\"3\"><p> p&lt;0.001 for superiority of TRULICITY 1.5mg compared to placebo, overall type I error controlled.</p></td></tr><tr><td colspan=\"3\"><p> p0.005 for superiority of TRULICITY 1.5mg compared to placebo, overall type I error controlled.</p></td></tr></tfoot><tbody><tr><td colspan=\"2\">28-Week Primary Time Point</td></tr><tr><td>Placebo</td><td>TRULICITY1.5mg</td></tr><tr><td>Intent-to-Treat (ITT) Population (N)</td><td>150</td><td>150</td></tr><tr><td colspan=\"3\">HbA1c (%) (Mean)</td></tr><tr><td>Baseline</td><td>8.3</td><td>8.4</td></tr><tr><td>Change from baselineb</td><td>-0.7</td><td>-1.4</td></tr><tr><td>Difference from placebob (95% CI)</td><td>-0.7 (-0.9, -0.5)</td></tr><tr><td>Percentage of patients HbA1c &lt;7.0%c</td><td>33</td><td>67</td></tr><tr><td colspan=\"3\">Fasting Serum Glucose (mg/dL) (Mean)</td></tr><tr><td>Baseline</td><td>156</td><td>157</td></tr><tr><td>Change from baselineb</td><td>-30</td><td>-44</td></tr><tr><td>Difference from placebob (95% CI)</td><td>-14 (-23, -4)</td></tr><tr><td colspan=\"3\">Body Weight (kg) (Mean)</td></tr><tr><td>Baseline</td><td>92.6</td><td>93.3</td></tr><tr><td>Change from baselineb</td><td>0.8</td><td>-1.3</td></tr><tr><td>Difference from placebob (95% CI)</td><td>-2.1 (-2.9, -1.4)</td></tr></tbody></table><p>Insulin Glargine-Controlled Trial (Combination with Prandial Insulin, with or withoutMetformin)</p><p>In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 26 weeks, 884 adult patients on 1 or 2 insulin injections per day were enrolled. Randomization occurred after a 9-week lead-in period; during the initial 2 weeks of the lead-in period, patients continued their pre-trial insulin regimen but could be initiated and/or up-titrated on metformin, based on investigator discretion; this was followed by a 7-week glycemic stabilization period prior to randomization.</p><p>At randomization, patients discontinued their pre-trial insulin regimen and were randomized to TRULICITY 0.75mg once weekly, TRULICITY 1.5mg once weekly, or insulin glargine once daily, all in combination with prandial insulin lispro 3 times daily, with or without metformin. Insulin lispro was titrated in each arm based on preprandial and bedtime glucose, and insulin glargine was titrated to a fasting plasma glucose goal of &lt;100mg/dL. Only 36% of patients randomized to glargine were titrated to the fasting glucose goal at the 26-week primary timepoint.</p><p>Patients had a mean age of 59 years; mean duration of type2 diabetes of 13 years; 54% were male; race: White, Black and Asian were 79%, 10% and 4%, respectively; and 33% of the trial population were in the US.</p><p>Treatment with TRULICITY 0.75mg and 1.5mg once weekly resulted in a reduction in HbA1c from baseline. The difference in observed effect size between TRULICITY 0.75mg and 1.5mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4% (Table12).</p><table><caption>Table12: Results at Week 26 of TRULICITY Compared to Insulin Glargine, Both in Combination with Insulin Lispro in Adult Patients with Type2 Diabetes Mellitusa</caption><tfoot><tr><td colspan=\"4\"><p>Abbreviation: HbA1c = hemoglobin A1c</p></td></tr><tr><td colspan=\"4\"><p>a Intent-to-treat population. Last observation carried forward (LOCF) was used to impute missing data. Data post-onset of rescue therapy are treated as missing. At Week 26, primary efficacy was missing for 14%, 15%, and 14% of individuals randomized to TRULICITY 0.75mg, TRULICITY 1.5mg and glargine, respectively.</p></td></tr><tr><td colspan=\"4\"><p>b Least-squares (LS) mean adjusted for baseline value and other stratification factors.</p></td></tr><tr><td colspan=\"4\"><p> Patients included in the analysis are a subset of the ITT population that had at least one post-baseline assessment. The primary analysis included 275, 273 and 276 individuals randomized to TRULICITY 0.75mg, TRULICITY 1.5mg, and glargine, respectively.</p></td></tr></tfoot><tbody><tr><td colspan=\"3\">26-Week Primary Time Point</td></tr><tr><td>TRULICITY0.75mg</td><td>TRULICITY1.5mg</td><td>Insulin Glargine</td></tr><tr><td>Intent-to-Treat (ITT) Population (N)</td><td>293</td><td>295</td><td>296</td></tr><tr><td colspan=\"4\">HbA1c (%) (Mean)</td></tr><tr><td>Baseline</td><td>8.4</td><td>8.5</td><td>8.5</td></tr><tr><td>Change from baselineb</td><td>-1.6</td><td>-1.6</td><td>-1.4</td></tr><tr><td colspan=\"4\">Fasting Serum Glucose (mg/dL) (Mean)</td></tr><tr><td>Baseline</td><td>150</td><td>157</td><td>154</td></tr><tr><td>Change from baselineb</td><td>4</td><td>-5</td><td>-28</td></tr><tr><td>Difference from insulin glargineb (95% CI)</td><td>32 (24, 41)</td><td>24 (15, 32)</td><td>-</td></tr><tr><td colspan=\"4\">Body Weight (kg) (Mean)</td></tr><tr><td>Baseline</td><td>91.7</td><td>91.0</td><td>90.8</td></tr><tr><td>Change from baselineb</td><td>0.2</td><td>-0.9</td><td>2.3</td></tr><tr><td>Difference from insulin glargineb (95% CI)</td><td>-2.2 (-2.8, -1.5)</td><td>-3.2 (-3.8, -2.6)</td><td>-</td></tr></tbody></table><h2>14.4 Glycemic Control Trials in Adults with Type2 Diabetes Mellitus and Moderate to Severe Chronic Kidney Disease</h2><p>In this open-label comparator trial (double-blind with respect to TRULICITY dose assignment) with primary endpoint at 26 weeks, a total of 576 adult patients with type2 diabetes were randomized and treated to compare TRULICITY 0.75mg and 1.5mg with insulin glargine (NCT01621178).</p><p>Patients on insulin and other antidiabetic therapy (e.g., oral antidiabetic drugs, pramlintide) had non-insulin therapies discontinued and had their insulin dose adjusted for 12 weeks prior to randomization. Patients on insulin therapy alone maintained a stable insulin dose for 3 weeks prior to randomization. At randomization, patients discontinued their pre-trial insulin regimen and patients were randomized to TRULICITY 0.75mg once weekly, TRULICITY 1.5mg once weekly, or insulin glargine once daily, all in combination with prandial insulin lispro. For patients randomized to insulin glargine, the initial insulin glargine dose was based on the basal insulin dose prior to randomization. Insulin glargine was allowed to be titrated with a fasting plasma glucose goal of 150mg/dL. Insulin lispro was allowed to be titrated with a preprandial and bedtime glucose goal of 180mg/dL.</p><p>Patients had a mean age of 65 years; a mean duration of type2 diabetes of 18 years; 52% were male; race: White, Black, and Asian were 69%, 16%, and 3%, respectively; and 32% of the trial population were in the US. At baseline, overall mean eGFR was 38mL/min/1.73m2, 30% of patients had eGFR &lt;30mL/min/1.73m2, and 45% of patients had macroalbuminuria. Patients on over 70units/day of basal insulin were excluded from the trial.</p><p>Treatment with TRULICITY 0.75mg and 1.5mg once weekly resulted in a reduction in HbA1c at 26-weeks from baseline. The difference in observed effect size between TRULICITY 0.75mg and 1.5mg, respectively, and glargine in this trial excluded the pre-specified non-inferiority margin of 0.4%. Mean fasting plasma glucose increased in the TRULICITY arms (Table13).</p><p>Mean baseline body weight was 90.9kg, 88.1kg, and 88.2kg in the TRULICITY 0.75mg, TRULICITY 1.5mg, and insulin glargine arms, respectively. The mean changes from baseline at Week 26 were -1.1, -2, and 1.9kg in the TRULICITY 0.75mg, TRULICITY 1.5mg, and insulin glargine arms, respectively.</p><table><caption>Table13: Results at Week 26 of TRULICITY Compared to Insulin Glargine, Both in Combination with Insulin Lispro, in Patients with Moderate to Severe Chronic Kidney Disease in Adult Patients with Type2 Diabetes Mellitusa</caption><tfoot><tr><td colspan=\"4\"><p>Abbreviation: HbA1c = hemoglobin A1c</p></td></tr><tr><td colspan=\"4\"><p>a Intent-to-treat population (all randomized and treated patients) was used in the analysis regardless of discontinuation of study drug or initiation of rescue therapy. At Week 26, primary efficacy was missing for 12%, 15%, and 9% of individuals randomized to and treated with TRULICITY 0.75mg, TRULICITY 1.5mg, and insulin glargine, respectively. Missing data were imputed using multiple imputation within treatment group.</p></td></tr><tr><td colspan=\"4\"><p>b Least-squares (LS) mean from ANCOVA pattern mixture model adjusted for baseline value and other stratification factors.</p></td></tr></tfoot><tbody><tr><td colspan=\"3\">26-Week Primary Time Point</td></tr><tr><td>TRULICITY0.75mg</td><td>TRULICITY1.5mg</td><td>Insulin Glargine</td></tr><tr><td>Intent-to-Treat Population (N)</td><td>190</td><td>192</td><td>194</td></tr><tr><td colspan=\"4\">HbA1c (%) (Mean)</td></tr><tr><td>Baseline</td><td>8.6</td><td>8.6</td><td>8.6</td></tr><tr><td>Change from baselineb</td><td>-0.9</td><td>-1.0</td><td>-1.0</td></tr><tr><td>Difference from insulin glargineb (95% CI)</td><td>0.0 (-0.2, 0.3)</td><td>-0.1 (-0.3, 0.2)</td></tr><tr><td>Percentage of patients HbA1c &lt;8.0%</td><td>73</td><td>75</td><td>74</td></tr><tr><td colspan=\"4\">Fasting Serum Glucose (mg/dL) (Mean)</td></tr><tr><td>Baseline</td><td>167</td><td>161</td><td>170</td></tr><tr><td>Change from baselineb</td><td>6</td><td>14</td><td>-23</td></tr><tr><td>Difference from insulin glargineb (95% CI)</td><td>30 (16, 43)</td><td>37 (24, 50)</td></tr></tbody></table><h2>14.5 Cardiovascular Outcomes Trial in Adults with Type2 Diabetes Mellitus and Cardiovascular Disease or Multiple Cardiovascular Risk Factors</h2><p>The REWIND trial (NCT01394952) was a multi-national, multi-center, randomized, placebo-controlled, double-blind trial. In this trial, 9901 adult patients with type2 diabetes mellitus and established cardiovascular (CV) disease or multiple cardiovascular risk factors were randomized to TRULICITY 1.5mg or placebo both added to standard of care. The median follow-up duration was 5.4 years. The primary endpoint was the time to the first occurrence of a composite 3-component Major Adverse Cardiovascular Events (MACE) outcome, which included CV death, non-fatal myocardial infarction (MI), and non-fatal stroke.</p><p>Patients eligible to enter the trial were 50 years of age or older who had type2 diabetes mellitus, had an HbA1c value 9.5% with no lower limit at screening, and had either established CV disease, or did not have established CV disease but had multiple CV risk factors. Patients who were confirmed to have established CV disease (31.5% of randomized patients) had a history of at least one of the following: MI (16.2%); myocardial ischemia by a stress test or with cardiac imaging (9.3%); ischemic stroke (5.3%); coronary, carotid, or peripheral artery revascularization (18.0%); unstable angina (5.9%); or hospitalization for unstable angina with at least one of the following: ECG changes, myocardial ischemia on imaging, or a need for percutaneous coronary intervention (12.0%). Patients confirmed to be without established CV disease, but with multiple CV risk factors, comprised 62.8% of the randomized trial population.</p><p>At baseline, demographic and disease characteristics were balanced between treatment groups. Patients had a mean age of 66 years; 46% were female; race: White, Black, and Asian were 76%, 7%, and 4%, respectively.</p><p>The median baseline HbA1c was 7.2%. The mean duration of type2 diabetes was 10.5 years and the mean BMI was 32.3kg/m2.</p><p>At baseline, 50.5% of patients had mild renal impairment (eGFR 60 but &lt;90mL/min/1.73m2), 21.6% had moderate renal impairment (eGFR 30 but &lt;60mL/min/1.73m2), and 1.1% of patients had severe renal impairment (eGFR &lt;30mL/min/1.73m2) out of 9713 patients whose eGFR were available.</p><p>At baseline, 94.7% of patients were taking antidiabetic medication, with 10.5% of patients taking three or more antidiabetic drugs. The most common background antidiabetic drugs used at baseline were metformin (81.2%), sulfonylurea (46.0%), and insulin (23.9%). At baseline, CV disease and risk factors were managed with ACE inhibitors or angiotensin receptor blockers (81.5%), beta blockers (45.6%), calcium channel blockers (34.4%), diuretics (46.5%), statin therapy (66.1%), antithrombotic agents (58.7%), and aspirin (51.7%). During the trial, investigators were to modify anti-diabetic and cardiovascular medications to achieve local standard of care treatment targets with respect to blood glucose, lipids, and blood pressure, and manage patients recovering from an acute coronary syndrome or stroke event per local treatment guidelines.</p><p>For the primary analysis, a Cox proportional hazards model was used to test for superiority. Type I error was controlled across multiple tests. TRULICITY significantly reduced the risk of first occurrence of primary composite endpoint of CV death, non-fatal MI, or non-fatal stroke (HR: 0.88, 95% CI 0.79, 0.99). Refer to Figure 6 and Table 14.</p><p>Vital status was available for 99.7% of patients in the trial. A total of 1128 deaths were recorded during the REWIND trial. A majority of the deaths in the trial were adjudicated as CV deaths, and non-CV deaths were comparable between the treatment groups (4.4% in patients treated with TRULICITY and 5.0% in patients treated with placebo). There were 536 all-cause deaths (10.8%) in the dulaglutide group compared to 592 deaths (12.0%) in the placebo group.</p><table><tbody><tr><td colspan=\"9\">Number of patients at risk</td></tr><tr><td>Placebo</td><td>4952</td><td>4791</td><td>4625</td><td>4437</td><td>4275</td><td>3575</td><td>742</td></tr><tr><td>Dulaglutide</td><td>4949</td><td>4815</td><td>4670</td><td>4521</td><td>4369</td><td>3686</td><td>741</td></tr></tbody></table><p>Figure 6. KAPLAN MEIER CURVE: Time to First Occurrence of MACE in the REWIND Trial</p><table><caption>Table 14: Treatment Effect for MACE and the Individual Components in the REWIND Trial, Median Trial Observation Time of 5.4 years in Adult Patients with Type2 Diabetes Mellitusa</caption><tfoot><tr><td colspan=\"4\"><p>a All randomized patients.</p></td></tr><tr><td colspan=\"4\"><p>b Cox-proportional hazards model with treatment as a factor. Type I error was controlled for the primary and secondary endpoints.</p></td></tr><tr><td colspan=\"4\"><p>c p=0.026 for superiority (2-sided).</p></td></tr><tr><td colspan=\"4\"><p>d Number and percentage of patients with events.</p></td></tr><tr><td colspan=\"4\"><p>e Results for components of MACE, fatal and non-fatal stroke, and fatal and non-fatal MI are listed descriptively for supportive purposes. No statistical significance should be inferred since these CIs are not adjusted for multiplicity.</p></td></tr></tfoot><tbody><tr><td>Time to First Occurrence of:</td><td>TRULICITYN=4949</td><td>PlaceboN=4952</td><td>Hazard Ratio(95% CI)b</td></tr><tr><td>Composite of non-fatal myocardial infarction, non-fatal stroke, cardiovascular death (MACE)d</td><td>594 (12.0%)</td><td>663 (13.4%)</td><td>0.88 (0.79, 0.99)c</td></tr><tr><td> Cardiovascular deathd,e</td><td>317 (6.4%)</td><td>346 (7.0%)</td><td>0.91 (0.78, 1.06)</td></tr><tr><td> Non-fatal myocardial infarctiond,e</td><td>205 (4.1%)</td><td>212 (4.3%)</td><td>0.96 (0.79, 1.16)</td></tr><tr><td> Non-fatal stroked,e</td><td>135 (2.7%)</td><td>175 (3.5%)</td><td>0.76 (0.61, 0.95)</td></tr><tr><td>Fatal or non-fatal myocardial infarctiond,e</td><td>223 (4.5%)</td><td>231 (4.7%)</td><td>0.96 (0.79, 1.15)</td></tr><tr><td>Fatal or non-fatal stroked,e</td><td>158 (3.2%)</td><td>205 (4.1%)</td><td>0.76 (0.62, 0.94)</td></tr></tbody></table><h2>14.6 Glycemic Control Trial in Pediatric Patients 10 Years of Age and Older with Type2 Diabetes Mellitus</h2><p>In this 26-week randomized, double-blind, placebo-controlled, parallel-arm, multicenter trial with an open-label extension for an additional 26 weeks,154 pediatric patients 10 years of age and older with type2 diabetes mellitus, who had inadequate glycemic control despite diet and exercise, were randomized to subcutaneous TRULICITY once weekly (0.75 mg and 1.5 mg) or subcutaneous placebo once weekly in combination with or without metformin and/or basal insulin treatment (NCT02963766).</p><p>Overall, in this trial demographic and baseline disease characteristics were comparable across the treatment groups. At baseline, 71% of patients were female, and the mean age was 14.5 years (ranging from 10 to 17 years). Overall, 55% were White, 15% were Black or African American, 12% were Asian, 10% were American Indian or Alaska Native, 5% were other races, and 3% had unknown race. Additionally, 55% were Hispanic or Latino, 42% were not Hispanic or Latino, and 3% had unknown ethnicity. At baseline, the mean duration of type 2 diabetes mellitus was 2 years, mean HbA1c was 8.1%, mean weight was 90.5kg and mean BMI was 34.1kg/m2.</p><p>In this trial, once weekly TRULICITY (0.75mg and 1.5mg, pooled) (with or without metformin and/or basal insulin) was superior to placebo (p&lt;0.001) in the change from baseline at Week 26 in HbA1c in pediatric patients 10 years of age and older with type2 diabetes mellitus (see Table15).</p><table><caption>Table 15: Glycemic Results at Week 26 in Pediatric Patients 10 Years of Age and Older with Type2 Diabetes Mellitus with Inadequate Glycemic Control Despite Diet and Exercise (With or Without Metformin and/or Basal Insulin)</caption><tfoot><tr><td colspan=\"5\"><p>Abbreviations: HbA1c = hemoglobin A1c.</p></td></tr><tr><td colspan=\"5\"><p>a Combined results for TRULICITY 0.75mg and 1.5mg. The comparison of the two dosages together and individually with placebo was prespecified with overall type I error controlled.</p></td></tr><tr><td colspan=\"5\"><p>b The change from baseline and difference from placebo were analyzed using analysis of covariance with effects for treatment, the baseline value as a covariate, and stratification factors which were HbA1c at screening (&lt; 8% vs &gt;= 8%), insulin use at baseline (yes/no), metformin use at baseline (yes/no).</p></td></tr><tr><td colspan=\"5\"><p>c For HbA1c and Fasting Blood Glucose, multiple imputation was performed for missing data guided by washout method. At Week 26 primary efficacy (HbA1c) was missing for 8%, 6%, and 10% of patients on placebo, TRULICITY 0.75mg and TRULICITY 1.5mg respectively.</p></td></tr><tr><td colspan=\"5\"><p>d For percentage of patients HbA1c &lt; 7%, missing data was imputed as not achieving the target.</p></td></tr></tfoot><tbody><tr><td>Placebo</td><td>TRULICITY 0.75mg once weekly</td><td>TRULICITY 1.5mg once weekly</td><td>TRULICITY once weeklyPooleda</td></tr><tr><td>Intent-to-Treat Population (N)</td><td>51</td><td>51</td><td>52</td><td>103</td></tr><tr><td colspan=\"5\">HbA1c (%) (Mean)c</td></tr><tr><td>BaselineChange from baseline at Week 26bDifference from placebo (95% CI)b</td><td>8.10.6-</td><td>7.9-0.6-1.2 (-1.8, -0.6)</td><td>8.2-0.9-1.5 (-2.1, -0.9)</td><td>8.0-0.8-1.4 (-1.9, -0.8)</td></tr><tr><td>Percentage of Patients with HbA1c &lt;7.0% at Week 26d</td><td>14%</td><td>55%</td><td>48%</td><td>52%</td></tr><tr><td colspan=\"5\">Fasting Blood Glucose (mg/dL) (Mean)c</td></tr><tr><td>BaselineChange from baseline at Week 26bDifference from placebo (95% CI)b</td><td>15917.1-</td><td>149-12.8-29.9 (-50.7, -9.1)</td><td>163-24.9-42.0 (-63.0, -20.9)</td><td>156-18.9-35.9 (-54.2, -17.6)</td></tr></tbody></table>",
      "howSupplied": "<h2>16.1 How Supplied</h2><p>TRULICITY (dulaglutide) injection is a clear and colorless solution supplied in single-dose pens. TRULICITY is packaged in a cardboard outer carton containing 4 single-dose TRULICITY pens and is supplied as follows:</p><table><tbody><tr><td>Total Strength per Total Volume</td><td>NDC</td></tr><tr><td>0.75mg/0.5mL</td><td>NDC 0002-1433-80</td></tr><tr><td>1.5mg/0.5mL</td><td>NDC 0002-1434-80</td></tr><tr><td>3mg/0.5mL</td><td>NDC 0002-2236-80</td></tr><tr><td>4.5mg/0.5mL</td><td>NDC 0002-3182-80</td></tr></tbody></table>",
      "useInSpecificPopulations": "<h1>8 USE IN SPECIFIC POPULATIONS</h1><h2>8.1 Pregnancy</h2><p>Risk Summary</p><p>Limited data with TRULICITY in pregnant women are not sufficient to determine a drug-associated risk for major birth defects and miscarriage. There are clinical considerations regarding the risks of poorly controlled diabetes in pregnancy [see Clinical Considerations]. Based on animal reproduction studies, there may be risks to the fetus from exposure to dulaglutide during pregnancy. TRULICITY should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p><p>In pregnant rats administered dulaglutide during organogenesis, early embryonic deaths, fetal growth reductions, and fetal abnormalities occurred at systemic exposures at least 6-times human exposure at the maximum recommended human dose (MRHD) of 4.5mg/week. In pregnant rabbits administered dulaglutide during organogenesis, major fetal abnormalities occurred at 5-times human exposure at the MRHD. Adverse embryo/fetal effects in animals occurred in association with decreased maternal weight and food consumption attributed to the pharmacology of dulaglutide [see Data].</p><p>The estimated background risk of major birth defects is 610% in women with pre-gestational diabetes with an HbA1c &gt;7% and has been reported to be as high as 2025% in women with an HbA1c &gt;10%. The estimated background risk of miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 24% and 1520%, respectively.</p><p>Clinical Considerations</p><p>Disease-associated maternal and/or embryo/fetal risk</p><p>Poorly controlled diabetes in pregnancy increases the maternal risk for diabetic ketoacidosis, pre-eclampsia, spontaneous abortions, preterm delivery and delivery complications. Poorly controlled diabetes increases the fetal risk for major birth defects, stillbirth, and macrosomia-related morbidity.</p><p>Data</p><p>Animal Data</p><p>Pregnant rats given subcutaneous doses of 0.49, 1.63, or 4.89mg/kg dulaglutide every 3 days during organogenesis had systemic exposures 2-, 6-, and 18-times human exposure at the maximum recommended human dose (MRHD) of 4.5mg/week, respectively, based on plasma area under the time-concentration curve (AUC) comparison. Reduced fetal weights associated with decreased maternal food intake and decreased weight gain attributed to the pharmacology of dulaglutide were observed at 1.63mg/kg. Irregular skeletal ossifications and increases in post-implantation loss also were observed at 4.89mg/kg.</p><p>In pregnant rabbits given subcutaneous doses of 0.04, 0.12, or 0.41mg/kg dulaglutide every 3 days during organogenesis, systemic exposures in pregnant rabbits were 0.5-, 2-, and 5-times human exposure at the MRHD, based on plasma AUC comparison. Fetal visceral malformation of lung lobular agenesis and skeletal malformations of the vertebrae and/or ribs were observed in conjunction with decreased maternal food intake and decreased weight gain attributed to the pharmacology of dulaglutide at 0.41mg/kg.</p><p>In a prenatal-postnatal study in F0 maternal rats given subcutaneous doses of 0.2, 0.49, or 1.63mg/kg every third day from implantation through lactation, systemic exposures in pregnant rats were 1-, 2-, and 7-times human exposure at the MRHD, based on plasma AUC comparison. F1 pups from F0 maternal rats given 1.63mg/kg dulaglutide had statistically significantly lower mean body weight from birth through postnatal day 63 for males and postnatal day 84 for females. F1 offspring from F0 maternal rats receiving 1.63mg/kg dulaglutide had decreased forelimb and hindlimb grip strength and males had delayed balano-preputial separation. Females had decreased startle response. These physical findings may relate to the decreased size of the offspring relative to controls as they appeared at early postnatal assessments but were not observed at a later assessment. F1 female offspring of the F0 maternal rats given 1.63mg/kg of dulaglutide had a longer mean escape time and a higher mean number of errors relative to concurrent control during 1 of 2 trials in the memory evaluation portion of the Biel water maze. These findings occurred in conjunction with decreased F0 maternal food intake and decreased weight gain attributed to the pharmacologic activity at 1.63mg/kg. The human relevance of these memory deficits in the F1 female rats is not known.</p><h2>8.2 Lactation</h2><p>Risk Summary</p><p>There are no data on the presence of dulaglutide in human milk, the effects on the breastfed infant, or the effects on milk production. The presence of dulaglutide in milk of treated lactating animals was not determined. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for TRULICITY and any potential adverse effects on the breastfed infant from TRULICITY or from the underlying maternal condition.</p><h2>8.4 Pediatric Use</h2><p>The safety and effectiveness of TRULICITY as an adjunct to diet and exercise to improve glycemic control in pediatric patients 10 years of age and older with type2 diabetes mellitus have been established. Use of TRULICITY for this indication is supported by a 26-week, multicenter, randomized, double-blind, parallel arm, placebo-controlled trial in 154 pediatric patients 10 years of age and older with type2 diabetes mellitus [see Clinical Studies (14.6)].</p><p>TRULICITY-treated pediatric patients reported a higher incidence of injection site-related reactions compared to TRULICITY-treated adults [see Adverse Reactions (6.1)].</p><p>The safety and effectiveness of TRULICITY have not been established in pediatric patients less than 10 years of age.</p><h2>8.5 Geriatric Use</h2><p>In the adult glycemic control trials [see Clinical Studies (14.2, 14.3)], 620 (19%) of TRULICITY-treated patients were 65 years of age or older and 65 (2%) of TRULICITY-treated patients were 75 years of age or older at baseline. In the TRULICITY 1.5mg treatment arm of the REWIND trial (cardiovascular outcomes trial in adults with type2 diabetes mellitus and cardiovascular disease or multiple cardiovascular risk factors) [see Clinical Studies (14.5)], 2,619 (53%) patients were 65 years of age or older, and 484 (10%) patients were 75 years of age or older at baseline.</p><p>No overall differences in safety or effectiveness for TRULICITY have been observed between patients 65 years of age and older and younger adult patients.</p><h2>8.6 Renal Impairment</h2><p>TRULICITY has been studied in patients with varying degrees of renal function, including a dedicated clinical trial in patients with moderate to severe chronic kidney disease. No overall differences in safety or effectiveness were observed in these studies according to renal function [see Clinical Studies (14.2, 14.3, 14.4)].</p><p>In a clinical pharmacology study in patients with renal impairment, including end-stage renal disease (ESRD), no clinically relevant change in dulaglutide pharmacokinetics (PK) was observed. In the 52-week trial in patients with type2 diabetes and moderate to severe renal impairment, the PK behavior of TRULICITY 0.75mg and 1.5mg once weekly was similar to that demonstrated in previous clinical studies [see Clinical Pharmacology (12.3)].</p><p>No dose adjustment is recommended in patients with renal impairment including end-stage renal disease (ESRD). Monitor renal function in patients with renal impairment reporting severe adverse gastrointestinal reactions. Use TRULICITY with caution in patients with ESRD [see Warning and Precautions (5.5), Clinical Pharmacology (12.3)].</p><h2>8.7 Hepatic Impairment</h2><p>In a clinical pharmacology study in patients with varying degrees of hepatic impairment, no clinically relevant change in dulaglutide PK was observed [see Clinical Pharmacology (12.3)]. However, there is limited clinical experience in patients with mild, moderate, or severe hepatic impairment; therefore, use TRULICITY with caution in these patient populations.</p><h2>8.8 Gastroparesis</h2><p>Dulaglutide slows gastric emptying. TRULICITY has not been studied in patients with preexisting gastroparesis. Use TRULICITY with caution in patients with gastroparesis.</p>",
      "description": "<p>Dulaglutide is a human glucagon-like peptide-1 (GLP-1) receptor agonist. It is a fusion protein with two identical, disulfide-linked chains, each containing an N-terminal GLP-1 analog sequence linked to the Fc portion of a modified human immunoglobulin G4 (IgG4) heavy chain. It is produced using mammalian cell culture and has a molecular weight of approximately 63 kilodaltons. TRULICITY (dulaglutide) injection is a clear, colorless, sterile, preservative-free solution for subcutaneous use. Each single-dose pen contains a 0.5 mL solution of 0.75 mg, 1.5 mg, 3 mg, or 4.5 mg of dulaglutide with excipients: citric acid anhydrous, mannitol, polysorbate 80, and trisodium citrate dihydrate, in water for injection.</p>",
      "nonclinicalToxicology": "<h1>13 NONCLINICAL TOXICOLOGY</h1><h2>13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility</h2><p>A 2-year carcinogenicity study was conducted with dulaglutide in male and female rats at doses of 0.05, 0.5, 1.5, and 5mg/kg (0.2-, 3-, 8-, and 24-fold the MRHD of 4.5mg once weekly based on AUC) administered by subcutaneous injection twice weekly. In rats, dulaglutide caused a dose-related and treatment-duration-dependent increase in the incidence of thyroid C-cell tumors (adenomas and/or carcinomas) compared to controls, at 3-fold the MRHD based on AUC. A statistically significant increase in C-cell adenomas was observed in rats receiving dulaglutide at 0.5mg/kg. Numerical increases in thyroid C-cell carcinomas occurred at 5mg/kg (24 times the MRHD based on AUC) and were considered to be treatment-related despite the absence of statistical significance.</p><p>A 6-month carcinogenicity study was conducted with dulaglutide in rasH2 transgenic mice at doses of 0.3, 1, and 3mg/kg administered by subcutaneous injection twice weekly. Dulaglutide did not produce increased incidences of thyroid C-cell hyperplasia or neoplasia at any dose.</p><p>Dulaglutide is a recombinant protein; no genotoxicity studies have been conducted.</p><p>Human relevance of thyroid C-cell tumors in rats is unknown and could not be determined by clinical studies or nonclinical studies [see Boxed Warning and Warnings and Precautions (5.1)].</p><p>In fertility and early embryonic development studies in male and female rats, no adverse effects of dulaglutide on sperm morphology, mating, fertility, conception, and embryonic survival were observed at up to 16.3mg/kg (55-fold the MRHD based on AUC). In female rats, an increase in the number of females with prolonged diestrus and a dose-related decrease in the mean number of corpora lutea, implantation sites, and viable embryos were observed at 4.9mg/kg (13-fold the MRHD based on AUC), which occurred in the presence of decreased maternal food consumption and body weight gain.</p><h2>13.2 Animal Toxicology and/or Pharmacology</h2><p>Zucker diabetic fatty (ZDF) rats were given 0.5, 1.5, or 5mg/kg/twice weekly of dulaglutide (1-, 3-, and 13-fold the MRHD based on AUC) for 3 months. Increases of 12% to 33% in total and pancreatic amylase, but not lipase, were observed at all doses without microscopic pancreatic inflammatory correlates in individual animals. Other changes in the dulaglutide-treated animals included increased interlobular ductal epithelium without active ductal cell proliferation (0.5mg/kg), increased acinar atrophy with/without inflammation (1.5mg/kg), and increased neutrophilic inflammation of the acinar pancreas (5mg/kg).</p><p>Treatment of monkeys for 12 months with 8.15mg/kg/twice weekly of dulaglutide (nearly 200-fold the MRHD based on AUC) demonstrated no evidence of pancreatic inflammation or pancreatic intraepithelial neoplasia. In 4 of 19 monkeys on dulaglutide treatment, there was an increase in goblet cells within the pancreatic ducts, but no differences from the control group in total amylase or lipase at study termination. There were no proliferative changes in the thyroid C-cells.</p>",
      "instructionsForUse": "<h1>TRULICITY 4.5 MG SINGLE-DOSE PEN INSTRUCTIONS FOR USE</h1><table><tbody><tr><td>Instructions for Use</td></tr><tr><td>TRULICITY(TRU-li-si-tee)(dulaglutide)injection, for subcutaneous use4.5mg/0.5mL Single-Dose Penuse 1 time each week (once weekly)</td></tr></tbody></table><p>Information About TRULICITY Single-Dose Pen</p><p>Please read this Instructions for Use and the Medication Guide carefully and completely before using your TRULICITY Single-Dose Pen. Talk to your healthcare provider about how to inject TRULICITY the right way.</p><ul><li>TRULICITY Single-Dose Pen (Pen) is a disposable, prefilled medicine delivery device. Each Pen contains 1 dose of TRULICITY (4.5mg/0.5mL). Each Pen should only be used 1 time.</li><li>TRULICITY is used 1 time each week. You may want to mark your calendar to remind you when to take your next dose.</li></ul><p>Before You Get Started</p><table><tbody><tr><td>Remove</td><td>Check</td><td>Inspect</td><td>Prepare</td></tr><tr><td>Remove the Pen from the refrigerator.Leave the Base Cap on until you are ready to inject.</td><td>Check the Pen label to make sure you have the right medicine and it has not expired.Expiration Date</td><td>Check the Pen to make sure that it is not damaged and inspect the medicine to make sure it is not cloudy, discolored or has particles in it.</td><td>Wash your hands.</td></tr></tbody></table><p>Choose Your Injection Site</p><p>Your healthcare provider can help you choose the injection site that is best for you.</p><table><tbody><tr><td>Change (rotate) your injection site each week. You may use the same area of your body, but be sure to choose a different injection site in that area.You may inject the medicine into your stomach (abdomen) or thigh.</td></tr><tr><td>Another person should give you the injection in the back of your upper arm.</td></tr></tbody></table><table><tbody><tr><td colspan=\"2\"><p>Step 1 Uncap the Pen Make sure the Pen is locked.</p><ul><li>Pull the Base Cap straight off and throw it away in your household trash.Do not put the Base Cap back on this could damage the needle.Do not touch the needle.</li></ul></td></tr><tr><td>Step 2 Place and Unlock<ul><li><p>Place the Clear Base flat and firmly against your skin at the injection site.</p></li></ul><p>Unlock by turning the Lock Ring.</p></td></tr></tbody></table><table><tbody><tr><td>Step 3 Press and Hold<ul><li><p>Press and hold the green Injection Button. You will hear a loud click.Continue holding the Clear Base firmly against your skin until you hear a second click. This happens when the needle starts retracting in about 5-10 seconds.</p></li><li>Remove the Pen from your skin.</li></ul></td></tr></tbody></table><p>Important Information</p><p>Disposal of Pen</p><p>Storage and Handling</p><p>Commonly Asked Questions</p><p>Other Information</p><p>Where to Learn More</p><table><tbody><tr><td>Disposing of Your Used Pens<ul><li>Put your used Pens in a FDA-cleared sharps disposal container right away after use. Do not throw away (dispose of) Pens in your household trash.</li><li>If you do not have a FDA-cleared sharps disposal container, you may use a household container that is:<dl><dt>-</dt><dd>made of a heavy-duty plastic,</dd><dt>-</dt><dd>can be closed with a tight-fitting, puncture-resistant lid, without sharps being able to come out,</dd><dt>-</dt><dd>upright and stable during use,</dd><dt>-</dt><dd>leak-resistant, and</dd><dt>-</dt><dd>properly labeled to warn of hazardous waste inside the container.</dd></dl></li><li>When your sharps disposal container is almost full, you will need to follow your community guidelines for the right way to dispose of your sharps disposal container. There may be state or local laws about how you should throw away used needles and syringes. For more information about safe sharps disposal, and for specific information about sharps disposal in the state that you live in, go to the FDA's website at: http://www.fda.gov/safesharpsdisposal.</li><li>Do not recycle your used sharps disposal container.</li></ul></td></tr></tbody></table><p>Storage and Handling</p><ul><li>Store your Pen in the refrigerator between 36F to 46F (2C to 8C).</li><li>You may store your Pen at room temperature below 86F (30C) for a total of 14 days.</li><li>Do not freeze your Pen. If the Pen has been frozen, throw the Pen away and use a new Pen.</li><li>Storage of your Pen in the original carton is recommended. Protect your Pen from direct heat and light.</li><li>The Pen has glass parts. Handle it carefully. If you drop it on a hard surface, do not use it. Use a new Pen for your injection.</li><li>Keep your TRULICITY Pen and all medicines out of the reach of children.</li></ul><p>Commonly Asked Questions</p><p>What if I see air bubbles in my Pen?</p><p>Air bubbles are normal.</p><p>What if I unlock the Pen and press the green Injection Button before pulling off the Base Cap?</p><p>Do not remove the Base Cap. Throw away the Pen and get a new Pen.</p><p>What if there is a drop of liquid on the tip of the needle when I remove the Base Cap?</p><p>A drop of liquid on the tip of the needle is normal.</p><p>Do I need to hold the Injection Button down until the injection is complete?</p><p>This is not necessary, but it may help you keep the Pen steady and firm against your skin.</p><p>I heard more than 2 clicks during my injection2 louder clicks and 1 soft one. Did I get my complete injection?</p><p>Some people may hear a soft click right before the second loud click. That is the normal operation of the Pen. Do not remove the Pen from your skin until you hear the second louder click.</p><p>What if there is a drop of liquid or blood on my skin after my injection?</p><p>This is normal.</p><p>I am not sure if my Pen worked the right way.</p><p>Check to see if you have received your dose. Your dose was delivered the right way if the gray plunger is visible (see step3). Also contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) for further instructions. Until then, store your Pen safely to avoid an accidental needle stick.</p><p>Other Information</p><ul><li>If you have vision problems, do not use your Pen without help from a person trained to use the TRULICITY Pen.</li></ul><p>Where to Learn More</p><ul><li>If you have any questions or problems with your TRULICITY Single-Dose Pen, contact Lilly at 1-800-Lilly-Rx (1-800-545-5979) or call your healthcare provider.</li><li>For more information about TRULICITY Single-Dose Pen, visit our website at: www.trulicity.com.</li></ul><table><tbody><tr><td>Scan this code to launch www.trulicity.com</td></tr></tbody></table><p>This Instructions for Use has been approved by the U.S. Food and Drug Administration.Eli Lilly and CompanyIndianapolis, IN 46285, USAUS License Number 1891TRULICITY is a registered trademark of Eli Lilly and Company.</p><p>Copyright 2020, 2023, Eli Lilly and Company. All rights reserved.</p><p>The TRULICITY Pen meets the current dose accuracy and functional requirements of ISO 11608-1:2012 and 11608-5:2012.</p><p>Implemented: 04/2023</p><p>TRU4.5MG-0002-IFU-20230407</p>",
      "mechanismOfAction": "<h2>12.1 Mechanism of Action</h2><p>TRULICITY contains dulaglutide, which is a human GLP-1 receptor agonist with 90% amino acid sequence homology to endogenous human GLP-1 (7-37). Dulaglutide activates the GLP-1 receptor, a membrane-bound cell-surface receptor coupled to adenylyl cyclase in pancreatic beta cells. Dulaglutide increases intracellular cyclic AMP (cAMP) in beta cells leading to glucose-dependent insulin release. Dulaglutide also decreases glucagon secretion and slows gastric emptying.</p>",
      "contraindications": "\n<p>TRULICITY is contraindicated in patients with:</p>\n<ul>\n<li>Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2) [see Warnings and Precautions (5.1)].</li>\n<li>Serious hypersensitivity reaction to dulaglutide or to any of the product components. Serious hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with TRULICITY [see Warnings and Precautions (5.4)].</li>\n</ul>",
      "highlights": {
        "dosageAndAdministration": "<p>Adult Dosage (2.1) </p><ul><li>Recommended starting dosage is 0.75mg injected subcutaneously once weekly.</li><li>After 4 weeks, the dosage may be increased to 1.5mg once weekly for additional glycemic control.</li><li>If additional glycemic control is needed, increase dosage in 1.5mg increments after at least 4 weeks on the current dosage.</li><li>Maximum recommended dosage is 4.5mg injected subcutaneously once weekly.</li></ul><p>Pediatric Dosage (2.2) </p><ul><li>Recommended starting dosage is 0.75mg injected subcutaneously once weekly.</li><li>If additional glycemic control is needed, increase dosage to the maximum recommended dosage of 1.5mg once weekly after at least 4 weeks on the 0.75mg dosage.</li></ul><p>Recommendations Regarding Missed Dose (2.3) </p><ul><li>If a dose is missed, administer the missed dose as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose.</li></ul><p>Important Administration Instructions (2.4) </p><ul><li>Administer once weekly at any time of day with or without food.</li><li>Inject subcutaneously in the abdomen, thigh, or upper arm.</li></ul>"
      },
      "metaDescription": "<p>Dulaglutide is a GLP-1 receptor agonist fusion protein with a molecular weight of 63 kDa, used in TRULICITY injections with various excipients.</p>",
      "useAndConditions": "<p><h3>Approved Indications</h3></p>\n<ul>\n<li>As an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.</li>\n<li>To reduce the risk of major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke, in adults with type 2 diabetes mellitus who have established cardiovascular disease or multiple cardiovascular risk factors.</li>\n</ul>",
      "contraIndications": "<h3>Contraindications</h3>\n<ul>\n<li>Personal or family history of medullary thyroid carcinoma (MTC) or in patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN2).</li>\n<li>Serious hypersensitivity reaction to dulaglutide or to any of the product components, including anaphylactic reactions and angioedema.</li>\n</ul>",
      "warnings": "<h3>Warnings and Precautions</h3>\n<ul>\n<li>Risk of Thyroid C-cell Tumors: Dulaglutide causes a dose-related increase in thyroid C-cell tumors in rodents. The relevance to humans is unknown. TRULICITY is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) or in patients with MEN2. Routine monitoring of serum calcitonin or using thyroid ultrasound is of uncertain value.</li>\n<li>Pancreatitis: TRULICITY has been associated with pancreatitis. If pancreatitis is suspected, discontinue TRULICITY. It has not been evaluated in patients with a prior history of pancreatitis.</li>\n<li>Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Increased risk of hypoglycemia when used with insulin secretagogues or insulin. Dose reduction of these agents may be necessary.</li>\n<li>Hypersensitivity Reactions: Serious hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported. TRULICITY is contraindicated in patients with a previous serious hypersensitivity reaction to dulaglutide.</li>\n<li>Acute Kidney Injury: Postmarketing reports of acute renal failure and worsening of chronic renal failure have been noted. Use caution in patients with renal impairment.</li>\n<li>Severe Gastrointestinal Adverse Reactions: Associated with severe gastrointestinal reactions. Not recommended in patients with severe gastrointestinal disease, including severe gastroparesis.</li>\n<li>Diabetic Retinopathy Complications: Increased risk of diabetic retinopathy complications in patients with a history of diabetic retinopathy. Monitor for progression.</li>\n<li>Acute Gallbladder Disease: Reports of cholelithiasis and cholecystitis. If suspected, appropriate clinical follow-up is indicated.</li>\n<li>Pulmonary Aspiration During General Anesthesia or Deep Sedation: Delays gastric emptying, with rare reports of pulmonary aspiration. Patients should inform healthcare providers prior to surgeries or procedures.</li>\n</ul>",
      "dosing": "<h3>Adult Dosing</h3>\n<ul>\n    <li>Starting dosage: 0.75 mg injected subcutaneously once weekly.</li>\n    <li>After 4 weeks, may increase to 1.5 mg once weekly for additional glycemic control.</li>\n    <li>If additional control is needed, increase in 1.5 mg increments after at least 4 weeks on the current dosage.</li>\n    <li>Maximum recommended dosage: 4.5 mg injected subcutaneously once weekly.</li>\n</ul>\n\n<h3>Pediatric Dosing</h3>\n<ul>\n    <li>Starting dosage: 0.75 mg injected subcutaneously once weekly.</li>\n    <li>If additional control is needed, increase to a maximum of 1.5 mg once weekly after at least 4 weeks on the 0.75 mg dosage.</li>\n</ul>\n\n<h3>Recommendations Regarding Missed Dose</h3>\n<ul>\n    <li>If a dose is missed, administer as soon as possible if there are at least 3 days (72 hours) until the next scheduled dose.</li>\n    <li>If less than 3 days remain before the next dose, skip the missed dose and continue with the regular schedule.</li>\n    <li>The day of weekly administration can be changed if the last dose was administered 3 or more days before the new day.</li>\n</ul>\n\n<h3>Important Administration Instructions</h3>\n<ul>\n    <li>Train patients and caregivers on proper injection technique.</li>\n    <li>Administer once weekly, any time of day, with or without food.</li>\n    <li>Inject subcutaneously in the abdomen, thigh, or upper arm.</li>\n    <li>Rotate injection sites with each dose.</li>\n    <li>Inspect visually before use; should appear clear and colorless. Do not use if particulate matter or coloration is seen.</li>\n    <li>When using with insulin, administer as separate injections and never mix. Injections can be in the same body region but not adjacent.</li>\n</ul>"
    }
  },
  {
    "drugName": "Verzenio",
    "setId": "be4bc0de-0fdc-4d46-8d25-be43c79e6a06",
    "slug": "verzenio-be4bc0d",
    "labeler": "Eli Lilly and Company",
    "label": {
      "genericName": "abemaciclib",
      "labelerName": "Eli Lilly and Company",
      "productType": "HUMAN PRESCRIPTION DRUG LABEL",
      "effectiveTime": "20241113",
      "title": "Verzenio",
      "indicationsAndUsage": "\n<h3>1.1 Early Breast Cancer</h3>\n<p>VERZENIO (abemaciclib) is indicated:</p>\n<ul>\n<li>In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence [see Clinical Studies (14.1)].</li>\n</ul>\n<h3>1.2 Advanced or Metastatic Breast Cancer</h3>\n<p>VERZENIO (abemaciclib) is indicated:</p>\n<ul>\n<li>In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.</li>\n<li>In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.</li>\n<li>As monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.</li>\n</ul>",
      "dosageAndAdministration": "\n<h3>2.1 Recommended Dose and Schedule</h3>\n<ul>\n<li>When used in combination with fulvestrant, tamoxifen, or an aromatase inhibitor, the recommended dose of VERZENIO is 150 mg taken orally twice daily. Refer to the Full Prescribing Information for the recommended dose of the fulvestrant, tamoxifen, or aromatase inhibitor being used.</li>\n<li>Pre/perimenopausal women and men treated with the combination of VERZENIO plus an aromatase inhibitor should be treated with a gonadotropin-releasing hormone agonist (GnRH) according to current clinical practice standards.</li>\n<li>Pre/perimenopausal women treated with the combination of VERZENIO plus fulvestrant should be treated with a GnRH according to current clinical practice standards.</li>\n<li>When used as monotherapy, the recommended dose of VERZENIO is 200 mg taken orally twice daily.</li>\n<li>For early breast cancer, continue VERZENIO until completion of 2 years of treatment or until disease recurrence, or unacceptable toxicity.</li>\n<li>For advanced or metastatic breast cancer, continue treatment until disease progression or unacceptable toxicity.</li>\n</ul>\n<p>VERZENIO may be taken with or without food [see Clinical Pharmacology (12.3)].</p>\n<p>Instruct patients to take their doses of VERZENIO at approximately the same times every day.</p>\n<p>If the patient vomits or misses a dose of VERZENIO, instruct the patient to take the next dose at its scheduled time. Instruct patients to swallow VERZENIO tablets whole and not to chew, crush, or split tablets before swallowing. Instruct patients not to ingest VERZENIO tablets if broken, cracked, or otherwise not intact.</p>\n<h3>2.2 Dose Modification</h3>\n<p>Dose Modifications for Adverse Reactions</p>\n<p>The recommended VERZENIO dose modifications for adverse reactions are provided in Tables 1-7. Discontinue VERZENIO for patients unable to tolerate 50 mg twice daily.</p>\n<table>\n<caption>Table 1: VERZENIO Dose Modification Adverse Reactions</caption>\n<thead>\n<tr>\n<th>Dose Level</th>\n<th>VERZENIO Dose Combination with Fulvestrant, Tamoxifen, or an Aromatase Inhibitor</th>\n<th>VERZENIO Dose for Monotherapy</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Recommended starting dose</td>\n<td>150 mg twice daily</td>\n<td>200 mg twice daily</td>\n</tr>\n<tr>\n<td>First dose reduction</td>\n<td>100 mg twice daily</td>\n<td>150 mg twice daily</td>\n</tr>\n<tr>\n<td>Second dose reduction</td>\n<td>50 mg twice daily</td>\n<td>100 mg twice daily</td>\n</tr>\n<tr>\n<td>Third dose reduction</td>\n<td>not applicable</td>\n<td>50 mg twice daily</td>\n</tr>\n</tbody>\n</table>\n<table>\n<caption>Table 2: VERZENIO Dose Modification and Management Hematologic Toxicities</caption>\n<thead>\n<tr>\n<th>CTCAE Grade</th>\n<th>VERZENIO Dose Modifications</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td colspan=\"2\">Monitor complete blood counts prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.</td>\n</tr>\n<tr>\n<td>Grade 1 or 2</td>\n<td>No dose modification is required.</td>\n</tr>\n<tr>\n<td>Grade 3</td>\n<td>Suspend dose until toxicity resolves to Grade 2. Dose reduction is not required.</td>\n</tr>\n<tr>\n<td>Grade 3 recurrent, or Grade 4</td>\n<td>Suspend dose until toxicity resolves to Grade 2. Resume at next lower dose.</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"2\">Abbreviation: CTCAE = Common Terminology Criteria for Adverse Events.</td>\n</tr>\n<tr>\n<td colspan=\"2\">If blood cell growth factors are required, suspend VERZENIO dose for at least 48 hours after the last dose of blood cell growth factor and until toxicity resolves to Grade 2. Resume at next lower dose unless already performed for the toxicity that led to the use of the growth factor. Growth factor use as per current treatment guidelines.</td>\n</tr>\n</tfoot>\n</table>\n<table>\n<caption>Table 3: VERZENIO Dose Modification and Management Diarrhea</caption>\n<thead>\n<tr>\n<th>CTCAE Grade</th>\n<th>VERZENIO Dose Modifications</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td colspan=\"2\">At the first sign of loose stools, start treatment with antidiarrheal agents and increase intake of oral fluids.</td>\n</tr>\n<tr>\n<td>Grade 1</td>\n<td>No dose modification is required.</td>\n</tr>\n<tr>\n<td>Grade 2</td>\n<td>If toxicity does not resolve within 24 hours to Grade 1, suspend dose until resolution. No dose reduction is required.</td>\n</tr>\n<tr>\n<td>Grade 2 that persists or recurs after resuming the same dose despite maximal supportive measures</td>\n<td>Suspend dose until toxicity resolves to Grade 1. Resume at next lower dose.</td>\n</tr>\n<tr>\n<td>Grade 3 or 4 or requires hospitalization</td>\n<td>Suspend dose until toxicity resolves to Grade 1. Resume at next lower dose.</td>\n</tr>\n</tbody>\n</table>\n<table>\n<caption>Table 4: VERZENIO Dose Modification and Management Hepatotoxicity</caption>\n<thead>\n<tr>\n<th>CTCAE Grade for ALT and AST</th>\n<th>VERZENIO Dose Modifications</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td colspan=\"2\">Monitor ALT, AST, and serum bilirubin prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated.</td>\n</tr>\n<tr>\n<td>Grade 1 (&gt;ULN-3.0 x ULN) Grade 2 (&gt;3.0-5.0 x ULN), WITHOUT increase in total bilirubin above 2 x ULN</td>\n<td>No dose modification is required.</td>\n</tr>\n<tr>\n<td>Persistent or Recurrent Grade 2, or Grade 3 (&gt;5.0-20.0 x ULN), WITHOUT increase in total bilirubin above 2 x ULN</td>\n<td>Suspend dose until toxicity resolves to baseline or Grade 1. Resume at next lower dose.</td>\n</tr>\n<tr>\n<td>Elevation in AST and/or ALT &gt;3 x ULN WITH total bilirubin &gt;2 x ULN, in the absence of cholestasis</td>\n<td>Discontinue VERZENIO.</td>\n</tr>\n<tr>\n<td>Grade 4 (&gt;20.0 x ULN)</td>\n<td>Discontinue VERZENIO.</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"2\">Abbreviations: ALT = alanine aminotransferase, AST = aspartate aminotransferase, ULN = upper limit of normal.</td>\n</tr>\n</tfoot>\n</table>\n<table>\n<caption>Table 5: VERZENIO Dose Modification and Management Interstitial Lung Disease/Pneumonitis</caption>\n<thead>\n<tr>\n<th>CTCAE Grade</th>\n<th>VERZENIO Dose Modifications</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Grade 1 or 2</td>\n<td>No dose modification is required.</td>\n</tr>\n<tr>\n<td>Persistent or recurrent Grade 2 toxicity that does not resolve with maximal supportive measures within 7 days to baseline or Grade 1</td>\n<td>Suspend dose until toxicity resolves to baseline or Grade 1. Resume at next lower dose.</td>\n</tr>\n<tr>\n<td>Grade 3 or 4</td>\n<td>Discontinue VERZENIO.</td>\n</tr>\n</tbody>\n</table>\n<table>\n<caption>Table 6: VERZENIO Dose Modification and Management Venous Thromboembolic Events (VTEs)</caption>\n<thead>\n<tr>\n<th>CTCAE Grade</th>\n<th>VERZENIO Dose Modifications</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td colspan=\"2\">Early Breast Cancer</td>\n</tr>\n<tr>\n<td>Any Grade</td>\n<td>Suspend dose and treat as clinically indicated. Resume VERZENIO when the patient is clinically stable.</td>\n</tr>\n<tr>\n<td colspan=\"2\">Advanced or Metastatic Breast Cancer</td>\n</tr>\n<tr>\n<td>Grade 1 or 2</td>\n<td>No dose modification is required.</td>\n</tr>\n<tr>\n<td>Grade 3 or 4</td>\n<td>Suspend dose and treat as clinically indicated. Resume VERZENIO when the patient is clinically stable.</td>\n</tr>\n</tbody>\n</table>\n<table>\n<caption>Table 7: VERZENIO Dose Modification and Management Other Toxicities</caption>\n<thead>\n<tr>\n<th>CTCAE Grade</th>\n<th>VERZENIO Dose Modifications</th>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Grade 1 or 2</td>\n<td>No dose modification is required.</td>\n</tr>\n<tr>\n<td>Persistent or recurrent Grade 2 toxicity that does not resolve with maximal supportive measures within 7 days to baseline or Grade 1</td>\n<td>Suspend dose until toxicity resolves to baseline or Grade 1. Resume at next lower dose.</td>\n</tr>\n<tr>\n<td>Grade 3 or 4</td>\n<td>Suspend dose until toxicity resolves to baseline or Grade 1. Resume at next lower dose.</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"2\">Excluding diarrhea, hematologic toxicity, hepatotoxicity, ILD/pneumonitis, and VTEs.</td>\n</tr>\n</tfoot>\n</table>\n<p>Refer to the Full Prescribing Information for coadministered fulvestrant, tamoxifen, or an aromatase inhibitor for dose modifications and other relevant safety information.</p>\n<p>Dose Modification for Use with Strong and Moderate CYP3A Inhibitors</p>\n<p>Avoid concomitant use of the strong CYP3A inhibitor ketoconazole.</p>\n<p>With concomitant use of strong CYP3A inhibitors other than ketoconazole, in patients with recommended starting doses of 200 mg twice daily or 150 mg twice daily, reduce the VERZENIO dose to 100 mg twice daily. In patients who have had a dose reduction to 100 mg twice daily due to adverse reactions, further reduce the VERZENIO dose to 50 mg twice daily. If a patient taking VERZENIO discontinues a CYP3A inhibitor, increase the VERZENIO dose (after 3-5 half-lives of the inhibitor) to the dose that was used before starting the strong inhibitor [see Drug Interactions (7.1) and Clinical Pharmacology (12.3)].</p>\n<p>With concomitant use of moderate CYP3A inhibitors, monitor for adverse reactions and consider reducing the VERZENIO dose in 50 mg decrements as demonstrated in Table 1, if necessary.</p>\n<p>Dose Modification for Patients with Severe Hepatic Impairment</p>\n<p>For patients with severe hepatic impairment (Child Pugh-C), reduce the VERZENIO dosing frequency to once daily [see Use in Specific Populations (8.7) and Clinical Pharmacology (12.3)].</p>\n<p>Refer to the Full Prescribing Information for the coadministered fulvestrant, tamoxifen, or aromatase inhibitor for dose modification requirements for severe hepatic impairment.</p>",
      "dosageFormsAndStrengths": "\n<p>50mg tablets: oval beige tablet with Lilly debossed on one side and 50 on the other side.</p>\n<p>100mg tablets: oval white to practically white tablet with Lilly debossed on one side and 100 on the other side.</p>\n<p>150mg tablets: oval yellow tablet with Lilly debossed on one side and 150 on the other side.</p>\n<p>200mg tablets: oval beige tablet with Lilly debossed on one side and 200 on the other side.</p>",
      "warningsAndPrecautions": "\n<h3>5.1 Diarrhea</h3>\n<p>Severe diarrhea associated with dehydration and infection occurred in patients treated with VERZENIO. Across four clinical trials in 3691 patients, diarrhea occurred in 81% to 90% of patients who received VERZENIO. Grade 3 diarrhea occurred in 8% to 20% of patients receiving VERZENIO [see Adverse Reactions (6.1)]. Most patients experienced diarrhea during the first month of VERZENIO treatment. The median time to onset of the first diarrhea event ranged from 6 to 8 days; and the median duration of Grade 2 and Grade 3 diarrhea ranged from 6 to 11 days and 5 to 8 days, respectively. Across trials, 19% to 26% of patients with diarrhea required a VERZENIO dose interruption and 13% to 23% required a dose reduction. Instruct patients to start antidiarrheal therapy such as loperamide at the first sign of loose stools, increase oral fluids, and notify their healthcare provider for further instructions and appropriate follow up [see Patient Counseling Information (17)]. For Grade 3 or 4 diarrhea, or diarrhea that requires hospitalization, discontinue VERZENIO until toxicity resolves to Grade 1, and then resume VERZENIO at the next lower dose [see Dosage and Administration (2.2)].</p>\n<h3>5.2 Neutropenia</h3>\n<p>Neutropenia, including febrile neutropenia and fatal neutropenic sepsis, occurred in patients treated with VERZENIO. Across four clinical trials in 3691 patients, neutropenia occurred in 37% to 46% of patients receiving VERZENIO. A Grade 3 decrease in neutrophil count (based on laboratory findings) occurred in 19% to 32% of patients receiving VERZENIO. Across trials, the median time to the first episode of Grade 3 neutropenia ranged from 29 days to 33 days, and the median duration of Grade 3 neutropenia ranged from 11 days to 16 days [see Adverse Reactions (6.1)]. Febrile neutropenia has been reported in less than 1% of patients exposed to VERZENIO across trials. Two deaths due to neutropenic sepsis were observed in MONARCH 2. Inform patients to promptly report any episodes of fever to their healthcare provider [see Patient Counseling Information (17)]. Monitor complete blood counts prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, or delay in starting treatment cycles is recommended for patients who develop Grade 3 or 4 neutropenia [see Dosage and Administration (2.2)].</p>\n<h3>5.3 Interstitial Lung Disease (ILD) or Pneumonitis</h3>\n<p>Severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis can occur in patients treated with VERZENIO and other CDK4/6 inhibitors. In VERZENIO-treated patients in early breast cancer (monarchE, N=2791), 3% of patients experienced ILD or pneumonitis of any grade: 0.4% were Grade 3 or 4 and there was one fatality (0.1%). In VERZENIO-treated patients in advanced or metastatic breast cancer (N=900) (MONARCH 1, MONARCH 2, MONARCH 3), 3.3% of VERZENIO-treated patients had ILD or pneumonitis of any grade: 0.6% had Grade 3 or 4, and 0.4% had fatal outcomes. Additional cases of ILD or pneumonitis have been observed in the postmarketing setting, with fatalities reported [see Adverse Reactions (6.2)]. Monitor patients for pulmonary symptoms indicative of ILD or pneumonitis. Symptoms may include hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams. Infectious, neoplastic, and other causes for such symptoms should be excluded by means of appropriate investigations. Dose interruption or dose reduction is recommended for patients who develop persistent or recurrent Grade 2 ILD or pneumonitis. Permanently discontinue VERZENIO in all patients with Grade 3 or 4 ILD or pneumonitis [see Dosage and Administration (2.2)].</p>\n<h3>5.4 Hepatotoxicity</h3>\n<p>Grade 3 ALT (2% to 6%) and AST (2% to 3%) were reported in patients receiving VERZENIO. Across three clinical trials in 3559 patients (monarchE, MONARCH 2, MONARCH 3), the median time to onset of Grade 3 ALT increases ranged from 57 to 87 days and the median time to resolution to Grade less than 3 was 13 to 14 days. The median time to onset of Grade 3 AST increases ranged from 71 to 185 days and the median time to resolution to Grade less than 3 ranged from 11 to 15 days. Monitor liver function tests (LFTs) prior to the start of VERZENIO therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, dose reduction, dose discontinuation, or delay in starting treatment cycles is recommended for patients who develop persistent or recurrent Grade 2, or any Grade 3 or Grade 4 hepatic transaminase elevation [see Dosage and Administration (2.2)].</p>\n<h3>5.5 Venous Thromboembolism</h3>\n<p>Across three clinical trials in 3559 patients (monarchE, MONARCH 2, MONARCH 3), venous thromboembolic events were reported in 2% to 5% of patients treated with VERZENIO. Venous thromboembolic events included deep vein thrombosis, pulmonary embolism, pelvic venous thrombosis, cerebral venous sinus thrombosis, subclavian and axillary vein thrombosis, and inferior vena cava thrombosis. In clinical trials, deaths due to venous thromboembolism have been reported in patients treated with VERZENIO. VERZENIO has not been studied in patients with early breast cancer who had a history of venous thromboembolism. Monitor patients for signs and symptoms of venous thrombosis and pulmonary embolism and treat as medically appropriate. Dose interruption is recommended for early breast cancer patients with any grade venous thromboembolic event and for advanced or metastatic breast cancer patients with a Grade 3 or 4 venous thromboembolic event [see Dosage and Administration (2.2)].</p>\n<h3>5.6 Embryo-Fetal Toxicity</h3>\n<p>Based on findings from animal studies and the mechanism of action, VERZENIO can cause fetal harm when administered to a pregnant woman. In animal reproduction studies, administration of abemaciclib to pregnant rats during the period of organogenesis caused teratogenicity and decreased fetal weight at maternal exposures that were similar to the human clinical exposure based on area under the curve (AUC) at the maximum recommended human dose. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with VERZENIO and for 3 weeks after the last dose [see Use in Specific Populations (8.1, 8.3) and Clinical Pharmacology (12.1)].</p>",
      "adverseReactions": "\n<p>The following adverse reactions are discussed in greater detail in other sections of the labeling:</p>\n<ul>\n<li>Diarrhea [see Warnings and Precautions (5.1)].</li>\n<li>Neutropenia [see Warnings and Precautions (5.2)].</li>\n<li>Interstitial Lung Disease (ILD) or Pneumonitis [see Warnings and Precautions (5.3)].</li>\n<li>Hepatotoxicity [see Warnings and Precautions (5.4)].</li>\n<li>Venous Thromboembolism [see Warnings and Precautions (5.5)].</li>\n</ul>\n<h3>6.1 Clinical Studies Experience</h3>\n<p>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.</p>\n<p>The safety population described in the Warnings and Precautions reflect exposure to VERZENIO in 3691 patients from four clinical trials: monarchE, MONARCH 1, MONARCH 2, and MONARCH 3. The safety population includes exposure to VERZENIO as a single agent at 200 mg twice daily in 132 patients in MONARCH 1 and to VERZENIO at 150 mg twice daily in 3559 patients administered in combination with fulvestrant, tamoxifen, or an aromatase inhibitor in monarchE, MONARCH 2, and MONARCH 3. The median duration of exposure ranged from 4.5 months in MONARCH 1 to 24 months in monarchE. The most common adverse reactions (incidence 20%) across clinical trials were: diarrhea, neutropenia, nausea, abdominal pain, infections, fatigue, anemia, leukopenia, decreased appetite, vomiting, headache, alopecia, and thrombocytopenia.</p>\n<p>Early Breast Cancer</p>\n<p>monarchE: VERZENIO in Combination with Tamoxifen or an Aromatase Inhibitor as Adjuvant Treatment</p>\n<p>Adult patients with HR-positive, HER2-negative, node-positive early breast cancer at a high risk of recurrence</p>\n<p>The safety of VERZENIO was evaluated in monarchE, a study of 5591 adult patients receiving VERZENIO plus endocrine therapy (tamoxifen or an aromatase inhibitor) or endocrine therapy (tamoxifen or an aromatase inhibitor) alone [see Clinical Studies (14.1)]. Patients were randomly assigned to receive 150mg of VERZENIO orally, twice daily, plus tamoxifen or an aromatase inhibitor, or tamoxifen or an aromatase inhibitor, for two years or until discontinuation criteria were met. The median duration of VERZENIO treatment was 24 months.</p>\n<p>The most frequently reported (5%) Grade 3 or 4 adverse reactions were neutropenia, leukopenia, diarrhea, and lymphopenia.</p>\n<p>Fatal adverse reactions occurred in 0.8% of patients who received VERZENIO plus endocrine therapy (tamoxifen or an aromatase inhibitor), including: cardiac failure (0.1%), cardiac arrest, myocardial infarction, ventricular fibrillation, cerebral hemorrhage, cerebrovascular accident, pneumonitis, hypoxia, diarrhea, and mesenteric artery thrombosis (0.03% each).</p>\n<p>Permanent VERZENIO treatment discontinuation due to an adverse reaction was reported in 19% of patients receiving VERZENIO, plus tamoxifen or an aromatase inhibitor. Of the patients receiving tamoxifen or an aromatase inhibitor, 1% permanently discontinued due to an adverse reaction. The most common adverse reactions leading to VERZENIO discontinuations were diarrhea (5%), fatigue (2%), and neutropenia (0.9%).</p>\n<p>Dose interruption of VERZENIO due to an adverse reaction occurred in 62% of patients receiving VERZENIO plus tamoxifen or aromatase inhibitors. Adverse reactions leading to VERZENIO dose interruptions in 5% of patients were diarrhea (20%), neutropenia (16%), leukopenia (7%), and fatigue (5%).</p>\n<p>Dose reductions of VERZENIO due to an adverse reaction occurred in 44% of patients receiving VERZENIO plus endocrine therapy (tamoxifen or an aromatase inhibitor). Adverse reactions leading to VERZENIO dose reductions in 5% were diarrhea (17%), neutropenia (8%), and fatigue (5%).</p>\n<p>The most common adverse reactions reported (20%) in the VERZENIO, plus tamoxifen or an aromatase inhibitor, arm and 2% higher than the tamoxifen or an aromatase inhibitor arm were: diarrhea, infections, neutropenia, fatigue, leukopenia, nausea, anemia, and headache. Adverse reactions are shown in Table 8 and laboratory abnormalities are shown in Table 9.</p>\n<table>\n<caption>Table 8: Adverse Reactions (10%) of Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of 2%] in monarchE</caption>\n<thead>\n<tr>\n<td colspan=\"3\">VERZENIO Plus Tamoxifen or an Aromatase Inhibitor N=2791</td>\n<td colspan=\"3\">Tamoxifen or an Aromatase Inhibitor N=2800</td>\n</tr>\n<tr>\n<td>All Gradesa%</td>\n<td>Grade 3%</td>\n<td>Grade 4%</td>\n<td>All Gradesb%</td>\n<td>Grade 3%</td>\n<td>Grade 4%</td>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td colspan=\"7\">Gastrointestinal Disorders</td>\n</tr>\n<tr>\n<td>Diarrhea</td>\n<td>84</td>\n<td>8</td>\n<td>0</td>\n<td>9</td>\n<td>0.2</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Nausea</td>\n<td>30</td>\n<td>0.5</td>\n<td>0</td>\n<td>9</td>\n<td>&lt;0.1</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Vomiting</td>\n<td>18</td>\n<td>0.5</td>\n<td>0</td>\n<td>4.6</td>\n<td>0.1</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Stomatitisc</td>\n<td>14</td>\n<td>0.1</td>\n<td>0</td>\n<td>5</td>\n<td>0</td>\n<td>0</td>\n</tr>\n<tr>\n<td colspan=\"7\">Infections and Infestations</td>\n</tr>\n<tr>\n<td>Infectionsd</td>\n<td>51</td>\n<td>4.9</td>\n<td>0.6</td>\n<td>39</td>\n<td>2.7</td>\n<td>0.1</td>\n</tr>\n<tr>\n<td colspan=\"7\">General Disorders and Administration Site Conditions</td>\n</tr>\n<tr>\n<td>Fatiguee</td>\n<td>41</td>\n<td>2.9</td>\n<td>0</td>\n<td>18</td>\n<td>0.1</td>\n<td>0</td>\n</tr>\n<tr>\n<td colspan=\"7\">Nervous System Disorders</td>\n</tr>\n<tr>\n<td>Headache</td>\n<td>20</td>\n<td>0.3</td>\n<td>0</td>\n<td>15</td>\n<td>0.2</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Dizziness</td>\n<td>11</td>\n<td>0.1</td>\n<td>0</td>\n<td>7</td>\n<td>&lt;0.1</td>\n<td>0</td>\n</tr>\n<tr>\n<td colspan=\"7\">Metabolism and Nutrition Disorders</td>\n</tr>\n<tr>\n<td>Decreased appetite</td>\n<td>12</td>\n<td>0.6</td>\n<td>0</td>\n<td>2.4</td>\n<td>&lt;0.1</td>\n<td>0</td>\n</tr>\n<tr>\n<td colspan=\"7\">Skin and Subcutaneous Tissue Disorders</td>\n</tr>\n<tr>\n<td>Rashf</td>\n<td>11</td>\n<td>0.4</td>\n<td>0</td>\n<td>4.5</td>\n<td>0</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Alopecia</td>\n<td>11</td>\n<td>0</td>\n<td>0</td>\n<td>2.7</td>\n<td>0</td>\n<td>0</td>\n</tr>\n</tbody>\n<tfoot>\n<tr>\n<td colspan=\"7\">a Includes the following fatal adverse reactions: diarrhea (n=1), and infections (n=4)</td>\n</tr>\n<tr>\n<td colspan=\"7\">b Includes the following fatal adverse reactions: infections (n=5)</td>\n</tr>\n<tr>\n<td colspan=\"7\">c Includes mouth ulceration, mucosal inflammation, oropharyngeal pain, stomatitis.</td>\n</tr>\n<tr>\n<td colspan=\"7\">d Includes all reported preferred terms that are part of the Infections and Infestations system organ class. Most common infections (&gt;5%) include upper respiratory tract infection, urinary tract infection, and nasopharyngitis.</td>\n</tr>\n<tr>\n<td colspan=\"7\">e Includes asthenia, fatigue.</td>\n</tr>\n<tr>\n<td colspan=\"7\">f Includes exfoliative rash, mucocutaneous rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash maculo-papular, rash maculovesicular, rash morbilliform, rash papular, rash papulosquamous, rash pruritic, rash vesicular, vulvovaginal rash.</td>\n</tr>\n</tfoot>\n</table>\n<p>Clinically relevant adverse reactions in &lt;10% of patients who received VERZENIO in combination with tamoxifen or an aromatase inhibitor in monarchE include:</p>\n<ul>\n<li>Pruritus-9%</li>\n<li>Dyspepsia-8%</li>\n<li>Nail disorder-6% (includes nail bed disorder, nail bed inflammation, nail discoloration, nail disorder, nail dystrophy, nail pigmentation, nail ridging, nail toxicity, onychalgia, onychoclasis, onycholysis, onychomadesis)</li>\n<li>Lacrimation increased-6%</li>\n<li>Dysgeusia-5%</li>\n<li>Interstitial lung disease (ILD)/pneumonitis-3% (includes pneumonitis, radiation pneumonitis, interstitial lung disease, pulmonary fibrosis, organizing pneumonia, radiation fibrosis lung, lung opacity, sarcoidosis)</li>\n<li>Venous thromboembolic events (VTEs)-3% (includes catheter site thrombosis, cerebral venous thrombosis, deep vein thrombosis, device related thrombosis, embolism, hepatic vein thrombosis, jugular vein occlusion, jugular vein thrombosis, ovarian vein thrombosis, portal vein thrombosis, pulmonary embolism, subclavian vein thrombosis, venous thrombosis limb)</li>\n</ul>\n<table>\n<caption>Table 9: Laboratory Abnormalities (10%) in Patients Receiving VERZENIO Plus Tamoxifen or an Aromatase Inhibitor [with a Difference between Arms of 2%] in monarchE</caption>\n<thead>\n<tr>\n<td colspan=\"3\">VERZENIO Plus Tamoxifen or an Aromatase Inhibitor N=2791</td>\n<td colspan=\"3\">Tamoxifen or an Aromatase Inhibitor N=2800</td>\n</tr>\n<tr>\n<td>All Grades%</td>\n<td>Grade 3%</td>\n<td>Grade 4%</td>\n<td>All Grades%</td>\n<td>Grade 3%</td>\n<td>Grade 4%</td>\n</tr>\n</thead>\n<tbody>\n<tr>\n<td>Creatinine increased</td>\n<td>99</td>\n<td>0.5</td>\n<td>0</td>\n<td>91</td>\n<td>&lt;0.1</td>\n<td>0</td>\n</tr>\n<tr>\n<td>White blood cell decreased</td>\n<td>89</td>\n<td>19</td>\n<td>&lt;0.1</td>\n<td>28</td>\n<td>1.1</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Neutrophil count decreased</td>\n<td>84</td>\n<td>18</td>\n<td>0.7</td>\n<td>23</td>\n<td>1.6</td>\n<td>0.3</td>\n</tr>\n<tr>\n<td>Anemia</td>\n<td>68</td>\n<td>1.0</td>\n<td>0</td>\n<td>17</td>\n<td>0.1</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Lymphocyte count decreased</td>\n<td>59</td>\n<td>13</td>\n<td>0.2</td>\n<td>24</td>\n<td>2.4</td>\n<td>0.1</td>\n</tr>\n<tr>\n<td>Platelet count decreased</td>\n<td>37</td>\n<td>0.7</td>\n<td>0.2</td>\n<td>10</td>\n<td>0.1</td>\n<td>0.1</td>\n</tr>\n<tr>\n<td>Alanine aminotransferase increased</td>\n<td>37</td>\n<td>2.5</td>\n<td>&lt;0.1</td>\n<td>24</td>\n<td>1.2</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Aspartate aminotransferase increased</td>\n<td>31</td>\n<td>1.5</td>\n<td>&lt;0.1</td>\n<td>18</td>\n<td>0.9</td>\n<td>0</td>\n</tr>\n<tr>\n<td>Hypokalemia</td>\n<td>11</td>\n<td>1.2</td>\n<td>0.1</td>\n<td>3.8</td>\n<td>0.1</td>\n<td>0.1</td>\n</tr>\n</tbody>\n</table>\n<p>Advanced or Metastatic Breast Cancer</p>\n<p>MONARCH 3: VERZENIO in Combination with an Aromatase Inhibitor (Anastrozole or Letrozole) as Initial Endocrine-Based Therapy</p>\n<p>Postmenopausal Women with HR-positive, HER2-negative locoregionally recurrent or metastatic breast cancer with no prior systemic therapy in this disease setting</p>\n<p>The safety of VERZENIO was evaluated in MONARCH 3, a study of 488 women receiving VERZENIO plus an aromatase inhibitor or placebo plus an aromatase inhibitor [see Clinical Studies (14.2)]. Patients were randomly assigned to receive 150mg of VERZENIO or placebo orally twice daily, plus physician's choice of anastrozole or letrozole once daily. Median duration of treatment was 15.1 months for the VERZENIO arm and 13.9 months for the placebo arm.</p>\n<p>The most frequently reported (5%) Grade 3 or 4 adverse reactions were neutropenia, diarrhea, leukopenia, increased ALT, and anemia.</p>\n<p>Deaths during treatment or during the 30-day follow up, regardless of causality, were reported in 11 cases (3%) of VERZENIO plus an aromatase inhibitor treated patients versus 3 cases (2%) of placebo plus an aromatase inhibitor treated patients. Causes of death for patients receiving VERZENIO plus an aromatase inhibitor included: 3 (0.9%) patient deaths due to underlying disease, 3 (0.9%) due to lung infection, 3 (0.9%) due to VTE, 1 (0.3%) due to pneumonitis, and 1 (0.3%) due to cerebral infarction.</p>\n<p>Permanent treatment discontinuation due to an adverse reaction was reported in 13% of patients receiving VERZENIO plus an aromatase inhibitor and in 3% of patients receiving placebo plus an aromatase inhibitor. Adverse reactions leading to permanent discontinuation for patients receiving VERZENIO plus an aromatase inhibitor were diarrhea (2%), ALT increased (2%), infection (1%), venous thromboembolic events (VTE) (1%), neutropenia (0.9%), renal impairment (0.9%), AST increased (0.6%), dyspnea (0.6%), pulmonary fibrosis (0.6%) and anemia, rash, weight decreased and thrombocytopenia (each 0.3%).</p>\n<p>Dose interruption of VERZENIO due to an adverse reaction occurred in 56% of patients receiving VERZENIO plus anastrozole or letrozole. Adverse reactions leading to VERZENIO dose interruptions in 5% of patients were neutropenia (16%) and diarrhea (15%).</p>\n<p>Dose reductions due to an adverse reaction occurred in 43% of patients receiving VERZENIO plus anastrozole or letrozole. Adverse reactions leading to dose reductions in 5% of patients were diarrhea and neutropenia. VERZENIO dose reductions due to diarrhea of any grade occurred in 13% of patients receiving VERZENIO plus an aromatase inhibitor compared to 2% of patients receiving placebo plus an aromatase inhibitor. VERZENIO dose reductions due to neutropenia of any grade occurred in 11% of patients receiving VERZENIO plus an aromatase inhibitor compared to 0.6% of patients receiving placebo plus an aromatase inhibitor.</p>\n<p>The most common adverse reactions reported (20%) in the VERZENIO arm and 2% than the placebo arm were: diarrhea, neutropenia, fatigue, infections, nausea, abdominal pain, anemia, vomiting, alopecia, decreased appetite, and leukopenia. Adverse reactions are shown in Table 10 and laboratory abnormalities in Table 11. Diarrhea incidence was greatest during the first month of VERZENIO dosing. The median time to onset of the first diarrhea event was</p>",
      "drugInteractions": "<h1>7 DRUG INTERACTIONS</h1><h2>7.1 Effect of Other Drugs on VERZENIO</h2><p>CYP3A Inhibitors</p><p>Strong and moderate CYP3A4 inhibitors increased the exposure of abemaciclib plus its active metabolites to a clinically meaningful extent and may lead to increased toxicity.</p><p>Ketoconazole</p><p>Avoid concomitant use of ketoconazole. Ketoconazole is predicted to increase the AUC of abemaciclib by up to 16-fold [see Clinical Pharmacology (12.3)].</p><p>Other Strong CYP3A Inhibitors</p><p>In patients with recommended starting doses of 200mg twice daily or 150mg twice daily, reduce the VERZENIO dose to 100mg twice daily with concomitant use of strong CYP3A inhibitors other than ketoconazole. In patients who have had a dose reduction to 100mg twice daily due to adverse reactions, further reduce the VERZENIO dose to 50mg twice daily with concomitant use of strong CYP3A inhibitors. If a patient taking VERZENIO discontinues a strong CYP3A inhibitor, increase the VERZENIO dose (after 3-5 half-lives of the inhibitor) to the dose that was used before starting the inhibitor. Patients should avoid grapefruit products [seeDosage and Administration (2.2) and Clinical Pharmacology (12.3)].</p><p>Moderate CYP3A Inhibitors</p><p>With concomitant use of moderate CYP3A inhibitors, monitor for adverse reactions and consider reducing the VERZENIO dose in 50mg decrements as demonstrated in Table 1, if necessary.</p><p>Strong and Moderate CYP3A Inducers</p><p>Coadministration of strong or moderate CYP3A inducers decreased the plasma concentrations of abemaciclib plus its active metabolites and may lead to reduced activity. Avoid concomitant use of strong or moderate CYP3A inducers and consider alternative agents [see Clinical Pharmacology (12.3)].</p>",
      "clinicalPharmacology": "<h1>12 CLINICAL PHARMACOLOGY</h1><h2>12.1 Mechanism of Action</h2><p>Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are activated upon binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single agent or in combination with antiestrogens resulted in reduction of tumor size.</p><h2>12.2 Pharmacodynamics</h2><p>Cardiac Electrophysiology</p><p>Based on evaluation of the QTc interval in patients and in a healthy volunteer study, abemaciclib did not cause large mean increases (i.e., 20ms) in the QTc interval.</p><h2>12.3 Pharmacokinetics</h2><p>The pharmacokinetics of abemaciclib were characterized in patients with solid tumors, including breast cancer, and in healthy subjects.</p><p>Following single and repeated twice daily dosing of 50mg (0.3 times the approved recommended 150mg dosage) to 200mg of abemaciclib, the increase in plasma exposure (AUC) and Cmax was approximately dose proportional. Steady state was achieved within 5days following repeated twice daily dosing, and the estimated geometric mean accumulation ratio was 2.3 (50% CV) and 3.2 (59% CV) based on Cmax and AUC, respectively.</p><p>Absorption</p><p>The absolute bioavailability of abemaciclib after a single oral dose of 200mg is 45% (19% CV). The median Tmax of abemaciclib is 8.0hours (range: 4.1-24.0 hours).</p><p>Effect of Food</p><p>A high-fat, high-calorie meal (approximately 800 to 1000 calories with 150 calories from protein, 250 calories from carbohydrate, and 500 to 600 calories from fat) administered to healthy subjects increased the AUC of abemaciclib plus its active metabolites by 9% and increased Cmax by 26%.</p><p>Distribution</p><p>In vitro, abemaciclib was bound to human plasma proteins, serum albumin, and alpha-1-acid glycoprotein in a concentration independent manner from 152ng/mL to 5066ng/mL. In a clinical study, the mean (standard deviation, SD) bound fraction was 96.3% (1.1) for abemaciclib, 93.4% (1.3) for M2, 96.8% (0.8) for M18, and 97.8% (0.6) for M20. The geometric mean systemic volume of distribution is approximately 690.3L (49% CV).</p><p>In patients with advanced cancer, including breast cancer, concentrations of abemaciclib and its active metabolites M2 and M20 in cerebrospinal fluid are comparable to unbound plasma concentrations.</p><p>Elimination</p><p>The geometric mean hepatic clearance (CL) of abemaciclib in patients was 26.0L/h (51% CV), and the mean plasma elimination half-life for abemaciclib in patients was 18.3 hours (72% CV).</p><p>Metabolism</p><p>Hepatic metabolism is the main route of clearance for abemaciclib. Abemaciclib is metabolized to several metabolites primarily by cytochrome P450 (CYP) 3A4, with formation of N-desethylabemaciclib (M2) representing the major metabolism pathway. Additional metabolites include hydroxyabemaciclib (M20), hydroxy-N-desethylabemaciclib (M18), and an oxidative metabolite (M1). M2, M18, and M20 are equipotent to abemaciclib and their AUCs accounted for 25%, 13%, and 26% of the total circulating analytes in plasma, respectively.</p><p>Excretion</p><p>After a single 150mg oral dose of radiolabeled abemaciclib, approximately 81% of the dose was recovered in feces and approximately 3% recovered in urine. The majority of the dose eliminated in feces was metabolites.</p><p>Specific Populations</p><p>Age, Gender, and Body Weight</p><p>Based on a population pharmacokinetic analysis in patients with cancer, age (range 24-91 years), gender (134 males and 856 females), and body weight (range 36-175kg) had no effect on the exposure of abemaciclib.</p><p>Patients with Renal Impairment</p><p>In a population pharmacokinetic analysis of 990 individuals, in which 381 individuals had mild renal impairment (60mL/min CLcr &lt;90mL/min) and 126 individuals had moderate renal impairment (30mL/min CLcr &lt;60mL/min), mild and moderate renal impairment had no effect on the exposure of abemaciclib [see Use in Specific Populations (8.6)]. The effect of severe renal impairment (CLcr &lt;30mL/min) on pharmacokinetics of abemaciclib is unknown.</p><p>Patients with Hepatic Impairment</p><p>Following a single 200mg oral dose of abemaciclib, the relative potency adjusted unbound AUC0-INF of abemaciclib plus its active metabolites (M2, M18, M20) in plasma increased 1.2-fold in subjects with mild hepatic impairment (Child-Pugh A, n=9), 1.1-fold in subjects with moderate hepatic impairment (Child-Pugh B, n=10), and 2.4-fold in subjects with severe hepatic impairment (Child-Pugh C, n=6) relative to subjects with normal hepatic function (n=10) [see Use in Specific Populations (8.7)]. In subjects with severe hepatic impairment, the mean plasma elimination half-life of abemaciclib increased to 55 hours compared to 24 hours in subjects with normal hepatic function.</p><p>Drug Interaction Studies</p><p>Effects of Other Drugs on Abemaciclib</p><p>Strong CYP3A Inhibitors: Ketoconazole (a strong CYP3A inhibitor) is predicted to increase the AUC of abemaciclib by up to 16-fold.</p><p>Coadministration of 500mg twice daily doses of clarithromycin (a strong CYP3A inhibitor) with a single 50mg dose of VERZENIO (0.3 times the approved recommended 150mg dosage) increased the relative potency adjusted unbound AUC0-INF of abemaciclib plus its active metabolites (M2, M18, and M20) by 2.5-fold relative to abemaciclib alone in cancer patients.</p><p>Moderate CYP3A Inhibitors: Verapamil and diltiazem (moderate CYP3A inhibitors) are predicted to increase the relative potency adjusted unbound AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by approximately 1.6-fold and 2.4-fold, respectively.</p><p>Strong CYP3A Inducers: Coadministration of 600mg daily doses of rifampin (a strong CYP3A inducer) with a single 200mg dose of VERZENIO decreased the relative potency adjusted unbound AUC0-INF of abemaciclib plus its active metabolites (M2, M18, and M20) by approximately 70% in healthy subjects.</p><p>Moderate CYP3A Inducers: Efavirenz, bosentan, and modafinil (moderate CYP3A inducers) are predicted to decrease the relative potency adjusted unbound AUC of abemaciclib plus its active metabolites (M2, M18, and M20) by 53%, 41%, and 29%, respectively.</p><p>Loperamide: Co-administration of a single 8mg dose of loperamide with a single 400mg dose of abemaciclib in healthy subjects increased the relative potency adjusted unbound AUC0-INF of abemaciclib plus its active metabolites (M2 and M20) by 12%, which is not considered clinically relevant.</p><p>Endocrine Therapies: In clinical studies in patients with breast cancer, there was no clinically relevant effect of fulvestrant, anastrozole, letrozole, exemestane, or tamoxifen on abemaciclib pharmacokinetics.</p><p>Effects of Abemaciclib on Other Drugs</p><p>Loperamide: In a clinical drug interaction study in healthy subjects, coadministration of a single 8mg dose of loperamide with a single 400mg abemaciclib (2.7 times the approved recommended 150mg dosage) increased loperamide AUC0-INF by 9% and Cmax by 35% relative to loperamide alone. These increases in loperamide exposure are not considered clinically relevant.</p><p>Metformin: In a clinical drug interaction study in healthy subjects, coadministration of a single 1000mg dose of metformin, a clinically relevant substrate of renal OCT2, MATE1, and MATE2-K transporters, with a single 400mg dose of abemaciclib (2.7 times the approved recommended 150mg dosage) increased metformin AUC0-INF by 37% and Cmax by 22% relative to metformin alone. Abemaciclib reduced the renal clearance and renal secretion of metformin by 45% and 62%, respectively, relative to metformin alone, without any effect on glomerular filtration rate (GFR) as measured by iohexol clearance and serum cystatin C.</p><p>Endocrine Therapies: In clinical studies in patients with breast cancer, there was no clinically relevant effect of abemaciclib on the pharmacokinetics of fulvestrant, anastrozole, letrozole, exemestane, or tamoxifen.</p><p>CYP Metabolic Pathways: In a clinical drug interaction study in patients with cancer, multiple doses of abemaciclib (200mg twice daily for 7 days) did not result in clinically meaningful changes in the pharmacokinetics of CYP1A2, CYP2C9, CYP2D6 and CYP3A4 substrates. Abemaciclib is a substrate of CYP3A4, and time-dependent changes in pharmacokinetics of abemaciclib as a result of autoinhibition of its metabolism were not observed.</p><p>In Vitro Studies</p><p>Transporter Systems: Abemaciclib and its major active metabolites inhibit the renal transporters OCT2, MATE1, and MATE2-K at concentrations achievable at the approved recommended dosage. The observed serum creatinine increase in clinical studies with abemaciclib is likely due to inhibition of tubular secretion of creatinine via OCT2, MATE1, and MATE2-K [see Adverse Effects (6.1)]. Abemaciclib and its major metabolites at clinically relevant concentrations do not inhibit the hepatic uptake transporters OCT1, OATP1B1, and OATP1B3 or the renal uptake transporters OAT1 and OAT3.</p><p>Abemaciclib is a substrate of P-gp and BCRP. Abemaciclib and its major active metabolites, M2 and M20, are not substrates of hepatic uptake transporters OCT1, organic anion transporting polypeptide 1B1 (OATP1B1), or OATP1B3.</p><p>Abemaciclib inhibits P-gp and BCRP. The clinical consequences of this finding on sensitive P-gp and BCRP substrates are unknown.</p><p>P-gp and BCRP Inhibitors: In vitro, abemaciclib is a substrate of P-gp and BCRP. The effect of P-gp or BCRP inhibitors on the pharmacokinetics of abemaciclib has not been studied.</p>",
      "clinicalStudies": "<h1>14 CLINICAL STUDIES</h1><h2>14.1 Early Breast Cancer</h2><p>VERZENIO in Combination with Standard Endocrine Therapy (monarchE)</p><p>Patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence</p><p>monarchE (NCT03155997) was a randomized (1:1), open-label, two cohort, multicenter study in adult women and men with HR-positive, HER2-negative, node-positive, resected, early breast cancer with clinical and pathological features consistent with a high risk of disease recurrence. To be enrolled, patients had to have HR-positive HER2-negative early breast cancer with tumor involvement in at least 1 axillary lymph node (pALN) and to be enrolled in cohort 1 had to have either:</p><ul><li>4 pALN or</li><li>1-3 pALN and at least one of:<dl><dd>tumor grade 3 or</dd><dd>tumor size 50mm</dd></dl></li></ul><p>Patients enrolled in cohort 2 could not have met the eligibility criteria for cohort 1. To be enrolled in cohort 2, patients had to have 1-3 pALN and Ki-67 score 20%. Breast tumor samples were tested at central sites using the Ki-67 IHC MIB-1 pharmDx (Dako Omnis) assay to establish if the Ki-67 score was 20%.</p><p>Patients were randomized to receive 2 years of VERZENIO plus physician's choice of standard endocrine therapy or standard endocrine therapy alone. Randomization to treatment was stratified by prior treatment (neoadjuvant chemotherapy versus adjuvant chemotherapy versus no chemotherapy); menopausal status (premenopausal versus postmenopausal); and region (North America/Europe versus Asia versus other). Men were stratified as postmenopausal. After the end of the study treatment period, standard adjuvant endocrine therapy was continued for a duration of at least 5years if deemed medically appropriate.</p><p>The major efficacy outcome measure was invasive diseasefree survival (IDFS). IDFS was defined as the time from randomization to the first occurrence of: ipsilateral invasive breast tumor recurrence, regional invasive breast cancer recurrence, distant recurrence, contralateral invasive breast cancer, second primary non-breast invasive cancer, or death attributable to any cause. Overall survival (OS) was an additional outcome measure.</p><p>A statistically significant difference in IDFS was observed in the intent-to-treat (ITT) population which was primarily attributed to the patients treated in cohort 1. While the OS data in cohort 2 remains immature, more deaths were observed among those receiving VERZENIO plus standard endocrine therapy compared to those receiving standard endocrine therapy alone (10/253 vs. 5/264).</p><p>Of 5637 patients randomized, 5120 (91%) were randomized in cohort 1. Patient median age was 51 years (range, 22-89 years), 99% were women, 70% were White, 24% were Asian, 1.7% were Black or African American, 2.1% were American Indian or Alaska Native, and 0.1% were Native Hawaiian or Other Pacific Islander. Forty-three percent of patients were premenopausal. Most patients received prior chemotherapy (37% neoadjuvant, 59% adjuvant) and prior radiotherapy (96%). Sixty-five percent of the patients had 4 or more positive lymph nodes with 22% having 10 positive lymph nodes, 41% had Grade 3 tumor, and 24% had pathological tumor size 50mm. The majority of patients (99%) had estrogen receptor positive disease and 87% had progesterone receptor positive disease. Initial endocrine therapy received by patients included letrozole (39%), tamoxifen (31%), anastrozole (22%), or exemestane (8%).</p><p>Efficacy results for cohort 1 are summarized in Table 16 and Figure 1. At the time of OS interim analysis 2, OS was immature and a total of 315 (6%) of patients had died in cohort 1.</p><table><caption>Table 16: Efficacy Results in monarchE in Cohort 1</caption><tfoot><tr><td colspan=\"3\"><p>Abbreviation: CI = confidence interval.</p></td></tr></tfoot><tbody><tr><td>VERZENIO PlusTamoxifen or an Aromatase InhibitorN=2555</td><td>Tamoxifen or an Aromatase InhibitorN=2565</td></tr><tr><td colspan=\"3\">Invasive DiseaseFree Survival (IDFS)</td></tr><tr><td> Number of patients with an event, n (%)</td><td>317 (12)</td><td>474 (18)</td></tr><tr><td> Hazard ratio (95% CI)</td><td colspan=\"2\"> 0.65 (0.57, 0.75)</td></tr><tr><td>IDFS at 48 months, % (95% CI)</td><td>85.5 (83.8, 87.0)</td><td>78.6 (76.7, 80.4)</td></tr></tbody></table><p>Figure 1: Kaplan-Meier Curves of Invasive DiseaseFree Survival VERZENIO plus Tamoxifen or an Aromatase Inhibitor versus Tamoxifen or an Aromatase Inhibitor in Cohort 1 (monarchE)</p><h2>14.2 Advanced or Metastatic Breast Cancer</h2><p>VERZENIO in Combination with an Aromatase Inhibitor (Anastrozole or Letrozole) (MONARCH 3)</p><p>Postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer with no prior systemic therapy in this disease setting</p><p>MONARCH 3 (NCT02246621) was a randomized (2:1), double-blinded, placebo-controlled, multicenter study in postmenopausal women with HR-positive, HER2-negative advanced or metastatic breast cancer in combination with a nonsteroidal aromatase inhibitor as initial endocrine-based therapy, including patients not previously treated with systemic therapy for breast cancer.</p><p>Randomization was stratified by disease site (visceral, bone only, or other) and by prior (neo)adjuvant endocrine therapy (aromatase inhibitor versus other versus no prior endocrine therapy). A total of 493 patients were randomized to receive 150mg VERZENIO or placebo orally twice daily, plus physician's choice of letrozole (80% of patients) or anastrozole (20% of patients). Patient median age was 63 years (range, 32-88 years) and the majority were White (58%) or Asian (30%). A total of 51% had received prior systemic therapy and 39% of patients had received chemotherapy, 53% had visceral disease, and 22% had bone-only disease.</p><p>Efficacy results are summarized in Table 17 and Figure 2. PFS was evaluated according to RECIST version 1.1 and PFS assessment based on a blinded independent radiologic review was consistent with the investigator assessment. Consistent PFS results were observed across patient stratification subgroups of disease site and prior (neo)adjuvant endocrine therapy. </p><table><caption>Table 17: Efficacy Results in MONARCH 3 (Investigator Assessment, Intent-to-Treat Population)</caption><tfoot><tr><td colspan=\"3\"><p>Abbreviations: CI = confidence interval; OS = overall survival; NR = not reached; NS = not statistically significant.</p></td></tr><tr><td colspan=\"3\"><p>a Complete response + partial response.</p></td></tr><tr><td colspan=\"3\"><p>b Based upon confirmed responses.</p></td></tr></tfoot><tbody><tr><td>VERZENIO plusAnastrozole or Letrozole</td><td>Placebo plusAnastrozole or Letrozole</td></tr><tr><td>Progression-Free Survival</td><td>N=328</td><td>N=165</td></tr><tr><td> Number of patients with an event, n (%)</td><td>138 (42)</td><td>108 (65)</td></tr><tr><td> Median in months (95% CI)</td><td>28.2 (23.5, NR)</td><td>14.8 (11.2, 19.2)</td></tr><tr><td> Hazard ratio (95% CI)</td><td colspan=\"2\">0.54 (0.42, 0.70)</td></tr><tr><td> p-value</td><td colspan=\"2\">&lt;0.0001</td></tr><tr><td>Overall Survival</td><td>N=328</td><td>N=165</td></tr><tr><td> Number of patients with an event, n (%)</td><td>198 (60)</td><td>116 (70)</td></tr><tr><td> Median in months (95% CI)</td><td>66.8 (59.2, 74.8)</td><td>53.7 (44.7, 59.3)</td></tr><tr><td> Hazard ratio (95% CI)</td><td colspan=\"2\">0.80 (0.64, 1.02)</td></tr><tr><td> p-value</td><td colspan=\"2\"> NS</td></tr><tr><td>Objective Response for Patients with Measurable Diseasea</td><td>N=267</td><td>N=132</td></tr><tr><td> Objective response rate n (%)a,b</td><td>148 (55)</td><td>53 (40)</td></tr><tr><td> 95% CI</td><td>49, 61</td><td>32, 49</td></tr></tbody></table><p>Figure 2: Kaplan-Meier Curves of Progression-Free Survival: VERZENIO plus Anastrozole or Letrozole versus Placebo plus Anastrozole or Letrozole in Intent-to-Treat Population (MONARCH 3)</p><p>VERZENIO in Combination with Fulvestrant (MONARCH 2)</p><p>Patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression on or after prior adjuvant or metastatic endocrine therapy</p><p>MONARCH 2 (NCT02107703) was a randomized, placebo-controlled, multicenter study in women with HR-positive, HER2-negative metastatic breast cancer in combination with fulvestrant in patients with disease progression following endocrine therapy who had not received chemotherapy in the metastatic setting. Randomization was stratified by disease site (visceral, bone only, or other) and by sensitivity to prior endocrine therapy (primary or secondary resistance). Primary endocrine therapy resistance was defined as relapse while on the first 2 years of adjuvant endocrine therapy or progressive disease within the first 6 months of first line endocrine therapy for metastatic breast cancer. A total of 669 patients were randomized to receive VERZENIO or placebo orally twice daily plus intramuscular injection of 500mg fulvestrant on days 1 and 15 of cycle 1 and then on day 1 of cycle 2 and beyond (28-day cycles). Pre/perimenopausal women were enrolled in the study and received the gonadotropin-releasing hormone agonist goserelin for at least 4weeks prior to and for the duration of MONARCH 2. Patients remained on continuous treatment until development of progressive disease or unmanageable toxicity.</p><p>Patient median age was 60years (range, 32-91 years), and 37% of patients were older than 65. The majority were White (56%), and 99% of patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. Twenty percent (20%) of patients had de novo metastatic disease, 27% had bone-only disease, and 56% had visceral disease. Twenty-five percent (25%) of patients had primary endocrine therapy resistance. Seventeen percent (17%) of patients were pre- or perimenopausal.</p><p>The efficacy results from the MONARCH 2 study are summarized in Table 18, Figure 3, and Figure 4. PFS assessment based on a blinded independent radiologic review was consistent with the investigator assessment. Consistent results were observed across patient stratification subgroups of disease site and endocrine therapy resistance for PFS and OS.</p><table><caption>Table 18: Efficacy Results in MONARCH 2 (Intent-to-Treat Population)</caption><tfoot><tr><td colspan=\"3\"><p>Abbreviation: CI = confidence interval, OS = overall survival.</p></td></tr><tr><td colspan=\"3\"><p>a Stratified by disease site (visceral metastases vs. bone-only metastases vs. other) and endocrine therapy resistance (primary resistance vs. secondary resistance)</p></td></tr><tr><td colspan=\"3\"><p>b Data from a pre-specified interim analysis (77% of the number of events needed for the planned final analysis) with the p-value compared with the allocated alpha of 0.021.</p></td></tr><tr><td colspan=\"3\"><p>c Complete response + partial response.</p></td></tr></tfoot><tbody><tr><td>VERZENIO plus Fulvestrant</td><td>Placebo plus Fulvestrant</td></tr><tr><td>Progression-Free Survival(Investigator Assessment)</td><td>N=446</td><td>N=223</td></tr><tr><td> Number of patients with an event n (%)</td><td>222 (50)</td><td>157 (70)</td></tr><tr><td> Median in months (95% CI)</td><td>16.4 (14.4, 19.3)</td><td>9.3 (7.4, 12.7)</td></tr><tr><td> Hazard ratio (95% CI)a</td><td colspan=\"2\">0.55 (0.45, 0.68)</td></tr><tr><td> p-valuea</td><td colspan=\"2\">p&lt;.0001</td></tr><tr><td colspan=\"3\">Overall Survivalb</td></tr><tr><td> Number of deaths n (%)</td><td>211 (47)</td><td>127 (57)</td></tr><tr><td> Median OS in months (95% CI)</td><td>46.7 (39.2, 52.2)</td><td>37.3 (34.4, 43.2)</td></tr><tr><td> Hazard ratio (95% CI)a</td><td colspan=\"2\">0.76 (0.61, 0.95)</td></tr><tr><td> p-valuea</td><td colspan=\"2\">p=.0137</td></tr><tr><td>Objective Response for Patients with Measurable Disease</td><td>N=318</td><td>N=164</td></tr><tr><td> Objective response rate n (%)c</td><td>153 (48)</td><td>35 (21)</td></tr><tr><td> 95% CI</td><td>43, 54</td><td>15, 28</td></tr></tbody></table><p>Figure 3: Kaplan-Meier Curves of Progression-Free Survival: VERZENIO plus Fulvestrant versus Placebo plus Fulvestrant (MONARCH 2)</p><p>Figure 4: Kaplan-Meier Curves of Overall Survival: VERZENIO plus Fulvestrant versus Placebo plus Fulvestrant (MONARCH 2)</p><p>VERZENIO Administered as a Monotherapy in Metastatic Breast Cancer (MONARCH 1)</p><p>Patients with HR-positive, HER2-negative breast cancer who received prior endocrine therapy and 1-2 chemotherapy regimens in the metastatic setting</p><p>MONARCH 1 (NCT02102490) was a single-arm, open-label, multicenter study in women with measurable HR-positive, HER2-negative metastatic breast cancer whose disease progressed during or after endocrine therapy, had received a taxane in any setting, and who received 1 or 2 prior chemotherapy regimens in the metastatic setting. A total of 132patients received 200mg VERZENIO orally twice daily on a continuous schedule until development of progressive disease or unmanageable toxicity.</p><p>Patient median age was 58years (range, 36-89years), and the majority of patients were White (85%). Patients had an Eastern Cooperative Oncology Group performance status of 0 (55% of patients) or 1 (45%). The median duration of metastatic disease was 27.6 months. Ninety percent (90%) of patients had visceral metastases, and 51% of patients had 3 or more sites of metastatic disease. Fifty-one percent (51%) of patients had had one line of chemotherapy in the metastatic setting. Sixty-nine percent (69%) of patients had received a taxane-based regimen in the metastatic setting and 55% had received capecitabine in the metastatic setting. Table 19 provides the efficacy results from MONARCH 1.</p><table><caption>Table 19: Efficacy Results in MONARCH 1 (Intent-to-Treat Population)</caption><tfoot><tr><td colspan=\"3\"><p>Abbreviations: CI = confidence interval, NR = not reached.</p></td></tr><tr><td colspan=\"3\"><p>a All responses were partial responses.</p></td></tr><tr><td colspan=\"3\"><p>b Based upon confirmed responses.</p></td></tr></tfoot><tbody><tr><td colspan=\"2\">VERZENIO 200mgN=132</td></tr><tr><td>Investigator Assessed</td><td>Independent Review</td></tr><tr><td>Objective Response Ratea,b, n (%)</td><td>26 (20)</td><td>23 (17)</td></tr><tr><td>95% CI</td><td>13, 28</td><td>11, 25</td></tr><tr><td>Median Duration of Response in months</td><td>8.6</td><td>7.2</td></tr><tr><td>95% CI </td><td>5.8, 10.2</td><td>5.6, NR</td></tr></tbody></table>",
      "howSupplied": "<p>How Supplied</p><p>VERZENIO 50mg tablets are oval beige tablet with Lilly debossed on one side and 50 on the other side.</p><p>VERZENIO 100mg tablet are oval white to practically white tablet with Lilly debossed on one side and 100 on the other side.</p><p>VERZENIO 150mg tablets are oval yellow tablet with Lilly debossed on one side and 150 on the other side.</p><p>VERZENIO 200mg tablets are oval beige tablet with Lilly debossed on one side and 200 on the other side.</p><p>VERZENIO tablets are supplied in 7-day dose pack configurations as follows:</p><table><tbody><tr><td><ul><li>200mg dose pack (14 tablets) each blister pack contains 14 tablets (200mg per tablet) (200mg twice daily)</li></ul></td></tr><tr><td>NDC 0002-6216-54</td></tr><tr><td><ul><li>150mg dose pack (14 tablets) each blister pack contains 14 tablets (150mg per tablet) (150mg twice daily)</li></ul></td></tr><tr><td>NDC 0002-5337-54</td></tr><tr><td><ul><li>100mg dose pack (14 tablets) each blister pack contains 14 tablets (100mg per tablet) (100mg twice daily)</li></ul></td></tr><tr><td>NDC 0002-4815-54</td></tr><tr><td><ul><li>50mg dose pack (14 tablets) each blister pack contains 14 tablets (50mg per tablet) (50mg twice daily)</li></ul></td></tr><tr><td>NDC 0002-4483-54</td></tr></tbody></table>",
      "useInSpecificPopulations": "<h1>8 USE IN SPECIFIC POPULATIONS</h1><h2>8.1 Pregnancy</h2><p>Risk Summary</p><p>Based on findings in animals and its mechanism of action, VERZENIO can cause fetal harm when administered to a pregnant woman [see Clinical Pharmacology (12.1)]. There are no available human data informing the drug-associated risk. Advise pregnant women of the potential risk to a fetus. In animal reproduction studies, administration of abemaciclib during organogenesis was teratogenic and caused decreased fetal weight at maternal exposures that were similar to human clinical exposure based on AUC at the maximum recommended human dose (see Data). Advise pregnant women of the potential risk to a fetus.</p><p>The background risk of major birth defects and miscarriage for the indicated population is unknown. However, the background risk in the U.S. general population of major birth defects is 2 to 4% and of miscarriage is 15 to 20% of clinically recognized pregnancies.</p><p>Data</p><p>Animal Data</p><p>In an embryo-fetal development study, pregnant rats received oral doses of abemaciclib up to 15mg/kg/day during the period of organogenesis. Doses 4mg/kg/day caused decreased fetal body weights and increased incidence of cardiovascular and skeletal malformations and variations. These findings included absent innominate artery and aortic arch, malpositioned subclavian artery, unossified sternebra, bipartite ossification of thoracic centrum, and rudimentary or nodulated ribs. At 4mg/kg/day in rats, the maternal systemic exposures were approximately equal to the human exposure (AUC) at the recommended dose.</p><h2>8.2 Lactation</h2><p>Risk Summary</p><p>There are no data on the presence of abemaciclib in human milk, or its effects on the breastfed child or on milk production. Because of the potential for serious adverse reactions in breastfed infants from VERZENIO, advise lactating women not to breastfeed during VERZENIO treatment and for 3weeks after the last dose.</p><h2>8.3 Females and Males of Reproductive Potential</h2><p>Based on animal studies, VERZENIO can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].</p><p>Pregnancy Testing</p><p>Verify pregnancy status in females of reproductive potential prior to initiating treatment with VERZENIO.</p><p>Contraception</p><p>Females</p><p>Advise females of reproductive potential to use effective contraception during VERZENIO treatment and for 3weeks after the last dose.</p><p>Infertility</p><p>Males</p><p>Based on findings in animals, VERZENIO may impair fertility in males of reproductive potential [see Nonclinical Toxicology (13.1)].</p><h2>8.4 Pediatric Use</h2><p>The safety and effectiveness of VERZENIO have not been established in pediatric patients.</p><h2>8.5 Geriatric Use</h2><p>Of the 2791 VERZENIO-treated patients in monarchE, 15% were 65 years of age or older and 2.7% were 75 years of age or older.</p><p>Of the 900 patients who received VERZENIO in MONARCH 1, MONARCH 2, and MONARCH 3, 38% were 65 years of age or older and 10% were 75 years of age or older. The most common adverse reactions (5%) Grade 3 or 4 in patients 65 years of age across MONARCH 1, 2, and 3 were: neutropenia, diarrhea, fatigue, nausea, dehydration, leukopenia, anemia, infections, and ALT increased.</p><p>No overall differences in safety or effectiveness of VERZENIO were observed between these patients and younger patients.</p><h2>8.6 Renal Impairment</h2><p>No dosage adjustment is required for patients with mild or moderate renal impairment (CLcr 30-89mL/min, estimated by Cockcroft-Gault [C-G]). The pharmacokinetics of abemaciclib in patients with severe renal impairment (CLcr &lt;30mL/min, C-G), end stage renal disease, or in patients on dialysis is unknown [see Clinical Pharmacology (12.3)].</p><h2>8.7 Hepatic Impairment</h2><p>No dosage adjustments are necessary in patients with mild or moderate hepatic impairment (Child-Pugh A or B).</p><p>Reduce the dosing frequency when administering VERZENIO to patients with severe hepatic impairment (Child-Pugh C) [see Dosage and Administration (2.2) and Clinical Pharmacology (12.3)].</p>",
      "description": "<p>Abemaciclib is a kinase inhibitor for oral administration, appearing as a white to yellow powder with the empirical formula C27H32F2N8 and a molecular weight of 506.59. Its chemical name is 2-Pyrimidinamine, N-[5-[(4-ethyl-1-piperazinyl)methyl]-2-pyridinyl]-5-fluoro-4-[4-fluoro-2-methyl-1-(1-methylethyl)-1H-benzimidazol-6-yl]-. VERZENIO (abemaciclib) tablets are immediate-release oval tablets in white, beige, or yellow. Inactive ingredients include microcrystalline cellulose 102, microcrystalline cellulose 101, lactose monohydrate, croscarmellose sodium, sodium stearyl fumarate, and silicon dioxide. Color mixture ingredients are polyvinyl alcohol, titanium dioxide, polyethylene glycol, talc, iron oxide yellow, and iron oxide red.</p>",
      "nonclinicalToxicology": "<h1>13 NONCLINICAL TOXICOLOGY</h1><h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2><p>Abemaciclib was assessed for carcinogenicity in a 2-year rat study. Abemaciclib was not carcinogenic in male and female rats at oral doses up to 3 mg/kg/day (approximately 1 time the exposure at the maximum recommended human dose based on AUC).</p><p>Abemaciclib and its active human metabolites M2 and M20 were not mutagenic in a bacterial reverse mutation (Ames) assay or clastogenic in an in vitro chromosomal aberration assay in Chinese hamster ovary cells or human peripheral blood lymphocytes. Abemaciclib, M2, and M20 were not clastogenic in an in vivo rat bone marrow micronucleus assay.</p><p>Abemaciclib may impair fertility in males of reproductive potential. In repeat-dose toxicity studies up to 3-months duration, abemaciclib-related findings in the testis, epididymis, prostate, and seminal vesicle at doses 10mg/kg/day in rats and 0.3mg/kg/day in dogs included decreased organ weights, intratubular cellular debris, hypospermia, tubular dilatation, atrophy, and degeneration/necrosis. These doses in rats and dogs resulted in approximately 2 and 0.02 times, respectively, the exposure (AUC) in humans at the maximum recommended human dose. In a rat male fertility study, abemaciclib had no effects on mating and fertility at oral doses up to 10 mg/kg/day (approximately 2 times the exposure at the maximum recommended human dose based on AUC).</p><p>In a rat female fertility and early embryonic development study, abemaciclib did not affect mating and fertility at doses up to 20 mg/kg/day (approximately 3 times the exposure at the maximum recommended human dose based on AUC).</p><h2>13.2 Animal Toxicology and/or Pharmacology</h2><p>In repeat-dose toxicity studies up to 6-months duration, oral administration of abemaciclib resulted in retinal atrophy of the eyes in mice at a dose of 150 mg/kg/day (approximately 10 times the exposure at the maximum recommended human dose based on AUC) and in rats at a dose of 30 mg/kg/day (approximately 5 times the exposure at the maximum recommended human dose based on AUC). In a 2-year rat carcinogenicity study, oral administration of abemaciclib resulted in retinal atrophy in the eyes at doses 0.3 mg/kg/day (approximately 0.05 times the exposure at the maximum recommended human dose based on AUC).</p>",
      "mechanismOfAction": "<h2>12.1 Mechanism of Action</h2><p>Abemaciclib is an inhibitor of cyclin-dependent kinases 4 and 6 (CDK4 and CDK6). These kinases are activated upon binding to D-cyclins. In estrogen receptor-positive (ER+) breast cancer cell lines, cyclin D1 and CDK4/6 promote phosphorylation of the retinoblastoma protein (Rb), cell cycle progression, and cell proliferation. In vitro, continuous exposure to abemaciclib inhibited Rb phosphorylation and blocked progression from G1 into S phase of the cell cycle, resulting in senescence and apoptosis. In breast cancer xenograft models, abemaciclib dosed daily without interruption as a single agent or in combination with antiestrogens resulted in reduction of tumor size.</p>",
      "contraindications": "<p>None.</p>",
      "highlights": {
        "dosageAndAdministration": "<p>VERZENIO tablets are taken orally with or without food. (2.1) </p><ul><li>Recommended starting dose in combination with fulvestrant, tamoxifen, or an aromatase inhibitor: 150mg twice daily. (2.1)</li><li>Recommended starting dose as monotherapy: 200mg twice daily. (2.1)</li><li>Dosing interruption and/or dose reductions may be required based on individual safety and tolerability. (2.2)</li></ul>"
      },
      "metaDescription": "<p>Abemaciclib is a kinase inhibitor with formula C27H32F2N8, weight 506.59. VERZENIO tablets are white, beige, or yellow with specific inactive ingredients.</p>",
      "useAndConditions": "<p><h3>Approved Indications</h3></p>\n<ul>\n<li>In combination with endocrine therapy (tamoxifen or an aromatase inhibitor) for the adjuvant treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-positive, early breast cancer at high risk of recurrence.</li>\n<li>In combination with an aromatase inhibitor as initial endocrine-based therapy for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer.</li>\n<li>In combination with fulvestrant for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer with disease progression following endocrine therapy.</li>\n<li>As monotherapy for the treatment of adult patients with HR-positive, HER2-negative advanced or metastatic breast cancer with disease progression following endocrine therapy and prior chemotherapy in the metastatic setting.</li>\n</ul>",
      "contraIndications": "<p>No contraindications</p>",
      "warnings": "<h3>Warnings and Precautions</h3>\n<ul>\n<li>Severe diarrhea associated with dehydration and infection occurred in patients treated with VERZENIO. Instruct patients to start antidiarrheal therapy at the first sign of loose stools, increase oral fluids, and notify their healthcare provider. For Grade 3 or 4 diarrhea, discontinue VERZENIO until toxicity resolves to Grade 1, then resume at the next lower dose.</li>\n<li>Neutropenia, including febrile neutropenia and fatal neutropenic sepsis, occurred in patients treated with VERZENIO. Monitor complete blood counts prior to the start of therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, reduction, or delay is recommended for Grade 3 or 4 neutropenia.</li>\n<li>Severe, life-threatening, or fatal interstitial lung disease (ILD) or pneumonitis can occur. Monitor patients for pulmonary symptoms. Dose interruption or reduction is recommended for persistent or recurrent Grade 2 ILD or pneumonitis. Permanently discontinue VERZENIO for Grade 3 or 4 ILD or pneumonitis.</li>\n<li>Grade 3 ALT and AST elevations were reported. Monitor liver function tests prior to therapy, every 2 weeks for the first 2 months, monthly for the next 2 months, and as clinically indicated. Dose interruption, reduction, or discontinuation is recommended for persistent or recurrent Grade 2, or any Grade 3 or 4 hepatic transaminase elevation.</li>\n<li>Venous thromboembolic events, including deep vein thrombosis and pulmonary embolism, were reported. Monitor for signs and symptoms of venous thrombosis and pulmonary embolism. Dose interruption is recommended for early breast cancer patients with any grade venous thromboembolic event and for advanced or metastatic breast cancer patients with a Grade 3 or 4 event.</li>\n<li>VERZENIO can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus and females of reproductive potential to use effective contraception during treatment and for 3 weeks after the last dose.</li>\n</ul>",
      "dosing": "<p><h3>Adult Dosing</h3></p>\n<ul>\n<li>Combination therapy with fulvestrant, tamoxifen, or an aromatase inhibitor: 150 mg orally twice daily.</li>\n<li>Monotherapy: 200 mg orally twice daily.</li>\n<li>Continue treatment for early breast cancer until completion of 2 years or until disease recurrence or unacceptable toxicity.</li>\n<li>Continue treatment for advanced or metastatic breast cancer until disease progression or unacceptable toxicity.</li>\n<li>May be taken with or without food.</li>\n<li>Take doses at approximately the same times every day.</li>\n<li>If a dose is missed or vomited, take the next dose at the scheduled time.</li>\n<li>Swallow tablets whole; do not chew, crush, or split.</li>\n</ul>\n\n<p><h3>Dose Modifications for Adverse Reactions</h3></p>\n<ul>\n<li>First dose reduction: Combination therapy - 100 mg twice daily; Monotherapy - 150 mg twice daily.</li>\n<li>Second dose reduction: Combination therapy - 50 mg twice daily; Monotherapy - 100 mg twice daily.</li>\n<li>Third dose reduction: Monotherapy only - 50 mg twice daily.</li>\n<li>Discontinue if unable to tolerate 50 mg twice daily.</li>\n</ul>\n\n<p><h3>Hematologic Toxicities</h3></p>\n<ul>\n<li>Grade 1 or 2: No dose modification required.</li>\n<li>Grade 3: Suspend dose until resolved to Grade 2; no dose reduction required.</li>\n<li>Grade 3 recurrent or Grade 4: Suspend dose until resolved to Grade 2; resume at next lower dose.</li>\n<li>Monitor complete blood counts regularly.</li>\n</ul>\n\n<p><h3>Diarrhea</h3></p>\n<ul>\n<li>Grade 1: No dose modification required.</li>\n<li>Grade 2: If unresolved within 24 hours, suspend dose until resolution; no dose reduction required.</li>\n<li>Persistent Grade 2 or Grade 3/4: Suspend dose until resolved to Grade 1; resume at next lower dose.</li>\n</ul>\n\n<p><h3>Hepatotoxicity</h3></p>\n<ul>\n<li>Grade 1 or 2 without bilirubin increase: No dose modification required.</li>\n<li>Persistent Grade 2 or Grade 3 without bilirubin increase: Suspend dose until resolved to baseline or Grade 1; resume at next lower dose.</li>\n<li>AST/ALT >3 x ULN with bilirubin >2 x ULN: Discontinue VERZENIO.</li>\n<li>Grade 4: Discontinue VERZENIO.</li>\n<li>Monitor liver function tests regularly.</li>\n</ul>\n\n<p><h3>Interstitial Lung Disease/Pneumonitis</h3></p>\n<ul>\n<li>Grade 1 or 2: No dose modification required.</li>\n<li>Persistent Grade 2: Suspend dose until resolved to baseline or Grade 1; resume at next lower dose.</li>\n<li>Grade 3 or 4: Discontinue VERZENIO.</li>\n</ul>\n\n<p><h3>Venous Thromboembolic Events (VTEs)</h3></p>\n<ul>\n<li"
    }
  }
]